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Introduction
In drug development, toxicity is an important factor for attrition, resulting in a failure 
rate of 30%-40%. Hepatotoxicity, nephrotoxicity, cardiovascular safety, reproduction 
toxicity, developmental toxicity (teratogenicity), genotoxicity and carcinogenicity are 
the main causes for attrition in safety assessment. 
Screening on these aspects in the early discovery phase of drug development and using 
these data for compound optimization and deselection might result in drug development 
candidates with an improved success rate. The present thesis focuses on early screening 
for genotoxicity and carcinogenicity. 
In recent years some progress has been made with assays to assess genotoxicity and non-
genotoxic carcinogenicity at the end of the discovery phase. However, the time point at 
which these genotoxicity and carcinogenicity assays are performed is still relatively late, 
only a few assays for such a strategy are available, the throughput of these assays is in 
general still low and most of them have not yet been validated extensively. An additional 
drawback is that the currently used in vitro assays for the detection of genotoxicity give 
a high rate of false positive results, which makes application in the early discovery phase 
of drug development cumbersome. 
The goal of this thesis is therefore to develop improved and new in vitro assays for 
detecting the genotoxic and non-genotoxic carcinogenic potential of chemicals, validate 
these assays with proper reference compounds, and to develop a strategy for application 
of these assays in the early discovery phase of drug development.  
The drug developmental process and drug attrition 
The costs spend on R&D have increased tremendously during the last decades. In 
spite of the increase in R&D expenses, the development of new assay methods, new 
techniques in liquid handling, robotics, analytical tools and software, the yearly number 
of approved new drugs has declined [1]. 
The process of drug development is shown in Figure 1 and can be divided into discovery, 
exploratory development, and the full development and launch of the drug. In the 
discovery phase biological targets are validated and high-throughput screening is used 
to fi nd molecules that interact with these targets (hits). After identifi cation of the most 
promising hit (lead molecule), this molecule is further optimized (lead optimization) to a 
compound that shows pharmacological activity in an animal model. This fi rst phase that 
ends with delivering a development candidate takes around 3-4 years.
The second, exploratory development phase, consists of preclinical development and 
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fi rst into man studies (FIM). In vitro and in vivo testing is performed to assess the 
safety of the compound. Assays to show genotoxic potential of compounds are also 
performed in this phase. When this fi rst set of regulatory assays shows no serious 
adverse effects an investigational new drug application (IND) is fi led to the regulatory 
authorities such as the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA). Then FIM phase I clinical studies can be initiated, to study the safety 
and pharmacodynamics of the compound in healthy humans. Successful completion of 
this second phase results in the acquirement of a statement of no objection (SNOB). The 
process from development candidate to SNOB takes again around 3-4 years.  
In the third phase large clinical studies (phase II, III) and complex in vivo animal 
studies like carcinogenicity testing are performed. Results that indicate the absence of 
adverse effects can lead to the delivery of a full development candidate (FDC) which 
after positive review by regulatory authorities will result in launch of a new prescription 
drug. This third phase takes around 6-8 years and is the most expensive part of drug 
development.
Thus the complete process of developing a new drug takes approximately 12-16 years. 
The average developmental costs of a new prescription drug are high and estimated at 
approximately 800 million USD [2]. This fi gure does not take into account the costs of 
failed drugs as there is a high attrition rate of 90%. When this high attrition rate is taken 
into account the costs of developing one new drug can go up to 1.5 billion.
Figure 1. Overview of the drug development process. The development of a new prescription drug 
takes around 12-16 years. The fi rst phase that takes around 3-4 years consist of target validation, hit/
lead fi nding and lead optimization and ends with the selection of a development candidate (DC). The 
second phase consists of preclinical safety studies and the fi rst into man clinical studies. This phase ends 
after around 3-4 years with a statement of no objection (SNOB). In the third phase that takes around 
6-8 years large clinical studies and complex preclinical studies are performed. This phase can deliver 
a full development candidate (FDC) and after review and registration result in market launch of a new 
prescription drug. Genotoxicity and carcinogenicity testing is respectively performed during exploratory 
and full development.
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Table 1. Percentage of failure for toxicity reasons of compounds that were developed at Roche, 
Merck&BMS and the legacy NV Organon between 1960 and 2000 [4,5]. The most important toxicities 
issues for attrition are indicated in bold (Σx =12).
Toxicity failure Roche Merck & BMS NV Organon
Genotoxicity/carcinogenicity
Reproductive toxicity
Hepatotoxicity
Cardiovascular safety
Skin toxicity
Central nervous system side effects
Blood toxicity
Renal toxicity
Gastrointestinal toxicity
6
2
20
16
10
10
  6
  4
  4
8
5
15
27
-
7
7
2
3
20
20
12
12
x
x
x
12
x
Approximately 30%-40% of the new drug candidates fail in the developmental phase 
due to toxicological side effects [1, 3]. Several unpredicted toxicities account for the 
failure of new chemical entities (NCEs). Main causes are hepatotoxicity, nephrotoxicity, 
cardiovascular safety, reproduction toxicity and developmental toxicity (teratogenicity), 
and genotoxicity/carcinogenicity (Table 1). The percentage of compounds that fails on 
each of these endpoints depends on the portfolio of disease related compound classes 
that a pharmaceutical company works on. Depending on the company, the detection of 
compounds with genotoxic or carcinogenic potential accounted for 6-20% of the drug 
failures. Prescreening on these aspects before the selection of a development candidate 
may therefore result in drug development candidates with an improved success rate.
Genotoxicity
Genotoxic compounds (genotoxicants) are compounds that cause mutations in the 
DNA. Mutations are defi ned as permanent changes in the DNA. Three types of mutations 
can be distinguished. Small changes in the DNA at the level of bases are the so-called 
single-point mutations or gene mutations. These small mutations can result in base-pair 
substitutions, deletions or addition of bases, the latter two resulting in so-called frameshift 
mutations. Moreover, there are two types of mutations that occur at the level of the 
chromosomes. Structural chromosomal aberrations are major changes in the structure of 
the DNA. These changes are due to breakages, deletions, exchanges, or rearrangements 
of DNA. Compounds that cause structural chromosomal changes are called clastogens. 
The third group of mutations are changes in the number of chromosomes. Such changes 
are called aneuploidy and are caused by aneugenic compounds. Compounds can cause 
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one or more types of mutations. 
Genotoxic compounds can be sub-classifi ed into compounds that are DNA reactive 
themselves (i.e. compounds that form DNA adducts and DNA cross-linkers), and 
compounds that are non-DNA reactive but react with certain proteins in the cell, like 
for example compounds that inhibit topoisomerase enzymes, and thereby cause DNA 
damage in an indirect way. Moreover, a lot of genotoxic compounds need to be activated 
metabolically before they show there genotoxic mode of action. Such compounds are 
called proximate genotoxicants or carcinogens. 
Carcinogenicity
Carcinogens are compounds that induce the incidence of tumor formation. Carcinogenic 
compounds can have a genotoxic or non-genotoxic mode of action. Two models lay the 
foundation for the description of tumor development (carcinogenesis). These models 
are the multistage model of Armitage and Doll [6] and the initiation promotion model 
of Berenblum [7]. It is assumed that the development of tumors is a multistage process 
in which several mutations are needed for the transformation of a normal cell into an 
autonomic growing cell (neoplastic cell). The fi rst phase (initiation phase) starts with 
DNA damage that is caused by endogenous factors or exogenous factors like for example 
DNA reactive or indirect genotoxic compounds. 
Besides the initiation phase in which the mutations are irreversibly fi xated in the DNA, 
there is a second phase, the promotion phase, in which the neoplastic cell develops into 
an observable and clinically manifest tumor. The third phase in the development of a 
tumor is the progression phase. This involves growth of the tumor, invasion into the 
surrounding tissue and metastasis.
Non-genotoxic carcinogens can induce tumor formation by several mechanisms 
[8]. These mechanisms may include receptor mediated induction/stimulation of 
carcinogenesis, cytotoxicity, endocrine modifi cation, immunosuppression, infl ammation, 
oxidative stress, hyper-/hypo-methylation and inhibition of gap-junction mediated 
intercellular communications. Especially the receptor mediated induction/stimulation is 
responsible for several forms of rodent specifi c carcinogenicity.  Examples are species 
specifi c activation of the aryl hydrocarbon receptor (AhR), the peroxisome proliferator 
activated receptor alpha (PPARα) and the constitutive androstane receptor (CAR) [8]. 
Assays that measure the activation of these receptors in rodent and human cells in the 
early phase of drug development might be useful for early detection of non-genotoxic 
carcinogens.
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Regulatory tests to detect compounds with genotoxic and 
carcinogenic potential
Regulatory tests to detect genotoxic potential
A stepwise approach (tiered approach) is applied in regulatory genotoxicity testing 
[9]. In vitro assays with a high sensitivity are used as a fi rst step to see whether the test 
compounds have intrinsic genotoxic activity. These tests are then followed by in vivo tests 
that are designed to assess the relevance of the in vitro result for the in vivo situation. In 
vivo genotoxicity studies are also performed for the reason that some genotoxicants are 
only detected in vivo [10]. A decision tree for regulatory genotoxicity testing including 
a description of necessary follow up testing is described in detail later in this chapter.
Genotoxicity testing is in comparison to regulatory testing of carcinogenicity relatively 
cheap and fast. Compounds without genotoxic liability can proceed to FIM clinical trials. 
The carcinogenic potential is further assessed in the full developmental phase of drug 
development.
The regulatory test strategy consists of a battery of tests because the three types of 
genotoxicity (gene mutations, clastogenicity and aneugenicity) cannot be detected by 
a single test. The standard test battery required for genotoxicity testing is described in 
ICH guideline S2B for the registration of pharmaceuticals for human use and consists 
of (1) the Ames assay to detect gene mutations in bacteria, (2) an in vitro chromosome 
aberration or mouse lymphoma TK assay in mammalian cells and (3) an in vivo 
chromosome damage assay (chromosome aberration or micronucleus assay). Specifi c 
technical aspects of these regulatory tests are described in ICH guideline S2A for the 
registration of pharmaceuticals for human use. 
The assays from the standard test battery have a different sensitivity, specifi city and 
predictivity for carcinogenicity. The performance defi nitions are shown in Table 2. For 
the calculations of the sensitivity, the results of the genotoxicity assays are compared 
with the results of the carcinogenicity tests. It is however important to note that several 
of the carcinogenic compounds act via a non-genotoxic mode of action. Genotoxicity 
tests will thus never reach a sensitivity of 100% for carcinogenicity. The assays from the 
regulatory genotoxicity test battery are described in more detail in the next sections and 
the performances scores are shown in Table 3. 
Table 2. Performance defi nitions for genotoxicity tests.
Term Defi nition
Sensitivity Percentage of carcinogens positive in the test
Specifi city Percentage of non-carcinogens negative in the test
Predictivity Percentage of all tested compound that was predicted correctly
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The Ames assay
The Ames test is an assay that was developed by Bruce Ames and is performed to 
assess the mutagenic potential of chemical compounds [11,12]. The assay is performed 
in Salmonella typhimurium bacteria that carry mutations in genes involved in histidine 
biosynthesis. As a consequence the bacterial cells require histidine for growth and are 
so-called histidine auxotrophes. Mutagenic compounds can cause a reverse mutation 
which results in bacteria that can grow on a histidine-defi cient medium. The number of 
bacteria that form colonies is then used as a measure for the mutagenic potential of a 
compound.
Several bacterial strains are used that have frameshift or point mutations in the genes 
required for histidine synthesis. These diverse strains are used to be able to detect mutagens 
acting via different mechanisms. Besides the mutations in the histidine synthesizing 
genes, the tester strains also have additional mutations to make the strains more sensitive 
for the detection of mutations. A mutation in the genes used for lipopolysaccharide 
synthesis makes the cell wall of the Salmonella typhimurium bacteria more permeable. 
Moreover, the strains have a mutation in their excision repair system [11]. 
The specifi city of the Ames assay is relatively high in comparison to the other in vitro 
genotoxicity tests (Table 3). The sensitivity, specifi city and predictivity of the Ames 
assay calculated by Kirkland et al. was 58.8%, 73.9%, and 62.5%, respectively [13]. 
To mimic metabolism in bacterial (and mammalian) mutagenicity assays, a liver fraction 
(S9 mixture) containing phase I and II drug metabolizing enzymes from Aroclor 1254 
treated male Sprague-Dawley rats is used. Aroclor 1254 stimulates the AhR, pregnane 
X receptor (PXR) and CAR and leads to high levels of cytochrome P450 (CYP) 1A1, 
CYP1A2, CYP2B and CYP3A, which are involved in the activation of a large number 
of proximate genotoxicants. Assays are performed in the presence and absence of S9 
mixture to study whether compounds are activated or inactivated by metabolism. 
Table 3. The sensitivity, specifi city and predictivity of the assays of the standard regulatory test battery 
for the assessment of genotoxic potential [13,14].
Assay Sensitivity (%) Specifi city (%) Predictivity (%)
Ames 58.8 73.9 62.5
Chromosome aberration  (CA) 65.6 44.9 59.8
Mouse lymphoma TK  (MLA) 73.1 39.0 62.9
Micronucleus in vitro 78.7 30.8 67.8
Micronucleus in vivo 40.0 75.0 48.0
The chromosome aberration assay
The chromosome aberration assay (CA) is performed in vitro in cultured mammalian 
cells. Structural and numerical damage is scored by microscopic examination of 
chromosomes in mitotic metaphase cells. Tests are carried out with and without S9 
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mixture [15,16].  This assay is often performed in Chinese hamster ovary k1 (CHO-k1) 
or lung cells (V79) or human lymphocytes. Scoring needs specialized training and 
experience. 
The sensitivity and predictivity of this test are 65.6%, and 59.8% respectively. The 
specifi city of this test is low with only 44.9% [13].
 
The mouse lymphoma TK assay
Thymidine monophosphate (TMP) is one of the four desoxyribonucleotide 
monophosphates, TMP does not undergo signifi cant conversion to other nucleotides. 
This conservation makes the TMP pool size quite small and constant under normal 
growth condition. Therefore the TMP pool serves as a regulator for DNA synthesis. 
If TMP is replaced by a lethal TMP analogue, cells will die. The phosphorylation of 
these analogues is mediated by the “salvage” enzyme thymidine kinase (TK), which 
phosphorylates thymidine into TMP in mammalian cells. TK-defi cient cells lack this 
enzyme activity and therefore are resistant to the cytotoxic effect of the lethal analogue. 
In the mouse lymphoma TK assay, the TK-competent L5178Y (TK+/+ or TK+/-) cells 
are treated with the test agents. After treatment, the cells are shifted to a selective medium 
containing a lethal TMP analogue such as trifl uorothymidine (TFT). Normally most cells 
will die, however in the presence of a mutagenic compound, TK -/- cells might have 
been formed which are resistant to the cytotoxicity. The number of cell colonies on test 
plates is therefore a measure for genotoxicity. The size of the colonies gives information 
about about chromosome damage as large changes in the DNA inhibit growth and result 
in small colonies, whereas large colonies denote gene mutation. 
The sensitivity and predictivity of the mouse lymphoma TK assay (MLA) are 73.1% 
and 62.9%. Similar to the chromosome aberration assay, the specifi city of this assay is 
low with only 39.0% [13].
The micronucleus assay
The fourth regulatory genotoxicity assay is the micronucleus assay. Chromosomal 
fragments or complete chromosomes that are the result from DNA damage or errors in 
the separation of chromosomes during the cell cycle, can sometimes be found outside the 
nucleus in one of the daughter cells. After division of the nucleus these DNA fragments 
will decondensate and form a so called micronucleus. By using DNA staining techniques 
these micronuclei become visible and countable under the microscope. The number of 
these micronuclei per 1,000 (bi-nucleated) cells is used as a measure for genotoxicity. 
This assay can be performed in vitro on cell lines like CHO-k1. Micronuclei can also be 
measured in red blood cells and bone marrow obtained from in vivo experiments. 
By using centromeric probes it is possible to determine whether micronuclei contain 
complete chromosomes or fragments of chromosomes. These results can then be used to 
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determine whether compounds have a clastogenic or aneugenic mode of action [17]. 
The sensitivity, specifi city and predictivity of the in vitro micronucleus assay are 
78.7%, 30.8%, and 67.8%, respectively. The specifi vity of the in vivo micronucleus 
assay in bone marrow is much higher with 75%. The sensitivity of the in vivo test is 
lower with 40% and the predictivity is 48% [13, 14].
The impact of positive fi ndings for genotoxic potential and follow up testing 
strategies
A decision tree for the tiered approach in regulatory genotoxicity testing is shown in 
Figure 2. In general, a combination of the Ames + MLA + (or) CA is used in regulatory 
in vitro testing for genotoxic potential [13]. A combination of the Ames + MLA + CA has 
a high sensitivity (84.7%) but low specifi city (22.9%) for carcinogenicity [13]. When 
these tests show no genotoxic potential, the in vivo micronucleus test is performed. 
This in vivo test is performed as there are several compounds that are poorly detected 
in vitro. For example proximate carcinogens that are activated by phase II enzymes [18, 
19]. When the in vivo micronucleus assay also shows a negative result it is likely that the 
compound has no genotoxic potential and the compound can proceed in development. 
More research is needed in the rare situation, where the in vivo micronucleus assay 
gives a positive result after negative results in vitro. It has been shown that compounds 
that increase or decrease the core body temperature for a sustained period, compounds 
that increase the erythropoiesis in the bone morrow, and compounds that inhibit protein 
synthesis induce the number of micronuclei in bone marrow in vivo. Experiments to 
show these modes of action have been described by an IWGT working group [20]. 
Such positive results are mostly irrelevant for humans. Mechanistic data to demonstrate 
lack of clinical relevance for humans or a non-DNA reactive mechanism can lead to 
continuation of the further development. For non-DNA reactive genotoxicants (e.g. 
topoisomerase inhibitors and spindle poisons) a threshold might be justifi ed. In case of 
a DNA reactive mode of action development is terminated. 
In the case of a positive result in the in vitro genotoxicity assays it is required to perform 
at least two follow up in vivo genotoxicity tests. These are the in vivo micronucleus assay 
and another test. In the past the UDS tests was often used. But nowadays the Comet 
assay is more preferred in the testing for human pharmaceuticals [21]. This because 
it has been shown that most in vivo micronucleus negative carcinogens giving DNA 
adducts are detected in the Comet assay. Of these compounds <20% are detected in the 
UDS assay [21].  Besides these two in vivo assays it might be useful to perform assays 
to elucidate the mode of action causing the positive result.
Mostly the in vivo genotoxicity assays will show a negative result after a positive 
in vitro result as the in vitro assays give a high number of false positive results. In 
retrospective analysis Kirkland et al. showed that the genotoxicity battery used in the 
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tiered approach is highly sensitive. About 80%-90% of the carcinogens are detected, 
however, the specifi city of especially the in vitro mammalian genotoxicity assays is very 
low [13, 22]. This is also supported by the retrospective analysis performed by Snyder 
and Green [23]. They showed that 50% of non-carcinogenic marketed drugs have a 
positive result in the mammalian genotoxicity assays, indicating the high false positive 
rate of these tests.
Two negative results in vivo overrule in principle a positive result in vitro, however in 
the case of development of pharmaceuticals for human use often additional investigations 
are performed to get a clue about the reason for the positive result. In the case, the in 
vivo tests are positive additional investigations might also be useful to show whether the 
positive in vivo result is relevant for humans or that the compound acts by a threshold 
mode of action. In this way the compound can be saved from attrition. A summary of 
human non-relevant, indirect or threshold mechanisms of genotoxicity is given in Table 
4. 
Table 4. Summary of human non-relevant, indirect or threshold mechanism of genotoxicity. The in 
vitro systems affected and the probability to obtain experimental evidence to support the mechanism are 
shown [24].
Mode of action Description In vitro system 
affected
Possibility to 
obtain 
experimental 
evidence
In vitro specifi c Rat S9 mixture specifi c effects All, except primary 
hepatocytes
Reasonable
Feeding effects Bacteria Reasonable
Direct DNA effect but Azo- and nitro- reduction Bacteria Reasonable
with a threshold DNA repair defi ciency All Diffi cult
Inadequate detoxifi cation All Reasonable
Metabolic overload (production 
of reactive oxygen species, lipid 
peroxidation and sulphydryl 
depletion)
Mammalian cells Reasonable
Indirect effect Inhibition of topoisomerases Mammalian cells Reasonable
Inhibition of kinases Mammalian cells Reasonable
Inhibition of DNA polymerases Mammalian cells Reasonable
Imbalance of DNA precursors Mammalian cells Reasonable
Energy depletion Mammalian cells Diffi cult
Inhibition of protein synthesis Mammalian cells Diffi cult
Nuclease release from lysosomes Mammalian cells Diffi cult
Protein denaturation Diffi cult
Aneuploidy Reasonable
High toxicity Reasonable
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Figure 2. Schematic overview of the decision tree and necessary follow up testing for regulatory 
genotoxicity testing in case of pharmaceuticals for human application.
In a paper from Kirkland et al. [24], in vitro approaches are described to determine 
whether these effects occur in or are relevant for humans. The diffi culty however is to 
predict what mechanism is affected by a compound giving a positive in vitro or in vivo 
genotoxicity result. Toxicogenomics approaches might be very valuable in this aspect as 
they can give a clue about the mechanism of action [25]. 
In general the following test strategy is used to assess the mode of action after a positive 
result in vitro that is suspected to be not relevant for the human situation or suspected 
to have a threshold [24]. Firstly in vitro assays are performed to show the indirect or 
threshold mode of action. Then in vivo tests are performed. When these tests are positive 
evidence must be obtained that this positive result is caused by the same mode of action. 
In case of a for human relevant non-DNA or threshold mode of action, the NOAEL (No 
Observed Adverse Effect Level) must be determined. When the anticipated human dose 
is much lower development of the compound might continue. In case of a for human 
relevant DNA reactive mode of action development of the compound is terminated.
Carcinogenicity testing
Testing of carcinogenicity is performed later in the process of drug development (parallel 
to phase II-III clinical studies) and is required for the fi nal market approval of a compound 
In vivo micronucleus assay
Second in vivo test (UDS or Comet)
Negative result
No genotoxic potential.
Development can continue.
In vitro test battery
Negative result
In vivo micronucleus assay
Positive result
Positive result
Additional in vitro and/or in vivo
testing to assess the mode of action
Development can continue.
A for humans relevant DNA reactive mode  
of action. Discontinuation of development.
Negative result
Discontinuation
of development.
Human non-relevant, indirect  
or threshold mode of action.  
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[26]. Upon availability of the results from the carcinogenicity studies, the genotoxicity 
results are used as part of the weight of evidence in cancer risk assessment.
The assessment of carcinogenicity is described in guideline ICH S1B for registration 
of pharmaceuticals for human use. According to this guideline the induction of tumors 
is monitored in a two-year, lifetime exposure of mice and rats [27]. As an alternative 
to the mouse bioassay a medium-term transgenic mouse model can be used [28]. There 
are several compounds that are carcinogens in rodents but act by a mechanism that is 
irrelevant for humans. For example compounds that activate the PPARα receptor in 
rodents. Therefore follow up testing to show the mechanism of action is necessary to 
assess relevance for humans.    
Screening for compounds with genotoxic and carcinogenic potential 
in the discovery phase of drug development
 The early screening of compounds for genotoxic/carcinogenic potential can be an 
attractive tool and makes use of these assays for the deselection and optimization of 
compounds in the discovery phase of drug development. This approach might be a way 
to improve the success rate of new chemical entities [29]. 
It has been shown that optimization of compounds in the early lead optimization 
phase on pharmacological properties  as well as on pharmacokinetics/bioavailability is a 
successful strategy, that results in a lower drug attrition rate due to these properties [30]. 
Likewise this strategy might be useful in the case of genotoxicity/carcinogenicity.
The pharmaceutical industry has already put effort in the optimization of compounds 
to avoid attrition due to genotoxicity and carcinogenicity. In silico QSAR analysis 
is often applicated in the lead optimization phase. Software programs like DEREK, 
Topcat, Multicase, and Mutalert are routinely used during lead optimization [31]. In 
addition potential drugs are often tested in non-GLP versions of the micronucleus assay 
and miniaturized version of the Ames test at the end of the lead optimization phase just 
before the selection of the development candidates. These miniaturized versions of the 
Ames assay are still laborious and need approximately 300 mg of compound which 
makes application of the assay in the early lead optimization phase diffi cult [32].
Screening in the early lead optimization phase raises several issues. The earlier screening 
is performed in the process of drug development, the higher is the number of compounds 
that have to be tested. Furthermore, in the early phase of drug development only a small 
amount of compound is available. Early testing for toxicological hazard means also that 
the specifi city of the assays has to be high as otherwise too many pharmacologically 
interesting compounds will be deselected. Therefore assays with a high-throughput and 
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specifi city needing a low amount of compound are necessary. The exact number of 
compounds that have to be tested depends on the time point in the lead optimization 
phase where the assays are performed. 
When assays are performed early in the lead optimization phase it is possible to use 
the assays for the optimization of compounds. When assays are used just before the 
selection of a development candidate, the assays are more deselection assays.
The regulatory genotoxicity assays have in general a very low throughput, need a 
high amount of compound, and are laborious. Therefore these assays are at least in their 
currently used format not suitable for medium- or high-throughput screening in the early 
discovery phase. Moreover, the specifi city of most in vitro genotoxicity assays is too 
low to use them in the lead optimization phase. There are already a few commercially 
available screening assays for genotoxicity. However, these assays have in general been 
validated with only a limited number of compounds.
Thus in conclusion for early genotoxicity screening better in vitro assays with a higher 
throughput, a lower amount of compound required and a higher specifi city are needed. 
These in vitro assays need validation with proper reference compounds.
Besides the detection of compounds that have the potential to be genotoxic carcinogens, 
it would be useful to detect compounds with non-genotoxic carcinogenic potential. As 
non-genotoxic carcinogens can have a wide variety of different mechanisms of action, 
this is even more challenging than testing for genotoxic potential. However, the activation 
of several receptors like the AhR, PPARα and CAR has been linked to non-genotoxic 
carcinogens. In these cases it might be possible to develop quick prescreens that measure 
the activation of such receptors.
The strategies that will be used in this thesis to develop, optimize and validate assays 
for genotoxic and non-genotoxic carcinogenicity are described on the next pages. High-
throughput assays based on bacteria, yeast and human/rodent cell lines are proposed to 
be useful in vitro models. In the case of human cell lines, the focus is on the HepG2 cell 
line as, for reasons also outlined below, the properties of HepG2 cells are expected to 
give a good prediction for in vivo genotoxicity. 
The detection of genotoxicity with bacterial screens
As an alternative for the Ames assay, the induction of genes involved in repair of 
bacterial DNA damage (SOS response) might be used as measure for the mutagenic 
potential of compounds. Assays that are based on these principles are the SOS chromotest 
and VitotoxTM assay.
The SOS chromotest is a colorimetric assay that measures the activation of the sfi A 
gene which is involved in the SOS response in bacteria [33]. In this assay, the promoter 
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of sfi A is linked to the lacZ gene. Activation of the SOS response therefore results in 
an increased production of the lacZ protein which can be measured colorimetrically. 
The VitotoxTM assay is a more modern version of this assay. The VitotoxTM assay is 
a bioluminescent assay with a medium-throughput test potential that also exploits the 
bacterial SOS response mechanism involved in DNA repair [34, 35]. One of the important 
proteins involved in the SOS response is the recN protein which is under non-stress 
conditions repressed by the LexA protein. In the VitotoxTM assay a genetically modifi ed 
Salmonella typhimurium strain TA104 is used that contains the lux operon of Vibrio 
fi scheri under transcriptional control of the promoter of the recN gene. After incubation 
of the bacteria in the presence of a genotoxic compound, the recN promoter is activated, 
as the repressor LexA protein is inactivated. This results in light production refl ecting 
genotoxicity (bacterial mutagenicity). The applicability of this assay for screening in the 
discovery phase will be tested in Chapter 2 of this thesis. 
The detection of genotoxicity with yeast screens
Bacterial tests have the disadvantage that these tests will not detect compounds that have 
solely a clastogenic or aneugenic mode of action. Eukaryotic yeast-based genotoxicity 
systems might be useful in this aspect. Like in the bacterial screens, the activation of 
genes involved in DNA repair might be used as a measure for detecting genotoxic 
potential in the assays. Several publications have described the application of a RAD54 
promoter linked to a Green Fluorescent Protein (GFP) protein [36-40]. Induction of 
the RAD54 promoter due to DNA damage results in increasingly fl uorescent cells. A 
quite similar assay is the RadarScreen assay which uses a RAD54 promoter linked to 
a β-galactosidase reporter that can be quantifi ed by a luminometric measurement. This 
luminometric read-out will have the advantage that autofl uorescence of compounds and 
S9 mixture does not hamper measurement. Studies to validate the RadarScreen assay 
with and without a S9 mixture are described in Chapter 2 of this thesis.
The detection of genotoxicity with human based cell line screens
Cell lines can also be used to determine the genotoxic potential of compounds. Human 
cell lines might even be more valuable as assays in these cells can refl ect the human 
situation better than assays using bacteria, yeast and rodent cell lines. An important 
aspect for the development of a human based genotoxicity assays, is the choice of the 
primary and/or permanent cell line. At fi rst instance primary cells seem the best choice. 
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However, for the fi xation of mutations, induction of cell cycle checkpoints and DNA 
repair, cells need to divide. Most primary cells brought into culture are not yet adapted 
to the high oxygen concentrations in the cell incubators, therefore have a lot of stress and 
divide only a few times. Thus dividing permanent cell lines may be more preferable. 
However, the problem with cell lines is that most have lost their p53 response, DNA 
repair response and metabolizing capacities. The application of the human hepatoma 
cell line HepG2 might be useful in this aspect because, as outlined in further detail 
below, these cells may display active p53, DNA repair and phase I and II metabolism. 
Three types of assays/techniques are applied in combination with the HepG2 cell line in 
this thesis. These are high content screening (HCS) to develop an in vitro micronucleus 
assay, toxicogenomics to fi nd biomarkers for genotoxicity, and luciferase based reporter 
assays for the detection of genotoxic potential. 
The HepG2 cell line
The HepG2 cell line is a liver hepatoma cell line that has retained activities of phase 
I and II metabolizing enzymes that are lost in most cultivated cells [41-43]. Normally 
S9 mixture is used to mimic metabolism in in vitro systems for genotoxicity testing. 
Although this mixture properly performs phase I metabolism, the metabolites might not 
be able to pass the human cell membranes due to the hydrophilicity of the metabolites. 
Other disadvantages of rat-S9 mixture are the absence of phase II metabolism and the 
fact that human specifi c metabolites will not be generated. 
At our laboratory HepG2 cells were used in two cytotoxicity studies [44, 45]. Several 
compounds like for example benzo[a]pyrene of which the metabolites are known to be 
toxic, were toxic in this cell line. This implicated that phase I metabolic activity was 
present in these HepG2 cells. Besides phase I metabolism, phase II metabolism is also 
important for genotoxicity testing. Phase II enzymes can play a role in detoxifi cation of 
reactive intermediates thereby reducing genotoxicity, but they may also play a role in 
bioactivation of proximate carcinogens. Phase II enzymes like sulfotransferases (SULTs) 
and N-acetyltransferases (NATs), for example, are important for the activation of many 
genotoxicants. Glatt et al. [18, 46] reported that more than 100 proximate mutagens 
are activated by SULTs.  These SULTs are inactive in S9 mixture due to the lack of the 
proper cofactor in S9 mixture. Addition of the particular cofactor is not directly solving 
this problem since the conjugates cannot easily enter the cells due to their charge and 
hydrophilic character. Therefore SULT activated proximate genotoxicants are missed 
in the standard in vitro test systems, whereas they have been reported as genotoxic in 
HepG2 cells [47]. NAT activity is important for the detection of heterocyclic amines 
like 2-amino-3-methyl imidazo[4,5-f]quinoline (IQ) because such compounds require 
acetylation for their activation. The levels of these enzymes are low in CHO-k1 cells. As 
a consequence of NAT activity in HepG2 cells, results from in vitro micronucleus tests 
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with heterocyclic amines in HepG2 cells correlated much better with the carcinogenic 
effects in vivo than results obtained with other cell lines like CHO-k1 cells. Results from 
micronucleus tests in these HepG2 studies correlated even better with carcinogenicity 
in laboratory animals, than in vivo micronucleus tests in bone marrow of mice [48]. 
Further examples are the application of HepG2 cells to elucidate the genotoxic potential 
of mycotoxins [49, 50]. These compounds are carcinogens in vivo, genotoxic in HepG2 
cells, but negative in all in vitro regulatory genotoxicity assays. Furthermore, HepG2 
cells give promising results as several human specifi c carcinogens are detected. In 
summary, there are several studies that report bioactivation of proximate genotoxins/
carcinogens by phase I or II metabolizing enzymes in the HepG2 cell line. However, 
a more detailed metabolic characterization of the HepG2 cell line is needed as it is not 
exactly known which phase I and II enzymes are present and inducible in the HepG2 cell 
line. This characterization is performed in Chapter 3 and 4 of the present thesis.
Another characteristic of the HepG2 cell line which is an advantage for genotoxicity 
testing is the fact that the HepG2 cell line has a functionally active p53 protein [51]. The 
tumor suppressor p53 is a potent transcription factor which stimulates the expression of 
genes involved in growth arrest, apoptosis, and DNA repair. Additionally, p53 is able to 
suppress the expression of a different set of genes including those involved in stimulating 
cell division [52]. Under normal circumstances, p53 is kept under tight control through 
its partnership with MDM2, an ubiquitin E3 ligase which mediates the ubiquitylation 
and degradation of p53. In response to a range of different cellular stresses [53], of which 
DNA damage is the most important one, p53-MDM2 protein interaction is interrupted 
with the result that p53 degradation is blocked [54]. As a consequence p53 is able to 
accumulate rapidly following DNA damage. The activation of p53-regulated genes 
results in either cell-cycle arrest allowing DNA repair or in p53-dependent apoptosis or 
cellular senescence in order to avoid the propagation of genetically defective cells [52, 
54]. One of the activated genes of p53 is the cyclin dependent kinase (Cdk) inhibitor 
protein p21. This protein binds to G1/S-Cdk and S-Cdk and thereby blocks entry into 
the S-phase. 
A functionally active p53 protein is also needed for a proper functional nucleotide 
excision repair and double strand break repair. Wang et al. [55] demonstrated that p53 
plays a prominent role in the damage recognition and assembly of the repair machinery 
during global genome repair. The recruitment of the xeroderma pigmentosa C gene 
(XPC) which plays a prominent role in nucleotide excision repair was p53 dependent. 
Chang et al. [56] showed in the alkaline comet assay that after the introduction of p53 in 
p53-null cells the excision activity was restored. Similar results were reported in a micro- 
array experiment [57]. The basal expression of XPC was relatively low in lymphoblasts 
that did not have a functionally active p53 protein. After the onset of DNA damage by 
radiation only minor changes in the expression of XPC occurred. In this study similar 
General introduction 
25
effects were observed for the radiation gene 51 homolog C (RAD51C) gene which plays 
a prominent role in double strand break repair [57].
Another, important characteristic of the HepG2 cell line is the presence of the 
nuclear transcription factor E2-related factor 2 (Nrf2) system [58]. Studies have shown 
that activation of the transcription factor Nrf2 induces the transcription of phase II 
detoxifi cating enzymes, antioxidant enzymes and transporters genes that protect against 
(geno-) toxic compounds. Examples of induced genes are glutathione S-transferase, 
NAD(P)H:quinone oxidoreductase 1, heme oxygenase-1, sulfotransferases, UDP-
glucuronosyltransferase and multidrug resistance-associated protein. The protective 
effect is based on the fact that reactive oxygen species and (geno-)toxic compounds are 
metabolized and excreted in a relative fast way. Under homeostatic conditions in a cell, 
Nrf2 is retained in the cytoplasm by the Keap1 protein. Due to oxidative stress, Nrf2 is 
released from Keap1 and can translocate to the nucleus. There it activates genes with 
an electrophile responsive element (also called anti-oxidant responsive element) in the 
promoter as the above mentioned phase II metabolizing enzymes, transporters (phase III 
enzymes), and anti-oxidant genes.
The presence of metabolism, a functionally active p53 protein, active DNA repair, 
and an active Nrf2 system in HepG2 cells might give this cell line an advantage in 
(geno-) toxicity testing over the more commonly used cell lines, like V79 and CHO-k1 
lines, in which these systems are absent or less functional. Several studies showed that 
the HepG2 cell line gives good results (high sensitivity and specifi city) in genotoxicity 
assays like the in vitro micronucleus (IVMN) test and Comet assay [59-65]. However, 
the compound sets used in these studies were small and almost only positive controls 
were used.
The presence of phase II enzymes in the context of their detoxifying properties and the 
presence of a functional p53 and Nrf2 system in HepG2 cells might result in a reduction 
of the number of falsely predicted positive results. HepG2 cells might also prove to be 
an adequate tool to study the role of these systems in genotoxicity. Assays that will be 
developed/performed with HepG2 cells are described in the next sections. 
The development of a high content screening micronucleus assay in HepG2 cells
High content screening (HCS) is the usage of (fl uorescent) microscopy coupled with 
automated image analysis. Normally the scoring of micronuclei in microscopic slides 
under the microscope is performed by trained operators. This is laborious and therefore 
the throughput of the micronucleus assay is very low. By using the technique of HCS the 
throughput of the assay becomes high, also because it uses 96-well plates. This makes 
this assay suited for screening purposes in the discovery phase. An evaluation of this 
technique was performed by Diaz et al. [66]. An advantage of the HCS technique is that 
also other parameters like for example cytotoxicity can be measured in the same cells. 
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This improves the interpretation of genotoxicity results.
As stated before the in vitro mammalian genotoxicity assays in CHO-k1 and V79 cells 
give in general too many falsely predicted positive results for genotoxicity. Knowing the 
importance of the defense mechanisms (i.e. p53, Nrf2, DNA repair, phase II metabolism) 
against genotoxicity, it is noteworthy to realize that differences in the extent of presence/
absence of these mechanisms in cell lines likely will have great infl uence on the 
sensitivity/specifi city of the in vitro cell lines in comparison to cells in vivo. 
Besides the development of a HCS micronucleus assay in HepG2 cells it will therefore 
be very useful to compare the sensitivity and specifi city of the HepG2 cells with the 
commonly used CHO-k1 cells that lack many of the defense mechanisms (Chapter 5 of 
this thesis). This might give more insight into the reasons for the high number of falsely 
predicted positive results in the CHO-k1 cell line. 
The development of luminescent based reporter assays in the HepG2 cell line
Human based genotoxicity assays for screenings purposes are rare, however, 
Gentronix has develop the Greenscreen HC GADD45a-GFP assay [67]. This assay links 
the regulation of the human GADD45a, which is induced after DNA damage, to the 
production of GFP. A disadvantage of this model system is that it has GFP as reporter 
gene. We identifi ed that many compounds (from the legacy of Organon) interfere with 
GFP measurement because of autofl uoresence at the same wavelength as GFP [4]. In 
addition, the human GADD45a cell line lacks metabolism. Application of S9 mixture is 
possible in the assay but this results in a low-throughput assay [67] with low sensitivity. 
Thus better assays are needed. 
Luminescent based reporter assays in HepG2 cell lines might be useful as model 
systems. Luminescent based reporter assays in HepG2 cells will be developed in this 
thesis. Toxicogenomics data will be used to select proper biomarkers (genes or responsive 
elements) for the detection of genotoxic compounds (Chapter 6 of this thesis). It is 
expected that useful promoters and responsive elements will have a role in stress responses 
like the p53 response, Nrf2 response, DNA repair, apoptosis, and cell cycle control. A 
selection of promoters/responsive elements will be used to generate luminescent based 
reporter assays, which then will be validated (Chapter 7 of this thesis).
Detection of (species specifi c) non-genotoxic carcinogenicity
Several receptors have a role in non-genotoxic carcinogenicity like for example the aryl 
hydrocarbon receptor (AhR), peroxisome proliferator activated receptor alpha (PPARα), 
constitutive androstane receptor (CAR), estrogen receptor, thyroid hormone receptor, 
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androgen receptor and progesterone receptor [8]. This thesis is only focused on species 
differences in AhR activation between rat and human.
The AhR was discovered as the receptor that binds the environmental contaminant 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [68]. The AhR is a basic helixloop-helix 
protein belonging to the Per-ARNT-Sim (PAS) family [69] and is located in the cytoplasm 
in an inactive complex with Hsp90 and p23. Binding of a ligand to the AhR leads to 
activation of the receptor and subsequently in its translocation to the nucleus. In the 
nucleus AhR releases its partner Hsp90 and forms a heterodimer with the AhR nuclear 
translocator (ARNT) protein. Further activation of this heterodimer by phosphorylation 
and/or dephosphorylation is required for DNA binding [70, 71].
Signifi cant activation of the AhR by TCDD results in toxic effects like wasting 
syndrome, thymic involution, endocrine disorders, and very important teratogenicity 
and (nongenotoxic) carcinogenicity. Activation of the AhR with dioxin results in an 
increased incidence of liver tumors in both rats and humans. Studies in AhR-null mice 
have been used to investigate the role of the AhR in mediating the toxic effects. The 
studies revealed that these mice were resistant to TCDD induced lesions, strongly 
suggesting that the toxic effects are mediated by the AhR [72]. Furthermore, skin tumors 
that appear after topical application of the AhR agonist benzo[a]pyrene (B[a]P) are not 
formed in AhR-null mice [73].
Important for this non-genotoxic carcinogenic effect might be the change in expression 
patterns of several factors that are involved in cellular growth and differentiation. A second 
effect contributing to carcinogenicity may be the impairment of the p53 response [74, 
75]. A third factor of importance is the strong induction of CYP1A1 which is involved in 
the metabolic activation of many potent proximate carcinogens like for example B[a]P.
Tumor promoting effects are both present in humans and rats although species dependent 
differences have been described [43]. The reported data about species differences are 
limited and therefore species differences in AhR induction in rat and human will be 
studied in Chapter 8 of this thesis.
Aim and outline of this thesis
The aim of the thesis was to develop high-throughput in vitro assays for the detection 
of compounds with genotoxic and non-genotoxic carcinogenic potential, validate these 
assays with proper reference compounds, and to develop a strategy for application of 
these assays in the early discovery phase of drug development. Such high-throughput 
assays may be applied for compound deselection, prioritization and/or optimization in 
the early discovery phase of drug development. A main goal was to develop in vitro 
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genotoxicity assays refl ecting in vivo genotoxicity more accurately than the current 
assays. 
Chapter 2 describes the validation of the high-throughput VitotoxTM (bacterial screen) 
and RadarScreen (yeast screen) assays. The validation of these two assays by using 62 
compounds that are described in a compound list published by the European Centre for 
the Validation of Alternative Methods (ECVAM) and an additional set of 192 compounds 
is presented.
Chapter 3 describes the characterization of phase I metabolism in HepG2 cells. HepG2 
cells were expected to give a better correlation with in vivo genotoxicity than yeast and 
other rodent cell lines like CHO-k1 and V79, which are often used in the regulatory 
in vitro studies for genotoxicity. Metabolic characterization of the HepG2 cell line 
was needed as confl icting results were reported about their metabolic capacities. We 
characterized the HepG2 cell line thoroughly under our culture conditions. The levels of 
CYP1A1, 1A2, 2B6, 2C9, 2D6, 2E1 and 3A4, NAT1 and EPHX1 in HepG2 cells were 
compared with the levels in primary human hepatocytes. Furthermore, their expression 
and enzyme activities after activation of the xenobiotic receptors AhR, PXR, CAR were 
measured. 
In Chapter 4, the focus is on the characterization of HepG2 phase II metabolism. 
The expression levels and enzyme activities of several UGTs, SULTs, GSTs, NAT1 
and EPHX1 were studied and compared to the levels in primary human hepatocytes. 
Moreover, the expression and enzyme activities after activation of the xenobiotic 
receptors AhR, PXR, CAR were assessed. 
Chapter 5 describes the development of a high-throughput micronucleus assay in 
HepG2 and CHO-k1 cells by using high content screening. These high content screening 
micronucleus assays in CHO-k1 and HepG2 cells were validated with 62 compounds 
from an ECVAM compound list and 16 additional genotoxic reference compounds. The 
sensitivity and specifi city of HepG2 and CHO-k1 cells were compared. 
In Chapter 6 gene expression profi ling in HepG2 cels was used to fi nd genes and 
responsive elements that can assess the genotoxic potential of compounds and discriminate 
genotoxic carcinogens from non-genotoxic liver toxicants.
Based on the HepG2 toxicogenomics data and data from literature four mechanism-
based HepG2 luciferase reporters assays were developed (Chapter 7). The promoter 
regions of RAD51C and cystatin A, as well as the responsive element of the p53 protein, 
were used. In addition, a luciferase based reporter assay was generated that measures the 
activation of the Nrf2 oxidative stress pathway. The assays were thoroughly validated 
with 62 reference compounds described by the ECVAM and an additional set of 192 
compounds.
In Chapter 8 the focus is on non-genotoxic carcinogenicity that is related to activation 
of the AhR receptor. Species differences between activation of the rat and human AhR 
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were studied. 
Finally the thesis is concluded with a summary, discussion, conclusion, and additional 
considerations in Chapter 9.
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Abstract
The VitotoxTM and RadarScreen assays were evaluated as early screens for bacterial 
mutagenicity and in vitro mammalian genotoxicity, respectively. The VitotoxTM assay is 
a bacterial reporter assay in Salmonella typhimurium based on the SOS response, and it 
contains a luciferase gene under control of the recN promoter. The RadarScreen assay is 
a RAD54 promoter-linked β-galactosidase reporter assay in yeast. 
Recently an ECVAM workgroup defi ned a list of 20 genotoxic and 42 non-genotoxic 
compounds [Mutat. Res 653 (2008) 99-108], that can be used for the validation and/
or optimization of in vitro genotoxicity assays. In the present study, this compound set 
was used for the validation of the assays. Moreover, an additional set of 192 compounds 
was used to broaden this validation study. The compounds of this additional set can be 
classifi ed as non-genotoxins and genotoxins and consists of both in-house and reference 
compounds. In case of the ECVAM compound list, the results from the VitotoxTM and 
RadarScreen assays were compared to the genotoxic/non-genotoxic classifi cation of 
the compounds in this list. In case of the additionally tested compounds, the results 
of the VitotoxTM and RadarScreen assays were compared, respectively, to bacterial 
mutagenicity (Ames) or in vitro mammalian genotoxicity data obtained in-house or 
from the literature. 
The validation with respect to the ECVAM compound list resulted in a sensitivity 
for both the VitotoxTM and RadarScreen assay of 70% (14/20). If both assays were 
combined the sensitivity increased to 85% (17/20). Both tests also gave a low number of 
false positive results. The specifi city of the VitotoxTM and RadarScreen assay was 93% 
(39/42) and 83% (35/42), respectively. This resulted in a predictivity of the VitotoxTM 
and RadarScreen assay of 85% (53/62) and 79% (49/62), respectively. In case both tests 
were combined the specifi city and the predictivity of the VitotoxTM and RadarScreen 
assay appeared 81% (34/42) and 82% (51/62), respectively. 
The results from the additional list of 192 compounds confi rmed the results found 
with the ECVAM compound list. The results from the VitotoxTM assay showed a high 
correlation with Ames results of 91% (132/145). Subsequently, the RadarScreen assay 
had a correlation with in vitro mammalian genotoxicity of 76% (93/123). The specifi city 
of the VitotoxTM assay was 94% (90/96) for Ames results and that of the RadarScreen assay 
was 74% (34/46) for in vitro mammalian genotoxicity. Moreover, the sensitivity of the 
VitotoxTM and RadarScreen assays were 86% (42/49) and 77% (59/77), respectively.
Implementation of the VitotoxTM and RadarScreen assays in the early research phase 
of drug development can lead to fast deselection for genotoxicity. It is expected that 
this application will reduce the number of compounds that have a positive score in the 
regulatory Ames and in vitro mammalian genotoxicity tests. 
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Introduction
Screening on genotoxicity and immediate deselection of genotoxic compounds in the 
early research phase of drug development can improve the success rate of new chemical 
entities. In the early research phase, medium- or high-throughput toxicity assays are a 
prerequisite as the number of compounds is high while the available amount of compound 
is limited. 
The regulatory genotoxicity tests like the Ames, micronucleus (MN), chromosome 
aberration (CA), mouse lymphoma assay (MLA), and sister chromatid exchange (SCE) 
tests are all relatively time-consuming and laborious and therefore, at least in their 
present format less applicable as an early screen.
The VitotoxTM and RadarScreen are two simple assays that may be useful for early 
genotoxicity screening. The VitotoxTM assay is a bacterial reporter assay based on the 
SOS response system; it contains a luciferase gene under control of the recN promoter 
[1]. Normally, this recN promoter is strongly repressed, but in the presence of a DNA-
damaging genotoxic compound, the RecA regulator protein recognizes the resultant free 
ends or mismatches in DNA. This initiates a cascade of reactions known as the SOS 
response that cleaves the LexA repressor and de-represses the strong recN promoter, 
which leads to an increased luciferase expression. This increase can be quantifi ed by 
measurement of luminescence after addition of luciferin. 
The results from the VitotoxTM assay correlate good with results from the Ames test 
[2]. Furthermore, for many compounds the lowest effective concentration (LEC) in the 
VitotoxTM assay was 5-100 times lower than the LEC measured in the Ames test [2]. This 
higher sensitivity for several compounds may be explained by the fact that induction of 
DNA repair already occurs at lower compound concentrations than fi xation of a mutation. 
Furthermore, the Ames assay measures only one specifi c mutation per strain.
The principle of using the induction of the SOS response in bacteria as a measure for 
Ames positive results has been used in several assays. Several genes playing a role in 
the SOS response were used as reporter genes. The SOS chromotest which is one of 
the best known of these assays has been validated in several studies [3-5]. One of the 
largest validation studies was performed by Mersch-Sundermann et al. [3], who tested 
a set of 330 chemicals. The predictivity of the SOS chromotest for the Ames test was 
86.4% in this study (sensitivity, 78.6%; specifi city, 100%). These results showed that the 
induction of the SOS response might be a good predictor for Ames results. This was the 
reason that the VitotoxTM assay was evaluated as an early screen to detect Ames-positive 
compounds.
The RadarScreen assay is based on yeast strain SKAM4 that contains a RAD54 
β-galactosidase reporter construct (reMYND, Leuven, Belgium). This β-galactosidase 
gene is under the transcriptional control of the RAD54 promoter and is expressed after 
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DNA damage to repair double-strand breaks by homologous recombination [6, 7]. 
Compounds supplied to the growth medium can therefore be evaluated for genotoxicity 
by determining their effect on reporter gene expression. The quantity of β-galactosidase 
can be measured easily by the addition of its specifi c substrate D-luciferin-o-β-
galactopyranoside (Promega, Madison, USA), which is cleaved into galactose and 
luciferin. The latter product can be measured luminometrically. The advantage of 
yeast compared with bacteria, is that clastogenic and aneugenic compounds causing 
chromosome aberrations, micronuclei formation and improper chromatid exchange may 
also be detected. The RAD54 promoter is also used in the GreenScreen assay from 
Gentronix [8, 9]. This GreenScreen assay is quite similar to the RadarScreen assay, 
however, it has a different read-out system with a Green Fluorescent Protein (GFP) 
gene under control of the RAD54 promoter. The advantage of the RadarScreen over 
the use of the GreenScreen assay is the sensitive read-out of luminescence. This even 
makes the use of S9 mixture for metabolic activation in a medium- or high-throughput 
assay setup possible. Furthermore, many (pharmaceutical) compounds can cause 
autofl uorescence and may interfere with the GFP measurement. Approximately 25% of 
the in-house compounds were missed due to these effects [10]. This can be prevented 
with a luminescent read-out.
A big concern with in vitro genotoxicity assays is the high number of (irrelevant) 
positive results compared with the in vivo results. For this reason the European Centre 
for the Validation of Alternative Methods (ECVAM) recently published a list of 62 
compounds that can be used for the validation/optimization of (new) in vitro genotoxicity 
tests [11]. Based on the available data, the compounds were defi ned by an expert panel 
as genotoxic or non-genotoxic. The list of compounds was divided into 20 genotoxic 
and 42 non-genotoxic compounds. The latter group also contained 19 non-genotoxic 
compounds that often give false positive results in in vitro genotoxicity assays. In 
the present validation study the compounds of this ECVAM list were tested. Also an 
additional set of 192 compounds was tested to broaden the study in order to obtain a higher 
comfort level. The compounds in this additional set can be classifi ed as non-genotoxins 
or genotoxins, and consisted of both in-house and reference compounds. The genotoxins 
acted via diverse mechanisms and belong to the direct-acting genotoxins (i.e. methyl 
methane sulfonate (MMS) and 4-nitroquinolin-1-oxide (4NQO), cross-linking agents 
(e.g. cisplatin), topoisomerase inhibitors (e.g. doxorubicin and ellipticin), nucleotide/
DNA synthesis inhibitors (i.e. 5-fl uorouracil and methotrexate), reactive oxygen species 
generators (i.e. hydrogen peroxide) and aneugens (i.e. colchicine). Furthermore the 
compound list contains several steroidal compounds which have been reported as being 
positive in in vitro mammalian genotoxicity tests [12].
In case of the ECVAM compound list the results from the VitotoxTM and RadarScreen 
assays were compared to the genotoxic/non-genotoxic classifi cation of the compounds 
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in this list. In case of the additionally tested compounds, the results of the VitotoxTM 
assay were compared with Ames scores. Subsequently, the results from the RadarScreen 
assay were compared with in vitro mammalian genotoxicity data obtained in-house or 
from the literature. These two comparisons were performed as the VitotoxTM assay is a 
pre-screen for bacterial mutagenicity (Ames test) and the RadarScreen assay is a pre-
screen for in vitro mammalian genotoxicity.
Materials and methods
Preparation of compound solutions 
Stock solutions of the reference and test compounds were freshly prepared in 100% 
dimethyl sulfoxide (DMSO). From the stocks, √10-fold dilution series were prepared 
in DMSO. All compounds were of analytical grade and ordered from Sigma-Aldrich or 
synthesized in-house. 
VitotoxTM assay
The VitotoxTM assay kit was purchased from Thermo Electron Corporation (Vantaa, 
Finland) and handled according to the manufacturer’s manual. Bacteria from the recN2-4 
strain, used for the induction of SOS repair, and the pr1 strain, used for cytotoxicity 
measurement, were grown overnight. Cultured bacteria were used when the optical-
density measurements at 595 nm (OD595) of the recN2-4 and pr1 strains were between 
0.2-0.5 and 0.4-0.6, respectively. When the densities were below these values the culture 
time was prolonged. After reaching the optimal densities, recN2-4 and pr1 cultures 
were diluted 10- and 2-fold with growth medium and water, respectively. For metabolic 
activation of the test compounds S9 mixture was added (V:V, 1:10) to this growth 
medium. S9 mixture consisted of 2.5% liver-S9 homogenate from Aroclor induced 
Wistar rats (NOTOX, ‘s-Hertogenbosch, The Netherlands), 15.2 mM KCl, 4.28 mM 
MgCl2, 1.86 mM β-NADP, 9.29 mM glucose 6-phosphate, and 93 mM phosphate buffer 
pH 7.4. The assay was carried out in white 384-well plates (Perkin-Elmer, Groningen, 
The Netherlands). To the plates 9 μl of compound solution was added leading to a 
fi nal concentration of DMSO in the well of 0.1 or 1%. Next 81 μl diluted recN2-4 or 
pr1 culture solution in the absence or presence of S9 mixture was added. Plates were 
sealed and the luminescence was read on the Victor II (Perkin-Elmer, Groningen, The 
Netherlands) at 26 ºC every 5 min for a period of 3 h. 
After completion of the assay the signal-to-noise ratio (S/N) of each measurement was 
calculated, i.e. the luminescence of exposed bacteria divided by the luminescence of 
DMSO treated bacteria. Values measured during the fi rst 45 min were not used since a 
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SOS response can not occur that quickly. A compound was considered to be genotoxic 
when the S/N ratio of the recN2-4 strain was greater than 1.3 and the S/N ratio of 
the recN2-4 strain divided by the S/N ratio of the pr1 strain was greater than 1.5. The 
highest test concentration in the VitotoxTM assay was limited at 0.1 mM, unless indicated 
otherwise.
RadarScreen assay
Yeast was grown overnight and thereafter the OD595 was measured. The yeast 
suspension was diluted with growth medium to an OD595 of 0.5. For testing with 
metabolic activation, the S9 mixture was prepared as described for the VitotoxTM assay, 
however, in case of the RadarScreen assay the fi nal concentration S9-liver fraction was 
2%. It is of practical importance that S9 mixture is mixed with the yeast suspension in 
advance of the addition to the wells. The assay was carried out in white and transparent 
96-well plates (Perkin-Elmer). A volume of 10 μl compound solution was added leading 
to a fi nal concentration of 1% DMSO in the assay. Subsequently, 90 μl of the yeast 
suspension in the presence or absence of S9 mixture was added. Plates were incubated 
for 6 h at 30 ºC. After the incubation period the absorbance was measured at 590 nm in 
the transparant plates with the Victor II. The decrease in the OD values of 1 mM MMS 
was set as 100% cytotoxicity, because almost all cells were killed at this concentration. 
The cytotoxicity of all other compounds was calculated relatively to MMS. In addition, 
blank plates containing yeast medium and only the compound concentrations similar to 
those in the test plates were checked for precipitation by visual inspection.
A volume of 50 μl Beta-Glo substrate (Promega, Madison, USA) was added to the 
plates. This β-galactosidase substrate is cleaved by β-galactosidase into galactose and 
luciferin. The luciferin is subsequently utilized by fi refl y luciferase to generate light. 
After addition of this substrate the plates were shaken for 45-60 minutes to allow cell 
lysis. Then the luminescence was measured on the Victor II. A compound was considered 
to be genotoxic when the response was induced by a factor 1.5 (50% increase=5.4 times 
the standard deviation of the background). Background means here yeast cells treated 
with 1% DMSO. In total 120 untreated controls were used to assess this value (derived 
from 10 independent experiments). The highest test concentration in this assay was 
1 mM. This top dose is the same as the recommended top dose for the regulatory in 
vitro mammalian genotoxicity (clastogenicity) tests. Two aspects that can cause false 
positive results are cytotoxicity and precipitation. Therefore, it was decided to discard 
measurements showing precipitation or more than 80% cytotoxicity.     
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Calculations
Compounds that are positive in the VitotoxTM or RadarScreen assay can show a positive 
(‘A’) or negative results in a second test (‘B’). Similarly, compounds with a negative 
score in the VitotoxTM or RadarScreen assay can give a positive (‘C’) or negative (‘D’) 
score in a second test. The second test that is used for a comparison gives A+C positive 
scores and B+D negative scores. By using these values the sensitivity, specifi city and 
predictivity can be calculated: sensitivity = A/(A+C); specifi city = D/(B+D); predictivity/
correlation = (A+D)/(A+B+C+D). 
In case of the ECVAM compound list, the results from the VitotoxTM and RadarScreen 
assay were compared to the (in vivo) genotoxic/non-genotoxic classifi cation of the 
compounds. In case of the additional list of compounds the results of the VitotoxTM 
and RadarScreen assay were respectively compared to the available Ames or in vitro 
mammalian genotoxicity data from in-house or from literature. In case the results 
from the screening tests were inconsistent with the results from the Ames or in vitro 
mammalian genotoxicity tests these results were called ‘false positive’ or ‘false negative’. 
A compound with one positive score in an in vitro mammalian genotoxicity assay was 
defi ned as positive (genotoxic). Compounds with inconsistent Ames data were discarded 
from the calculations. 
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Results 
Validation of the assay procedure with reference compounds and reproducibility of 
the assay method
4-Nitroquinoline-1-oxide (4NQO) and benzo[a]pyrene (B[a]P) were used as positive 
controls in the VitotoxTM assay. The concentration-dependent response is shown in 
Figure 1. As expected, the direct-acting genotoxin 4NQO showed a concentration-
related induction of the luminescence in the absence of S9 mixture. However, due to 
cytotoxicity the SOS response started later for 4NQO at a concentration of 10-4 M. In the 
presence of S9 mixture the genotoxic activity was decreased (detoxifi cation). However, 
at higher concentrations activation of the SOS response was visible again. In the absence 
of S9 mixture B[a]P showed no enhancement of the luminescence. B[a]P was activated 
by the addition of S9 mixture and showed a concentration-dependent increase in the 
induction of the luminescence. 
Figure 1. Concentration-dependent genotoxicity of 4-nitroquinoline-1-oxide (4NQO) and benzo[a]
pyrene (B[a]P) in the VitotoxTM assay in the absence and presence of S9 mixture. Compounds were 
tested in 20 independently performed experiments. A representative curve is shown.
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Figure 2. Concentration dependent genotoxicity of benzo[a]pyrene (B[a]P), cisplatin, doxorubicin, 
methyl methanesulfonate (MMS) and 4-nitroquinoline-1-oxide (4NQO) in the RadarScreen assay in the 
absence and presence of S9 mixture. Compounds were tested at least in two independently performed 
experiments. A representative curve is shown. The dashed line represents the genotoxicity threshold.
MMS and B[a]P were used as positive controls in the RadarScreen assay. The 
concentration-dependent response of these two positive controls and a representative set 
of 3 other genotoxins being cisplatin, doxorubicin and 4NQO are shown in Figure 2. The 
compounds were tested in at least two independent experiments. B[a]P already showed a 
genotoxic effect in the absence of S9 mixture. However, this effect was only seen at very 
high concentrations as the LEC was 10-3 M. At this concentration an induction of the 
luminescence of 1.8-fold was observed. As expected, the addition of S9 mixture resulted 
in metabolic activation of B[a]P. In the presence of S9 mixture the LEC was 3.16x10-6 M 
and a maximum induction of 2.6-fold was observed at a concentration of 3.16x10-5 M.
Cisplatin showed the largest activity in the absence of S9 mixture. The LEC of cisplatin 
was 3.16x10-5 M in the absence of S9 mixture and 1.00x10-3 M in the presence of S9 
mixture. Doxorubicin only showed activity at the highest test dose of 1.00x10-3 M in 
the absence of S9 mixture. MMS showed activity in the presence and absence of S9 
mixture, but the largest activity was shown in the absence of S9 mixture with a LEC of 
10-5 M. Likewise, 4NQO showed the highest activity in the absence of S9 mixture. In 
absence of S9 mixture the LEC was ≤ 10-6 M and after the addition of S9 mixture the 
LEC increased to 3.16x10-5 M. At the highest test concentrations the luminescent signal 
showed a steep decrease due to the cytotoxic effect of 4NQO.
To show the reproducibility of the RadarScreen assay, MMS and B[a]P were tested 
in nine independent experiments (Figure 3). Without S9 mixture MMS had a LEC 
of 3.16x10-6 M in six experiments. In the remaining three experiments the LEC was 
1.00x10-5 M. In the presence of S9 mixture, MMS was less genotoxic and the variation 
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in the LEC was larger. The LEC was 3.16x10-5 M in two experiments, 1.00x10-4 M in 
two experiments, 3.16x10-4 M in three experiments, and 1.00x10-3 M in two experiments. 
The results observed for B[a]P showed a high reproducibility. Without S9 mixture B[a]
P had a LEC of 3.16x10-4 M in eight experiments. Only in one experiment the LEC 
was 1.00x10-3 M. In the presence of S9 mixture B[a]P was activated and the LEC was 
3.16x10-6 M in seven experiments and 1.00x10-5 M in two experiments. The experiments 
with these two reference compounds give a fi rst indication that the reproducibility of the 
RadarScreen assay is good. 
The reproducibility of the cytotoxicity measurement in the RadarScreen was also tested. 
In nine independently performed experiments, the cytotoxicity of MMS was assessed 
in the absence and presence of S9 mixture. The high reproducibility of this method is 
shown in Figure 4. The highest test concentration of MMS kills almost all yeast cells 
and reduces the OD590 in all experiments almost to the background level (wells with 
culture medium and 1% DMSO). The toxicity of the other compounds was calculated 
relatively to the toxicity of 1.00x10-3 M MMS, which was set at a toxicity of 100%
Figure 3. The reproducibility of the concentration-dependent genotoxicity of methyl methanesulfonate 
(MMS) and benzo[a]pyrene in the RadarScreen assay in the absence and presence of S9 mixture in nine 
independently performed experiments. The dashed line represents the genotoxicity threshold.
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Figure 4. The reproducibility of the concentration dependent cytotoxicity of methyl methanesulfonate 
(MMS) in the RadarScreen assay in the absence and presence of S9 mixture in nine independently 
performed experiments. The dashed line represents the background. The lowest concentration in the 
curves represents the control (yeast + 1% DMSO).
Validation of the VitotoxTM and RadarScreen assays with respect to the ECVAM 
compound list
The effects of the 62 ECVAM compounds were tested in the VitotoxTM and RadarScreen 
assay. The overall results are shown in Tables 1-3. 
The sensitivity, specifi city and predictivity of the two single tests and the combination 
of these tests were calculated (Table 4). The sensitivity to detect genotoxic compounds 
was 70% (14/20) for both the VitotoxTM and RadarScreen assay. When results from both 
tests were combined the sensitivity increased to 85% (17/20). Thereby the tests detect a 
different but overlapping set of compounds. Sodium arsenite, taxol and chloramphenicol 
were not detected with both assays (Table 1).
Both tests have a high specifi city of more than 83% which means that the number 
of false positives in both tests is low. The number of false positive results slightly 
increased after combining the tests, however, the specifi city still remains high with 81% 
(34/42). Of the 19 compounds that give often false positive results only four (tertiary-
butylhydroquinone, curcumin, sodium xylene sulfonate and 2,4-dichlorophenol) and 
two (tertiary-butylhydroquinone and 2,4-dichlorophenol) compounds gave a positive 
score in the RadarScreen and VitotoxTM assays, respectively. Of the non-DNA reactive 
chemicals that have not been reported to give positive results in vitro (23 compounds), 
ampicillin trihydrate, progesterone and hexachloroethane gave a positive result in the 
RadarScreen assay. In the VitotoxTM assay only phenanthrene gave a positive result. The 
overall predictivity of both tests for genotoxicity is 82% (51/62), while these values were 
85% (53/62) and 79% (49/62) for the VitotoxTM and RadarScreen assay, respectively.
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Validation of the VitotoxTM and RadarScreen assays with respect to the additional set 
of 192 compounds
Besides the compounds from the ECVAM list, the assays were further validated with an 
additional set of 192 compounds. The data set was not complete for all the compounds. 
Ames data were available for 145 compounds and in vitro mammalian genotoxicity 
data for 124 compounds. The results from the VitotoxTM and RadarScreen assays and 
additional genotoxicity data that were available for these compounds are shown in Tables 
5 and 6. From the in-house prepared compounds the Org codes and chemical names are 
summarized in Table 7.
As the VitotoxTM assay is meant as a pre-screen for the Ames assay, the results from 
this test were compared to Ames results. The sensitivity, specifi city and predictivity/
correlation of the VitotoxTM results for Ames scores were calculated (Table 8). The 
RadarScreen is a pre-screen for in vitro mammalian genotoxicity (chromosome damage). 
Therefore the sensitivity, specifi city and predictivity/correlation of the RadarScreen 
results for in vitro mammalian genotoxicity scores were calculated (Table 8).
Table 2. Results from the VitotoxTM and RadarScreen assays regarding the ECVAM compounds that 
were defi ned as non-DNA-reactive chemicals (including non-genotoxic carcinogens), metabolic poisons 
and others that should give negative results in in vitro genotoxicity tests but have been reported to induce 
chromosomal aberrations or tk mutations in mouse lymphoma cells, often at high concentrations or at 
high levels of cytotoxicity. The false positive results are indicated in bold.
Chemical CAS 
number
VitotoxTM LEC 
(mol/l)
Radar-
Screen
LEC
(mol/l)
I. Non-carcinogens that are negative or equivocal for genotoxicity in vivo  
D,L-menthol 15356-70-4 N N
Phthalic anhydride 85-44-9 N N
Tertiary-butylhydroquinone 1948-33-0 Y(S9) 3.16x10-6 Y(S9)a 3.16x10-6
o-Anthranilic acid 118-92-3 N N
1,3-Dihydroxybenzene (resorcinol) 108-46-3 N N
2-Ethyl-1,3-hexanediol 94-96-2 N N
Sulfi soxazole 127-69-5 N N
II. Non-carcinogens with no in vivo genotoxicity data   
Ethionamide 536-33-4 N N
Curcumin 458-37-7 N Y 1.00x10-5
Benzyl alcohol 100-51-6 N N
Urea 57-13-6 N N
II. Non-genotoxic carcinogens or carcinogenic by irrelevant (for humans) mechanism  
Sodium saccharin 128-44-9 N N
IV. Supplementary list (prediction of in vitro genotoxicity results less clear)  
Propyl gallate 121-79-9 N N
p-Nitrophenol 100-02-7 N N
Sodium xylene sulfonate 1300-72-7 N Y 1.00x10-3
Ethyl acrylate 140-88-5 N N
Eugenol 97-53-0 N N
Isobutyraldehyde 78-84-2 N N
2,4-Dichlorophenol 120-83-2 Y 1.00x10-4 Y 3.16x10-4
a Compounds that are activated by S9 mixture but already show some activity without the addition of 
S9 mixture.
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Table 4. Results from the VitotoxTM and RadarScreen validation with respect to the ECVAM 
compound list.
VitotoxTM (%) RadarScreen (%) VitotoxTM + RadarScreen (%) N
Sensitivity 70 (14/20) 70 (14/20) 85 (17/20) 20
Specifi city 93 (39/42) 83 (35/42) 81 (34/42) 42
Predictivity 85 (53/62) 79 (49/62) 82 (51/62) 62
Table 3. Results from the VitotoxTM and RadarScreen assays regarding the ECVAM compounds that 
were defi ned as non-DNA-reactive chemicals (including non-genotoxic carcinogens).The false-positive 
results are indicated in bold.
Chemical CAS 
number
VitotoxTM LEC
(mol/l)
Radar
Screen
LEC 
(mol/l)
I. Non-carcinogens with negative in vivo genotoxicity data
Ampicillin trihydrate 7177-48-2 N Y(S9) 1.00x10-3
D-mannitol 69-65-8 N N
II. Non-carcinogens with no in vivo genotoxicity data
Phenformin HCl 834-28-6 N N
n-Butyl chloride 109-69-3 N N
(2-Chloroethyl)trimethyl-ammonium chloride 999-81-5 N N
Cyclohexanone 108-94-1 N N
N,N-dicyclohexyl thiourea 1212-29-9 N N
Trisodium EDTA trihydrate 150-38-9 N N
Ephidrine sulphate 134-72-5 N N
Erythromycin stearate 643-22-1 N N
Fluometron 2164-17-2 N N
Phenanthrene 85-01-8 Y(S9)a 3.16x10-6 N
III. Non-genotoxic carcinogens
D-limonene 5989-27-5 N N
Di-(2-ethylhexyl)phthalate 117-81-7 N N
Amitrole 61-82-5 N N
Tert-butyl alcohol 75-65-0 N N
Diethanolamine 111-42-2 N N
Melamine 108-78-1 N N
Methyl carbamate 598-55-0 N N
Progesterone 57-83-0 N Y 3.16x10-6
Pyridine 110-86-1 N N
Tris(2-ethylhexyl)phosphate 78-42-2 N N
Hexachloroethane 67-72-1 N Y 3.16x10-4
a Compounds that are activated by S9 mixture but already show some activity without the addition of 
S9 mixture.
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Table 7. Overview of the in-house compound codes and the corresponding chemical names.
Org code Chemical name
CERM 
11884
N-(2,6-Dimethylphenyl)-beta-[(2-methylpropoxy)methyl]-N-(phenylmethyl)-1-pyrrolidineethanamine 
hydrochloride
CERM 
13061
trans-D,L-N-(1,3-Benzodioxol-5-yl)-2-[(cyclohexyloxy)methyl]-1-methyl-N-(phenylmethyl)-3-
piperidinamine hydrochloride(1:1) salt
Org 10325 N-Hydroxy-5,6-dimethoxy-1H-indene-2-carboximidamide hydrochloride
Org 10490 6,7,8,9-Tetrahydro-7-methyl-5H-dibenz[b,i][1,6]oxazecine(Z)-2-butenedioate (1:1)
Org 13011 1-[4-[4-[4-(Trifl uoromethyl)-2-pyridinyl]-1-piperazinyl]butyl]-2-pyrrolidinone(E)-2-butenedioate (1:1)
Org 20091 5-Chloro-4-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-2-thiazolamine(E)-2-butenedioate (2:1)salt
Org 20223 2-Amino-N-(2-phenylethyl)-N-propyl-5-thiazoleethanamine (E)-2-butenedioate (1:1)salt
Org 20241 N-Hydroxy-4-(3,4-dimethoxyphenyl)-2-thiazolecarboximidamide
Org 20350 4-(1-Butyl-1,2,5,6-tetrahydro-3-pyridinyl)-5-chloro-2-thiazolamine(Z)-2-butenedioate (1:1) salt
Org 20494 4,5-Dihydro-5-methyl-6-[6-[2-(1-piperidinyl)ethoxy]benzo[b]thien-2-yl]-3(2H)-
pyridazinonehydrochloride
Org 20660 2-Chloro-11-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)dibenzo[b,f][1,4]thiazepine (E)-2-
butenedioate (1:1) salt
Org 2249 2,3,9,13b-Tetrahydro-2-methyl-1H-dibenz[c,f]imidazo[1,5-a]azepine
Org 2408 1,2,3,4,10,14b-hexahydro-2,7-dimethyldibenzo(c,f)pyrazino(1,2-a)azepine^(z)-2-butenedioate (1:1)
Org 2508 1-(n-hydroxyamidino)-benzocyclobutenehydrochloride
Org 30002 5,6,7,8-Tetrahydro-6-methyldibenz[b,h][1,5]oxazonine hydrochloride hemihydrate
Org 30029 N-Hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamide hydrochloride
Org 30189 1-[2-Chloro-3-(2-methylpropoxy)propyl]pyrrolidinemonohydrochloride
Org 30251 2,3,4,5,6,7-Hexahydro-N-hydroxy-1H-benz[e]indene-2-carboximidamide hydrochloride
Org 30535 cis-1,2,3,12b-Tetrahydro-2,7-dimethyl-3aH-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-3a-ol 
Z)-2-butenedioate (1:1)
Org 30701 1-[1-[(2-Methylpropoxy)methyl]-2-[[1-(1-propynyl)cyclohexyl]oxy]ethyl]pyrrolidinehydrochloride
Org 31710 (6beta,11beta,17beta)-11-[4-(Dimethylamino)phenyl]-4’,5’-dihydro-6-methylspiro[estra-
4,9-diene-17,2’(3’H)-furan]-3-one 
Org 32018 1-[2-(Phenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride
Org 3240 n-hydroxy-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-triene-7-carboximidamide^hydrochloride
Org 32608 2-[2-(4-Chlorophenoxy)phenyl]-4,5-dihydro-1H-imidazole[Z]-2-butenedioate (1:1)
Org 32782 2-(3,4-Dichlorophenoxy)benzenemethanaminehydrochloride
Org 3362 n-hydroxy-3,5-dimethylbicyclo(4.2.0)octa-1,3,5-triene-7-carboximidamide^hydrochloride
Org 34037 R(-)-6-(4-Chlorophenyl)-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinoline(E)-2-
butenenedioate (1:1) salt
Org 34694 (7alpha,11E,17alpha)-11-Ethylidene-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one 
Org 34850 (11beta,17alpha)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-21-[4-(methylsulfonyl)phenyl]-19-
norpregna-4,9-dien-20-yn-3-one
Org 34901 (11beta,17alpha)-17-Hydroxy-3-oxo-11-(1-propynyl)-19-norchola-4,20-dien-24-oicacid deltalactone 
Org 37445 (3alpha,11beta,17alpha)-11-(2-Propenyl)-19-norpregn-5(10)-en-20-yne-3,17-diol 
Org 39735 (7alpha,17beta)-7-Ethyl-17-hydroxyestra-4,14-dien-3-one 
Org 4060 (11beta,17alpha)-11-Ethyl-17-hydroxy-19-norpregn-4-en-20-yn-3-one 
Org 4122 N-Hydroxy-3,4-dimethoxybenzenepropanamide
Org 42671 2,8-dihydroxy-10 chloro-11H-[b]-benzofl uorene
Org 42788 (3alpha,7alpha,11beta,16alpha,17alpha)-7,11,16-Trimethyl-19-nor^pregn-5(10)-en-20-yne-3,17-diol 
Org 4330 n-hydroxy-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-triene-7-carboxamide
Org 4428 cis-1,3,4,13b-Tetrahydro-2,10-dimethyldibenz[2,3:6,7]oxepino[4,5-c]pyridin-4a(2H)-ol
Org 4433 (11beta,17alpha)-11-Ethynyl-17-hydroxy-19-norpregn-4-en-20-yn-3-one 
Org 4874 n,3,4-trimethoxybenzenepropanamide
Org 5168 3a,4,9,9a-Tetrahydro-6,7-dimethoxy-1H-benz[f]isoindole-1,3(2H)-dione
Org 5694 N-(Acetyloxy)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamide
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Table 7. Continued
Validation of the VitotoxTM assay against Ames results
The results from the VitotoxTM assay were compared to the Ames data obtained from 
in-house experiments or from the literature (Table 8). This resulted in a sensitivity of 
86% (42/49). The number of false positive results was low, as only six compounds were 
identifi ed, which leads to a specifi city of 94% (90/96). The correlation of the VitotoxTM 
assay with respect to Ames results was 91% (132/145).
The false positive and false negative results are summarized in Table 9. Of the six 
false positive compounds fi ve compounds were also positive in the RadarScreen assay. 
Furthermore, three of these compounds being chlorpromazine HCl, Org 30029 and Org 
30251 gave a positive result for in vitro mammalian genotoxicity. This means that the 
number of irrelevant positive results is even lower than the six compounds and is in the 
range of 1-3 out of 145 compounds.
For two of the fi ve false negative compounds, cyclophosphamide and melphalan, 
it is known that a SOS response is not activated in Salmonella [4, 13]. For the other 
compounds no clear explanation can be given for the negative result. Overall, the results 
suggest that the VitotoxTM assay is an early screening tool that predicts Ames results very 
well. Moreover, several compounds that were positive in the RadarScreen and/or in in 
vitro mammalian genotoxicity assays were detected in the VitotoxTM assay.
      Org code Chemical name
Org 5695 3,4-Dimethoxy-N-[[(methylamino)carbonyl]oxy]bicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamide
Org 5697 3-(3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)-5-(trifl uoromethyl)-1,2,4-oxadiazole
Org 5710 N,N’-Dihydroxy-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamide
Org 5741 N-Hydroxy-3,4-dimethoxy-N-methylbicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamide hydrochloride
Org 5784 N-Hydroxy-3,4-dimethoxy-N’-methylbicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamidehydrochloride
Org 5796 N-Hydroxy-3,4-dimethoxy-7-methylbicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamide (Z)-2-
butenedioate
Org 5867 N,3,4-Trimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboximidamide hydrochloride
Org 5907 cis-N-Hydroxy-3,4-dimethoxy-8-methylbicyclo[4.2.0]octa-1,3,5-triene-7-
carboximidamidehydrochloride
Org 7258 2-(4-Chlorophenyl)-4-phenyl-1H-indene-1,3(2H)-dione
Org 7797 (16alpha,17beta)-17-(Methylamino)estra-1,3,5(10)-triene-3,16-diol(Z)-2-butenedioate
Org 9063 3,4-Dihydro-N-hydroxy-6,7-dimethoxy-2-naphthalenecarboximidamide hydrochloride(1:1)salt
Org 9150 3-(5,6-Dimethoxy-1H-inden-2-yl)-2-propenenitrile
Org 9217 (E)-N-Hydroxy-3-(5,6-dimethoxy-2-benzofuranyl)-2-propenimidamidehydrochloride
Org 9250 Sodium 5,6-dimethoxy-N-hydroxybenzo[b]thiophene-2-carboxamidemonohydrate
Org 9252 4-Chloro-N-hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamidehydrochloride
Org 9340 DL-(1alpha,2beta,4alpha)-4-([1,1’-Biphenyl]-4-ylmethyl)-2-[(1,1-dimethylethyl)amino]
cyclohexanolmethanesulfonate (1:1) salt
Org 9935 4,5-Dihydro-6-(5,6-dimethoxybenzo[b]thien-2-yl)-5-methyl-3(2H)-pyridazinone
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Validation of the RadarScreen assay against in vitro mammalian genotoxicity tests (in 
vitro SCE, chromosome aberration and micronucleus tests)
The RadarScreen assay was evaluated as a pre-screen for chromosome damage by 
comparing the results with the in vitro mammalian genotoxicity data that were available 
for the additional set of 192 compounds. The sensitivity, specifi city and correlations are 
presented in Table 8. The sensitivity was 77% (59/77), the specifi city 74% (34/46), and 
the correlation 76% (93/123). The compounds that had a false positive or false negative 
result are summarized in Table 10.
 One of the false positive results, Org 7797, had clearly genotoxic properties as this 
compound was positive in the Ames and VitotoxTM assay. Org 32782 had structural 
alerts for genotoxicity, but no positive results were observed in other genotoxicity 
assays. Bishydroxycoumarin (dicumarol) induces oxidative stress which might lead to 
genotoxic effects. However, also in this case other tests did not show any genotoxicity. 
The remaining compounds with a false positive result were all steroidal compounds, 
except the anti-estrogen raloxifen. For structurally related compounds genotoxic 
potential has been reported. 
Of the false negative results bromobenzene and carbon tetrachloride are both very 
lipophylic compounds. These compounds do not dissolve properly in growth medium 
and are, therefore, in our view of doubtful value. However, these compounds were not 
skipped from analysis. Acetaminophen and dexamethasone probably show genotoxic 
effects due to an irrelevant mechanism of cytotoxicity [14]. In our assay system no 
genotoxic effect was measured. The aneugenic compound colchicine was not detected 
in the RadarScreen assay. As the aneugenic compounds taxol (ECVAM compound list) 
and noscapine HCl were also not detected in the RadarScreen assay this might suggest 
that compounds with an aneugenic mode of action are not or diffi cult to detect in the 
RadarScreen assay. Despite the structural resemblance between both anti-estrogens 
raloxifen and tamoxifen, one appeared false positive and the other false negative. Ment-
bucyclate was thought to be a false negative since bucyclate normally should induce 
clastogenicity. However, it may be that bucyclate is not formed under the conditions in 
this assay.
Table 8. Validation of the VitotoxTM and RadarScreen assays with respect to the additional set of 192 
compounds. VitotoxTM and RadarScreen results were, respectively, compared with Ames or in vitro 
mammalian genotoxicity data.
VitotoxTM-Ames RadarScreen-in vitro mammalian genotoxicity 
Score (%) N Score (%)      N
Sensitivity 86 (42/49) 49 77 (59/77)      77
Specifi city 94 (90/96) 96 74 (34/46)      46
Correlation 91 (132/145) 145 76 (93/123)      123
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Discussion
The reporter assays
There is a demand for medium- and/or high-throughput genotoxicity tests that can 
be used for the risk assessment of genotoxicity in the early research phase of drug 
development. These tests should have a high-throughput and sensitivity, as well as a 
high specifi city. Ideally such a test or combination of tests should predict the Ames 
test and the occurrence of clastogenicity/aneugenicity. Drug attrition due to these two 
aspects is relatively high in the pharmaceutical industry. For example, at Organon the 
attrition rate due to a positive result in the Ames assay during the period of 1970-2003 
was 19% (internal data).
In the present study the VitotoxTM and RadarScreen assay were validated as pre-
screens for respectively bacterial mutagenicity and in vitro mammalian genotoxicity 
(chromosome damage). As this is the fi rst paper that describes the RadarScreen assay, 
experiments were performed to get a fi rst impression about the reproducibility of 
the RadarScreen assay. Experiments with the reference chemicals MMS and B[a]P 
showed that the genotoxic effects of these compounds were reproducible. Furthermore, 
the reproducibility was shown of the method that was used to assess cytotoxicity in 
the RadarScreen assay. All compounds used in the present study were tested in two 
independently performed experiments. The results from one representative experiment 
were shown in this paper. For only seven of the 254 tested compounds inconsistent 
results were found. These results also indicate that the reproducibility of this assay 
is good. The seven compounds with inconsistent results were reordered and retested. 
Based on these results a decision about the genotoxicity in the RadarScreen was made. 
Although already some experiments were performed to show the reproducibility of the 
RadarScreen assay, more work needs to be done to measure other robustness parameters, 
for example, inter-laboratory variation.
It is diffi cult to select a well-defi ned compound set for a validation study as especially 
clastogenicity (mammalian genotoxicity) data in literature are often inconsistent and 
incomplete, whereas the quality of the data is diffi cult to judge. Recently a compound 
list was published as a follow-up of an ECVAM workshop considering ways to reduce 
the number of irrelevant positive results in in vitro (mammalian) genotoxicity tests. An 
expert panel identifi ed chemicals that could be used in the evaluation of modifi ed or new 
in vitro genotoxicity assays. This ‘ECVAM compound list’ was used as a starting point 
for the validation in the present study. 
Validation of the assays with the ECVAM compound list
The results showed that both the VitotoxTM and RadarScreen tests had a sensitivity of 
70% (14/20). When both tests were combined the sensitivity increased to 85% (17/20). 
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This may indicate that the tests can detect compounds with a different mode of action. 
This is something that was expected as the VitotoxTM is a pre-screen for the Ames test 
and the RadarScreen assay is able to detect chromosome damage. 
Cyclophosphamide was negative in the VitotoxTM assay although it is positive 
in the Ames test. However, it is known that this compound does not induce a SOS 
response [4]. Furthermore, dimethylnitrosamine was negative in the Vitotox assay. This 
might be explained by the fact that this compound needs CYP2E1 for its activation 
which is only present in low amounts in rat-S9 mixture [11]. On the other hand, this 
compound was already identifi ed as positive in the RadarScreen assay in the absence 
of S9 mixture indicating that endogenous metabolism appears active in the yeast cells. 
Addition of S9 mixture increased the response of dimethylnitrosamine. The presence 
of endogenous metabolism in yeast is further supported by the fact that benzo[a]pyrene 
and cyclophosphamide are already positive in the assay in absence of S9 mixture. 
Nevertheless the activity of these compounds is signifi cantly increased after the addition 
of S9 mixture. Sodium arsenite, taxol and chloramphenicol, defi ned in the ECVAM 
compound list as genotoxic compounds, gave a negative response in the VitotoxTM as 
well as the RadarScreen assay. As these three compounds are negative (or equivocal) 
in the Ames assay it is not surprising that these compound show a negative result in the 
VitotoxTM assay. No clear explanation can be given for the negative results of sodium 
arsenite and chloramphenicol in the RadarScreen assay. Taxol is an aneugenic compound. 
The inability to detect aneugenic compounds (like taxol) with the RadarScreen assay is 
discussed later. The specifi city and the predictivity of the two tests combined was 81% 
(34/42) and 82% (51/62), respectively. These results show that both tests give only a low 
number of false positive results. 
For two of the ECVAM compounds that are in the ‘false positive group’, tertiary-
butylhydroquinone and curcumin, there is still discussion within the ECVAM working 
group whether these compounds are real genotoxic positives as these compounds give 
rise to oxidative stress which can result in DNA damage (David Kirkland, personal 
communication). In the present study tertiary-butylhydroquinone gave a positive response 
in both the VitotoxTM and RadarScreen assay. Curcumin gave a positive response in 
only the RadarScreen assay. Moving these two compounds to the list with genotoxic 
compounds would increase the overall sensitivity (+1%, 86%) and specifi city (+7%, 
88%) of the combined pre-screen.
Validation of the assays with an additional set of compounds including a large set of 
steroidal compounds
As the ECVAM compound list is relatively small, an additional set of 192 compounds 
were tested. These compounds were non-genotoxins and genotoxins with diverse 
mechanisms of action. However, for a large number of these compounds the mechanism 
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is still unknown. The compound list also included many in-house compounds from 
Organon for which genotoxicity data were available. Because a lot of steroids cause 
genotoxicity in vitro at high (non-physiological) concentrations estrogens, progestagens, 
androgens, and glucocorticoids were included in this compound list.
The Ames data from the additional list of compounds were in general very consistent 
and this facilitated a direct comparison of these data with the VitotoxTM and RadarScreen 
assay results. Diffi culties occurred with the in vitro mammalian genotoxicity data, as 
less information was available. These data were often inconsistent which made a proper 
judgment diffi cult. However, as the RadarScreen assay is a test that is meant for pre-
screening this test should detect compounds that have the ability to give a positive 
score in the regulatory genotoxicity tests. This gives the opportunity of de-selecting 
such compounds or gives time for issue resolution. Therefore, it was decided to defi ne 
compounds that have a positive score in one mammalian test as genotoxic. However, the 
goal was not to (re-) classify genotoxic/non-genotoxic compounds.
The results obtained with the additional 192 compounds showed that the VitotoxTM 
assay had a high correlation (91%; 132/145) with the Ames test results. Similar high 
correlations between SOS induction and Ames scores were found by others. Quillardet 
et al. [5] showed that 90% of Ames positive compounds were detected in the SOS 
chromotest. Von der Hude et al. [15] reported a sensitivity of SOS induction for Ames-
positive epoxides of 70%. However, the sensitivity score is dependent on the compound 
class that is considered. Vasilieva et al. [16] showed that SOS induction correlated closely 
with Ames results for phenanthrenequinones and fl uorenones. However, biphenyls that 
were positive in the Ames test did not induce the SOS response. Similar results were 
also reported by Van Gompel et al.  [9], who also showed that the sensitivity of the 
VitotoxTM assay for Ames-positive compounds is low for some compound classes. The 
specifi city, however, was for all compound classes relatively high. 
Gentaur (who now distributes the VitotoxTM test) reports that the sensitivity of the 
VitotoxTM assay for several compounds can be improved by modifi cation of the treatment 
time from 180 min to 240 min. However, such an increase in sensitivity might result in 
a decrease of the specifi city. More studies are needed to show whether it is preferred to 
increase the incubation time. 
The top dose in the VitotoxTM assay was limited at 0.1 mM. This was not the case for 
the ECVAM compound list and available Ames data for the additional 192 compounds. 
Not limiting the top dose might have resulted in a higher sensitivity but also a lower 
specifi city. The reason for using this top dose is that it was expected that the VitotoxTM 
assay was more sensitive than the Ames assay (with exception of some compound classes 
that bypass the SOS response). 
In the present study also steroidal compounds were tested. Many of these steroids have 
been reported to show genotoxicity. However, only for catechol estrogens positive results 
Evaluation of the VitotoxTM and RadarScreen assays 
63
for bacterial mutagenicity were demonstrated. Of the six catechol estrogens that were 
tested 2-hydroxy-estradiol, 2-hydroxy-estrone, 2-methoxy-estradiol and 4-hydroxy-
estrone showed a positive effect in the VitotoxTM assay. 2-Methoxy-estrone and 4-hydroxy-
estradiol did not show such an effect. Although some catechol estrogens gave a negative 
response in the VitotoxTM assay all catechol estrogens scored positive in the Radarscreen 
assay. Of the other steroidal compounds tested only four were positive being equilin, 
7α-equilin, dehydropiandrosterone and lilopristone (with an additional carbon in the 
17α chain). Ames data for equilin and 7α-equilin were not available. However, these 
two compounds were reported as clastogenic (Table 5). Dehydropiandrosterone is not 
genotoxic in the regulatory tests, however this compound was positive in the VitotoxTM 
assay as well as in the RadarScreen assay. No in vitro mammalian genotoxicity data 
were available for the lilopristone. This compound was positive in the VitotoxTM assay 
as well as in the RadarScreen assay in the presence of S9 mixture.
The VitotoxTM assay also detected some compounds that were positive in yeast or 
mammalian cells, but negative in the Ames. The reporter gene recN plays an important 
role in double strand break repair in bacteria. This might be an explanation for the fact 
that some clastogenic compounds are also detected in this assay. Of the six false positive 
results in the VitotoxTM assay, three compounds were positive in the regulatory in vitro 
mammalian tests. Although some clastogenic compounds were detected in the VitotoxTM 
assay, the sensitivity for and correlation with in vitro mammalian genotoxicity was 
low with scores of respectively 27% (21/78) and 50% (62/124). The specifi city on the 
other hand was high with a score of 89% (41/46). Overall it can be concluded that the 
VitotoxTM assay is a very valuable tool for the early screening process. The test shows 
a high correlation with the Ames test for many structural classes. However, for a few 
classes it was reported that the correlation with the Ames was poor. Therefore the Ames 
test cannot be omitted in a later phase of the development.
The correlation of the RadarScreen assay with bacterial mutagenicity (Ames) was only 
54% (78/144). Subsequently, the sensitivity and specifi city of the RadarScreen for the 
comparison with Ames results were also low with scores of, respectively, 55% (27/49) 
and 54% (51/95). These results show that the RadarScreen assay cannot be used to predict 
the Ames results. For in vitro mammalian genotoxicity however, a correlation of 76% 
(93/123) was obtained. The RadarScreen assay detected direct-acting genotoxins (i.e. 
4-nitroquinoline-N-oxide, cisplatin), topoisomerase inhibitors (i.e. doxorubicin), cross-
linking agents (i.e. cisplatin), nucleotide/DNA synthesis inhibitors (i.e. 5-fl uorouracil), 
and reactive oxygen species generators (i.e. hydrogen peroxide). These results indicate 
that the RadarScreen assay can detect compounds with different modes of action. Also 
in-house compounds with often an unknown mode of action and from different structural 
classes were detected in this assay. The three aneugenic compounds tested, i.e. taxol, 
colchicine, and noscapine HCl were not detected in the RadarScreen assay. Therefore it 
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can be concluded that this test cannot be used to detect compounds with an aneugenic 
mode of action. However, the application of this test in the lead optimization phase 
will result in compounds of higher quality in the pre-clinical phase. The regulatory 
genotoxicity tests in the pre-clinical phase will detect compounds with an aneugenic 
mode of action. Reporter assays that can (also) detect compounds with an aneugenic 
mode of action in the early phase of drug development would be very useful in this 
aspect and are currently under development in our lab.
Like in the regulatory in vitro mammalian genotoxicity assays, many of the tested 
steroids produced a positive result in the RadarScreen assay. In comparison with the 
reported data from the regulatory in vitro mammalian genotoxicity assays even more 
steroids showed a positive result in the RadarScreen assay. This indicates the high 
sensitivity of the RadarScreen assay for this compound class. Of the 12 false positive 
compounds in the RadarScreen assay, seven compounds were steroidal compounds. The 
mechanism(s) that cause(s) a clastogenic or aneugenic result for non-catechol steroids 
has not yet been elucidated. Therefore, more mechanistic studies are needed.
Overall it has been shown that the VitotoxTM assay predicts Ames results and the 
RadarScreen assay in vitro mammalian genotoxicity. The specifi city of the VitotoxTM 
and RadarScreen assay were high for respectively Ames results and in vitro mammalian 
genotoxicity. The low number of false positive results is also found when all compounds 
are selected that were negative in both the Ames and in vitro mammalian genotoxicity test. 
Of these 33 compounds 22 have a negative score in both the VitotoxTM and RadarScreen 
assay (67%). Two aspects that can cause false positive results are cytotoxicity and 
precipitation. Therefore it was decided to discard measurements showing precipitation 
or more than 80% cytotoxicity. However, the data showed that not using these rules 
wouldn’t have changed the number of positive/negative scores. One of the reasons might 
be that precipitation of compounds decreases the luminescent signal. Thus inductions 
that occur at a precipitating concentration will be diffi cult to measure in the present 
system.
Implementation of the VitotoxTM assay in the research phase of Organon in 2003 
already affected the number of positive results in the Ames test (GLP test). Prior to the 
implementation of the VitotoxTM test 19% of the compounds were positive in the Ames 
test. After the implementation of the VitotoxTM assay and deselection of compounds 
with a positive result in the VitotoxTM assay Ames positive compounds were eliminated. 
Implementation of the RadarScreen is expected to reduce the number of compounds that 
are positive in in vitro mammalian genotoxicity assay.
Comparison of the RadarScreen assay with other reporter assay
The GreenScreen RAD54 assay was also tested at our lab. Although this assay, as 
described in various studies, responded well to known genotoxic reference compounds , 
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the autofl uorescence of a large number of in-house compounds interfered with the GFP 
measurement [10]. Surprisingly many compounds became fl uorescent after incubation 
with yeast cells, possibly through metabolism. It has been described that the problem of 
autofl uorescence can be avoided successfully by using fl uorescence polarization (FP) 
[17]. However, in the case of our in-house compounds this method did not work properly. 
This was one of the reasons that the RadarScreen assay was introduced and validated. 
With luminescence as measurement technique the problems with autofl uorescence were 
avoided. A second advantage of the highly sensitive luminescence read-out is that S9 
mixture can be used to test metabolic activation of compounds in a high throughput set-
up. In the GreenScreen RAD54 assay in yeast and GreenScreen HC assay, S9 mixture 
can be used but only in a non-HTS format  [18, 19]. In comparison to the VitotoxTM 
assay a relatively high concentration of S9 mixture was needed in the RadarScreen assay 
(2%). However, in this assay compounds like benzo[a]pyrene and cyclophosphamide 
showed the expected positive response in the presence of S9 mixture.
The disadvantage of the assays used in the present study may be the use of non-human 
cells and a non-human activation system. Recently a GADD45a-GFP assay in the human 
lymphoblastoid cell line TK6 (GreenScreen HC, Gentronix) was developed by Hastwell 
et al. [18]. Their validation study showed that this assay had a high sensitivity and 
specifi city of, respectively, 71% and 100% for in vivo genotoxicity. With a different 
compound set Olaharski et al. [20] showed that the sensitivity of this assay dropped to 
only 30% (comparison with in vitro mammalian genotoxicity). However, the specifi city 
was 97% which makes this assay still useful for deselecting compounds in the early 
research phase. In response to this study Walmsley et al. send a letter to the editor [21]. 
In their letter they reanalyzed the data. Given the fact that in vitro genotoxicity tests give 
often false positive results, a carcinogen with positive in vitro mammalian genotoxicity 
data might still be a non-genotoxic carcinogen. They tried to make a better classifi cation 
of genotoxic carcinogens and non-genotoxic carcinogens. In their analysis the sensitivity 
of the GADD45 assay increased to 75%. However, the compound set became smaller as 
it is very diffi cult to classify a lot of compounds. Moreover, as stated by Olaharski et al. 
such an analysis of the data might also introduce subjectivity. However, the importance 
of the comments made by Walmsley et al. surely is that in vitro mammalian genotoxicity 
tests give often false positive results and that this does not always refl ect the classifi cation 
of genotoxic/non-genotoxic carcinogenicity. Therefore it might indeed be better to 
compare data to the in vivo genotoxicity tests when a prediction for carcinogenicity is 
made. This comparison was not made in this chapter but is shown in Chapter 7.
In the present study, RadarScreen data were compared with in vitro mammalian 
genotoxicity data. As the yeast line used in the present study lacks features like phase II 
metabolism which are present in the in vivo situation, this test is expected to give more 
positive scores than the in vivo genotoxicity test. However, testing of the ECVAM list 
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showed that the number of false positive scores might be on the lower side. On the other 
hand, results from especially the steroidal compounds suggest the opposite. 
A disadvantage of the GADD45 reporter assay is the use of GFP which can interfere 
with the autofl uorescence of compounds. Furthermore, the cell line that is used has not 
been reported to contain endogenous metabolism which makes the use of a rat S9 mixture 
necessary which is a problem in combination with a GFP readout. It may therefore be 
useful to validate reporter assays with human HepG2 cells, which have endogenous 
metabolism [22, 23]. Such reporter cell lines which have phase II metabolism and a 
mammalian DNA repair system are expected to have a better correlation with in vivo 
genotoxicity. These cell lines are currently being developed in our lab.
Conclusion
In conclusion, the VitotoxTM assay has a good predictivity for Ames test results and the 
RadarScreen for in vitro mammalian genotoxicity. Implementation of the VitotoxTM and 
RadarScreen assays in the early research phase of drug development may be useful as it 
can lead to a rapid deselection of genotoxic compounds. 
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Abstract
Early in vitro toxicity screening might improve the success rate of new chemical entities 
in pharmaceutical development. In previous studies, the advantage of cytotoxicity 
screening with the HepG2 cell line was shown. Cytotoxicity could be identifi ed for 70% 
of the compounds in these assays as compared with known toxicity in either in vitro 
assays in primary hepatocytes, in in vivo assays in rats, or in (pre-)clinical development 
in humans. The low phase I and II enzyme levels in HepG2 cells might have been 
responsible for the fact that 30% of the compounds scored negative. Therefore, we 
performed two follow-up studies in which cytochrome P450 (CYP) enzymes and phase 
II metabolism were examined. 
In the present study, the transcript levels of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 
2C19, 2D6, 2E1, and 3A4 were measured with quantitative PCR. Results showed that 
transcripts of all CYPs were present in HepG2 cells, however, mRNA levels of most 
CYPs were dramatically lower than in primary human hepatocytes. These results were 
confi rmed with luminometric assays which were used to measure the enzyme activities 
of CYP1A1, 1A2, 2C9, and 3A4. 
Regulation of CYP1A1, 1A2, 2B6, 2C8, 2D6, 2E1, and 3A4 by the aryl hydrocarbon 
receptor (AhR), pregnane X receptor (PXR) and constitutive androstane receptor 
(CAR) was studied in HepG2 cells at the mRNA and/or enzyme level. Regulation of 
CYP1A1, 1A2, 2B6, and 3A4 mRNA levels was similar to the regulation in primary 
human hepatocytes. In contrast, CYP2C8 mRNA levels are inducible in primary human 
hepatocytes, but not in HepG2 cells, after treatment with PXR/CAR activators. Consistent 
with other studies, CYP2D6 and 2E1 transcript levels were not changed after treatment 
with AhR, PXR, and CAR activators. Moreover, CYP1A1 and 1A2 enzyme levels could 
be induced by AhR agonists and CYP3A4 by PXR agonists.
As a consequence of the low levels of CYPs in HepG2 cells, cytotoxicity of several 
compounds might have been missed or underestimated as compared with cytotoxicity in 
primary human hepatocytes. Inducing HepG2 cells with particular receptor stimulators 
might lead to higher toxicity for several of the tested compounds. Compared to primary 
human hepatocytes, HepG2 cells are a relatively easy-to-handle tool to study the up-
regulation of CYP1A1, 1A2, 2B6, and 3A4.  
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Introduction 
Approximately 40% of the new drug candidates fail in the developmental phase due 
to toxicological side effects [1]. Screening on toxicity and deselection in an early phase 
of development of drugs may improve the success rate of new chemical entities [2]. 
However, this strategy implies a large number of compounds for which only a small 
amount of material is available. Therefore medium or high-throughput screening 
methods are necessary. 
In two previous studies [3, 4] the advantage of early toxicity medium-throughput 
screening was shown with seven different fl uorometric assays on four different cell lines. 
In these studies cytotoxicity could be shown for 70% of the compounds with known 
toxicity in either in vitro assays in primary hepatocytes, in in vivo assays in rats, or in 
(pre-)clinical development in humans. Toxicity of the remaining 30% of compounds 
could not be established. The human hepatoma cell line HepG2 was chosen for further 
toxicity screening as detoxication and activation processes of compounds are studied 
most optimally in liver cells. However, a discrepancy exists between Cytochrome P450 
(CYP) and phase II metabolism of primary hepatocytes and HepG2 cells. Low CYP 
and phase II enzyme levels in HepG2 cells might have been responsible for the fact that 
30% of the compounds were falsely classifi ed as non-toxic [5-7]. However, a recent 
study with Cellulomics techniques on HepG2 cells counteracts the hypothesis that 
the metabolic competence of HepG2 cells is signifi cantly limiting the production of 
reactive metabolites [8]. With this novel method, cytotoxicity in HepG2 cells could be 
established for more than 90% of 243 drugs with varying degrees of toxicity including 
drugs that produce their toxicities by a reactive metabolite. Nevertheless we performed 
two follow-up studies in which CYP enzymes and phase II metabolism were examined. 
In the present study the focus is on CYPs.
The role of phase I enzymes is to introduce a new functional group (i.e. hydroxylation) 
or modify an existing functional group (i.e. O-dealkylation) so as to facilitate phase 
II conjugation reactions. Whilst phase I reactions generally result in a more polar 
metabolite, it is the conjugation reactions (e.g. glucuronidation, sulfonation) that result 
in marked increases in water solubility and facilitate excretion.   
This transformation in two steps facilitates excretion and detoxicates a wide variety of 
xenobiotics. For example the phase II enzyme glutathione S-transferase P1-1 prevents 
4-nitroquinoline 1-oxide (4-NQO) DNA-adduct formation by the formation of 4-NQO 
glutathione conjugates [9,10]. However, many xenobiotics are also toxicated by CYPs 
and phase II enzymes [11]. A well known example is the carcinogenicity of benzo[a]
pyrene in which the activities of CYP1A1 and epoxide hydrolase lead to the formation 
of the carcinogenic metabolite benzo[a]pyrene-7,8-diol-9,10-epoxide [12,13]. 
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The CYP and phase II enzymes are mainly regulated by ligand-activated nuclear 
transcription factors, such as the aryl hydrocarbon receptor (AhR; for the CYP1A family), 
the constitutive androstane receptor (CAR; for the CYP2B family) and the pregnane X 
receptor (PXR; for the CYP3A family) [14-17]. 
In the present study we characterized CYP metabolism in HepG2 cells. Transcript 
levels and enzyme activities in the HepG2 cell line were compared with levels and 
activities in cryopreserved primary human hepatocytes. Quantitative PCR was used to 
measure mRNA levels of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4. 
Enzyme activities of CYP1A1, 1A2, 2C9, and 3A4 were measured using luminometric 
P450-Glo substrates [18]. Furthermore, the inducibility of CYPs in HepG2 cells was 
studied after exposure of HepG2 cells to agonists of the xenobiotic receptors AhR, CAR 
and PXR. Indigo, indirubin, β-naphthofl avone (BNF), 3-methylcholanthrene (3MC), 
and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) were used as AhR agonists [19-21] 
Tularik T0901317, CITCO, rifampicin (RIF), and phenobarbital (PB) were used as PXR 
and/or CAR agonists. T0901317 is in principle a potent LXR ligand that is also capable 
of activating human PXR [22]. CITCO and RIF are potent CAR and PXR activators, 
respectively [23]. PB is an activator of the PXR and although it does not appear to bind 
directly to CAR, it is also an activator of CAR [24].
A parallel study deals with phase II metabolism and compared the mRNA levels and 
activities of several phase II enzymes in HepG2 cells with those of cryopreserved primary 
human hepatocytes [25]. Moreover, induction of phase II enzymes was studied.
Materials and methods 
Materials
All compounds and reagents were of analytical grade. Indirubin was obtained from 
BIOMOL International (Exeter, UK), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
from Promochem (Wesel, Germany), Tularik T0901317 from NV Organon (Oss, The 
Netherlands), and P450-Glo substrates for CYP1A1, 1A2, 2C9, and 3A4 from Promega 
(Madison, USA). All other compounds were obtained from Sigma-Aldrich (St. Louis, 
Missouri, USA).
Cell culture
HepG2 cells were obtained from the American Type Culture Collection (Rockville, 
MD, USA). Cells were cultured in Dulbecco’s Modifi ed Eagles medium and Nutrient 
mixture F-12 (In Vitro Technologies Inc., Baltimore, USA) mixed in a ratio of 1:1 with 
10% defi ned supplemented bovine calf serum (dBCS) from Hyclone (Utah, USA) 
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and 1% Penicillin-Streptomycin (10,000 U/ml, Gibco). Cultures were maintained in a 
humidifi ed atmosphere with 5% CO2 at 37 °C and medium was refreshed every three or 
four days with subculturing. All experiments in HepG2 cells were performed between 
passage 8 and 16. During this period, no signifi cant change in the CYP expression was 
observed. For the comparison of the mRNA expression levels in HepG2 with primary 
hepatocytes, cells from passage 8 and 9 were used. For induction studies in HepG2, cells 
from passage 12, 14, and 16 were used. 
Cryopreserved primary human hepatocytes
Vials containing 5x106 cryopreserved primary human hepatocytes were purchased from 
In Vitro Technologies. After thawing the viability of the hepatocytes was assessed by 
using trypan blue exclusion. The viability of all vials used was >80%. Measured enzyme 
activities were corrected for viability. Hepatocytes from two donors were used: EG, 68 
years, white female (did not use tobacco, alcohol or other substances; medical history 
of hypertension); HRU, 55 years, white male (did not use tobacco, alcohol or other 
substances; medical history of seizures and hypertension). Furthermore, 10-donor pooled 
cryopreserved hepatocytes with lot number KDN were used. At In Vitro Technologies the 
CYP and phase II enzyme activities in hepatocytes were routinely checked after thawing 
and hepatocytes were only released when activities were comparable to activities in 
fresh primary hepatocytes. Appropriate substrates were used to check the CYP1A2, 
2A6, 2C9, 2C19, 2D6, 2E1, 3A4, sulfotransferase, and UDP-glucuronosyltransferase 
activity.
Preparation of compound solutions
Compounds were dissolved in 100% dimethyl sulfoxide (DMSO). From the stock, 
10-fold dilution series were prepared in DMSO. DMSO solutions were added to culture 
medium leading to a fi nal DMSO concentration of 0.1%. 
RNA isolation and cDNA synthesis
HepG2 cells were seeded on petri-dishes with a density of 4500 cells/cm2 in culture 
medium with 10% dBCS. After 24 h this medium was replaced with medium containing 
different concentrations of the inducers 3MC, BNF, indirubin, indigo, TCDD, CITCO, 
RIF, PB, T0901317, or vehicle alone (0.1% DMSO). After exposure for 24 h, total 
cellular RNA was isolated using Trizol reagent according to the manufacturer’s protocol 
(Invitrogen, Karlsruhe, Germany).
Cryopreserved primary hepatocytes were not cultured but were directly used for RNA 
isolation. A vial containing 5x106 hepatocytes was thawed and cells were added to 10 
ml culture medium. Next cells were collected by centrifugation for 5 min at 272 g. The 
supernatant was removed and total cellular RNA was isolated with Trizol reagent.
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For cDNA synthesis 2.5 μg total RNA from HepG2 cells or primary hepatocytes was 
used and 0.5 μg random hexamer primer (GE Healthcare Bio-Sciences Corp, Piscataway, 
USA) was added. The mixture was heated at 70°C for 10 min and thereafter quickly 
chilled on ice for 2 min. cDNA was synthesized in a total volume of 25 μl containing 50 
mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 0.5 mM dNTPs 
and 200 U Superscript II Rnase H- Reverse Transcriptase (Invitrogen). This mixture was 
incubated for 1 h at 42°C. Undiluted cDNA was used for the analysis of CYP2A6, 2C9 
and 2C19 expression in HepG2 cells. For all other measurements cDNA was diluted to 
a concentration equivalent of 10 ng/μl RNA. 
Quantitative PCR
Quantitative PCR was performed using an ABI PRISM 7900 HT Sequence Detection 
system (Applied Biosystems, Inc. Foster City, USA). Specifi c primers were designed 
using Primer Express software (version 2.0, Applied Biosystems). To avoid the infl uence 
of DNA contamination, primer pairs were designed to span an intron-exon boundary 
(Table 1). Quantitative PCR was performed using cDNA equivalent to 50 ng of total RNA 
in a volume of 25 μl. Due to the low expression in HepG2 cells, a cDNA concentration 
equivalent to 500 ng of total RNA was used for analysis of CYP2A6, 2C9, and 2C19. 
The total mixture contained cDNA, 300 nM forward primer, 300 nM reverse primer and 
1X SYBRgreen PCR Master Mix (Applied Biosystems). The program used was 10 min 
at 95°C, 40 cycles of 15 s at 95°C and 1 min at 60°C 100%, followed by a dissociation 
curve step. Expression levels were normalized by using the β-actin housekeeping gene.
Specifi city of luminometric P450-Glo substrates
The luminometric P450-Glo substrates are derivates of D-luciferin and converted by 
CYP enzymes into D-luciferin [18]. The specifi city of Luciferin(Luc)-CEE, Luc-ME, 
Luc-H, and Luc-BE for CYP enzymes, was assessed for CYP1A1, 1A2, 2A6, 2B6, 2C8, 
2C9, 2C19, 2D6, 2E1, and 3A4. Firstly, a NADPH regenerating system was prepared 
in phosphate buffered saline (pH 7.4). This mixture contained 2.6 mM NADP+, 6.6 
mM glucose-6-phosphate, 6.6 mM MgCl2 and 0.8 Units per ml glucose-6-phosphate 
dehydrogenase. The cofactor solution was prewarmed at 37ºC for 10 min. Supersomes 
(BD Biosciences, USA) expressing one CYP were added to this cofactor mixture. The 
fi nal concentration of supersomes in the cofactor mixture was 10 pmol/ml. The cofactor/
supersome mixture was kept at 37ºC. Subsequently, 50 μl of either 60 μM Luc-CEE, 200 
μM Luc-Me, 200 μM Luc-H, or 200 μM Luc-BE in PBS was added to a well of a white 
96-well plate (PerkinElmer, Groningen, The Netherlands). The plates with substrates 
were pre-heated at 37ºC for 5 min. Next, 50 μl from the cofactor/supersome mixture was 
added to one of the substrates. Substrates were incubated with the enzymes for 30 min 
and the luminescence was measured on a luminometer (TopCountNT, PerkinElmer). 
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Comparison of CYP1A1, 1A2, 2C9 and 3A4 enzyme activities in primary human 
hepatocytes and HepG2 cells with P450-Glo substrates
The P450-Glo assays were performed according to the manufacturer’s protocol 
(Promega). Hepatocytes or HepG2 cells (5x104) were washed with PBS and resuspended 
in 50 μl PBS. Next 50 μl of either 60 μM Luc-CEE (CYP1A1), 200 μM Luc-ME 
(CYP1A2), 200 μM Luc-H (CYP2C9), or 200 μM Luc-BE (CYP3A4) was added. In 
each assay the substrate was present at a concentration equal to the Km value (Promega). 
HepG2 cells and primary hepatocytes were incubated with P450-Glo substrates for 
up to 1 h. Under these test conditions, substrate conversion remained linear in time 
with all enzymes. Due to the aspecifi city of Luc-ME, CYP1A2 activity was always 
determined in the presence of 10-6 M sulphaphenazole. This concentration blocks the 
CYP2C9 activity completely and the CYP2C8 activity for 60% in human supersomes 
(data not shown). In some experiments CYP activity was blocked by coincubation with 
inhibitors to show the specifi city of the P450-Glo substrates. CYP1A1 activity was 
blocked with 10-6 M ketoconazole, CYP1A2 activity with 10-6 M furafylline, CYP2C9 
activity with 10-6 M sulphaphenazole, and CYP3A4 activity with 10-6 M ketoconazole. 
Subsequently, 50 μl luciferin detection reagent was added. Plates were shaken for 10 
min and the luminescence signal was measured on a TopCountNT luminometer. The 
conversion rate expressed as the increase in luminescence per minute per 105 cells 
(Δluminescence/min/105 cells) was calculated in the linear part of the reaction time. For 
calculation of the amount of D-luciferin formed, a D-luciferin standard curve was made. 
Furthermore, cell lysates were made and the protein content of HepG2 cells and primary 
human hepatocytes was measured with the BCA protein assay kit from Pierce (Pierce 
Biotechnologies, Rockford, USA) [25]. 
Measurement of induction of CYP1A1, 1A2 and 3A4 enzyme activities in HepG2 
cells
HepG2 cells were trypsinized, counted and resuspended in culture medium to a fi nal 
concentration of 3x104 cells/well for the CYP1A1 and CYP1A2 assay and to 1.5x105 
cells/well for the CYP3A4 assay. 190 μl cell suspension was added to a well of a white 
96-well culture plate (Perkin Elmer). The 96-well microtiter plates were incubated 
for 24 h in a humidifi ed atmosphere at 37°C under 5% CO2. Next day 10 μl medium 
containing different concentrations of 3MC, BNF, indirubin, indigo, TCDD, CITCO, 
RIF, PB, T0901317, or vehicle alone (0.1% DMSO) was added. Subsequently, plates 
were incubated for another 24 h in a humidifi ed atmosphere at 37°C under 5% CO2. 
After exposure, plates were washed twice with PBS and the CYP1A1, 1A2, and 3A4 
activities were assessed by using 50 μl Luc-CEE (30 μM), Luc-ME (100 μM), or Luc-
BE (100 μM). In each assay the substrate was present at a concentration equal to the Km 
value. Under these test conditions, substrate conversion remained linear in time with all 
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enzymes. Next 50 μl luciferin detection reagent was added and plates were shaken for 
10 min. Then the luminescence signal was measured with a TopCountNT luminometer. 
For calculation of the amount of D-luciferin formed, a D-luciferin standard curve was 
made.
Statistical analysis
Each experiment was performed in duplicate in three independent experiments except 
where indicated otherwise. Data are expressed as mean ± SEM. Data obtained from 
mRNA and enzyme activity induction studies were compared for statistically signifi cant 
differences using the unpaired Student’s t test (p<0.05). For the mRNA induction studies, 
only induction levels above 2-fold with statistically signifi cant differences were seen as 
relevant.
Results
Comparison of CYP mRNA expression in HepG2 cells and primary human 
hepatocytes
Transcripts of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 were 
present in both cryopreserved hepatocytes and HepG2 cells, although mRNA levels of 
most CYP enzymes were much lower in HepG2 cells (Figure 1). CYP1A1 levels were 
3- and 37-fold higher in hepatocytes from donor EG and HRU. In contrast CYP1A1 
levels in the donor pool were 10-times lower than those in HepG2 cells. Levels of 
the second CYP1A family member, CYP1A2, were 24-, 386-, and 55-fold higher in 
hepatocytes from donor EG, HRU, and the pool. Likewise, Cyp2B6 transcript levels 
were 10-fold higher in the donor pool and more than 100-fold higher in donor EG and 
HRU. Expression levels of CYP2D6 differed less than 100-fold between the hepatocytes 
and HepG2 cells. Levels of CYP2D6 were 92-, 44-, and 7-fold higher in hepatocytes 
from donor EG, HRU, and the pool. Furthermore, levels of CYP2A6, 2C8, 2C9, 2C19, 
2E1, and 3A4 were generally between 100- and 1000-fold higher in the hepatocytes.
Specifi city of P450-Glo substrates
The specifi city of the luminometric substrates was assessed for 11 human CYP isoforms 
(Figure 2). Luc-CEE showed the greatest specifi city for CYP1A1 and showed very little 
reactivity with the other CYPs. The second luminometric substrate Luc-ME showed 
the greatest reactivity with CYP1A2 as expected. However, this substrate also reacted 
substantially with CYP2C8 and 2C9. CYP2C8 and 2C9 reactivity was 24% and 32% of 
the reactivity with CYP1A2. 
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Figure 1. Cytochrome P450 (CYP) 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 mRNA 
expression levels in cryopreserved primary human hepatocytes (donor EG, donor HRU, 10-donor pool) 
and HepG2 cells. Results are presented as the mean mRNA levels expressed in copy number ratio of the 
CYP and β-actin transcripts of two independent measurements.
Thus to assess CYP1A2 activity, CYP2C8 and 2C9 were inhibited with 10-6 M 
sulphaphenazole. This concentration blocked CYP2C9 completely and 60% of CYP2C8 
activity but had no effect on CYP1A2 activity (data not shown). Luc-H was very specifi c 
and reacted only with CYP2C9. Luc-BE was quite specifi c for CYP3A4 and showed 
only little reactivity with CYP1A1 (16%) and 2C8 (14%).
Comparison of CYP enzyme activities in HepG2 cells and primary human 
hepatocytes
The CYP activities in HepG2 cells and donor EG expressed in Δluminescence/min/105 
cells are shown in Figure 3. Results were in concordance with the mRNA levels measured. 
CYP1A1 activity was higher in donor EG as compared with activity in HepG2 cells and 
could be inhibited with 10-6 M ketoconazole. CYP1A2 activity was detectable in both 
primary hepatocytes and HepG2 cells, but was 80-times lower in HepG2 cells. The 
CYP1A2 activity could be blocked completely with 10-6 M furafylline. The activity of 
CYP2C9 was high in donor EG but not detectable in HepG2 cells. CYP2C9 activity in 
the hepatocytes could be blocked completely with 10-6 M sulphaphenazole. Furthermore, 
results showed that CYP3A4 activity in HepG2 cells was detectable, but 15-times lower 
than the activity in donor EG. Activities could be inhibited substantially with 10-6 M 
ketoconazole. A D-luciferin standard curve showed that an increase of 10,000 light units 
is equal to the formation of 0.62 pmol D-luciferin (data not shown). Moreover, the protein 
content of 105 HepG2 cells and hepatocytes was 0.28 and 0.16 mg, respectively. 
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Figure 2. Specifi city of Luciferin(Luc)-CEE (A), Luc-ME (B), Luc-H (C), and Luc-BE (D) for the 
human cytochrome P450 isotypes 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, and 3A4. 
Results are presented as the mean activity of 3 independent measurements ± SEM.
Figure 3. Cytochrome P450 (CYP) 1A1, 1A2, 2C9, and 3A4 activity (Δluminescence/min/105 cells) 
in cryopreserved primary human hepatocytes (donor EG) and HepG2 cells. CYP1A1, 1A2, 2C9, and 
3A4 enzyme activities were blocked with 10-6 M ketoconazole, furafylline, sulphaphenazole, and 
ketoconazole, respectively. Results are presented as the mean activity of two independent measurements 
(-, basal activity; +, activity with inhibitor).
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Effects of AhR activators on CYP mRNA expression
The transcript levels of CYP1A1, 1A2, 2B6, 2C8, 2D6, 2E1, and 3A4 were measured 
after 24 h exposure to AhR agonists. The very low expression and consequently the large 
amount of cDNA needed made it impossible to study the up-regulation of CYP2A6, 
2C9, and 2C19. None of the AhR agonists changed CYP2C8, 2D6 and 2E1 transcript 
levels (data not shown). The effects on the transcript levels of CYP1A1, 1A2, 2B6, and 
3A4 are presented in Figure 4.
As expected, transcript levels of CYP1A1 were highly induced after exposure to the 
fi ve AhR agonists. The lowest activation doses for BNF, indirubin, indigo, TCDD, 
and 3MC were 10-7 M, 10-8 M, 10-8 M, 10-10 M, and 10-8 M, respectively. The highest 
activation doses for BNF, indirubin, indigo, TCDD and 3MC (with fold changes in 
parentheses) were 10-4 M (239), 10-4 M (1359), 10-4 M (85), 10-7 M (452), and 10-5 M 
(487), respectively. 
Likewise, CYP1A2 was induced after exposure to the fi ve AhR agonists. The lowest 
activation doses for BNF, indirubin, indigo, TCDD and 3MC were 10-7 M, 10-8 M, 10-8 
M, 10-10 M, and 10-8 M. The highest activation doses for BNF, indirubin, indigo, TCDD 
and 3MC (with fold changes in parentheses) were 10-4 M (51), 10-4 M (244), 10-4 M 
(444), 10-7 M (487), and 10-5 M (276), respectively.
Figure 4. Induction of cytochrome P450 (CYP) 1A1, 1A2, 2B6, and 3A4 mRNA expression in HepG2 
cells after 24 h treatment with the AhR activators β-naphthofl avone (BNF), indirubin, indigo, TCDD, 
and 3-methylcholanthrene (3MC). The level in uninduced HepG2 cells is set at 1. Data are presented as 
the mean expression ± SEM (n=3). *Signifi cant difference (p<0.05) 
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Surprisingly, CYP2B6 and CYP3A4 transcript levels were also enhanced after 
treatment with some of the AhR agonists, but fold changes were 10- to 100-fold lower 
than for the CYP1A isoforms.
CYP2B6 transcript levels were induced after treatment with BNF, indirubin and 3MC. 
However, indigo and TCDD treatment did not change the CYP2B6 mRNA levels. The 
lowest activation dose for BNF, indirubin, and 3MC was 10-5 M. The maximum induction 
of 3- to 4-fold was observed at 10-4 M for BNF and indirubin, and at 10-5 M for 3MC.
CYP3A4 was induced after exposure to indirubin, indigo and 3MC. No effect of BNF 
and TCDD was observed. After exposure to 10-4 M indirubin and indigo an induction 
of 3.5- and 2-fold was measured. A higher induction of 10-fold was observed at 10-5 M 
3MC. 
Effects of PXR and CAR activators on CYP mRNA expression
The expression levels of CYP enzymes in HepG2 cells were measured after 24 h 
exposure to several PXR/CAR agonists. Transcript levels of CYP2C8, 2D6, and 2E1 
were not enhanced by the CAR/PXR agonists (data not shown). CYP1A1, 1A2, 2B6, 
and 3A4 mRNA levels were signifi cantly induced by one or more of the tested activators 
(Figure 5).  
Figure 5.  Induction of cytochrome P450 (CYP) 1A1, 1A2, 2B6, and 3A4 mRNA expression in HepG2 
after 24 h treatment with the PXR/LXR activator T0901317, PXR activator rifampicin (RIF), the CAR/
PXR activator phenobarbital (PB), and the CAR activator CITCO. The level in uninduced HepG2 cells 
is set at 1. Data are presented as the mean expression ± SEM (n=3).  *Signifi cant difference (p<0.05) 
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CYP1A1 mRNA levels were enhanced after exposure to 10-5 M T0901317 and CITCO, 
and 10-4 M PB. However, induction was only very small (2- to 4-fold) in comparison to 
inductions of between 100- and more than 1000-fold observed after treatment with the 
AhR agonists. CYP1A2 transcript levels were only slightly increased after exposure to 
10-5 M T0901317.
CYP2B6 was induced 3.5-fold after treatment with 10-7 M CITCO. No effect of 
T0901317, RIF, and PB on CYP2B6 expression was observed. 
CYP3A4 transcript levels were induced after treatment with T0901317 and RIF. No 
effects were seen with PB and CITCO. The lowest activation doses for T0901317 and 
RIF were 10-7 M and 10-5 M. The highest activation doses for T0901317 and CITCO 
were 10-7 M and 10-4 M, leading to 2.6- and 4.7-fold induction, respectively.
Effects of activators on enzyme activities of CYP1A1, 1A2, and 3A4
The CYP1A1 and 1A2 activities were assessed with Luc-CEE and Luc-ME for BNF, 
indirubin, indigo, TCDD, and 3MC. The induction of CYP1A1 and 1A2 enzyme activities 
by AhR agonists are shown in Figure 6. The AhR agonists tested induced the CYP1A1 
enzyme activities above the basal CYP1A1 activity in HepG2 cells. TCDD was the most 
potent CYP1A1 inducer with a maximum induction of almost 1000-fold at 10-8 M and a 
signifi cant induction of almost 10-fold at 10-11 M. Indirubin, indigo and 3MC were also 
potent inducers (>100-fold). Indirubin, indigo and 3MC induced CYP1A1 activity at 
concentrations as low as 10-8 M. BNF was the weakest inducer of CYP1A1 (10-fold). 
Moreover, the fi ve AhR agonists induced CYP1A2 enzyme activities above the basal 
CYP1A2 activity. TCDD induced CYP1A2 activity at concentrations as low as 10-10 
M and at 10-9 M the maximum induction was 15-fold. Indirubin enhanced CYP1A2 
enzyme activity at all tested concentrations, induction being observed at 10-8 M and the 
maximal induction of 25-fold was observed at 10-6 M. BNF, indigo and 3MC were weaker 
inducers of the CYP1A2 enzyme activity than TCDD and indirubin. These compounds 
showed a maximum induction of between 5- and almost 10-fold. The lowest activation 
dose for BNF and indigo was 10-6 M, while for 3MC it was 10-7 M.
CYP3A4 activity was assessed with Luc-BE for T0901317 and PB. RIF could not 
be tested because the dark red color of this compound disturbs the luminescence 
measurement. Treatment with T0901713 induced CYP3A4 activity signifi cantly above 
the basal activity (Figure 7). A maximum induction just above 2-fold was measured at 
10-5 M. No effect of PB on CYP3A4 expression was observed.
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Figure 6. Dose dependent induction of cytochrome P450 (CYP) 1A1 and 1A2 enzyme activities 
(Δluminescence/min/105 cells) after 24 h treatment with β-naphthofl avone (BNF), indirubin, indigo, 
TCDD, and 3-methylcholanthrene (3MC). The dashed lines indicate the basal enzyme activities in 
HepG2 cells. Data are presented as the mean activity ± SEM (n=3).
Figure 7. Dose dependent induction of cytochrome P450 (CYP) 3A4 activity (Δluminescence/min/105 
cells) after 24 h treatment with T0901317. The dashed line indicates the basal CYP3A4 activity in 
HepG2 cells. Data are presented as the mean activity ± SEM (n=3). 
Discussion
In the present study the CYP mRNA expression and enzyme activities in HepG2 cells 
and cryopreserved primary human hepatocytes were compared. The HepG2 cell line is 
derived from a Caucasian human hepatoblastoma and has both phase I and II metabolizing 
enzymes [5, 26, 27]. Hewitt and Hewitt [5] showed that the enzyme activities depend 
on the source and culture conditions and that consequently characterization of HepG2 
cells is essential.  
Results from the present study showed that the transcript levels and enzyme activities 
of most CYPs were much lower in HepG2 cells as compared to levels in primary human 
hepatocytes. The mRNA levels of CYP1A1, 1A2, 2B6, 2C8, 2C9, and 2C19 in the three 
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primary hepatocyte sources showed a variation of more than 10-fold. This might have 
been due to genotype or food intake.
CYPs play a pivotal role in the toxication of some compounds [28, 29]. Thus the 
low enzyme levels in HepG2 cells might result in an underestimation of the toxicity of 
compounds as compared with toxicity in primary human hepatocytes. On the other hand, 
cytotoxicity was observed in HepG2 for several compounds like iproniazid, dacarbazine, 
nitrofurantoin, and benzo[a]pyrene that need metabolic activation via CYP3A4, 1A1, 
and/or 1A2 [3, 4]. Similar observations were made by O’Brien et al. [8]. This implies 
that for several compounds, the CYP activities in HepG2 cells are high enough or that the 
compounds themselves activate a xenobiotic receptor, which induces CYP expression. 
Rodriguez et al. [6] showed that the low CYP expression in HepG2 and other 
permanent hepatoma cells is caused by a decreased CYP transcription. A change in 
hepatic transcription factors might be involved in this process. Support for this hypothesis 
comes from transfection studies with C/EBPα in HepG2 cells, leading to higher levels of 
CYP2B6, 2C9, and 2D6 [30]. Another way to induce CYP enzyme levels is by treatment 
with AhR, CAR, and PXR agonists.
CYP1A1 contributes to the toxicity of many carcinogens, especially PAHs [31, 32, 
33]. The main pathway for CYP1A1 induction is through activation of the AhR pathway 
[34]. In the present study all fi ve AhR activators used highly induced CYP1A1 mRNA 
levels and enzyme activities. TCDD was the most potent inducer followed by indirubin 
and indigo. Indirubin and indigo were identifi ed in human urine in normal donors and 
can be endogenous ligands of the AhR as both compounds are present in the human 
serum at a concentration of 10-8 M [19]. In yeast AhR activation assays, these compounds 
were comparable or even more potent than TCDD [35]. Remarkably also the PXR/CAR 
activators PB, CITCO, and T0901317 induced CYP1A1 transcript levels, although to 
much lower levels than real AhR agonists. CYP1A1 and/or CYP1A2 induction by PXR/
CAR activators has been observed in other studies as well [36, 37].
CYP1A2 activates PAHs, nitrosamines and aryl amines into DNA-binding forms 
[38]. CYP1A2 induction on transcriptional level can occur through AhR dependent and 
independent pathways [39] or through post-transcriptional pathways [40]. In the present 
investigation all fi ve AhR activators induced the CYP1A2 transcript levels by 10- to 
100-fold, which was only slightly weaker than observed for CYP1A1. Of the PXR/CAR 
activators only T0901317 showed statistically signifi cant induction. Before induction, 
CYP1A2 levels were between 24- and 386-fold lower. The induction leads to comparable 
or even higher mRNA and enzyme levels than in cryopreserved hepatocytes.
CYP2B6 metabolizes endogenous substances such as testosterone [41], serotonin 
[42], and xenobiotics of which clinical drugs such as cyclophosphamide [43] and 
bupropion [44] are examples. In the present study, CYP2B6 was  induced by the specifi c 
CAR agonist CITCO, while RIF showed only a tendency for induction. Regulation of 
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CYP2B6 by these ligands via CAR and PXR has also been documented by others [15, 
45, 46]. T0901317 and PB did not induce CYP2B6 levels although CYP2B6 induction 
by PB was described in primary human hepatocytes by others [45, 47]. Madan et al. 
(2003) [45] showed a large variation in CYP2B6 induction from 1.3-fold induction to a 
17-fold induction in 13 different donors. Surprisingly, the AhR agonists BNF, indirubin, 
and 3MC also induced CYP2B6 expression in HepG2 cells. The concentrations needed 
for CYP2B6 activation were higher than those for CYP1A1 and CYP1A2. Classical 
AhR ligands and atypical CYP1A inducers were recently profi led in rats by microarray 
experiments [48]. These authors also found that some of the AhR activators including 
fl utamide, omeprazole and indole-3-carbinol showed cross-talk at high concentrations 
with PXR/CAR pathways leading to CYP2B and CYP3A induction. Similar data were 
found for CYP2B6 in human hepatocytes with benzo[a]pyrene [7]. These fi ndings 
suggest that at high concentrations, some AhR agonists give cross-talk with the CAR/
PXR pathway. Enzyme levels of CYP2B6 have not yet been measured since a proper 
specifi c fl uorophore or luminophore is still unavailable.
CYP3A4 metabolizes approximately 50% of the drugs that are currently on the market 
and plays an important role in the toxication of compounds [29]. Examples are CYP3A4 
metabolites of fl utamide, troglitazone, and isoniazid which cause hepatotoxicity [49-51]. 
CYP3A4 is regulated by CAR and PXR [52-54]. In this study CYP3A4 mRNA regulation 
was shown with the PXR agonists RIF and T0901317, the latter being more potent. 
CYP3A4 was not induced by the CAR agonists CITCO and PB. It has recently been 
observed in human hepatocytes that although PXR and CAR both regulate CYP3A4 
and CYP2B6 like in rodents, human CAR preferentially induces CYP2B6 relative to 
CYP3A4 because of its weak binding and activation of CYP3A4 ER6 [47]. In the study 
of Faucette et al. [47] treatment of human hepatocytes with 0.5-1 μM CITCO resulted in 
a more than 2-fold mRNA induction of CYP3A4 in only one out of six donors. Cross-talk 
of the AhR agonists indirubin, indigo and 3MC with the PXR/CAR pathways leading to 
induction of CYP3A4 was also demonstrated in the present study.
The CYP2C subfamily contains four members of which CYP2C8, CYP2C9, and 
CYP2C19 are expressed in the liver [55]. In the present study, regulation of CYP2C8 
was studied. CYP2C8 plays a role in the oxidative metabolism of taxol, arachidonic 
acid, and retinoids [56]. In human hepatocytes CYP2C8 is inducible with PXR/CAR 
activators such as CITCO, dexamethasone, RIF, and PB [57, 58]. None of the AhR, 
PXR, and CAR activators used in the present study changed the transcript levels of 
CYP2C8. These results are not consistent with fi ndings in primary human hepatocytes.
Consistent with other reports, CYP2D6 was a non-inducible enzyme [37, 59]. 
Regulation of CYP2E1 can occur by exposure to xenobiotics, such as alcohol, isoniazid, 
and pyridine [60-63]. However, as for CYP2D6, no involvement of the AhR, PXR, CAR 
or other nuclear receptors in the regulation of CYP2E1 has been observed in this study 
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or by others. 
In conclusion, HepG2 cells have low levels of CYPs. The results regarding CYP1A1, 
1A2, 2B6, and 3A4 induction show that there is a good correlation with earlier results 
observed in primary human hepatocytes. Furthermore, CYP2D6 and CYP2E1 could, like 
in primary hepatocytes, not be induced with AhR, PXR, and CAR agonists. In contrast 
to results observed in primary human hepatocytes no regulation of CYP2C8 with PXR/
CAR activators was found in HepG2 cells. Still, HepG2 cells are an easy to handle 
tool in contradiction to primary hepatocytes to study the regulation of CYP1A1, 1A2, 
2B6, and 3A4. Prestimulating HepG2 cells with AhR, PXR, and CAR activators before 
performing cytotoxicity assays might lead to a better predictivity of toxicity.
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Abstract
The HepG2 cell line is a valuable tool for screening for cytotoxicity in the early phase 
of pharmaceutical development. Some compounds which produce reactive and toxic 
metabolites, are classifi ed as being toxic in HepG2 cells. In contrast, other compounds, 
which are toxic in primary human hepatocytes, are not toxic in HepG2 cells. A difference 
in metabolism between HepG2 cells and primary human hepatocytes might be the reason. 
To investigate this, cytochrome P450 and phase II enzyme levels were characterized. In 
the present study the focus is on phase II enzyme metabolism.
Transcript levels of UDP-glucuronosyl transferases (UGTs), sulfotransferases (SULTs), 
glutathione S-transferases (GSTs), N-acetyltransferase-1 (NAT1) and epoxide hydrolase 
(EPHX1) were measured with quantitative PCR in HepG2 cells and cryopreserved 
primary human hepatocytes. Levels of SULT1A1, 1A2, 1E1, 1A2, and 2A1, microsomal 
GST 1, GST μ1, NAT1, and EPHX1 in HepG2 cells were almost similar to levels in 
primary human hepatocytes. In contrast, levels of UGT1A1 and 1A6 transcripts were 
between 10- and more than 1000-fold higher in the primary hepatocytes.
The regulatory processes of phase II enzymes by the aryl hydrocarbon receptor, 
pregnane X receptor and constitutive androstane receptor were studied in HepG2 cells 
and appeared quite similar to those in primary human hepatocytes. 
Due to the involvement of phase II enzymes in the toxication of some compounds, 
HepG2 cells can be a valuable cellular system to predict toxicity for these compounds. 
On the other hand, the normal expression of most phase II enzymes in combination 
with the lower expression of cytochrome P450 enzymes in HepG2 cells might result 
in an underestimation of toxicity for several compounds. Compared to primary human 
hepatocytes, HepG2 cells are a relatively easy-to-handle tool to study the up-regulation 
of phase II enzymes.
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Introduction 
For screening purposes in the early phase of pharmaceutical development, the HepG2 
cell line can be useful [1-4]. For instance, tamoxifen, benzo[a]pyrene, and nitrofurantoin 
which need metabolic activation in order to express their toxicity, show cytotoxicity 
in HepG2 cells [2-5]. In contrast, some compounds reported as being toxic in primary 
human hepatocytes, are classifi ed as non-toxic in HepG2 cells. A difference in metabolism 
between HepG2 cells and primary human hepatocytes might cause this discrepancy 
[6-8]. Therefore we performed two studies in which either cytochrome P450 (CYP) or 
phase II metabolism in HepG2 cells was characterized. In the present study the focus is 
on phase II metabolism. 
In phase II metabolism a polar group in a compound is used for the conjugation reaction 
with an endogenous hydrophilic compound. The phase II reactions generally lead to 
more polar molecules and facilitate biliary and renal excretion. The major phase II 
metabolizing enzymes are the UDP-glucuronosyltransferases (UGTs), sulfotransferases 
(SULTs), glutathione S-transferases (GSTs), arylamine N-acetyltransferases (NATs), 
and epoxide hydrolases (EPHXs). The products of phase II reactions are often less toxic 
than the parent compound or products of phase I reactions. An example of a detoxication 
reaction is the detoxication of 4-nitroquinoline 1-oxide (4NQO). 4NQO induces DNA 
adduct formation and is detoxicated by the formation of 4NQO-glutathione conjugates 
[9, 10].
However, phase II biotransformations can also result in enhanced toxicities. A few 
examples are the role of epoxide hydrolase in the activation of benzo[a]pyrene [11], the 
conversion of the pesticide ethylene dibromide to a half-mustard/episulfonium ion by 
glutathione transferases [12], and the modifi cation of aryl hydroxylamines and benzylic 
alcohols by sulfonylation which leads to the formation of reactive nitrenium ions and 
carbocations respectively [13].
Some polymorphisms in phase II enzymes are linked to higher risks towards side 
effects of drugs [14]. A polymorphism in NAT2, leading to reduced enzyme activity, is 
proposed to lead to a higher risk for side effects of isoniazid treatment [15]. Furthermore, 
slow acetylator phenotypes are associated with a weaker induction of the micronucleus 
frequency after treatment with radioactive iodine and fast acetylators are associated with 
a higher risk for colorectal cancer [16, 17]. Polymorphisms in UGT1A1 may lead to 
mild or severe hyperbilirubinemia, i.e. Gilbert’s syndrome and Crigler-Najjar syndrome 
[18]. Phase II enzymes are mainly regulated by the aryl hydrocarbon receptor (AhR), the 
constitutive androstane receptor (CAR), and pregnane X receptor (PXR) [19-22]. 
In the present study we characterized phase II metabolism in HepG2 cells. Transcript 
levels and enzyme activities in the HepG2 cell line were compared with those in 
cryopreserved primary human hepatocytes. Quantitative PCR was used to measure 
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transcript levels of UGT1A1, 1A6, SULT1A1, 1A2, 1E1, 2A1, microsomal GST 1 
(mGST-1), GST μ1, NAT1, and EPHX1. Monochlorobimane and 4-methylumbelliferone 
were used to measure the overall GST enzyme activity [23, 24] and the overall UGT 
activity [25], respectively. In addition, the induction of phase II enzymes in HepG2 cells 
was determined after exposure to several AhR, CAR, and PXR agonists.
Materials and methods
Materials
All compounds and reagents were of analytical grade. Most compounds, as well as 
monochlorobimane (MCB), 4-methylumbelliferone (4MU) and uridine diphosphate 
glucuronic acid (UDPGA) were obtained from Sigma-Aldrich (St. Louis, Missouri, 
USA). Indirubin was obtained from BIOMOL International (Exeter, UK), T0901317 
from NV Organon (Oss, The Netherlands), and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 
(TCDD) from Promochem (Wesel, Germany).
Cell culture
HepG2 cells were obtained from the American Type Culture Collection (Rockville, 
MD, USA). Cells were cultured in Dulbecco’s Modifi ed Eagles medium and Nutrient 
mixture F-12 (Invitrogen, Kalsruhe, Germany) mixed in a ratio of 1:1 with 10% defi ned 
supplemented bovine calf serum (dBCS) from Hyclone (Utah, USA) and 1% Penicillin-
Streptomycin (10,000 U/ml, Invitrogen). Cultures were maintained in a humidifi ed 
atmosphere with 5% CO2 at 37 °C and medium was refreshed every 3 or 4 days with 
subculturing. All experiments in HepG2 cells were performed between passage 8 and 
16. During this period, no signifi cant change in the phase II enzyme expression was 
observed (data not shown). For the comparison of the mRNA expression levels in HepG2 
with primary hepatocytes, cells from passage 8 and 9 were used. For induction studies in 
HepG2, cells from passage 12, 14, and 16 were used. 
Cryopreserved primary hepatocytes
Vials containing 5x106 cryopreserved primary human hepatocytes were purchased from 
In Vitro Technologies (Baltimore, USA). After thawing, the viability of the hepatocytes 
was assessed by using trypan blue exclusion. The viability of all vials used was above 
80%. The measured enzyme activities were corrected for viability. Hepatocytes from 
two donors were used: EG, white female (68 years, did not use tobacco, alcohol or other 
substances; medical history of hypertension); HRU, white male (55 years, did not use 
tobacco, alcohol or other substances; medical history of seizures and hypertension). 
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Furthermore, 10-donor pooled cryopreserved hepatocytes with lot number KDN were 
used. At In Vitro Technologies the CYP and phase II enzyme activities in hepatocytes 
were routinely checked after thawing and hepatocytes were only released when activities 
were comparable to activities in fresh primary hepatocytes. Appropriate substrates 
were used to check the CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4, SULT, and UGT 
activities. 
Preparation of compound solutions
Compounds were dissolved in 100% dimethyl sulfoxide (DMSO). From the stock, 
10-fold dilution series were prepared in DMSO. DMSO solutions were added to culture 
medium leading to a fi nal DMSO concentration of 0.1%. 
Compound incubation, RNA isolation and cDNA synthesis
Cryopreserved primary hepatocytes were not cultured but were directly used for RNA 
isolation. A vial containing 5x106 hepatocytes was thawed and cells were added to 10 
ml culture medium. Next cells were collected by centrifugation for 5 min at 272 g. 
The supernatant was removed and total cellular RNA was isolated with Trizol reagent 
according to the manufacturer’s protocol (Invitrogen).
HepG2 cells were seeded on petri-dishes with a density of 4500 cells/cm2 in culture 
medium with 10% dBCS. After 24 h this medium was replaced by medium containing 0.1% 
DMSO or a dose range of various AhR, PXR, and CAR agonists. 3-methylcholanthrene 
(3MC), β-naphthofl avone (BNF), indirubin, indigo, and TCDD were used as AhR 
agonists [26-28]. Rifampicin (RIF) and Tularik T0901317 were used as PXR agonists 
[29], CITCO as CAR agonist [30] and phenobarbital (PB) as an agonist of the PXR and 
CAR receptor [31]. The cytotoxicity of the activators was tested in the Calcein-AM and 
glutathione depletion assays as described previously [3, 4]. Of the activators used 3MC 
and TCDD showed a cytotoxic effect at 3.16x10-5 and 1.00x10-6 M, respectively. 3MC 
was in the induction studies used up to a non-toxic maximum concentration of 1x10-5 
M. The highest concentration TCDD (10-6 M) used in the induction studies, showed a 
cytotoxic effect (40% inhibition). 
After an incubation period with the activators of 24 h, RNA was isolated using Trizol 
reagent. For cDNA synthesis 2.5 μg total RNA from HepG2 cells or primary human 
hepatocytes was used and 0.5 μg random hexamer primer (GE Healthcare Bio-Sciences 
Corp, Piscataway, USA) was added. The mixture was heated at 70°C for 10 min and 
thereafter quickly chilled on ice for 2 min. cDNA was synthesized in a total volume 
of 25 μl containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM 
dithiothreitol, 0.5 mM dNTPs and 200 U Superscript II Rnase H- Reverse Transcriptase 
(Invitrogen). After incubation for 1 h at 42°C, cDNA was diluted to a concentration 
equivalent of 10 ng/μl RNA.
Chapter 4 
98
Quantitative PCR
Quantitative PCR was performed using an ABI PRISM 7900 HT Sequence Detection 
system (Applied Biosystems, Inc. Foster City, USA). Specifi c primers were designed 
using Primer Express software (version 2.0, Applied Biosystems). To avoid the infl uence 
of DNA contamination, primer pairs were designed to span an intron-exon boundary, 
except for NAT1 which is an intronless gene [32] (Table 1).
Quantitative PCR was performed using cDNA equivalent to 50 ng RNA in a total 
of 25 μl PCR mix. The total mixture contained cDNA, 300 nM forward primer, 300 
nM reverse primer and 1X SYBRgreen PCR Master Mix (Applied Biosystems). The 
program used was 10 min at 95°C, 40 cycles of 15 s at 95°C and 1 min at 60°C (100% 
ramp), followed by a dissociation curve step. Expression levels were normalized by 
using the β-actin housekeeping gene.
Preparation of cell lysates for enzyme analysis
HepG2 cells (3x107) were trypsinized and added to 10 ml culture medium. A vial 
containing 5x106 primary human hepatocytes was thawed and added to 10 ml culture 
medium. Next HepG2 cells and primary human hepatocytes were centrifuged for 10 min 
at 300 g. Subsequently, cells were resuspended in 600 μl cold 0.25 M sucrose solution, 
buffered with 0.01 M Tris-HCl (pH 7.4), and chilled on ice. A cell suspension of 200 
μl was lysed by three subsequent sonifi cations with a sonifi er (Branson Ultrasonics 
Corporation, Danbury, USA) at 4 °C for 20 s with a 40 s interval between the pulses.
UGT activity measurements with 4-methylumbelliferone
The overall UGT activity was determined by using 4-MU as substrate. The reaction 
mixture contained 4-MU (50 μM), the cofactor uridine diphosphate glucuronic acid 
(UDPGA, 1mM), and cell lysate in a fi nal volume of 100 μl. 
The amount of protein in the reaction mixture was 0.55-0.64 mg and 0.04-0.08 mg for 
HepG2 cells and human hepatocytes, respectively. Substrate and lysate were preincubated 
for 2 min at 37ºC. The reaction was started by addition of UDPGA and followed for 20 
min at 37ºC. The decrease in fl uorescent signal was measured each minute on the Victor 
II (Perkin Elmer, Groningen, The Netherlands). The excitation wave length was set at 
340 nm and the emission was measured at 460 nm. The conversion rate was calculated 
in the linear part of the reaction curve. For calculation of the amount of 4-MU converted, 
a 4-MU standard curve was made. 
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GST activity measurements with monochlorobimane
The overall GST enzyme activity was assayed fl uorometrically with monochlorobimane 
(MCB). The reaction mixture contained 40 μM MCB, 1 mM reduced glutathione 
(GSH), and cell lysate in a total volume of 100 μl. The amount of protein in the reaction 
mixture was 0.12-0.15 mg and 0.04-0.08 mg for HepG2 cells and human hepatocytes, 
respectively. The reaction was started by the addition of GSH. Conjugation of MCB 
with glutathione results in formation of the fl uorescent product Gs-bimane which was 
measured at 37°C on the Victor II for 10 min every 20 s. The excitation wave length 
was set at 355 nm and the emission was measured at 460 nm. The conversion rate was 
calculated in the linear part of the reaction curve. The glutathione adduct of MCB (Gs-
bimane) is not commercially available. Therefore the method described by Bai et al. 
[33] was used for the calculation of the amount of Gs-bimane formed. Under optimized 
reaction circumstances (surplus enzyme and cofactor) several amounts of MCB (10-50 
μM with steps of 5 μM) were completely converted into Gs-bimane. The resulting 
standard curve was used for the calculation of the amount Gs-bimane formed.  
Protein quantifi cation
Protein concentration of cell lysates was measured with the BCA protein assay kit 
from Pierce (Pierce Biotechnologies, Rockford, USA) which is based on bicinchoninic 
acid (BCA) for the colorimetric detection and quantifi cation of total protein. The assay 
was performed according to the manufacturer’s protocol.
Statistical analysis
Each experiment was performed in duplicate in three independent experiments except 
where indicated otherwise. Data are expressed as mean ± SEM. The obtained data were 
compared for statistically signifi cant differences using the unpaired Student’s t test 
(p<0.05). Only induction levels above 2-fold with statistically signifi cant differences 
were seen as relevant.
Results
Comparison of phase II enzyme expression between HepG2 cells and primary human 
hepatocytes
The transcripts of UGT1A1 and 1A6, SULT1A1, 1A2, 1E1, and 2A1, mGST-1, GST 
μ1, NAT1 and EPHX1 were present in both HepG2 cells and hepatocytes (Figure 1). 
With exception of UGTs, the mRNA levels in HepG2 cells differed only slightly from 
levels in cryopreserved human hepatocytes. 
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Transcript levels of UGT1A1 were dramatically lower in HepG2 cells as compared to 
cryopreserved hepatocytes. The levels were 235-, 838-, and 163-fold higher in donor 
EG, HRU, and the pool, respectively. Likewise, UGT1A6 mRNA expression was 397-, 
2749- and 14-fold higher in donor EG, HRU, and the pool, respectively. 
SULT1A1 and 1A2 mRNA expression was almost similar in HepG2 cells and the 
hepatocytes (<3-fold difference). Transcript levels of SULT1E1 were 4- and 2-fold 
higher in donor HRU and the donor pool respectively and 13-fold lower in donor EG. 
The levels of the fourth SULT isotype analyzed, SULT2A1, were 3-fold higher in donor 
EG and the donor pool. Substantially higher levels (32-fold) were measured in donor 
HRU. 
Transcript levels of the GST isotypes, mGST-1 and GST μ1, were only slightly 
different from levels in HepG2 cells. mGST-1 mRNA expression in donor EG, HRU, 
and the pool was 14- and 20-fold higher or 7-fold lower, respectively. The difference 
between expression of GST μ1 in hepatocytes and HepG2 cells was even less. Expression 
was 5-fold higher, almost equal, and 14-fold lower in donor EG, HRU, and the pool, 
respectively. 
NAT1 transcript levels were almost equal in donor HRU, slightly higher in donor EG 
(5-fold), and slightly lower in the donor pool (4-fold). 
EPHX1 mRNA levels were almost equal in HepG2 and the donor pool. Somewhat 
greater differences were observed between HepG2 cells and donor EG and HRU in 
which transcript levels were 6- and 34-fold higher, respectively.
Figure 1. UDP-glucuronosyltransferases (UGT1A1 and 1A6), sulfotransferases (SULT1A1, 1A2, 1E1, 
and 2A1), glutathione S-transferases (mGST-1, GST μ1), N-acetyltransferase 1 (NAT1), and epoxide 
hydrolase 1 (EPHX1) expression levels in cryopreserved primary human hepatocytes (donor EG, donor 
HRU, 10-donor pool) and HepG2 cells. Results are presented as the mean mRNA levels expressed in 
copy number ratio of the phase II enzyme and β-actin transcripts of two independent measurements.
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Comparison of phase II enzyme activities in HepG2 cells and primary human 
hepatocytes
The overall UGT and GST activities were detectable in both HepG2 cells and the 
donor pool, but activities were signifi cantly higher in the donor pool (Figure 2). 
The low transcript levels in HepG2 cells of UGT1A1 and 1A6 are associated with a 
lower UGT enzyme activity (47-fold). The GST activity in HepG2 cells differed only 
slightly with the activity in the donor pool. 
Although expression levels of the GST isotypes mGST-1 and GST μ1 were around 
10-fold higher in HepG2 cells as compared with the donor pool, the overall GST enzyme 
activity was 4-fold lower in HepG2 cells.
Figure 2. UDP-glucuronosyl (UGT) and glutathione S-transferase (GST) activity (Δfl uorescence/min/
mg protein) in cryopreserved primary human hepatocytes and HepG2 cells. Results are presented as the 
mean activity ± SEM (n=3). A Δfl uorescence/min of 100,000 is equal to the conversion of 0.33 nmol/
min 4-MU and formation of 0.89 nmol/min GS-bimane. *Signifi cant difference (p<0.05) 
Effects of AhR activators on phase II enzyme expression in HepG2 cells
The effects of several AhR agonists on the transcript levels of the UGT- and SULT-
isoforms analyzed are presented in Figure 3. 
Transcript levels of UGT1A1 were markedly increased after exposure to the AhR 
agonists. Exposure to the inducers resulted in a dose-dependent induction of UGT1A1 
expression. The lowest activation doses for BNF, indirubin, indigo, TCDD, and 3MC 
were 10-7, 10-8, 10-7, 10-10, and 10-8 M, respectively. The highest activation doses for 
BNF, indirubin, indigo, TCDD, and 3MC (with fold changes in parentheses) were 10-4 
(8), 10-5 (20), 10-5 (6), 10-8 (6), and 10-5 M (22). Likewise, exposure to the AhR inducers 
resulted in increased UGT1A6 transcript levels. The lowest activation doses for BNF, 
indirubin, indigo, TCDD, and 3MC were 10-8, 10-8, 10-7, 10-10, and 10-6 M, respectively. 
The highest activation doses for BNF, indirubin, indigo, TCDD, and 3MC (with fold 
changes in parentheses) were 10-4 (16), 10-5 (19), 10-4 (6), 10-8 (23), and 10-5 M (5). 
Induction of the SULT isotypes by the AhR activators was less prominent. SULT1A1 
was induced by all AhR activators, with exception of 3MC. The lowest activation doses 
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were 10-7 M for BNF and TCDD, and 10-5 M for indirubin, and indigo. The maximum 
induction of 2- to 3-fold was observed for BNF, indirubin, indigo, TCDD at 10-6, 10-5, 
10-5 , and 10-7 M, respectively. 
SULT1A2 transcript levels were induced after exposure to BNF, indirubin, indigo, and 
3MC, in contrast to TCDD which did not show an effect. The induction was observed 
at a concentration as low as 10-7 M for BNF and indirubin, and at 10-6 M for indigo and 
3MC. The maximum induction (2- to 6-fold) was observed at 10-5 M for indirubin, and 
at 10-6 M for BNF, indigo and 3MC.
None of the inducers changed SULT1E1 transcript levels (data not shown).
Figure 3. Induction of UDP-glucuronosyltransferase (UGT) 1A1 and 1A6, sulfotransferase (SULT) 
1A1, 1A2, 1E1, and 2A1 mRNA expression in HepG2 cells after 24 h treatment with the AhR agonists 
β-naphthofl avone (BNF), indirubin, indigo, TCDD, and 3-methylcholanthrene (3MC). The level in 
uninduced HepG2 cells is set at 1. Data are presented as the mean expression ± SEM (n=3). *Signifi cant 
difference (p<0.05)
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SULT2A1 was induced by indirubin, indigo and 3MC. The lowest activation doses 
observed were 10-8 M and 10-6 M for indirubin and indigo, respectively. The maximum 
induction for both compounds was observed at 10-5 M, leading to 5- and 2.8-fold 
induction for indirubin and indigo, respectively. 3MC caused only a slight increase in 
SULT2A1 levels that was only signifi cant at 10-6 M (2-fold). BNF and TCDD did not 
show an effect.
The effects of the AhR inducers on the mRNA levels of mGST-1, GST μ1, NAT1, and 
EPHX1 are presented in Figure 4. mGST-1 transcript levels were enhanced by BNF, 
indirubin and indigo. The lowest activation doses for BNF, indirubin, and indigo were 
10-7, 10-8, and 10-5 M. The highest activation doses for BNF, indirubin, and indigo (with 
fold changes in parentheses) were 10-6 (5.6), 10-4 (3.8), and 10-5 M (2.7), respectively. 
GST μ1 was slightly induced (2.8-fold) after treatment with 10-5 M indirubin. NAT1 
was also only signifi cantly induced after exposure to indirubin at 10-4 M, which caused 
a 2.5-fold induction of the mRNA expression. Induction of EPHX1 transcript levels 
after exposure to AhR inducers was more prominent. The fi ve AhR agonists all caused 
a concentration dependent induction of EPHX1. The lowest activation doses for BNF, 
indirubin, indigo, TCDD, and 3MC were 10-6, 10-6, 10-5, 10-9, and 10-6 M, respectively. 
The highest activation doses for BNF, indirubin, indigo, TCDD, and 3MC were 10-4, 
10-5, 10-5, 10-7, and 10-5 M, respectively, resulting in a 2- to 7-fold induction.
Figure 4. Induction of microsomal glutathione S-transferase 1 (mGST-1), glutathione S-transferase Mu 
1 (GST μ1), N-acetyltransferase 1 (NAT1), and epoxide hydrolase 1 (EPHX1) mRNA expression in 
HepG2 after 24 h treatment with the AhR agonists β-naphthofl avone (BNF), indirubin, indigo, TCDD, 
and 3-methylcholanthrene (3MC). The level in uninduced HepG2 cells is set at 1. Data are presented as 
the mean expression ± SEM (n=3).  *Signifi cant difference (p<0.05)
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Effects of PXR and CAR activators on phase II enzyme expression in HepG2 cells
The mRNA induction of phase II enzymes was assessed after 24 h exposure T0901317, 
RIF, PB, and CITCO (Figure 5). None of these activators changed the transcript levels 
of UGT1A6, SULT1A1, SULT1E1, mGST-1, GST μ1, and EPHX1 (data not shown). 
Treatment with the CAR and/or PXR agonists resulted in induction of UGT1A1 
expression. However, induction was less prominent than induction with the AhR 
agonists. A maximum induction of approximately 3-fold was measured at 10-6, 10-5, 
10-4, and 10-7 M for T0901317, RIF, PB, and CITCO, respectively. Induction was already 
signifi cant at concentrations as low as 10-7, 10-6, 10-8 and 10-9 M for T0901317, RIF, PB, 
and CITCO, respectively.
SULT1A2 expression was induced by RIF at a concentration as low as 10-7 M with a 
maximum induction of 2.7-fold at 10-5 M. The lowest effective concentration of PB was 
also 10-7 M and the maximum induction of 2.6-fold was observed at 10-6 M. Induction by 
CITCO already occurred at 10-8 M with a maximum induction of 3.5-fold at 10-7 M. In 
contrast T0901317 did not affect SULT1A2 mRNA expression.
CITCO induced SULT2A1 transcript levels at a concentration as low as 10-9 M and at 
10-7 M the maximum induction was observed (4.4-fold). PB did not cause such a 
prominent induction, however, at 10-5 M and 10-6 M an induction of 2-fold was measured. 
No changes in transcript levels were observed after exposure to T09001317 and RIF. 
NAT1 was signifi cantly induced (2-fold) after exposure to PB and CITCO. 
Figure 5. Induction of UDP-glucuronosyltransferase 1A1 (UGT1A1), sulfotransferase (SULT) 1A2 and 
SULT2A1, and N-acetyltransferase 1 (NAT1) mRNA expression in HepG2 after 24 h treatment with 
the PXR/LXR agonists T0901317, PXR agonist rifampicin (RIF), the CAR/PXR agonist phenobarbital 
(PB), and the CAR agonist CITCO. The level in uninduced HepG2 cells is set at 1. Data are presented 
as the mean expression ± SEM (n=3).  *Signifi cant difference (p<0.05) 
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Discussion
It was demonstrated that HepG2 cells have with exception of UGTs a complete set 
of phase II enzymes. Levels of SULT1A1, 1A2, 1E1, mGST-1, GST μ1, NAT1 and 
EPHX1 in HepG2 cells differed only modestly from those in human cryopreserved 
primary hepatocytes. Also the overall GST enzyme activity in HepG2 cells was almost 
equal to that of primary hepatocytes. On the other hand, the mRNA levels of UGT1A1 
and 1A6 and the overall UGT enzyme activity were much higher in hepatocytes than in 
HepG2 cells. These results are consistent with fi ndings in other studies [6, 8, 34]. The 
fact that UGTs from the UGT1 family are highly inducible by agonists of the AhR, PXR, 
and CAR [19, 35] might have been due to this difference. Ritter et al. [35] showed that 
the levels of UGT1A1 in freshly isolated hepatocytes decreased dramatically after three 
days in culture. They hypothesized that a lack of induction factors, i.e. AhR, PXR, CAR 
agonists, caused this drop in activity. Consistent with our fi ndings Wilkening et al. [8] 
found a high mRNA expression and SULT enzyme activity. In contrast Grant et al. [37] 
observed a low SULT activity and a high UGT activity in HepG2 cells as compared 
to human hepatocytes. This stresses that characterization of HepG2 cells is important. 
Hewitt and Hewitt [6] found that the mRNA expression levels and activities of phase I 
and II enzymes in HepG2 cells are dependent on the source and culture conditions.
As shown previously, the levels of CYP enzymes in HepG2 cells are low as compared 
to levels in primary human hepatocytes [38]. Due to these low CYP enzyme levels and 
more physiological levels of most phase II enzymes there might be a balance towards 
the detoxication process for some of the compounds. This might explain why some 
compounds with known toxicity in primary hepatocytes remain non-toxic in HepG2 cells, 
whereas others like tamoxifen, benzo[a]pyrene and nitrofurantoin, being AhR, PXR and/
or CAR inducers, remain toxic in both HepG2 cells [3, 4] and primary hepatocytes.
Phase II enzymes can also play a crucial role in the toxication of several compounds. 
For these compounds the high levels of most phase II enzymes might refl ect the 
cytotoxic effects in both HepG2 cells and primary hepatocytes. For example, HepG2 
cells having high NAT levels predict mutagenicity of heterocyclic aromatic amines in in 
vitro micronucleus tests better than cell lines with low levels of NAT [34]. However, low 
levels of UGTs in HepG2 cells might underestimate the toxicity of some compounds, 
since excessive glucuronidation leads to toxicity with clofi bric acid and gemfi brozil [39, 
40]. 
We also examined the regulation of phase II enzymes by AhR, PXR and CAR agonists. 
UGT1A1 was shown to be responsive to 3MC, BNF, PB and RIF in primary human 
hepatocytes [41]. This can be explained by the fact that AhR, PXR and CAR binding 
motifs are present in the promoter region of UGT1A1 [19, 35]. Consistent with these 
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fi ndings, UGT1A1 was in the present study induced after treatment with all the AhR, 
PXR  and CAR agonists used. Induction with the AhR agonists was most prominent. 
UGT1A6 was also induced by treatment with the fi ve AhR agonists, but no effects 
were seen with PXR and CAR agonists. This is in agreement with the study of Bock 
and Kohle [19]. Regulation of UGT1A6 by the AhR is also supported by the fact that 
UGT1A6 is not inducible by TCDD in AhR knockout mice [42].
The superfamily of sulfotransferases consists of at least ten functional genes in humans. 
Four members (SULT1A1, 1A2, 1E1, and 2A1) which are expressed in the liver, were 
studied. SULT1A1 is involved in the detoxication and bioactivation of many xenobiotics, 
including proximate carcinogens. SULT1A1 transcript levels were in the present study 
upregulated by the AhR inducers BNF, indirubin, indigo, and TCDD. A tendency of 
induction was shown with 3MC. Therefore, it is likely that SULT1A1 is regulated via 
the AhR pathway. These results are in line with a study in which treatment of HepG2 
cells with BNF resulted in induction of SULT1A1 expression [43]. None of the PXR and 
CAR agonists affected SULT1A1 mRNA levels. Likewise, in other studies treatment of 
human hepatocytes with PXR/CAR inducers like PB, CITCO, dexamethasone, and RIF 
did not result in SULT1A1 mRNA induction [44]. 
In vitro studies have shown that SULT1A2 can activate proximate carcinogenic 
heterocyclic aromatic amines more effi ciently into carcinogenic metabolites than 
SULT1A1. However, SULT1A2 protein has not yet been detected in vivo and data 
about regulation of SULT1A2 are not reported [45, 46]. Here, exposure of HepG2 cells 
to BNF, indirubin, indigo, and 3MC resulted in increased SULT1A2 transcript levels, 
however, TCDD did not show any effect. SULT1A2 expression was also induced by 
the PXR/CAR agonists RIF, PB, and CITCO. These results suggest that AhR, PXR and 
CAR might all play a role in the regulation of SULT1A2 expression. 
SULT1E1, is known as an estrogen sulfotransferase and has been extensively studied 
due to its important role in steroid homeostasis [47, 48]. No induction of SULT1E1 
transcript levels by AhR, PXR, or CAR agonists was shown by us and others.
The SULT2 family mainly sulfonates neutral steroids and sterols. An important member 
of this family is SULT2A1, which catalyzes sulfonation of a number of endogenous 
hydroxysteroids, bile acids, and polycyclic xenobiotics such as certain aromatic 
carcinogens and therefore plays an important role in activation or detoxication reactions 
[49, 50]. It has been shown that SULT2A1 is regulated by the farnesoid X receptor [51], 
vitamin D receptor [52, 53], CAR, and PXR [54]. In the present, study SULT2A1 was 
regulated by the CAR inducers CITCO and PB. Although induction of SULT2A1 by 
PXR agonists has been reported, treatment of HepG2 cells with RIF and T0901317 did 
not result in induction of SULT2A1 mRNA expression. Also the AhR agonists BNF and 
TCDD did not affect SULT2A1 expression. However, up-regulation was observed with 
the AhR agonists indirubin, 3MC and indigo. 
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Glutathione S-transferases detoxicate a large number of electrophiles [55]. Nevertheless 
they are also involved in the activation of some proximate carcinogens such as haloethanes 
and haloalkenes [56]. GSTs can be classifi ed into cytosolic and membrane bound GSTs. 
The regulation of membrane bound mGST-1 and cytosolic GST μ1 which are both 
abundantly present in the liver were studied. Induction of membrane bound GSTs after 
in vivo treatment of rats with PB and BNF have been reported [57]. In the present study 
none of the PXR and/or CAR agonists affected mGST-1 transcript levels. However, the 
AhR inducers BNF, indirubin, and indigo increased mGST-1 mRNA levels. TCDD did 
not show an effect and, although not signifi cant, 3MC showed a tendency of induction. 
These results suggest that there might be a role for AhR in mGST-1 regulation. The 
regulation of the different cytosolic GSTs has been studied in detail in rat and human 
hepatocytes [58, 59]. In these studies 3MC and PB both induced cytosolic GSTs, 
however, no or very small inductions of GST μ1 were observed. Consistent with this, 
in the present study also very slight or no effects were seen with the AhR, PXR and/or 
CAR inducers. 
NAT1 was induced 2-fold after exposure to indirubin, CITCO, and PB. The effects of 
the CAR agonists CITCO and PB suggest that CAR might play a role in the regulation 
of NAT1. Indirubin was the only AhR agonist that affected NAT1 transcript levels. 
Therefore it is probably not AhR but crosstalk with another receptor that caused this 
effect. In another study the AhR activator benzo[a]pyrene also increased NAT1 transcript 
levels in HepG2 cells and primary human hepatocytes [8]. 
EPHX1 transcript levels were increased after treatment with the fi ve AhR inducers 
tested. Regulation of EPHX1 by AhR agonists was consistent with results from previous 
studies in which induction of EPHX1 was shown with benzo[a]pyrene [8] and Araclor 
1254 [60]. Several studies reported a slight induction (<2-fold) of EPHX1 after treatment 
with PB [60, 61]. Here no induction with the PXR and CAR inducers was observed. 
At the highest concentration of TCDD used (10-6 M), 40% cytotoxicity was shown 
in the glutathione depletion and Calcein-AM assay. This might explain the drop in 
UGT1A1, UGT1A6, SULT1A1, and EPHX1 induction seen at 10-6 M.
In conclusion, HepG2 cells have with exception of UGTs a complete set of phase 
II enzymes. However, mosts conclusions are based on mRNA expression and not on 
enzyme activities since proper (specifi c) fl uorometric or luminometric substrates for 
NAT1, SULTs, and EPHX1 are not yet available. Regulation of phase II enzymes in 
HepG2 cells shows that there is a good correlation with previous results in primary 
human hepatocytes. Therefore, in contradiction to primary hepatocytes, HepG2 cells are 
a relatively easy-to-handle tool for studying regulation of phase II enzymes in human 
liver cells. 
Because of the role of these phase II enzymes in catalyzing the toxication of several 
compounds, HepG2 cells might become a valuable tool system to predict toxicity. On the 
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other hand, levels of most CYPs are low in HepG2 cells without pretreatment of AhR/
PXR/CAR agonists [38]. Therefore for compounds in which CYP metabolism plays a 
crucial role in toxication and phase II metabolism plays a pivotal role in detoxication, 
toxicity might be underestimated due to a shift towards phase II metabolism. This 
imbalance might explain why some compounds with known toxicity in primary human 
hepatocytes remain non-toxic in HepG2 cells. 
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Abstract
In the present study an automated image analysis assisted in vitro micronucleus assay 
was developed using both the in regulatory genotoxicity assays commonly used rodent 
CHO-k1 cell line as well as the human HepG2 hepatoma cell line. The HepG2 cell line 
was chosen because the properties of this cell line including the presence of a functionally 
active p53 protein, a functionally competent DNA repair system, enzymes for phase I 
and II metabolism, and an active Nrf2 electrophile responsive system, might result in an 
assay with a high predictivity for in vivo genotoxicity. 
The CHO-k1 and HepG2 based assays were both evaluated by testing a compound 
list recommended by the European Centre for the Validation of Alternative Methods 
(ECVAM) that contains in vivo genotoxins and non-genotoxins. The sensitivity 
(percentage of genotoxic compounds that tested positive) (80%; 16/20) and specifi city 
(percentage of non-genotoxic compounds that tested negative) (88%; 37/42) of the 
CHO-k1 cell line were high. Although the sensitivity of the HepG2 cell line was lower, 
being 60% (12/20), the specifi city was high amounting to 88% (37/42). These results 
were confi rmed by testing an additional set of 16 genotoxic compounds. For both the 
CHO-k1 as well as HepG2 cell line it was possible to size-classify micronuclei enabling 
discrimination of aneugens from clastogens.
It is concluded that two high-throughput micronucleus assays were developed that can 
detect genotoxic potential and allow differentiation into clastogens and aneugens. The 
performance scores of both the CHO-k1 and HepG2 cell line for in vivo genotoxicity 
were high. Application of these assays in the early discovery phase of drug development 
may proof to be a useful strategy to early assess genotoxic potential. 
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Introduction
In drug development toxicity is an important factor for drug attrition. Genotoxicity is 
one of the causes of toxicity. The current regulatory in vitro genotoxicity assays used 
for determining genotoxic potential, have a low-throughput and need a relatively large 
amount of compound and are therefore in their present format less applicable in the 
early discovery phase. Toxicity screening in the early discovery phase, requires assays 
that have a high-throughput and need a low amount of compound. High-throughput 
assays based on the use of bacteria, yeast, and rodent/human cell lines are proposed to 
be useful in vitro models. 
In the present study a high content screening (HCS) technique was used to develop 
a high-throughput in vitro micronucleus assay in the rodent Chinese Hamster Ovarian 
k1 (CHO-k1) cell line as well as the human HepG2 cell line. In the HCS technique 
(fl uorescence) microscopy is used to analyze cell lines in 96-well plates (or even 384-well 
plates). Aspects that are of importance for development of a fast HCS micronucleus 
assay are automatic scoring, the choice of the cell line, the validation with proper 
reference compounds, and the ability of the test system to discriminate clastogens from 
aneugens.
Scoring of micronuclei in the regulatory in vitro micronucleus (IVMN) assay is a labor 
intense method that is performed manually on microscopic slides by trained operators. 
The manual scoring of micronuclei using microscopic slides results in inter-observer 
and intra-observer variability, with a scorer specifi c, coeffi cient of variation between 
5.5 and 9.5% [1]. One approach to improve the effi ciency is the automated counting of 
micronuclei by image analysis [1]. With this aim Diaz et al. [2] developed a HCS IVMN 
assay in CHO-k1 cells. Validation with reference compounds showed that their CHO-k1 
HCS IVMN assay was a high-throughput alternative with respect to the manual scoring 
of micronuclei in microscopic slides. This method was in the present study further 
optimized with respect to speed and stability of the stains.
To assess the use of HCS in the development of an IVMN assay two cell lines were 
compared in the present study being the CHO-k1 and HepG2 cell line. The CHO-k1 cell 
line is frequently used in the regulatory IVMN assay where it showed a high sensitivity 
(78.7%) (percentage of carcinogenic compounds that tested positive) but a low 
specifi city (30.8%) (percentage of non-carcinogenic compounds that tested negative) for 
carcinogenicity [3]. This low specifi city makes the regulatory assay not very practical 
for toxicity screening in early discovery phase of drug development, as it may lead to 
ineffi cient deselection of pharmacologically interesting compounds. The low specifi city 
of the CHO-k1 cell line may be due to a mutation in the p53 protein (Thr211 > Lys211) that 
affects its functionality [4-6]. This p53 protein plays a pivotal role in cell cycle control 
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and activation of DNA repair and apoptosis. CHO-k1 cells do not show endogenous phase 
I and II metabolism, which makes the addition of a metabolic fraction (i.e. S9 mixture), 
necessary. Application of S9 mixture can give false positive results in comparison to in 
vivo genotoxicity due to excessive phase I metabolism (outside the cellular membrane) 
without phase II metabolism [7]. As HepG2 cells contain phase I and II metabolism, an 
active Nrf2 electrophile responsive system, a functionally active p53 protein, and active 
DNA repair, the predictivity for in vivo genotoxicity may be higher [8-12]. 
The HCS IVMN assays in the two cell lines were evaluated by using a list of 62 
reference compounds for validation of new in vitro genotoxicity tests, published by 
the European Centre for the Validation of Alternative Methods (ECVAM) [13]. Based 
on available data, 20 compounds were defi ned by an ECVAM expert panel as being 
genotoxic and 42 compounds as non-genotoxic. This non-genotoxic group contains 
19 compounds that are frequently scored as falsely positive. Besides these compounds 
an additional set of 16 reference compounds including several estrogenic compounds, 
scoring positive for genotoxicity, were tested. The sensitivity (percentage of genotoxic 
compounds that test positive) and specifi city (percentage of non-genotoxic compounds 
that test negative) of the CHO-k1 and HepG2 cell line based assays were compared.
Another aspect that has to be taken into account when developing a micronucleus assay 
is the discrimination of clastogens from aneugens. In the conventional IVMN assay, 
clastogens and aneugens are discriminated by using fl uorescent in situ hybridization 
(FISH) analysis. This method is diffi cult to perform in a high-throughput format. 
Recently Hashimoto et al. [14] have shown that size-classifi cation of micronuclei is 
a reliable measure which is as effective as the commonly used FISH analysis for the 
discrimination of aneugens from clastogens. For the new automated image analysis 
based assays a HCS method to size-classify micronuclei to discriminate aneugens from 
clastogens was developed and incorporated in the image analysis software.
In summary, the focus in the present study is on 4 subsequent steps all required for 
development of a new micronucleus assay including (1) the development and optimization 
of an automated image analysis assisted HCS in vitro micronucleus assay in the rodent 
CHO-k1 cell line as well as the human HepG2 cell line, (2) the validation of these HCS 
IVMN assays with proper model compounds for genotoxicity, (3) the comparison of the 
performances of the CHO-k1 and HepG2 cell line and (4) development of a method to 
discriminate aneugens from clastogens based on size-classifi cation of the micronuclei. 
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Materials and methods
Materials
Dulbecco’s modifi ed Eagles medium, Nutrient Mixture F-12 (DMEM/HAM F12 
medium in a ratio of 1:1) was ordered from Gibco (Invitrogen, Carlsbad, CA, USA) and 
defi ned supplemented bovine calf serum was ordered from Hyclone (Thermo Scientifi c, 
Logan, Utah, USA). Both Collagen I and poly-D-lysine coated black/clear 96-wells 
microplates were obtained from BD Biosciences (San Jose, California, USA). 
Compounds
Stock solutions of the compounds were prepared in 100% dimethyl sulfoxide (DMSO). 
From the stocks, √10-fold dilution series were prepared in DMSO. All compounds 
were of analytical grade. Most of the compounds were ordered from Sigma-Aldrich 
(St. Louis, Missouri, USA), except 2-amino-3-methylimidazo[4, 5-f]quinoline (IQ) 
which was ordered from Wako (Richmond, Virginia, USA), and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP.HCl) which was ordered from Toronto research 
(North York, Ontario, Canada).
Cell culture
CHO-k1 and HepG2 cells were obtained from the American Type Culture Collection 
(Rockville, MD, USA). Both cell lines were used between passage 5 and 15. Cells were 
cultured in Dulbecco’s Modifi ed Eagles medium and Nutrient mixture F-12 (In Vitro 
Technologies Inc., Baltimore, USA) mixed in a ratio of 1:1 with 10% defi ned supplemented 
bovine calf serum from Hyclone (Utah, USA), 1% Penicillin-Streptomycin (10,000 U/
ml, Gibco), and 0.05% of an aqueous mixture containing ethanolamine (2.44 ml/l), 
sodium selenite (0.9 mg/l) and 2-mercaptoethanol (4.2 ml/l). Cultures were maintained 
in a humidifi ed atmosphere with 5% CO2 at 37 °C and medium was refreshed every 
three or four days with sub-culturing.
Preparation of assay plates 
The most appropriate plate coating of 96-well plates was assessed with respect to an 
even distribution and stretching of cells. This is especially an issue with HepG2 cells 
as these cells form easily clumps and grow in layers, which results in unfocused areas 
during imaging. 
For CHO-k1 cells collagen-I coated plates gave good results (Figure 1). However, 
HepG2 cells formed easily clumps and multiple layers on this coating. For HepG2 cells 
poly-D-lysine plates gave proper results, with only a limited number of cell clumps 
(Figure 1). Therefore CHO-k1 cells were seeded on collagen-I plates and HepG2 cells 
on poly-D-lysine plates. 
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The cell densities used were the most appropriate for each condition to reach at 
least 1,000 (binuclear) cells per well per plate per 10 image fi elds. For CHO-k1 cells, 
compounds were tested in three different conditions, i.e. for 3h with and without S9 
mixture and for 24h without S9 mixture. Depending on the condition, 10,000 cells/well 
were seeded for the 3h condition with S9 mixture (CHO-k1 3h+S9); 5,000 cells /well for 
the 3h condition without S9 mixture (CHO-k1 3h-S9); and 3,000 cells/well for the 24h 
condition without S9 mixture (CHO-k1 24h-S9). 
HepG2 cells were treated for 24h with the compounds without the addition of S9 
mixture as these cells have intrinsic metabolic activity. A protocol for S9 treatment of 
HepG2 cells was developed and tested for a few compounds, which showed activity in 
the CHO-k1 cells in the presence of S9 mixture but didn’t show activity in the HepG2 
cell line. In these cases HepG2 cells were treated for 3h with the compounds in the 
presence of S9 mixture. HepG2 cells were seeded in a density of 20,000 cells/well for 
the condition with S9 mixture (HepG2 3h+S9) and in a density of 10,000 cells/well for 
the condition without S9 mixture (HepG2 24h-S9).
Both CHO-k1 and HepG2 cells were seeded in a total volume of 190 μl for each 
well and thereafter left in the laminar fl ow hood for 30 min at RT to obtain an even 
distribution of the cells over the well surface. The cells were cultured for 24h.
Compound treatment
The cells were fi rst treated with 5 model compounds to determine the effectiveness of 
the newly developed assays. The reproducubility was tested with taxol and thereafter the 
assays were evaluated with the 62 compounds from the ECVAM compound list and an 
additional set of 16 genotoxic references including estrogenic compounds.
Seven serial dilutions (√10 steps) of the compounds or a control sample were added 
as 10 μl fractions to the cells leading to a fi nal DMSO concentration of 1%. The highest 
                 CHO-k1                                       HepG2
Figure 1. Representative image of the distribution and stretching of CHO-k1 and HepG2 cells in respec-
tively collagen-I and poly-D-lysine coated 96-well plates. 
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test concentration of each compound was 1 mM. The different methods that were used 
for the conditions without and with S9 mixture are described below. Experiments were 
performed in duplicate on two different 96-well plates. All experiments were repeated 
at least twice independently.
Conditions without S9 mixture: 
CHO-k1 cells were exposed to the compounds for 3h and 24h without the addition of 
S9 mixture. After these periods, three μg/ml cytochalasin B was added to the cells to 
block cytokinesis. Cells were cultured for another 24h; thereafter cells were fi xed and 
stained. 
HepG2 cells were exposed to the compounds for 24h without the addition of S9. 
Thereafter, six μg/ml cytochalasin B was added to the cells. HepG2 cells were cultured 
for 48h; then cells were fi xed and stained.
Conditions with S9 mixture:
For the conditions with S9 mixture (CHO-k1 3h+S9 and HepG2 3h+S9), S9 mixture 
was present during compound exposure (1:10, v/v). S9 mixture consisted of 2.5% S9 
liver homogenate from Aroclor-induced Wistar rats (NOTOX, ‘s Hertogenbosch, The 
Netherlands), 15.2 mM KCl, 4.28 mM MgCl2, 1.86 mM β-NADP+, 9.29 mM glucose-
6-phosphate and 93 mM phosphate buffer pH 7.4. CHO-K1 and HepG2 cells were 
incubated with S9 mixture for 3h, thereafter medium was removed, and cells were 
briefl y washed with Dulbeco’s phosphate buffered saline (PBS) from Gibco (Invitrogen, 
Carlsbad, CA, USA). 
In case of CHO-K1 cells, PBS was replaced by medium containing 5% defi ned 
supplemented bovine calf serum and 3 μg/mL cytochalasin B (Sigma-Aldrich, St. Louis, 
Missouri, USA). After 21h, CHO-k1 cells were fi xed and stained. 
In case of HepG2 cells, PBS was replaced by culture medium containing 5% defi ned 
supplemented bovine calf serum and HepG2 cells were cultured for 21h to allow the cells 
to divide and recover. Then cytochalasin B was added leading to a fi nal concentration 
of 6 μg/ml. HepG2 cells were cultured for another 48h and thereafter fi xed and stained.
Staining of the micronucleus assay
After compound and cytochalasin B treatment, medium was removed from the cells 
and the cells were fi xed for 20 min at RT by addition of 100 μl 4% paraformaldehyde 
in PBS. After fi xation and washing with PBS, the cells were incubated with 100 μl 
staining solution for 30 min at RT. The staining solution contained 2 μg/ml Hoechst 
33342 (Sigma-Aldrich, St. Louis, Missouri, US) to stain the nuclei and micronuclei  and 
2 μM DRAQ5 (Biostatus Limited, Shepshed, UK) to stain the cytoplasm. After removal 
of the staining solution, 100 μl PBS was added to each well.
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Imaging and image analysis of the micronucleus assay
Imaging was performed by using an Operetta imaging system equipped with Harmony 
software version 2.0.1 (Perkin Elmer, Hamburg, Germany). A 20x wide fi eld objective 
was used to acquire the images. For all conditions without S9 mixture, 10 fi elds per well 
were imaged to reach the minimum number of 2,000 binuclear cells needed for analysis. 
For most treatments without S9 mixture higher numbers were reached. Because cell 
growth was decreased in the case of conditions with S9 mixture, 20 fi elds per well were 
imaged for these conditions.
Analysis of the images was performed using Acapella Studio Suite (Perkin Elmer, 
Hamburg, Germany). Software for micronucleus analysis was developed in cooperation 
with Perkin Elmer. Image analysis was based on previously published guidelines for 
micronuclei scoring [15-17], i.e. both nuclei of similar size and intensity, micronuclei 
intensity similar to intensity of nucleus, and micronuclei size of 0.0625 up to ≤ 0.33-times 
the size of the main nuclei. The analysis software contains several modules. A schematic 
overview of the main modules in the analysis software is given in Figure 2. Firstly, 
binuclear cells are determined by nuclei detection (column 1) and assessment of nuclear 
pairing (column 2). Secondly, the cytoplasm of the cells is assessed (column 3). Finally, 
micronuclei are detected (column 4). Several additional modules were also present to 
fi ne-tune the assay, i.e. a module to detect fl uorescent compound precipitation (number 
of fragments outside cell borders), a module to exclude areas with cell clumps (‘cloud 
detection’), and a module to detect apoptotic bodies.
Scoring and calculations of the micronucleus assay
To determine whether a compound was genotoxic or not, the cytotoxicity was taken into 
account. Two methods were used to assess cytotoxicity. First, the percentage cytotoxicity 
was calculated based on a decrease of the number of cells after compound treatment: 
((Number of cells)C-(Number of cells)T) / (Number of cells)C * 100% 
(Number of cells)C = number of cells in control wells (1% DMSO treated) 
(Number of cells)T = number of cells in compound treated wells.
Second, cytotoxicity was calculated by using the cytotoxicity block proliferation index 
(CBPI). This method is based on the principle that cytotoxicity often results in cell 
cycle arrest which is refl ected in a decreased ratio of the percentage of binuclear cells to 
mononuclear cells when using cytochalasin B. The assessment of cytotoxicity by using 
the CBPI is defi ned as follows: 
100-100((CBPIT-1)/ (CBPIC-1))
CBPI = (number of mononucleated cells + 2* number of binucleated cells + 3* number 
of polynucleated cells) / total number of cells 
CBPIT = CBPI of treated cells
CBPIC = CBPI of control cells (1% DMSO) 
  
121
Development and validation of a HCS IVMN assay in CHO-k1 and HepG2 cells 
The following procedure was used for scoring:
1. The sum of the number of micronuclei in binuclear cells in the two duplicate plates 
was calculated. The same procedure was done for the number of binucleated cells, the 
number of mononucleated cells, the number of micronuclei in mononucleated cells, and 
the total number of cells. 
2. As main output value, the percentage binuclear cells with micronuclei were calculated: 
(Number of binuclear cells with micronuclei / number of binuclear cells)*100%.
3. A concentration was defi ned as positive when the percentage of binuclear cells with 
micronuclei showed at least a 1.8 fold induction as compared to the percentage in the 
DMSO (1%) treated cells. This factor was chosen, based on signifi cant fold inductions 
for all conditions and addition of two times the standard error. 
4. Treatments causing compound precipitation were excluded. 
5. Treatments causing cytotoxicity in either of the two methods at a level equal to or 
higher than 80% were excluded.
6. The duplicate values of a positive concentration were checked. When the coeffi cient 
of variation was <30% the concentration was defi ned as positive, if not the result of the 
treatment in that experiment was considered as equivocal. 
7. The second independently performed experiment was scored in the same way as 
described in points 1-6.
9. When the fi rst experiment showed an equivocal result and the second a positive result, 
Figure 2. Schematic overview of the HCS in vitro micronucleus assay analysis software. The main 
modules in the analysis software are used for nuclei detection (column 1), pairing of nuclei (column 2), 
cytoplasm detection (column 3), and micronuclei detection (column 4). A selection of critical param-
eters is shown in the four modules.
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the compound was considered to be positive. 
10. When the fi rst experiment showed an equivocal result and the second a negative 
result, the compound was considered to be negative.
11. In the case of two experiments that gave an equivocal result, a third test was performed 
to fi nally determine whether a compound was positive, negative or equivocal.
After scoring the sensitivity, specifi city, predictivity, positive predictive value, and 
negative predictive value were calculated:
Sensitivity: Percentage of genotoxic compounds (as described in the literature) that 
tested positive in the high throughput in vitro micronucleus assays.
Specifi city: Percentage of non-genotoxic compounds (as described in the literature) that 
tested negative in the high throughput in vitro micronucleus assays.
Predictivity: Percentage of all tested compounds that was predicted correctly 
Positive predictive value: Percentage of compounds that tested positive in the high 
throughput in vitro micronucleus assays and that are truly genotoxic (as described in the 
literature).
Negative predictive value: Percentage of compounds that tested negative in the high 
throughput in vitro micronucleus assays and that are truly non-genotoxic (as described 
in the literature).
Discrimination of aneugens from clastogens based on size-classifi cation 
The area of micronuclei that was calculated in the analysis software, was used to 
discriminate between small size micronuclei that contain most likely chromosomal 
fragments (type I micronuclei) and large micronuclei that contain most likely complete 
chromosomes (type II micronuclei). 
The threshold of the fractional area of micronuclei (parameter representing micronuclei 
size) for discrimination between type I and II micronuclei was assessed for CHO-k1 
cells. MMS and taxol were used to set this threshold, as MMS and taxol have a strong 
clastogenic and aneugenic mode of action, respectively. The results are presented in 
Figure 3. As can be seen the most optimal threshold that gives the best discrimination 
between taxol and MMS seems to be 0.17 in CHO-k1 cells (the same threshold was used 
for HepG2 cells). The percentage type II micronuclei belonging to this threshold that 
separates both compounds is 30% (Figure 3). Based on these results it was defi ned that 
compounds with a median above 30% are classifi ed as aneugens and compounds with a 
median less or equal to 30% are classifi ed as clastogens.
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Results
Development of a HCS in vitro micronucleus assay 
The automated analysis software was developed and optimized in collaboration with 
Perkin Elmer. An example of image analysis in the case of CHO-k1 cells is shown in 
Figure 4, which shows the main steps in the image analysis. Firstly, micronuclei are 
detected and paired, secondly the cytoplasm of the cells is detected, and fi nally the 
micronuclei are detected. 
Figure 3. Discrimination of clastogens (i.e. MMS) from aneugens (i.e. taxol) by using different fraction-
al area thresholds. The percentage type II micronuclei at different thresholds are shown. The borders of 
the bars represent the maximum and minimum values and the line within the bar represents the median.
Figure 4. Representative images of the micronucleus image analysis software for CHO-k1 
cells. The three main steps during image analysis are shown, i.e. the detection and pairing of nu-
clei (A), the detection of the cytoplasm (B), and detection of micronuclei within the cytoplasm 
of a binuclear cell depicted as a pink dot (C).
    A.                                         B.                                         C.
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Figure 5 shows an example of the fi nal result of image analysis of control cells (1% 
DMSO treated) and 1.00x10-5 M taxol treated cells for both CHO-k1 and HepG2 cells. 
During analysis a differentiation is made between mononuclear and binuclear cells and 
micronuclei are indicated as pink dots. Multiple pink dots can be seen after treatment 
with the genotoxic compound taxol.
Testing of model compounds and reproducibility 
To get a fi rst impression about the effectiveness of the assays, fi ve model 
compounds were tested (i.e. afl atoxin B1, benzo[a]pyrene (B[a]P), cyclophosphamide, 
7,12-dimethylbenzanthracene (DMBA), and MMS). The concentration dependent fold 
induction of the fraction of binuclear cells with micronuclei after exposure to these 
compounds is shown in Figure 6 for the CHO-k1 (3 conditions) and HepG2 HCS IVMN 
assays.
Figure 5. Representative results of the image analysis of control and taxol treated CHO-k1 and HepG2 
cells. Mononucleated (yellow nuclei) and binucleated cells (green nuclei) can be distinguished. Addi-
tionally, no micronuclei are observed within the control image fi eld whereas in the image fi elds of the 
treated cells many micronuclei (pink dots) can be observed.
HepG2
CHO-k1
HepG2
CHO-k1
                      Control                Taxol
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In the CHO-k1 3h-S9 condition, only B[a]P and DMBA showed an effect above the 
genotoxicity threshold. The lowest effective concentration (LEC) was in both cases 
3.16x10-5 M. As both compounds are proximate genotoxins that are activated by enzymes 
of the cytochrome P450 (CYP) 1A or CYP1B family, these enzymes appear to be active 
in the CHO-k1 cell line used. 
The addition of S9 mixture (CHO-k1 3h+S9) metabolically activated the proximate 
genotoxins afl atoxin B1 and cyclophosphamide, which are respectively activated 
by CYP3A4 and CYP2B6. The LEC of afl atoxin B1 was 1.00x10-4 M and that of 
cyclophosphamide 1.00x10-5 M. Both B[a]P and DMBA showed a much lower activity 
after the addition of S9 mixture in comparison to the 3h condition without S9 mixture, 
the effect of DMBA was even just below the threshold.  B[a]P had a LEC of 3.16x10-4 
M. MMS did not show any effect. 
In the CHO-k1 24h-S9 condition all compounds showed a genotoxic effect. B[a]P was 
the most potent compound with an LEC of 1.00x10-5 M. Afl atoxin B1 and DMBA had an 
LEC of 3.16x10-5 M. MMS and cyclophosphamide were the weakest active compounds 
Figure 6. HCS in vitro micronucleus assay in CHO-k1 and HepG2 cells. The dose response curves 
of fi ve model compounds are shown, i.e. afl atoxin B1, benzo[a]pyrene (B[a]P), cyclophosphamide, 
7,12-dimethylbenzanthracene (DMBA), and MMS. The dashed line indicates the genotoxicity threshold 
(see M&M). 
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with a LEC of 1.00x10-4 and 1.00x10-3M, respectively. As with exception of MMS, the 
compounds are proximate genotoxins, enzyme systems that activate these compounds 
must be present in the cells.
All fi ve compounds showed also a genotoxic effect in the HepG2 cell line. The potency 
of the compounds showed almost the same order as in the CHO-k1 cell line in the 
CHO-k1 24h-S9 condition.  
The reproducibility of the genotoxicity determination in the HCS in vitro micronucleus 
assays was investigated using taxol as reference compound (Figure 7). Four independent 
experiments were performed except for the CHO-K1 3h-S9 condition, for which only 
three replicates were performed. For the CHO-k1 3h-S9 condition the LEC was one 
time 3.16x10-7 M and two times 1.00x10-6 M. For the CHO-k1 3h+S9 condition the LEC 
was reproducible with two times 3.16x10-5 M and two times 1.00x10-4 M. For the 24h 
incubation condition, the LEC value was two times 1.00x10-7 M and two times 1.00x10-6 
M. 
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Figure 7. Reproducibility of the genotoxic effect of taxol in the HCS in vitro micronucleus assay for 
CHO-k1 and HepG2 cells. Three or four independent experiments were performed. The dashed line in-
dicates the genotoxicity threshold (see M&M). Variation in the LEC is limited. At higher concentrations 
there is more variation due to high levels of cytotoxicity (see Figure 8).
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For the CHO-k1 3h-S9 condition the LEC was one time 3.16x10-7 M and two times 
1.00x10-6 M. For the CHO-k1 3h+S9 condition the LEC was reproducible with two 
times 3.16x10-5 M and two times 1.00x10-4 M. For the 24h incubation condition, the 
LEC value was two times 1.00x10-7 M and two times 1.00x10-6 M. 
The variation in the HepG2 HCS in vitro micronucleus assay was larger. The LEC of 
taxol was different in all four experiments, i.e. 1.00x10-7 M, 3.16x10-7 M, 1.00x10-6 M 
and 3.16x10-6 M. 
The variation in the maximum induction between the experiments was much larger. 
This was due to cytotoxicity. For concentrations higher than 1.00x10-6 M the cytotoxicity 
of taxol rapidly increased to 60-80% for the conditions without S9 (see also Figure 8). 
Cytotoxicity was less in the presence of S9 mixture.
The reproducibility of the two methods to assess cytotoxicity was also tested (Figure 
8). This was tested for taxol in both the CHO-k1 (CHO-k1 24h-S9 condition) and HepG2 
cell line (HepG2 24h-S9). 
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Figure 8. Reproducibility of the cytotoxic effect of taxol based on number of cells (nCells) and CBPI in 
the HCS in vitro micronucleus assay for CHO-k1 (CHO-k1 24h-S9 condition) and HepG2 cells. The two 
dashed line at 20% and 80% cytotoxicity represent the minimal toxic concentration and toxicity level 
above which genotoxicity measurement are excluded (see M&M), respectively.
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Cytotoxicity measurement based on the number of cells (nCells) showed the lowest 
variation. In CHO-k1 cells, the minimum toxic dose (MTD; 20% cytotoxicity) was two 
times 1.00x10-6 M and two times 3.16x10-7 M. The MTD in HepG2 cells was similar 
with three times 1.00x10-6 M and one time 3.16x10-7 M. 
Cytotoxicity based on the CBPI showed more variation. The MTD was in CHO-k1 
cells one time 3.16x10-6 M, one time 1.00x10-6 M, and two times 3.16x10-7 M. In HepG2 
cells the MTD was two times 1.00x10-6 M and two times 1.00x10-7 M.
Overall the experiments in this section showed that reference compounds gave 
the expected genotoxic effects. In addition, the reproducibility of the HCS in vitro 
micronucleus assays is good. Therefore the assays were further validated by using a 
larger set of genotoxic and non-genotoxic compounds.
Validation with the ECVAM compound list
The HCS in vitro micronucleus assays in CHO-k1 and HepG2 cells were validated by 
testing the 62 ECVAM compounds. The overall results are shown in Tables 1-3. 
Of the 20 genotoxic compounds (Table 1) ENU, dimethylnitrosamine, 
2,4-diaminotoluene, and hydroquinone were tested negative in the CHO-K1 cell line. 
Eight genotoxins tested negative in the HepG2 cell line. Like in the CHO-k1 cells, ENU 
and hydroquinone were tested negative. Another six compounds were also tested negative, 
i.e. 2-acetylaminofl uorene, IQ, cadmium chloride, p-chloroaniline, azidothymidine, and 
chloramphenicol.
Of the 19 non-genotoxic compounds that have been reported to show often false 
positive results in mammalian in vitro genotoxicity assays (Table 2), three showed a 
positive result in CHO-k1 cells, i.e. ethionamide, propyl gallate and 2,4-dichlorophenol. 
None of these 19 compounds gave a positive result in HepG2 cells. 
Of the 23 non-DNA-reactive chemicals that have not been reported to give positive 
results in vitro (Table 3), two compounds were positive in the CHO-k1 assay, i.e. 
N-dicyclohexyl thiourea and progesterone. In HepG2 cells fi ve of these 23 compounds 
showed a positive result, i.e. phenformin HCl, ephedrine sulfate, phenanthrene, 
progesterone (+S9) and tris(2-ethylhexyl)phosphate. 
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The sensitivity, specifi city, predictivity, positive predictive value and negative predictive 
value were calculated as shown in Table 4. The sensitivity of the HCS IVMN assay in 
CHO-k1 cells was with 80% (16/20) higher than the sensitivity of 60% (12/20) that was 
observed for HepG2 cells. The number of false positive results in both tests was low 
with a specifi city of 88% (37/42). The scores resulted in an overall predictivity of the 
assay in CHO-k1 and HepG2 cells of 85% (53/62) and 79% (49/62), respectively. 
In addition, the positive and negative predictive values were calculated for the HCS 
IVMN assay in both cell lines. The positive predictive values were 76% (16/21) and 
71% (12/17) for the CHO-K1 and HepG2 assay, respectively. Negative predictive values 
were 90% (37/41) for the CHO-k1 and 82% (37/45) for the HepG2 assay.
Testing of 16 additional genotoxic compounds
An additional set of 16 genotoxic compounds, including several estrogenic compounds, 
were tested in both the CHO-k1 and HepG2 HCS IVMN assays (Table 5). Of the 16 
genotoxic compounds, 11 gave a positive result in the CHO-k1 HCS IVMN assay (69%). 
Like observed with the compounds from the ECVAM list, the sensitivity of the HepG2 
HCS IVMN assay was lower as here only nine compounds showed to be positive (56%). 
For most genotoxic compounds the fold induction was lower in the HepG2 cell line. Of 
the compounds that were genotoxic in the CHO-k1 HCS IVMN assay, three compounds 
were negative in the HepG2 cell line, i.e. 2,7-dinitrofl uorene, 4-hydroxy-estrone, and 
cytarabine. Methotrexate was genotoxic in HepG2 cells but showed no genotoxicity in 
the CHO-k1 cell line. 
Discrimination of aneugens from clastogens based on size-classifi cation 
Two types of micronuclei were defi ned, i.e. type I micronuclei containing chromosomal 
fragments and type II micronuclei containing complete chromosomes. Based on the size 
of micronuclei the genotoxic compounds can be classifi ed as clastogens (percentage 
type II micronuclei<30%) or aneugens (percentage type II micronuclei>30%). See 
M&M section.
Table 4. Validation of the CHO-k1 and HepG2 HCS IVMN 
assays with respect to the ECVAM compound list.
CHO-k1 (%) HepG2 (%)
Sensitivity 80 (16/20) 60 (12/20)
Specifi city 88 (37/42) 88 (37/42)
Predictivity 85 (53/62) 79 (49/62)
Positive predictive value 76 (16/21) 75 (12/17)
Negative predictive value 90 (37/41) 82 (37/45)
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All compounds that showed a genotoxic response in the CHO-k1 HCS IVMN assay 
were classifi ed as clastogens or aneugens. The results are presented in Figure 9. Most 
compounds have a percentage type II micronuclei with a median that is lower than 
30%, indicating that these compounds have most likely a clastogenic mode of action. 
The percentage type II among these clastogenic compounds has a wide range of 0% 
for cisplatin up to 26.8% for IQ which refl ects clastogens giving small and larger 
chromosomal fragments. The variation in the percentage of type II micronuclei for 
sodium arsenite made classifi cation of this compound diffi cult. The compounds that 
were classifi ed as aneugenic are propyl gallate, taxol, 17β-estradiol, 2-methoxy-estradiol, 
2,4-dichlorophenol, 17β-ethinylestradiol and chloramphenicol. 
As the total number of binuclear cells per 10 fi elds was lower for HepG2 cells and in 
general also the induction factors were lower, it was diffi cult to do the same classifi cation 
for all genotoxic compounds in the HepG2 cell line. However, to show that the principle 
works in HepG2 cells, the number of type II micronuclei was assessed for the strong 
aneugen taxol; and for B[a]P and DMBA which were (strong) clastogens in the CHO-k1 
cell line (Figure 10). The results clearly show that taxol gives like in the CHO-k1 cell line 
a high percentage of type II micronuclei; while B[a]P and DMBA give like in CHO-k1 
cells a low percentage of type II micronuclei and are therefore most likely clastogens. 
These results show that the classifi cation method also can be used for the HepG2 cell 
line.
Usage of S9 mixture to explain differences between results in the HCS IVMN assays 
in CHO-k1 and HepG2 cells.
Several compounds that were activated in the CHO-k1 3h+S9 condition, showed no 
activity in the HepG2 cell line. It was investigated whether the addition of S9 mixture to 
HepG2 cells would result in a genotoxic effect in this cell line as well. The HCS IVMN 
assay for the HepG2 condition with S9 mixture was performed for eleven compounds, i.e. 
cyclophosphamide, ENU, 7,12-diaminotoluene, IQ, cadmium chloride, p-chloroaniline, 
etoposide, hydroquinone, azidothymide, chloramphenicol and progesterone. Moreover, 
afl atoxin B1 was used to test the S9 protocol. 
The results are shown in Figure 11. The application of S9 mixture resulted in a 10-fold 
potentiation of the genotoxic effect of afl atoxin B1, indicating that the protocol that was 
used in case of CHO-k1 cells is also applicable for the HepG2 cell line. In the presence 
and absence of S9 mixture the cytotoxicity of afl atoxin B1 remained unchanged. Only 
for two of the eleven compounds an effect on the induction of micronuclei with S9 
mixture was observed.
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Figure 9. The percentage type II micronuclei (MN) for genotoxins in the CHO-k1 HCS IVMN assay. 
Concentrations causing an induction of MN were used for the asesssment of type II MN. The top of the 
lines represents the maximum, the bottom the minimum, and the triangle the median. Compounds with 
a median higher than 30% were defi ned as compounds with an aneugenic mode of  action (see M&M); 
compounds with a median less or equal than 30% were defi ned as clastogens (horizontal dashed line).  
Figure 10. The percentage type II micronuclei for 7,12-Dimethylbenzanthracene (DMBA), benzo[a]
pyrene (B[a]P) and taxol determined in the HCS IVMN assay in HepG2 cells. The borders of the bars 
represent the minimum and maximum values and the line within the bars the median.
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Etoposide showed no genotoxic effect in the absence of S9 mixture. In this condition 
there was already 70% cytotoxicity at a concentration of 1.00x10-6 M. Addition of S9 
mixture resulted in a large decrease of cytotoxicity as now a 100-fold higher concentration 
of 1.00x10-4 M etoposide was needed to reach this level of cytotoxicity. A clear genotoxic 
effect was observed at a concentration of 3.16x10-6 M. 
Progesterone was not genotoxic in the absence of S9 mixture and the compound was 
cytotoxic at a concentration of 1.00x10-5 M. Addition of S9 mixture clearly resulted in 
detoxifi cation and a genotoxic effect was now observed at the highest test concentration 
of 1.00x10-3 M. 
Discussion
Development and optimization of HCS IVMN assays 
Two HCS IVMN assays have been developed, one in the CHO-k1 and one in the 
HepG2 cell line. Imaging and scoring of the number of MN in these assays has a 
much higher throughput than manual scoring of MN in microscopic slides. Imaging 
of 10 fi elds per well for one 96-well plate takes 50 min. Analysis of these 960 images 
takes 3h. Depending on the hardware confi guration it is possible to perform up to six 
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Figure 11. Effect of S9 mixture in the HepG2 HCS IVMN assay.  For an explanation of the thresholds 
see M&M.
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analyses in parallel. Compared to the HCS assay that was described by Diaz et al. [2], 
the throughput of the present assays is higher. In their assay it took 12h to image and 
analyze 11 compounds in duplicate, which would with our assay method in the most 
simple hardware confi guration take about 8h. 
In addition, the reproducibility of the assays was good and two relatively cheap as well 
as up to at least eight months stable fl uorescent stains were used. The cytoplasmic stain 
used by Diaz et al. [2] was not that stable as plates had to be measured within three days 
after staining.
Validation with the ECVAM compound list
The HCS IVMN assays were validated by using 62 chemicals that were described in 
an ECVAM compound list that can be used for the optimization or validation of in vitro 
genotoxicity assay [13]. 
The specifi city of both cell lines was high with 88% (37/42). In both assays only 
fi ve compounds out of the 42 non-genotoxic compounds showed a positive result. This 
specifi city is much higher than the specifi city score of 30.8% for carcinogenicity that 
was reported by Kirkland et al. [3]. In the study described by Kirkland, the specifi city 
was based on a relative small number of 26 non-carcinogenic compounds. There was 
almost no overlap of compounds with the present study; only for propyl gallate, which 
was positive in the present study, an equivocal result was reported. The difference in 
compound set or method of scoring might have been the reason, but the large difference 
is unexpected. The HCS IVMN assay described by Diaz et al. had also a high specifi city 
of 100%. However, in this study only 13 non-genotoxic compounds were tested which 
is a relatively small number. None of these 13 compounds were tested in the present 
study. 
The 42 non-genotoxic compounds that were tested contained 19 compounds that are 
known to give often false positive results in mammalian in vitro genotoxicity assays. 
Of these 19 compounds, only three gave a positive score in the CHO-k1 cell line, 
i.e. ethionamide, propyl gallate, and 2,4-dichlorophenol. Both propyl gallate and 2, 
4-dinitrophenol were activated by the addition of S9 mixture. None of the 19 compounds 
showed a positive result in the HepG2 cell line.
Of the remaining 23 non-genotoxic compounds, two gave a false positive result in the 
CHO-k1 cell line, i.e. N,N-dicyclohexyl thiouria and progesterone which is activated by 
S9 mixture. For progesterone it has been shown that it is a weak inducer of MN in the liver 
[18]. In HepG2 cells fi ve of these 23 compounds showed a positive result. Three were 
in the subgroup of non-carcinogens with no in vivo genotoxicity data, i.e. phenformin 
HCl, ephidrine sulphate, and phenanthrene. The other two positive results were in the 
group of non-genotoxic carcinogens; like in CHO-k1 cells progesterone showed a weak 
positive result (+S9 mixture) and in addition tris(2-ethylhexyl)phosphate was positive.
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The low number of false positive results is also refl ected by the high negative 
predictive values of 90% and 82% for the CHO-k1 and HepG2 HCS IVMN assays. 
These low numbers of false positive results make both assays suitable candidates for 
implementation in the early phases of drug development, since not too many compounds 
will be excluded from further development based on false positive genotoxicity results.
Also the sensitivity of the assays needs to be high for implementation of the assays. The 
sensitivity of the assay in CHO-k1 cells was high with 80% (16/20), which is comparable 
to the sensitivity of 78.7% reported by Kirkland et al. [3] and that of the automated in vitro 
micronucleus assay in CHO-K1 cells as developed by Diaz et al., which obtained 88% 
sensitivity [2]. Further investigation of the four compounds that gave a false negative 
result (i.e. ENU, dimetylnitrosamine, 2,4-diaminotoluene, hydroquinone) shows that 
dimethylnitrosamine is metabolized by CYP2E1 [13]. This CYP is not highly expressed 
in rat liver S9 which might explain the negative result. For the three other compounds 
no clear explanation for the negative result can be given. 
The sensitivity of the HCS assay in HepG2 cells was lower with 60% (12/20). The 
relatively low levels of phase I enzymes in combination with normal levels of phase 
II enzymes might be the reason for the lower sensitivity, as metabolism might shift to 
detoxifi cation [11, 12]. Moreover, the HepG2 cell line contains a functionally active 
p53 protein and DNA repair which will make it more diffi cult to detect DNA damage. 
Biomarkers that indicate activation of these pathways like for example activation of p53 
might be a more sensitive method to detect genotoxic potential in the HepG2 cells.
Testing of 16 additional compounds
Testing of an additional set of 16 genotoxic compounds confi rmed results that were 
obtained with the ECVAM compound list. The sensitivity of the CHO-k1 cell line was 
with 69% (11/16) higher than the sensitivity of 56% (9/16) that was obtained for the 
HepG2 cell line. Combining the genotoxic compounds in both compound sets results in 
a sensitivity of 75% (27/36) for the CHO-k1 cell line and of 58% (21/36) for the HepG2 
cell line. 
Discrimination of aneugens from clastogens based on size-classifi cation 
The standard method to make a discrimination between clastogens and aneugens in 
the micronucleus is by making use of CREST-staining or in situ hybritization [19-22]. 
These two staining techniques both visualize the centromeric region of the chromosome. 
With clastogenic compounds, a lower percentage (approximately 2-23%) of centromere 
positive micronuclei is found as compared to aneugens (approximately 74-94%) [21]. 
In addition, telomeric probes can be used to differentiate between whole chromosomes 
formed by aneugenic compounds and centric chromosome fragments formed by 
clastogenic compounds [23]. These standard methods are in principle applicable in a 
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HCS format however these methods are laborious, as additional staining, imaging (100x 
up to a 1000x magnifi cation), and analysis is needed [22, 23].
A method that is more transferable into a high-throughput format is the recently 
published method by Hashimoto et al. [14] which uses size-discrimination of micronuclei 
to classify between clastogens and aneugens. This method was in the present study 
modifi ed into a high content screening method. 
Of the 32 compounds that were genotoxic in the CHO-k1 cell line, seven showed 
an aneugenic effect in the CHO-k1 cell line, i.e. propyl gallate, taxol, 17β-estradiol, 
2-methoxy-estradiol, 2,4-dichlorophenol, 17β-ethinylestradiol, and chloramphenicol. 
For the natural estrogens 17β-estradiol and 2-methoxy-estradiol it has been reported 
that these compounds are aneugenic [24]. The synthetic estrogen 17β-ethinylestradiol 
gave a percentage of type II MN that was just higher than that of 2-methoxy-estradiol. 
4-Hydroxy-estrone was also reported to cause microtubule disruption however this 
compound was 20-times less active than 2-methoxy-estradiol [24]. In the present study 
4-hydroxy-estrone was classifi ed as clastogenic; induction of DNA strand breaks has 
been reported for 4-hydroxy-estrone [25]. For chloramphenicol, 2,4-dichlorophenol 
and propyl gallate the data about clastogenicity or aneugenicity is very limited. For 
propyl gallate and chloramphicol weak genotoxic effects causing DNA fragmentation 
were reported [26, 27]. For the 2, 4-dichlorophenol no such data are available. The 
topoisomerase II inhibitors doxorubicin, etoposide, and ellipticin that were classifi ed 
as clastogens in this study, can show clastogenic as well as aneugenic effects, however 
clastogenic effects seem to be the most prominent [28, 29]. Sodium arsenite which had 
a median that was just below the threshold of 30%, has been reported to be a clastogenic 
compounds [13]. For the remaining compounds the mode of action is probably indeed 
clastogenic [13]. 
The usage of a liver-S9 metabolic fraction in CHO-k1 and HepG2 cells 
Like in the regulatory IVMN assay (draft guideline) a S9-liver metabolic fraction was 
used to mimic metabolism in the CHO-k1 HCS IVMN assay. This metabolic fraction 
was able to activate most proximate genotoxins, i.e. cyclophosphamide (CYP2B6), 
2-acetylaminofl uorene (CYP1A2), IQ (N-acetyl transferases), PhIP.HCl (N-acetyl 
transferases). 
The proximate genotoxins benzo[a]pyrene and DMBA, which are activated by 
CYP1A1 and/or CYP1B1 [13], clearly showed activity without S9 mixture in CHO-k1 
cells, which suggests that these CYPs are present in the CHO-k1 cells. Literature about 
CYP1A1/1B1 activity in CHO-k1 cells is not available; however the aryl hydrocarbon 
receptor that activates these enzymes is functionally active in the CHO-k1 cell line 
[30]. The presence of S9 mixture even resulted in a decrease of the genotoxic effects of 
B[a]P and DMBA, indicating that formation of reactive metabolites within the cell is 
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more effective than formation outside the cell. 
Three compounds which in principle do not need metabolic activation, i.e. 
p-chloroaniline, azidothymidine, and chloramphenicol [13], showed higher genotoxic 
effects in the presence than absence of S9 mixture. Here a decrease of cytotoxicity 
resulted in more prominent genotoxic effects.
HepG2 cells were in principle only tested without the presence of S9 mixture as a 
certain level of metabolism is present in these cells. However, to explain differences 
between the two cell lines we tested all compounds that were activated by S9 mixture 
in CHO-k1 cells but lacked activity in HepG2, in HepG2 cells in the presence of S9. 
The protocol gave satisfactory results for this cell line as we clearly could activate the 
genotoxicity of afl atoxin B1, etoposide and progesterone. Like in the CHO-k1 cell line, 
two different modes of action activated the compounds. In case of afl atoxin B1 it was 
metabolic activation. In case of progesterone and etoposide application of S9 mixture 
resulted in lower cytotoxicity which made it possible for the genotoxic effect to appear. 
For another nine compounds no effect of the addition of S9 mixture was observed.  
In summary, two automated image analysis assisted HCS in vitro micronucleus assays 
were developed and validated by using 62 reference compounds from an ECVAM 
compound list and an additional set of 16 genotoxic compounds. The predictivity of both 
assays for in vivo genotoxicity was satisfactory and in the same order of magnitude. In 
addition, the two developed assays in CHO-k1 and HepG2 cells allow differentiation of 
genotoxins in clastogens and aneugens. Application of these assays in the early discovery 
phase of drug development may proof to be a useful strategy to early assess genotoxic 
potential. 
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Abstract
In the present study gene expression profi ling in HepG2 cells was used to fi nd biomarkers 
(genes and responsive elements) that can be used for the development of high-throughput 
luciferase based reporter assays that can assess the genotoxic potential of compounds 
and discriminate genotoxic carcinogens from non-genotoxic liver toxicants. 
HepG2 cells were exposed to cytotoxic concentrations of the non-genotoxic liver 
toxicants as cytotoxicity can activate stress pathways, may cause DNA damage, and may 
thus result in a false-positive in vitro prediction for in vivo genotoxicity. The differences 
between the expression profi les of the genotoxic and liver non-genotoxic toxicants 
were used to determine biomarker genes or responsive elements that are specifi c for 
genotoxins. Application of such biomarkers may result in a high-throughput luciferase 
based assay with a good sensitivity for genotoxicity and low false positive rate for non-
carcinogens and in vivo genotoxicity.
HepG2 cells were treated with four genotoxic and seven non-genotoxic liver toxicants 
for 6h, 24h and 72h. Discrimination between the two classes of compounds was limited 
when all differentially expresses genes (DEG) were used. Pathway analysis of the 
DEG in the class of genotoxins revealed multiple affected pathways, of which the main 
ones at the three time points were involved in cell cycle control. At 72h several of the 
genotoxicity pathways were also activated by the non-genotoxic liver toxicants (i.e. p53 
pathway, ATM pathway, G2/M cell cycle checkpoint regulation). 
Additional data analysis with Qlucore Omics Explorer was performed to fi nd genes that 
differentiate both classes of compounds. This analysis yielded for each time point a subset 
of genes (6h, 362 genes; 24h, 1914 genes; 72h, 498 genes). Pathway analysis showed 
that the 6h and 24h gene subsets were mainly involved in the cell cycle, apoptosis, and 
DNA repair. No discriminating pathways were revealed by the 72h subset of genes. 
The most pronounced induced genes (top 10) in the three sets of genes were mainly 
downstream targets of p53, involved in apoptosis or the oxidative stress response. Several 
other pivotal genes involved in the DNA damage response were also present in the three 
subsets (i.e. GADD45A, GADD45B, PCNA, POLH, and XPC). 
In conclusion, gene expression analysis with Qlucore Omics Explorer revealed a 6h, 
24h, and 72h gene subset that discriminated genotoxic from non-genotoxic toxicants 
exerting their effect through cytotoxicity. The most prominent induced genes in the three 
subsets of genes were mainly involved in cell cycle control and downstream targets of 
p53. Further studies are undergoing to assess the role of the individual gene expression 
in luciferase based reporter assays which may provide a tool for screening genotoxicity 
with lower levels of false positives.
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Introduction
In drug development toxicity is an important factor for drug attrition [1]. Genotoxicity 
is one of the important causes of toxicity [2]. Toxicity screening in the early discovery 
phase, requires the use of assays that have a high-throughput with the need for a low 
amount of compound [2, 3]. In this respect luciferase based reporter assays in bacteria, 
yeast, and (human) cell lines have been proposed as useful model systems to early assess 
genotoxic potential. 
We have explored the bacterial based luciferase reporter assay VitotoxTM assay as pre-
screen for bacterial mutagenicity [4]. The VitotoxTM appeared to be a valid high-throughput 
pre-screen for the Ames assay. In addition the yeast based reporter assay RadarScreen 
was explored as assay to detect chromosome damage [4, 5]. The RadarScreen assay 
showed a high sensitivity for genotoxicity, however also a high false positive rate for 
non-carcinogens and in vivo genotoxicity. A high false positive rate for non-carcinogens 
is also observed with the regulatory in vitro mammalian genotoxicity assays [6]. Factors 
that may play a role in the high false positive rate of currently applied mammalian 
cell lines are their lack of phase I and II metabolism, the absence of an active Nrf2 
electrophile responsive system or functionally active p53 protein and their lack of active 
DNA repair [7-11]. Not only the rodent cell lines used in regulatory genotoxicity assays 
but also the recently validated yeast strain (RadarScreen) generally are defi cient in one 
or more of these properties [7-10]. As HepG2 cells contain these properties [5, 11-13], 
the development of luciferase based assays in the HepG2 cell line may result in a high-
throughput assay with an improved predictivity for genotoxicity (viz. good sensitivity 
and low rate of false positives).
In the present study gene expression profi ling in HepG2 cells was used to assess genes 
or responsive elements that can be used for the development of luciferase based reporter 
assays to detect genotoxic potential at a low false positive rate. 
HepG2 cells have been successfully used to discriminate genotoxic from non-genotoxic 
carcinogens by gene expression profi ling [14-16]. Classifi ers that discriminated 
genotoxic and non-genotoxic carcinogens were involved in cell cycle regulation, 
cell cycle arrest, DNA damage related processes, immune and stress responses, and 
apoptosis [14-16]. Expression profi ling in HepG2 cells showed that genotoxic and non-
genotoxic carcinogens could be discriminated at a relative short exposure period (12h) 
and at longer exposure periods (24h and 48h). Additional studies in primary mouse 
hepatocytes have shown that the difference between the expression profi les of genotoxic- 
and non-genotoxic compounds becomes more apparent in time, which improved the 
classifi cation [17]. The focus in these studies was on the determination of genotoxic and 
non-genotoxic pathways involved in carcinogenesis and therefore in these studies non-
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toxic concentrations of the non-genotoxic carcinogens were used. 
In the present study gene expression profi ling in HepG2 cells was used to fi nd genes 
and responsive elements that can not only assess the genotoxic potential of compounds 
but also discriminate genotoxic carcinogens from non-genotoxic liver toxicants. HepG2 
cells were exposed to the non-genotoxic liver toxicants at concentrations that give a 
clear cytotoxic response. Cytotoxic concentration of the non-genotoxic liver toxicants 
were used since cytotoxicity can activate stress pathways, may cause DNA damage, 
and may thus result in a false-positive in vitro prediction for non-carcinogens or in vivo 
genotoxicity [8]. The selection of genes and responsive elements that are specifi c for 
genotoxic carcinogens and are thus not activated by non-genotoxic liver toxicants might 
identify genes or response elements to use in the development of a luciferase based 
reporter assay with a good sensitivity and low false positive rate. 
HepG2 cells were treated with four well known genotoxic carcinogens and seven 
non-genotoxic toxicants. The genotoxic carcinogens used in the present study were 
the topoisomerase II inhibitor doxorubicin [18, 19], the topoisomerase I inhibitor 
camptothecin [19-21], the DNA crosslinker cisplatin [22], and the adduct former 
benzo[a]pyrene (B[a]P). B[a]P is a proximate genotoxin that is activated by cytochrome 
P450 (CYP) 1A and epoxide hydrolase 1 [23]. Moreover, B[a]P activates the aryl 
hydrocarbon receptor [24]. The non-genotoxic liver toxicants used were the necrotic 
compounds paracetamol (APAP, acetaminophen) [25], carbon tetrachloride (CCl4) [26] 
and iproniazid [25]. The two liver cholestatic compounds used were chlorpromazine and 
α-naphthylisothiocyanate (ANIT) [25]. Subsequently gliotoxin, a compound causing 
apoptosis [27], and TNFα, an inducer of infl ammation were tested.
HepG2 cells were treated with the compounds for 6h, 24h, and 72h to be able to study 
the level of discrimination between the genotoxic and non-genotoxic toxicants in time 
and to study the activation of typical pathways involved in genotoxic responses for both 
the genotoxins compared to the non-genotoxic toxicants in time.
Materials and methods
HepG2 cell culture
HepG2 cells were obtained from the American Type Culture Collection (Rockville, 
MD, USA). Cells were cultured in Dulbecco’s Modifi ed Eagles medium and Nutrient 
mixture F-12 (In Vitro Technologies Inc., Baltimore, USA) mixed in a ratio of 1:1 
with 10% defi ned supplemented bovine calf serum from Hyclone (Utah, USA), 1% 
Penicillin-Streptomycin (10,000 U/ml, Gibco), and 0.05% of an aqueous mixture 
containing ethanolamine (2.44 ml/l), sodium selenite (0.9 mg/l) and 2-mercaptoethanol 
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(4.2 ml/l). Cultures were maintained in a humidifi ed atmosphere with 5% CO2 at 37 °C 
and medium was refreshed every three or four days with sub-culturing.
Compound Treatment
HepG2 cells were seeded in 9 cm Petri dishes in a density of 5x105 cells/ml in a total 
volume of 10 ml. Cells were cultured overnight at 37º C and a humidifi ed atmosphere 
with 5% CO2. Then medium was replaced by medium containing the genotoxic or 
non-genotoxic compounds. All compounds were of analytical grade and obtained 
from Sigma-Aldrich (St. Louis, Missouri, USA). Compounds were dissolved in 100% 
dimethyl sulfoxide (DMSO). DMSO solutions were added to culture medium leading 
to a fi nal DMSO concentration of 1%. The concentrations of the genotoxins used were 
based on genotoxic concentrations in the VitotoxTM and or RadarScreen assay [4]. The 
non-genotoxins were tested at concentrations causing 20%-50% cytotoxicity [28] with 
the exception of TNFα, which was tested at a concentration giving a maximum induction 
of the caspase-3 activity in HepG2 cells (based on unpublished MSD data). 
RNA isolation and quality control
After exposure, total cellular RNA was isolated. To this end, cell culture medium was 
removed and cells were washed once with 10 ml PBS (without Ca2+/Mg2+). Then PBS 
was removed and 1 ml of Trizol Reagent (Invitrogen) was added to the Petri dishes. 
After a short incubation period of 1 minute, Trizol reagent containing cell lysate was 
collected in a 2 ml Eppendorf tube and mixed. Then 200 μl chloroform was added and 
the tubes were shaken vigorously by hand. Samples were centrifuged for 15 min at 
12,000g at 4°C. The upper aqueous phase was transferred to a new Eppendorf vial and 
placed on ice. Of the supernatant, 200 μl was used for further purifi cation steps. The 
remaining supernatant was stored in a freezer at -80 ºC. Then 200 μl of 70 % ethanol 
were added to an equal volume of supernatant. After mixing, the sample was loaded on 
a Purelink™ Micro-to-Midi total RNA Purifi cation System column (Invitrogen). RNA 
was purifi ed according to the manufacturer’s protocol. RNA was eluted by using 30 μl 
of RNAse free water.  
The RNA concentration and quality of the samples was determined with use of the 
nanodrop ND-1000 spectrophotometer and bioanalyzer 2100 (Agilent Technologies, 
Amstelveen, The Netherlands). The OD260/OD280 values of all samples were >1.8 and 
the RNA integrity values [29] were >9. 
RNA processing, DNA hybridization and staining of the arrays
The GeneChip 3’IVT Express kit (Affymetrix, Santa Clara, CA) was used to generate 
biotinylated DNA from the RNA template. Labelled cDNA was fragmented, checked 
on the Bioanalyzer 2100 and hybridization mixtures were prepared (Affymetrix 
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hybridization wash and stain kit). Then 300 μl 50 ng/μl labeled DNA were hybridized at 
45 ºC for 16-17 h to the Affymetrix GeneChip HGU133_Plus_2. Gene chips were washed 
and stained by using an Affymetrix fl uidics station 450. The arrays were laser scanned 
with a GeneChip scanner 3000 (Affymetrix). All steps were performed according the 
manufacturer’s instructions. 
Data processing and gene expression analysis
First, the complete set of data was processed and analyzed. Second, Qlucore Omics 
Explorer 2.1 (Qlucore AB, Lund, Sweden) was used to assess subsets of genes that 
discriminated the genotoxic from non-genotoxic toxicants. 
Affymetrix CEL fi les were processed in Rosetta Resolver (v7.2, buid 7.2.2.0.0). 
Intensity Profi les were built using the Affymetrix Rosetta-Intensity Profi le Builder 
using PM and MM probes. Affymetrix Rosetta-Intensity Experiment Builder combines 
the expression values for individual profi les and normalizes the data. Ratios were 
calculated from simple arithmetic averages of numerator (compound treated samples) 
and denominator (vehicle treated samples). The corresponding p-values were calculated 
using a two-sided two-sample t test. Probesets that did not produce signifi cant ratios 
(p<0.05) in any contrast were removed from the dataset.
Subsequent data analysis was performed on log10ratios in Qlucore Omics Explorer 2.1 
(Qlucore AB, Lund, Sweden). At each of the time points 6h, 24h and 72h a t-test identifi ed 
the signifi cantly discriminating genes (p ≤ 0.01) between samples from genotoxic and 
non-genotoxic toxicants.
CoPub and Ingenuity Pathway Analysis 
The differentially expressed genes (>2-fold, p<0.05) were analyzed by using Ingenuity 
Pathways Analysis (Ingenuity® Systems, www.ingenuity.com). Ingenuity pathway 
analysis was performed to identify the pathways from the Ingenuity Pathways Analysis 
library of canonical pathways that were most signifi cant to the data set (p<0.001). 
In addition, the three time-related gene sets (6h, 24, 72h subset) acquired with Qlucore 
Omics Explorer 2.1 were analyzed (p<0.001) through the use of CoPub (www.copub.
org) [30] and Ingenuity Pathways Analysis (IPA). CoPub was used to link genes to 
biomedical pathways. CoPub uses thesaurus-based keyword matching in Medline 
abstracts to link genes to pathways [30].  
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Results
1. Analysis of gene expression profi les by using the complete gene set 
Analysis of the expression profi les, revealed that 22,243 genes were signifi cantly 
regulated (p<0.05) in at least one of the treatments at the three time points. The number 
of differentially expressed genes (DEG) per compound and time point are summarized 
in Table 1 (>2-fold up- or down-regulation, p<0.05). All compound treatments were 
effective as they caused a signifi cant number of expression changes at 6h, 24h, and 
72h. 
Table 1. The number of differentially expressed genes (DEG) per compound treatment and time point.
The threshold for regulation was set at 2-fold (p<0.05).
Compound Concentra-
tion (mol/l)
Time 
point (h)
Total number 
of DEG 
Up-regulated
DEG
Down-regulated 
DEG
Genotoxins
Benzo[a]pyrene 1.00x10-4 6 7681 1571 6110
24 3880 1426 2454
Camptothecin 1.00x10-6 6 5451 1672 3779
24 7536 2889 4647
72 6547 2809 3738
Cisplatin 3.16x10-4 6 1429 1045 384
24 1076 584 492
72 1062 641 421
Doxorubicin 3.16x10-7 6 1253 927 326
24 3069 1374 1695
72 4071 2407 1664
Non-genotoxic liver toxicants
ANIT 1.00x10-6 6 219 91 128
24 246 133 113
72 1726 151 1575
APAP 1.00x10-3 6 320 86 234
24 302 144 158
CCl4 1.00x10
-3 6 203 79 124
24 365 86 279
Chlorpromazine 1.00x10-5 6 212 118 94
24 323 187 136
72 2924 2312 612
Gliotoxin 1.00x10-6 6 511 164 347
24 491 169 322
72 1829 1388 441
Iproniazid 1.00x10-3 6 234 79 155
24 292 88 204
TNF-α 50 ng/ml 6 415 196 219
24 565 373 192
72 3778 2700 1078
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Figure 1 shows the total number of DEG for the class of genotoxins and non-genotoxic 
toxicants at 6h, 24h, and 72h. Treatment with the genotoxins gave more pronounced 
expression changes at all time points compared to the non-genotoxic toxicants. The total 
number of DEG was already maximal at 6h and declined thereafter. The number of DEG 
increased in time for the class of non-genotoxic toxicants amounting to 6541 DEG at 
72h.  
The overlap in time of the DEG at 6h, 24h and 72h was analyzed for both classes of 
compounds and is shown in a Venn diagram (Figure 2). The overlap between the DEG 
in the class of genotoxins at the three time points was substantial. Of all 11739 DEG at 
6h, 47% (5526 genes) were also present at 24h. Of all 10310 DEG at 24h, 57% (5842 
genes) were also present at 72h.
The overlap in time between the DEG in the class of non-genotoxic toxicants was 
(signifi cantly) less prominent compared to the genotoxins. Of all 1656 DEG at 6h, 31% 
(514 genes) were also present at 24h. Subsequently, of all 1978 DEG at 24h, 38% (759 
genes) were also differentially expressed at 72h. 
For the four genotoxins, signifi cantly altered pathways were assessed with ingenuity 
pathway analysis (IPA). Multiple pathways were signifi cantly affected by the genotoxic 
compounds at 6h, 24h and 72h (Table 2). For each genotoxic compound there were 
some unique altered pathways, but there were also shared pathways. The p53 pathway 
was signifi cantly affected by all four genotoxins. In addition four other pathways in 
which p53 and MDM2 play an pivotal role were affected by two or three genotoxins, 
i.e. the ‘molecular mechanisms of cancer pathway’, the ATM pathway, the cell cycle: 
G1/S checkpoint regulation pathway, and the cell cycle: G2/M DNA damage regulation 
pathway. 
Figure 1. Total number of differentially expressed genes in the compound class of genotoxins and non-
genotoxic liver toxicants at 6h, 24h and 72h (see results section 1).
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The activation of these pathways was also analyzed for the seven non-genotoxic 
toxicants. None of the non-genotoxic toxicants activated these pathways at 6h and 24h. 
However, activation of these pathways was observed at 72h which indicates a correlation 
between activation of these pathways and induced cytotoxicity. The results are shown 
in Figure 3, which also shows the activation of these pathways by camptothecin, which 
Figure 2. Venn diagram showing the overlap of the differentially expressed genes at 6h, 24h, and 72h for 
the compound class of (A) genotoxins and (B) non-genotoxic liver toxicants (see results section 1).
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Figure 3. The activation of four pathways involved in the DNA damage response for the topoisomerase 
I inhibitor camptothecin at 6h, 24h, and 72h and for four non-genotoxic liver toxicants at 72h (see results 
section 1).
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was one of the four genotoxic carcinogens used in the present study. The activation 
of the pathways by the non-genotoxic liver toxicants was less prominent compared to 
activation by camptothecin.  
The overlap of DEG between the two compound classes was also analyzed (Venn 
diagram not shown). Of all 1656 DEG in the class of non-genotoxic liver toxicants at 
6h, 60% (986 genes) were also present in the 6h set of DEG for the class of genotoxins. 
These values were 66% (1309 genes) for 24h and 52% (3388 genes) for 72h. This analysis 
clearly shows that many of the DEG in the class of non-genotoxic liver toxicants, were 
also DEG in the class of genotoxins, pointing at DEG that do not provide good candidate 
biomarkers for discriminating between the two classes on the basis of DEG. On the 
other hand there are many DEG specifi c for the class of genotoxins. 
Table 2. Summary of the signifi cantly affected pathways assessed with IPA (p<0.001) per genotoxic 
compound and time point. A maximum of ten pathways are shown. The most signifi cantly affected 
pathways are shown fi rst.
Compound Time 
point (h)
Signifi cantly affected pathways 
Benzo[a]pyrene 6 Protein ubiquitination pathway, role of BRCA1 in DNA damage response, 
hereditary breast cancer signaling, JAK/Stat signaling, estrogen receptor 
signaling, glucocorticoid receptor signaling
24 p53 Signaling, AhR signaling, molecular mechanisms of cancer pathway, cell 
cycle: G1/S checkpoint regulation
Camptothecin 6 Molecular mechanisms of cancer pathway, prolactin signaling, RAR activation, 
estrogen receptor signaling, glucocorticoid receptor signaling, TGF-β signaling, 
PDGF signaling, factors promoting cardiogenesis in vertebrates, B cell receptor 
signaling, ERK5 signaling
24 Molecular mechanisms of cancer pathway, role of BRCA1 in DNA damage 
response, ATM signaling, role of CHK proteins in cell cycle checkpoint control, 
cell cycle: G2/M DNA damage checkpoint regulation, mitotic roles of polo-like 
kinase, p53 signaling, protein ubiquitination pathway, hereditary breast cancer 
signaling, cell cycle: G1/S checkpoint regulation
72 Molecular mechanisms of cancer pathway, p53 signaling, ATM signaling, cell 
cycle: G2/M DNA damage checkpoint regulation, mitotic roles of polo-like 
kinase
Cisplatin 6 p53 Signaling
24 TR/RXR activation
72 TR/RXR activation,  LXR/RXR activation, biosynthesis of steroids
Doxorubicin 6 Cell cycle: G2/M DNA damage checkpoint regulation
24 p53 Signaling, AhR signaling
72 Hereditary breast cancer signaling, role of BRCA1 in DNA damage response, 
p53 signaling, role of CHK proteins in cell cycle checkpoint control, molecular 
mechanisms of cancer, pyrimidine metabolism, AhR signaling, ATM signaling, 
purine metabolism, renal cell carcinoma signaling
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Principal component analysis (PCA) was performed to study the discrimination of the 
two compound classes (Figure 4A). PCA shows that it is not possible to discriminate the 
class of genotoxic and non-genotoxic toxicants at the 6h time point. At 24h and 72h it 
was possible to slightly distinguish the two compound classes. The limited discrimination 
between the two compound classes that was observed with the PCA is probably caused 
by the substantial overlap of DEG between the two compound classes at the three time 
points. 
   A (see results section 1)                              B (see results section 2)                                   
6h
24h
6h
24h
72h 72h
Figure 4. PCA pictures showing the discrimination of the genotoxins (blue color) and non-genotoxic 
liver toxicants (yellow) by using all differentially expressed genes (A) and the gene subsets calculated 
by Qlucore (B) at the three time points. 
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Pathway analysis of the complete set of DEG indicated that pathways involved in cell 
cycle control may contain genes that can be used as biomarkers as these pathways were 
signifi cantly activated by the four genotoxicants tested. However, not all genes in these 
pathways seem to be good biomarkers as these pathways were moderately activated by 
the non-genotoxic toxicants at 72h. Additional analysis of the gene expression profi les 
was performed to fi nd a specifi c set of DEG that can discriminate the two classes of 
compounds at the three time points.
2. Analysis of gene expression profi les by using Qlucore Omics Explorer
2.1 The identifi cation of potential biomarker genes 
The complete set of 22,243 DEG was further analyzed by using Qlucore Omics 
Explorer 2.1 to identify potential biomarker genes that discriminate the genotoxic from 
the non-genotoxic toxicants. For each time point, a subset of genes containing potential 
biomarkers was generated (6h, 362 genes; 24h, 1914 genes; 72h, 498 genes). The three 
subsets of genes are specifi ed in detail in Table 3, which shows the number of genes, the 
relative expression of the genes, and the difference in fold induction per gene between 
the two compound classes. The mean induction per class was used for the calculations.
The overlap between the three subsets was limited and is shown in a Venn diagram 
(Figure 5). The 6h-24h and 24h-72h sets of genes, have an overlap of 52 and 81 genes, 
respectively. Only 15 genes were present in both the 6h and 72h subset and four genes 
were present at all three time points. 
These four genes were cyclin-dependent kinase inhibitor 1A (CDKN1A, p21), MDM2, 
MDM4, and diacylglycerol kinase, which are all downstream targets of p53 [31]. 
The CDKN1A protein has multiple functions. CDKN1A is a potent cyclin-dependent 
kinase inhibitor. CDKN1A binds to and inhibits the activity of cyclin-CDK2 or -CDK4 
complexes, and functions as a regulator of cell cycle progression at G1. This protein 
also regulates proliferating cell nuclear antigen (PCNA), which has a regulatory role in 
DNA repair and S phase DNA replication [32, 33]. PCNA is present in the 72h set of 
biomarkers. MDM2 is a nuclear phosphoprotein that binds and inhibits transactivation 
by tumor protein p53, as part of an autoregulatory negative feedback loop. MDM4 plays 
a role in stabilizing p53 and thereby protects p53 from MDM2 mediated degradation 
[34]. Diacylglycerol kinase is a kinase that competes with protein kinase C for 
diacylglycerol.
A PCA by using the 6h, 24h and 72h subsets of genes that were acquired with Qlucore 
Omics Explorer is shown in Figure 4B. At each time point there is a clear discrimination 
between the two compound classes. Although the total number of genes in the 72h gene 
subset was less than at 24h, the difference between the two compound classes in the PCA 
was larger. This is due to the larger difference in expression between the two compound 
classes at 72 h. 
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2.2 Further analysis of the most prominent induced genes 
After Qlucore analysis, the most prominent induced genes in the class of genotoxins at 
6h, 24h, and 72h may provide the most promising leads for the generation of luciferase 
based reporter assays that can detect genotoxic potential. These most prominent induced 
genes (top 10) were analyzed in detail (Table 4; abbreviations of the genes are also 
clarifi ed in this table).
In the 6h subset, ATF3 (3.22 fold) showed the highest fold induction. ATF3 is a 
transcription regulator that acts like a stress sensor which activates p53 by blocking its 
ubiquitination [35, 36]. PLK2, CDKN1A, MDM2, and BTG2 are downstream target 
genes of p53. As described earlier CDKN1A and MDM2 have pivotal roles in the 
p53 response. PLK2 and BTG2 have a role in cell cycle checkpoints [37, 38]. Of the 
remaining 5 genes, SERTAD1 and DUSP1 (MKP1) have a role in cell cycle regulation 
(p53 independent) [39, 40]. PVRL4 encodes an adhesion receptor that functions in cell-
cell adhesion and has been proposed as a diagnostic and therapeutic target for lung 
cancer [41]. In addition, induction of GABRE was observed in the class of genotoxicants. 
GABRE is coding for an ion channel protein that is activated by several classes of 
drugs including genotoxins [42]. ICOSLG is a co-stimulator ligand that increases the 
Table 3. Specifi cation of the 6h, 24h, and 72h gene subsets assessed with Qlucore Omics Explorer 2.1. 
Qlucore 
gene 
subset
Total 
number of 
genes
Genes with higher expression in 
the class of genotoxins 
Genes with lower expression in the 
class of genotoxins
Total
number
Difference in fold 
induction per gene
Total 
number
Difference in fold 
induction per gene
6h 362 189 0.87 173 -0.41
24h 1914 913 0.98 1001 -0.34
72h 498 240 0.80 248 -0.65
24h6h
72h
4
77
48
11
299
406
1785
Figure 5. Venn diagram showing the overlap of the 6h, 24h, and 72h subsets of genes that were as-
sessed with expression analysis using Qlucore Omics Explorer 2.1 (see results section 2.1).
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production of cytokines [43]. With exception of ICOSLG the most prominent induced 
genes in the 6h subset were also present in one or both of the 24h and 72h subsets. 
In the 24h subset, RRAD showed the most pronounced induction. RRAD is a GTPase 
that plays a role in carcinogenesis. This gene is silenced by methylation in a variety of 
cancers like prostate, lung, breast and cervical carcinoma [44-46]. Regulation by the p53 
downstream target stratifi n has been reported [47]. The p53 downstream targets CEL, 
PLK3 and TP53I3 were also present in the 24h set of biomarkers. CEL has a physiological 
role in cholesterol and lipid-soluble vitamin ester hydrolysis and absorption. The link 
with genotoxicity is presently unknown. However, CEL has been reported to be a p53 
downstream target [48]. PLK3 and TP53I3 have a function in the response to oxidative 
stress [49]. For the remaining six genes no link with p53 has been reported. RASD1 is 
a suppressor of cell growth [50], and CSTA is an anti-apoptotic protein [51, 52], CYGB 
is involved in the oxidative stress response [53] and MR1 has a role in the immune 
response (antigen presentation). CABYR is a calcium binding tyrosine phosphorylation 
regulated fi brous sheath protein that is an antigen that is specifi cally expressed in certain 
tumors and has therefore been proposed as a promising target for immunotherapy for 
lung cancer patients [54]. PVRL4 was, similar to the 6h set, one of the top 10 induced 
genes in the 24h subset. CEL, PLK3, CYGB, MR1 were also present in another subset. 
The average fold changes were higher at 24h and 72h compared to 6h for the top 10 
induced genes.
In the 72h subset, CEL was the gene with the highest induction. Other p53 downstream 
targets present in the 72h subset were SULF2 [55], MDM2 and DDB2. DDB2 participates 
in nucleotide excision repair [56]. Of the remaining six genes, PDE4C has a role in 
regulation of apoptosis and the cell cycle and FDXR and CYGB have a role in the 
oxidative stress response [49]. APL1 is involved in L-methionine salvage [57], BMP8A 
[58] is a growth factor and  ELOVL3 has a function in fatty acid chain elongation [59]. 
To illustrate the specifi city of the biomarker genes box plots are given for CEL, MDM2 
and CSTA (Figure 6). Five of the most pronounced genes at 72h were also present in 
another subset. 
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2.3 Further analysis of genes involved in the DNA repair response
The expression changes of six genes involved in the DNA repair response were 
analyzed. These genes were GADD45A, GADD45B, PCNA, POLH, RAD51C, and 
XPC (Table 5). Of these genes RAD51C was the only gene that was not present in 
one of the three Qlucore gene subsets. Box plots for GADD45A and XPC are given as 
illustration for the specifi city of the genes (Figure 6). 
The GADD45 gene encoded proteins are a group of critical signal transducers, that 
are involved in many cellular regulations like growth arrest, DNA repair, cell survival, 
and apoptosis [60, 61]. PCNA is involved in translesion synthesis (the bypass of DNA 
lesions) [32, 33]. POLH is involved in post replication repair and defects in this gene 
result in humans in a Xeroderma pigmentosum like illness with a defect in UV damage 
repair [62]. RAD51C is involved in double strand DNA break repair and XPC in 
nucleotide excision repair [63, 64]. For RAD51C, the expression changes of doxorubicin 
and camptothecin alone are also shown in Table 5 as these are topoisomerase inhibitors 
which cause double strand DNA breaks. These data indicate that RAD51C might be a 
good classifi er for DNA double strand breaks. 
Table 5. Expression changes of several genes involved in the DNA repair response for the class of 
genotoxic and non-genotoxic liver toxicants. Numbers in bold indicate expression changes higher than 
1.5 fold and cells with a grey background indicate the presence of the gene in the gene subset at that 
time point. 
Gene 
symbol
Gene name Mean induction 
genotoxic toxicants
Mean induction 
non-genotoxic liver 
toxicants
  6h 24h 72h 6h 24h 72h
GADD45A Growth arrest and DNA-damage-inducible, alpha 1.84 2.60 1.59 0.99 1.03 1.21
GADD45B Growth arrest and DNA-damage-inducible, beta 5.96 3.40 1.17 1.21 1.05 0.90
PCNA Proliferating cell nuclear antigen 1.03 1.27 2.38 1.00 1.01 0.99
POLH Polymerase (DNA directed), eta 1.58 3.71 4.00 0.96 0.93 1.08
RAD51C RAD51 homolog C 1.25 1.45 2.08 0.94 0.99 1.58
RAD51Ca RAD51 homolog C 1.07 2.02 3.27 0.94 0.99 1.58
XPC Xeroderma pigmentosum, complementation group C 1.14 2.24 2.64 1.14 1.07 1.00
aMean fold induction of camptothecin and doxorubicin
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Figure 6. Boxplots showing the induction (log ratio) of six potentially useful biomarker genes, i.e. CEL, 
CSTA, MDM2, DDB2, GADD45A, and XPC, for the genotoxic (GT) and non-genotoxic liver toxicants 
(NGT) at 6h, 24h and 72h (see results sections 2.2 and 2.3)
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2.4 Pathway analysis with CoPub and IPA 
The three subsets (6h, 24h, 72h) of genes that were assessed with Qlucore Omics 
Explorer and give the best discrimination between the genotoxic and non-genotoxic 
toxicants were analyzed for affected pathways by using Copub and IPA.
CoPub software analysis was used to link the three subsets of genes to pathways (Table 
6). At 6h, the most affected pathway by the subset of genes was the cell cycle. This was 
mainly caused by the set of up regulated genes in the class of genotoxins. The down 
regulated genes in the class of genotoxins could not be linked to a specifi c pathway. At 
24h, the subset of genes was linked to the cell cycle, DNA replication, apoptosis, S-phase 
regulation of the cell cycle, protein degradation, and DNA repair. The up regulated genes 
in the class of genotoxins showed the strongest association with the protein degradation 
pathway, apoptosis, and the cell cycle regulation. The down regulated genes in the class 
of genotoxins were associated with DNA replication, translation, and the ribosome 
pathway. At 72h, no pathways were signifi cantly affected. 
IPA was also used to analyze the pathways affected by the gene three subsets (Table 7). 
Analysis yielded quite similar results as found with CoPub. At 6h, the affected pathways 
were mainly associated with regulation of the cell cycle. The p53 signaling pathway, ataxia 
telangiectasia mutated (ATM) signaling pathway and G2/M DNA damage checkpoint 
regulation were the most affected. At 24h, six pathways were affected. Like observed at 
6h, the p53 and ATM signaling pathways were found to be affected. In addition ‘hypoxia 
signaling in the cardiovascular system’ was found to be affected as well as ‘LPS/IL-a 
mediated inhibition of retinoic acid receptor (RXR) function’, ‘molecular mechanisms 
of cancer’, and xenobiotic signaling. At 72h, IPA yielded in concordance with CoPub 
analysis no signifi cantly affected pathways.
Table 6. Pathway analysis with CoPub (p<0.001) of the Qlucore Omics Explorer gene subsets. 
Gene subset Genes up-regulated by 
genotoxins
Genes down-regulated by 
genotoxins
Complete subset of genes
6h Cell cycle None Cell cycle
24h Protein degradation DNA replication Cell cycle
Apoptosis Translation DNA replication
Cell cycle Ribosome Apoptosis
S-phase
Protein degradation
DNA repair
72h None None None
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Discussion
1. Analysis of gene expression profi les by using the complete gene set
The present study focused on the differences between expression profi les of HepG2 cells 
treated with genotoxins and cytotoxic concentrations of non-genotoxic liver toxicants. 
HepG2 cells were treated with four genotoxic and seven non-genotoxic liver toxicants 
for 6h, 24h or 72h. The responses to the genotoxins were not only more pronounced 
in time but also in number of DEG. Initial pathway analysis revealed that the DEG in 
the class of genotoxicants were mainly involved in cell cycle control.The fact that the 
genotoxins caused a quick response is in line with previous studies that reported that the 
activation of the p53 protein and DNA repair already happened 3h after DNA damage 
[22, 65, 66]. 
Based on PCA the discrimination between the two compound classes was less 
apparent. The moderate overlap between the DEG between the two compound classes 
was probably the reason. Pathway analysis indicated that pathways involved in cell 
cycle control might contain genes that discriminate genotoxicants from non-genotoxic 
toxicants as these pathways were activated by the four genotoxicants at 6h and 24h but 
not by the non-genotoxic toxicants. At 72h a moderate activation of these pathways 
was also observed for the non-genotoxic toxicants indicating that not all genes in these 
pathways are specifi c biomarkers for genotoxicity. Additional analysis was therefore 
needed to determine genes that discriminated both classes of compounds. For this 
analysis Qlucore Omics Explorer was used.
Table 7. Pathway analysis of the 6h, 24h, and 72h Qlucore Omics Explorer gene subsets with IPA. 
Pathways affected with p<0.001 are shown.
Gene subset Affected pathways
6h p53 Signaling
ATM signaling
Cell cycle: G2/M DNA damage checkpoint regulation
24h p53 Signaling
Hypoxia signaling in the Cardiovascular system
ATM signaling
LPS/IL-a mediated inhibition of RXR function
Molecular mechanisms of cancer
Xenobiotic signaling
72h None
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2. Analysis of gene expression profi les by using Qlucore Omics Explorer
2.1 Identifi cation of potential biomarker genes 
Qlucore Omics Explorer analysis yielded three subsets of genes that discriminated the 
genotoxic from the non-genotoxic liver toxicants at the three time points. At the early 
time point of 6h there was a set of 362 genes that distinguished the two classes. Qlucore 
analysis at the 24h time point yielded the highest number of potential biomarkers (1914 
genes). Although the number of discriminating genes dropped at 72h, the discrimination 
between the genotoxic and non-genotoxic toxicants by using these 498 biomarkers was 
good and even better than the discrimination at 6h and 24h (Figure 4B). The activation 
of pathways involved in the cell cycle and DNA repair response (i.e. p53 pathway, ATM 
pathway, G2/M cell cycle checkpoint regulation, ‘molecular mechanisms of cancer 
pathway’) by the non-genotoxic liver toxicants contributed to the decrease in number of 
discriminating genes in the 72h subset.
This is in line with the discrimination between genotoxic and non-genotoxic carcinogens. 
Mathijs et al. [67] showed in primary mouse hepatocytes that the discrimination between 
genotoxic and non-genotoxic carcinogens became more apparent in time. 
Although it was possible to assess three subsets of genes that clearly discriminated 
the genotoxic and non-genotoxic liver toxicants, the overlap between genes in the three 
subsets was limited. Only four genes were present in the 6h, 24h as well as the 72h 
subset of genes. These four genes were CDKN1A, MDM2, MDM4 and DIGK, all 
downstream targets of p53. The importance of the p53 pathway for classifi cation of 
genotoxic compounds was later on confi rmed by analysis of the most prominent induced 
genes (see results section 2.2) and by pathway analysis (see results section 2.4). 
2.2 Analysis of the most prominent induced genes and genes involved in DNA repair  
The most prominent induced genes (top 10) in the three subsets were analyzed in more 
detail. Many of the prominent inducers were downstream targets of p53. The remaining 
pronounced induced genes had mainly a role in cell cycle regulation, apoptosis or were 
stress sensors. More than 50% of the top 10 inducers were present in two Qlucore gene 
subsets. Therefore these potential biomarker genes may be useful at more than one time 
point.  
Analysis also showed that several genes involved in the DNA repair response might be 
valuable biomarker genes. These genes were GADD45A, GADD45B, PCNA, POLH, 
and XPC. In previous studies a GADD45A reporter assay (GreenScreen HC) has 
been extensively validated and shows a good sensitivity and specifi city for genotoxic 
carcinogens [68-70].  
Besides general biomarkers that discriminate the genotoxic carcinogens versus 
non-genotoxin liver toxicants, more specifi c biomarkers that clarify the mechanism 
of genotoxins might be very useful. Topoisomerase inhibitors like doxorubicin and 
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camptothecin damage the DNA by the formation of double strand breaks. Such breaks are 
at fi rst instance repaired by non-homologous end-joining or homologous recombination 
[71-72]. The RAD51 gene and homologs play an important role in double strand repair by 
homologous recombination. The results of the present study indicated that the RAD51C 
gene might be a specifi c biomarker for the generation of double strand breaks. 
In the present study we analyzed the Fanconi genes as these enzymes are involved in 
repair of DNA crosslinks [73]. Activation of these genes might be valuable to detect 
the mode of action of DNA crosslinkers like cisplatin. However, no clear and specifi c 
activation of these genes was found in the present study. Therefore it seems that these 
genes are not good markers in the current HepG2 system. 
2.3 Pathway analysis with CoPub and IPA 
Genes in the three subsets of genes that were assessed with Qlucore Omics Explorer 
and discriminate the two compounds classes were analyzed with Copub and IPA. CoPub 
analysis showed that the genes in the 6h subset had a prominent role in the cell cycle. This 
was confi rmed by IPA analysis which showed that the 6h subset genes were involved in 
the p53 pathway, ATM pathway and G2/M DNA damage checkpoint regulation. 
The pathways in CoPub that were affected at the 24h time point were again mainly 
involved in the cell cycle. Results of CoPub suggested the occurrence of cell cycle 
arrest, as DNA replication, translation and ribosome pathways were down-regulated by 
the genotoxic compounds. Cell cycle arrest as a consequence results in more time for 
DNA repair. CoPub analysis indeed showed that the DNA repair pathway was activated. 
Because of DNA damage, the apoptosis and protein degradation pathways were probably 
also activated. This is confi rmed by IPA analysis, where it was shown that p53, ATM, and 
molecular mechanisms of cancer signaling pathways were induced. In these pathways, 
p53, MDM2 and their downstream targets play a prominent role. 
One additional pathway that was also analyzed in more detail was the IPA pathway 
‘Hypoxia signaling in the cardiovascular system’. Analysis of this pathway showed a 
prominent role for MDM2 and p53. Activation of these genes by genotoxicity, but not 
by hypoxia, was likely the reason for the positive response of this pathway. 
The xenobiotic signaling pathway was also affected and unexpectedly CYP3A4, 3A5 
and 3A7 were signifi cantly induced by the four genotoxic compounds. None of the 
genotoxins used in the present study has been reported to activate the CAR or PXR 
directly. The activation of the xenobiotic signaling pathway might be PXR/CAR 
independent which has been reported for for several other compounds [74]. In these 
cases there was no direct link with genotoxicity. Activation of the Nrf2 pathway might 
be involved in this activation [74]. Another gene in the xenobiotic signaling pathway, 
RXR, was approximately 2-fold down-regulated by all genotoxic compounds. Retinoid 
X receptors have been reported to play a pivotal role in the regulation of growth and 
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differentiation in normal and tumor cells. Deregulation of RXR expression has been 
reported in for example non-small cell lung cancer [75]. The mechanism underlying 
the impaired expression of RXRs is not exactly known although methylation associated 
down-regulation might play a role [75]. Down-regulation of RXR, and up-regulation 
of the CYP3A genes was the main reason for the IPA pathway ‘LPS/IL-a mediated 
inhibition of RXR function’ to be signifi cantly affected by the 24h subset of genes. 
Pathway analysis by neither CoPub nor IPA did reveal signifi cantly enriched pathways 
in the 72h subset of biomarkers. Activation of the typical genotoxicity pathways by 
the non-genotoxic liver toxicants is probably the reason (see results section 1). Overall 
pathway analysis clearly indicated that the p53 responsive element or one of the pivotal 
p53 downstream targets like for example CDKN1A and MDM2 might contain valuable 
promoters or responsive elements for the generation of reporter assays. 
In conclusion, gene expression analysis with Qlucore Omics Explorer revealed a 
6h, 24h, and 72h gene subset that discriminated genotoxic from non-genotoxic liver 
toxicants exerting their effect through cytotoxicity. The most prominent induced genes 
in the three subsets of genes were mainly involved in cell cycle control and downstream 
targets of p53. Further studies are undergoing to assess the role of the individual gene 
expression in luciferase based reporter assays which may provide a tool for screening 
genotoxicity with lower levels of false positives.
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Abstract
Four different mechanism-based high-throughput luciferase reporter assays were 
developed in human HepG2 cells, which contain phase I and II metabolic activity and 
a functionally active p53 protein. The promoter regions of RAD51C and Cystatin A, as 
well as the responsive element of the p53 protein, were selected for the generation of the 
genotoxicity reporter assays. Moreover, a luciferase based reporter assay was generated 
that measures the activation of the Nrf2 oxidative stress pathway.
Validation with respect to the ECVAM compound list [Mutat. Res 653 (2008) 
99-108] resulted in an overall sensitivity of the HepG2 genotoxicity reporter assays 
for genotoxicity of 85% (17/20). The specifi city and predictivity were high with 81% 
(34/42) and 82% (51/62), respectively. Various compounds had a positive score although 
metabolic activation was needed. The HepG2 reporter data were also compared with the 
available data of bacterial mutagenicity (Ames test), in vitro mammalian genotoxicity 
and in vivo genotoxicity for an additional set of 192 compounds. The predictivity for 
mutagenicity results was 74% (sensitivity, 61%, 30/49; specifi city, 80%, 77/96) and 
for in vitro mammalian genotoxicity 59% (sensitivity, 45%, 35/78; specifi city 83%, 
38/46). The correlation between results from the HepG2 genotoxicity reporter assays 
and in vivo genotoxicity was higher with 77% (sensitivity, 74%, 28/38; specifi city 81%, 
26/32). Results from the Nrf2 reporter assay showed that a large number of genotoxic 
compounds activated the Nrf2 oxidative stress pathway. 
In conclusion, four high-throughput mechanism-based reporter assays in the HepG2 
cell line were developed, which can be applied for screening in the early research 
phase of drug development. The use of these assays may reduce the attrition rate due to 
genotoxicity in the developmental phase of drug development.
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Introduction
Regulatory genotoxicity tests like the Ames, sister chromatid exchange (SCE), 
micronucleus (MN), mouse lymphoma assay (MLA) and chromosome aberration (CA) 
tests are time-consuming, laborious and not applicable for screening of large numbers 
of compounds in the early research phase of drug development. In this phase of drug 
development medium-throughput (~10-100 compounds/month) or high-throughput 
(>~100 compounds/month) screening methods are essential. 
Recently, the medium throughput VitotoxTM (Salmonella typhimurium) and Radarscreen 
(yeast) assays were validated [1]. The results showed that the VitotoxTM and RadarScreen 
have a high predictivity for bacterial mutagenicity and in vitro mammalian genotoxicity 
, respectively. Especially, the number of false positive scores (due to cytotoxicity) in 
these in vitro assays was relatively low. The regulatory genotoxicity assays as well as the 
medium-throughput VitotoxTM and Radarscreen assays have the disadvantage that they 
are mainly non-human assays which require rat-S9 mixture for metabolic activation. 
Therefore these assays provide only limited amount information regarding the genotoxic 
mode of action in humans. Thus genotoxicity assays in human metabolically competent 
cell lines of human origin are demanded. 
In the present study, four luciferase-based reporter assays were developed and 
validated in the human HepG2 cell line. The promoter regions of RAD51C and Cystatin 
A, and the p53 and Nrf2 responsive elements were used to control the expression of a 
luciferase gene, which can be quantifi ed easily. The HepG2 cell line was chosen because 
it contains many functional phase I and II enzymes which are lost in most cultured cell 
lines [2, 3]. Moreover, the HepG2 cell line is wild-type for the tumour suppressor gene 
p53 [4] whereas the V79 and CHO cell lines that are commonly used in genotoxicity 
assays have a mutated and non-functional p53 protein (no or less DNA repair) and lack 
metabolic activity. The presence of (phase II) metabolism and a functionally active 
p53 enzyme in HepG2 cells most likely results in less falsely predicted in vivo results 
in comparison with results obtained with CHO and V79 cells. Other studies already 
showed the suitability and applicability of HepG2 cells in genotoxicity assays such as 
the MN and Comet assay [5-11]. 
DNA damage is often used as end point in genotoxicity assays. In the present study 
the induction of stress pathways/proteins was measured to get mechanism-based insight 
into the genotoxic mode(s) of action of compounds. The choice for the four pathways 
was based on the results of micro-array experiments with genotoxic compounds in 
HepG2 cells. The relevance of each of these pathways is explained in more detail in the 
paragraphs below. 
Double strand breaks are a primary or secondary effect of exposure to many genotoxic 
compounds. Homologous recombination is an important mechanism to repair these 
Chapter 7 
174
double strand breaks during the S- or G2-phase of the cell cycle [12]. In humans, several 
proteins have been reported to play a crucial role in this process. Important proteins 
are RAD51, RAD52, RAD54, replication protein A, MRE11/RAD50/NBS1, and the 
RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3. Following 
DNA damage, RAD51 accumulates at the sites where repair reactions must take 
place. RAD51C forms a complex that includes either XRCC2 or XRCC3 [12]. The 
RAD51C/XRCC2 complex plays a role in RAD51 mediated strand exchange [13] and 
the RAD51C/XRCC3 complex has a function in resolving Holliday junctions in the late 
stage of homologous recombination [14, 15]. In addition, RAD51C has been reported 
to have an important role in maintaining the correct number of centrosomes in mitosis 
[16]. Based on the microarray and literature data a luciferase-based RAD51C reporter 
assay was generated.
Moreover, a Cystatin A promoter luciferase-reporter assay was generated. Cystatin A 
is a cysteine protease inhibitor that belongs to family 1 of the cystatin superfamily. It 
effi ciently inhibits cathepsin B with an inhibitor constant (Ki) of 8 nM [17, 18]. Unlike 
many other cystatins, Cystatin A does not contain a signal peptide for secretion and is 
consequently retained within the cell [17, 18]. Expression has been reported in poly-
morphonuclear granulocytes, spleen, keratinocytes, and liver [19, 20]. After treatment 
of keratinocytes with UVB Cystatin A caused an anti-apoptotic effect [20]. Cystatin 
A inhibited apoptosis caused by caspase-3 induction. Anti-apoptotic effects have also 
been reported in the rat hepatoma cell line H4IIE [21] where Cystatin A reduced bile 
salt-induced apoptosis. The induction which is seen after treatment with genotoxic 
compounds suggests that activation of this protein allows the cell more time for DNA 
repair.
The p53 tumour suppressor gene is the pivotal protein in the response to DNA damage, 
mitotic spindle disruption and activation of oncogenes [22]. Under non-stress situations 
the p53 protein is a short-lived transcription factor. Activation of the G2/M checkpoint 
by the ATM and ATR proteins results in phosphorylation of the checkpoint kinase Chk2. 
Subsequently, this kinase phosphorylates p53 which prevents the binding of p53 to mdm2 
that targets p53 for ubiquitylation. Targets of the activated p53 proteins are pathways 
involved in cell cycle arrest, DNA repair and apoptosis. The p53 transcription factor 
binds to a p53 responsive element in the promoter of target genes. In the present study, 
a luciferase based construct containing a p53 responsive element was used to measure 
p53 activation.
An important stress pathway that protects the cell against genotoxic and cytotoxic 
compounds is the Nrf2 pathway [23-25]. Nrf2 is a basic-leucine zipper heterodimer. It has 
a tissue-restricted subunit, p45, complexed with a small, ubiquitous member of the Maf 
protein family [26, 27]. Nrf2 is a transcription factor that activates phase II detoxifying 
enzymes and antioxidant-stress proteins. In an environment without oxidative stress, 
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the Keap-1 protein binds to Nrf2 and sequesters Nrf2 in the cytoplasm. Under stress 
conditions, antioxidants interact with the thiol groups of Keap-1. This causes the release 
of Nrf2 and translocation of Nrf2 to the nucleus where it heterodimerizes with the small 
Maf protein. This complex binds to the antioxidant responsive elements, which can 
activate the expression of several genes [23]. A luciferase based reporter assay driven by 
the Nrf2 responsive element was used in the present study.
Recently, an ECVAM workgroup defi ned a list of 20 genotoxic and 42 non-genotoxic 
compounds [28] that can be used for the validation and/or optimization of in vitro 
genotoxicity assays. In the present study, this compound set was used for the evaluation 
of the RAD51C, Cystatin A, p53 and Nrf2 reporter assays. Moreover, an additional set of 
192 compounds was used to broaden this validation study [1]. This set of compounds is 
described in more detail in a previous study that evaluated the VitotoxTM and RadarScreen 
assay (Chapter 2) [1]. The compounds of this additional set can be classifi ed as non-
genotoxins and genotoxins; the set consisted of in-house and reference compounds. The 
genotoxins act according to diverse mechanisms and the compound list also contains 
many steroidal compounds that have been reported as clastogenic or aneugenic [1, 29]. 
The assays performed in this study may give more insight into the genotoxic mode 
of action of these steroids. Results from the 192 compounds were compared with the 
available results on bacterial mutagenicity (Ames test), in vitro mammalian genotoxicity 
and in vivo genotoxicity. 
Materials and methods
Preparation of compound solutions 
Stock solutions of the reference and test compounds were prepared in 100% dimethyl 
sulfoxide (DMSO). From the stocks, √10-fold dilution series were prepared in DMSO. 
All compounds were of analytical grade and ordered from Sigma-Aldrich or synthesized 
in-house. More details on the chemical constituents of the in-house compounds are 
described by [1].
Cell culture
HepG2 cells were obtained from the American type culture collection (Rockville, MD, 
USA). HepG2 cells were cultured in Dulbecco’s modifi ed eagles medium and nutrient 
mixture F-12 mixed in a ratio of 1:1 (Invitrogen) with 10% defi ned supplemented bovine 
calf serum from Hyclone (UT, USA) and 1% penicillin-streptomycin (10,000 U/ml, 
Invitrogen). Cultures were maintained in a humidifi ed atmosphere with 5% CO2 at 37 
ºC and medium was refreshed every 3 or 4 days with sub-culturing.
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Development of a RAD51C, and Cystatin A luciferase reporter vector
DNA was isolated from HepG2 cells with the DNeasy kit (Qiagen, Germatown, USA). 
PCR reactions were performed to isolate the promoter regions of RAD51C and Cystatin 
A. The PCR mixture contained 5 μl 10x PCR buffer, 1 μl 10 mM dNTP mixture, 1.5 
μl 25 mM MgCl2, 2.5 μl 5 μM forward and reverse primer, 50 ng DNA, 2.5 U Taq 
polymerase, and 0.25 U Pfu polymerase. Milli-Q was added to get a total volume of 50 
μl. The program used was 5 min at 94ºC, followed by 30 cycles of 30 s at 94ºC, 30 s 
at 58ºC or 55ºC for respectively Cystatin A and RAD51C, and 1 or 2 min at 72 ºC for 
respectively Cystatin A and RAD51C, followed by 7 min at 72ºC. 
The sequence of the human RAD51C promoter was adapted from the eukaryotic 
promoter database (www.epd.isb-sib.ch) [30]. The RAD51C promoter has not been 
analyzed in detail. However, the paralog, RAD51B (RAD51L1) has been investigated 
[31]. This gene is also induced after DNA damage. Analysis of this promoter showed 
that it contains several UV-responsive elements and - in the region 1630-1700 bp before 
the transcription start site - it contains two p53 binding sites separated by a spacer. 
This region with the p53 binding sites was essential for the UV responsiveness of the 
promoter. In addition this region was also essential for silencing the promoter when 
there was no induction by UV.
The sequence of the RAD51C promoter site starting 2100 bp downstream the 
transcription start site was aligned with the sequence from the RAD51B promoter. 
The results showed that one region in the RAD51C promoter has great similarity 
(>80%) with part of the RAD51B promoter. This region contained three UV responsive 
elements. Moreover, in the RAD51C promoter two possible p53 binding sites separated 
by a spacer were found at approximately 1400 bp before the transcription start site. In 
the present study a primer pair was used that amplifi ed the region from 2073 bp before 
the transcription start until 11 bp after the transcription start site. The sequences of the 
primers were: Forward primer 5’-GCATAAGCATGAAATCTCCCTGAA-3’; Reverse 
primer 5’-CATTTCAAAGCGGAACGTC-3’.
The Cystatin A promoter was analyzed in detail in the literature [19]. The region 
till approximately 650 bp before the transcription start site appeared to be essential 
for a functional promoter. The primers used in the present study amplifi ed the 
region from 700 bp before the transcription start site till the transcription start. The 
sequence of the primers that were used for the promoter isolation were: Forward 
primer 5’-CCGGTACCGGCACCAGTACTTTGCCTTCTG-3’; Reverse primer 
5’-GAAGATCTTCCAGGGAAGTGTGGAGACTCG-3’. 
Next the TOPO TA cloning kit (Invitrogen) was used for cloning the PCR products 
containing the RAD51C and Cystatin A promoters. Four microliters of PCR product 
were added to 1 μl salt solution and 1 μl TOPO vector. The solution was gently mixed 
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and incubated for 5 min at room temperature. Two microliters were used for the 
transformation of DH5α competent cells. Clones that appeared on the LB agar plates 
were checked for the insert by PCR. Clones on the plate were touched by a toothpick. 
The toothpick was used to inoculate 25 μl PCR reaction mixture and a tube containing 
1 ml LB medium. The same PCR protocol as for the promoter isolation was used. The 
inoculated media from clones that were positive for the insert were added to 50 ml LB 
medium containing 100 μg/ml ampicillin. The following day, 3 μl bacteria suspension 
was used to check for the insert again. When positive for the insert, plasmid DNA was 
isolated and checked for the insert by PCR. The plasmid DNA was then sequenced. 
The pGL4.17 vector (Promega, GenBank accession number DQ188837) was used 
for the generation of the reporter construct. A pGL4.17 vector needs the addition of 
a complete promoter including elements like for example a TATA box to drive the 
expression of the luciferase gene. For Cystatin A, the pGL4.17 vector and TOPO vector 
containing the promoter were restricted with Kpn I and Bgl II. The Kpn I and Bgl II 
restriction sites were introduced by the Cystatin A primers that were used. The promoter 
sequence of Cystatin A itself does not contain these restriction sites. Products of the 
restriction reaction were loaded onto an 1 % agarose gel and the restricted vector and 
Cystatin A promoter (700 bp) were isolated from the gel and purifi ed with the DNA 
and gel band purifi cation kit (Amersham Pharmacia Biotech). The restricted vector 
and promoter sequence were ligated. Then 2 μl ligation mixture was used to transform 
DH5α competent cells. Like after transformation with the TOPO vector, clones were 
checked for the insert by PCR and positive clones were used to inoculate 50 ml LB 
medium containing 100 μg/ml ampicillin medium. The following day plasmid DNA 
was isolated. For the generation of the RAD51C luciferase reporter, the pGL4.17 vector 
and the TOPO vector containing the promoter were restricted with Kpn I and EcoR V. 
These two restriction sites are present in the multiple cloning site of the TOPO vector. 
Moreover, the 2000 bp sequence of the promoter does not contain these restriction sites. 
The orientation of the insert in the TOPO vector was checked by restricting the vector 
with a combination of Kpn I and Bgl II. Depending on the orientation, fragments of 
600, 2400, and 2800 bps (correct orientation) or 1400, 1600, and 2900 bps were formed. 
Plasmids with the correct orientation were selected for the experiments. The remaining 
part of the protocol was similar to that used for Cystatin A.
Development of a p53 and Nrf2 luciferase reporter vector
A luciferase based reporter vector containing four p53 responsive elements was 
generated. An oligo with the sequence 5’-GGGGTACCCC-(AGGCATGTCT)4-
GAAGATCTTC-3’ was hybridized with the complementary sequence. Of both oligos 
5 μg were added to a 1x PCR buffer without magnesium (Invitrogen) in a total volume 
of 50 μl in a well of a 96-well PCR plate (Applied Biosystems). The plate was put in 
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a GeneAmp PCR System 9700 (Applied Biosystems). The program used was 5 min at 
94ºC followed by 10 min at 71ºC. The resulting DNA fragment contained four repeats of 
the p53 binding site 5’-AGGCATGTCT-3’ and a Kpn I restriction site at the 5’ end and 
a Bgl II restriction site at the 3’ end.
For the generation of the Nrf2 reporter an oligonucleotide with the sequence 
5’-GGGGTACCCCAGTCACAGTGACTCAGCAGAATCGTAAGATCTTC-3’ was 
hybridized with its complementary sequence. The procedure was similar to that described 
for the generation of the p53 reporter vector.
A pGL3-promoter vector containing a fi refl y luciferase gene (Promega, GenBank 
accession number U47298) was double digested with Kpn I and Bgl II. The pGL3 vector 
needs only the addition of a responsive element and contains all other sequences that are 
necessary for a good working promoter. The same restriction reaction was performed 
with the p53 and Nrf2 reporter constructs. Restriction enzymes were heat inactivated by 
heating the samples at 70ºC for 20 min. The restriction product of the plasmid was loaded 
onto an 1% agarose gel and run for 1 h. Next the digested plasmid DNA was cut from the 
gel and purifi ed with a DNA and Gel Band Purifi cation kit. Thereafter, the rapid DNA 
ligation kit from Roche (Basel, Switzerland) was used to ligate the restricted vector and 
insert. One hundred ng vector (pGL3 or pGL4) and three times the equimolar amount 
of insert were diluted in 1x DNA dilution buffer in a volume of 10 μl. Subsequently 10 
μl 2x ligase buffer and 1 μl containing 5 Weiss Units T4 DNA ligase were added. The 
ligation reaction was performed for 5 min at room temperature.
Then DH5α competent cells (Invitrogen) were transformed with the ligation product. 
Product of the ligation reaction (2μl) was added to the competent cells. Cells were 
incubated on ice for 30 min. The tubes were heat-pulsed in a 42 ºC water bath for 40 s 
and thereafter chilled on ice for 2 min. Next, 0.9 ml SOC medium (Promega) of 42 ºC 
was added. Cells were incubated for 1 h at 37ºC with shaking at 250 rpm. 100 μl of the 
transformation mixture was plated on LB agar plates containing 100 μg/ml ampicillin. 
Clones that appeared on the plate were checked for an insert by PCR (Forward primer, 
5’-GCAAGTGCAGGTGCCAGAAC-3’; Reverse primer, 5’-GCCTCGGCCTCTGC 
ATAAA-3’). Bacteria that were positive for an insert were used to inoculate 50 ml LB-
medium containing 100 μg/ml ampicillin. Bacteria were grown overnight and glycerol 
stocks of the bacteria were prepared and plasmid DNA was isolated. Clones were again 
checked for an insert by PCR and a double digestion with Xho I and Bgl I. A fi nal check 
for the insert was performed by sequencing. 
Transfection and generation of stable single cell clones
HepG2 cells were trypsinized, counted and resuspended in culture medium to a fi nal 
concentration of 3x104 per well. To each well of a white 96-well culture plate (Perkin 
Elmer) 90 μl cell suspension was added. One 96-well plate was prepared per construct. 
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The plates were incubated overnight for 24 h in a humidifi ed atmosphere at 37ºC under 
5% CO2.
Transfection mixtures were prepared by diluting Fugene-6 transfection reagent 
(Hoffmann-La Roche, Basel, Switzerland) with serum-free Optimem medium 
(Invitrogen) in a ratio of 1:16. This mixture was incubated for 5 min at room temperature. 
Then vectors were added resulting in a Fugene-6:plasmid DNA ratio of 6μl:1μg. In case 
of the p53 and Nrf2 reporter, cells were cotransfected with a pcDNA3.1+ (Invitrogen) 
vector. This vector harbors a neomycin resistence operon that enables the selection of 
stable transfectants. In case of the RAD51C_luc and Cystatin A_luc vectors a neomycin 
marker is already present. The Fugene-6:plasmid DNA mixture was gently shaken and 
incubated for 30 min at room temperature. Per well, mixture containing 100 ng plasmid 
DNA was added for the transfection reaction. After transfection, the plate was incubated 
for 24 h at 37ºC. Then standard culture medium was exchanged with culture medium 
containing 1% geneticin. Culture medium was refreshed every 3 or 4 days. The majority 
of the cells died due to the presence of geneticin, but some cell clusters survived. After 
two weeks the transfectants were trypsinized and homogeneously spread in an empty 
transparent 96-well plate. Stably transfected cells were scaled up to confl uent 6-well 
plates. The cell pools were trypsinized and each well was resuspended in 2 ml culture 
medium. From this suspension eight aliquots of 50 μl were seeded in a white 96-well 
culture plate. The other part was transported to a NunclonTM culture easyfl ask of 25 cm2. 
To the white plate 40 μl medium was added and these cells were incubated for 24 h. The 
next day, 10 μl doxorubicin in a dose range of 10-5 to 10-8 M (√10-fold steps) or vehicle 
alone in DMSO was added leading to a fi nal concentration of 0.1% DMSO. The cells 
were incubated for 24 h. Subsequently 50 μl LucLite reagent (Perkin Elmer) containing 
lysis reagent, ATP and luciferin was added and after 45 min shaking on a plate shaker 
the luminescence was measured for 1 s on a TopCount® NT Microplate scintillation 
and luminescence counter (Perkin Elmer). The 15 clones showing the highest induction 
were selected and scaled up to confl uency in fl asks of 175 cm2. A part of the cells was 
stored at -80ºC with medium containing 20% DMSO. Stable single cell clones were then 
selected. Cells of the best 3-5 pools (>5-10 fold induction) were seeded single cell by 
adding 600 cells in the fi rst well in a transparent plate and thereafter diluting them 1:2 in 
culture medium until the last well. Per cell pool fi ve plates were prepared. The ultimate 
amount of culture medium was 200 μl in each well. The fi rst well contained 100 μl and 
the last well contained 300 μl. After one and a half week single cell clones were selected 
by microscopic inspection and medium in these wells was refreshed every 3-4 days. 
After 3-4 weeks the single cell clones were transported to a transparent 96-well plate 
and scaled up to 6-well plates. The same protocol as for the pools was used to test the 
induction of luminescence after doxorubicin treatment. Then up to 10 single cell clones 
showing the highest induction were selected and cell stocks were frozen. Medium was 
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replaced by medium without geneticin and cells were cultured for two months. Every 
week the luciferase induction by doxorubicin was tested. Cells showing a reproducible 
induction over a period of two months in culture were defi ned as stably transfected single 
cell clones. Cell stocks from these cells were stored in the freezer. The stable single cell 
clones with the highest induction were used for compound testing. The developed cell 
lines were called HepG2 RAD51C_luc, Cystatin A_luc, p53_luc, and Nrf2_luc.
Evaluation of the assays with compounds
The HepG2 reporter cells were trypsinized, counted and resuspended in culture medium 
leading to a fi nal concentration of 2x104 cells/well (90 μl) in a white 96-well plate. The 
plates were incubated for 24 h in a humidifi ed atmosphere at 37 ºC under 5% CO2. 
Following the pre-incubation, seven serial dilutions (√10 steps) of the compounds or a 
control sample were added as 10 μl fractions to HepG2 cells leading to a fi nal volume of 
100 μl (1% DMSO). Doxorubicin and benzo[a]pyrene were used as positive controls in 
every assay. These compounds were added to the lanes 1 and 2 in each plate. The highest 
tested concentration of the compounds was 10-3 M. An exception was doxorubicin for 
which the highest tested concentration was 10-4 M. Compounds were tested in duplicate 
on two separate plates. After the addition of the compounds the plates were incubated 
for 48 h in a humidifi ed atmosphere at 37 ºC under 5% CO2. Subsequently, 50 μl LucLite 
reagent was added. Plates were shaken for 1 h and the luminescence was measured with 
the TopCount NT microplate scintillation and luminescence counter. All experiments in 
the present study were performed in at least two independently performed experiments. 
Results from one representative experiment are shown in this chapter.
The compounds that were used for the validation study are described in more detail 
in a Chapter 2 [1]. In vivo genotoxicity data were added for the 192 additionally tested 
compounds. These data was acquired from the CPDB, IARC, and ICSAS databases.
Calculations
After testing, the values of the two duplicate plates were averaged. Then the average 
of the 12 controls (1% DMSO) was calculated and this value was used to assess the 
induction factor of the compounds. 
A compound was considered to be positive in the HepG2 RAD51C_luc, Cystatin A_luc 
and p53_luc assay when the response was induced by 1.5-fold (50% increase ≥ 5 times 
the standard deviation of the background). Background means here HepG2 reporter 
cells treated with 1% DMSO. 
In total, 120 untreated controls were used to assess the threshold of 1.5-fold (derived 
from 10 independent experiments). In the HepG2 Nrf2_luc assay the threshold for a 
positive results was set at an induction factor of 2-fold. The procedure used to assess this 
threshold was the same as for the other reporter assays.
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The highest test concentration in the assays was 1 mM. This top dose is the same as the 
proposed top dose for the regulatory in vitro mammalian tests (ICH guideline S2(R1), 
under revision). However, this revision has yet to be ratifi ed.
Compounds that are positive in the HepG2 reporter assays can show a positive (‘A’) 
or negative results in a second test (‘B’). Similarly, compounds with a negative score in 
the reporter assays can give a positive (‘C’) or negative (‘D’) score in a second test. The 
second test that is used for a comparison gives A+C positive scores and B+D negative 
scores. By using these values the sensitivity, specifi city and predictivity/correlation 
were calculated: sensitivity = A/(A+C); specifi city = D/(B+D); predictivity/correlation 
= (A+D)/(A+B+C+D). 
An aspect that can cause false positive results is precipitation. Therefore, it was decided 
to discard measurements showing precipitation. Moreover, an Alamar Blue assay was 
performed to assess cytotoxicity [32]. Measurements showing more than 80% cytotoxicity 
were discarded. Non-transfected HepG2 cells were used for this cytotoxicity assay. It was 
assumed that the transfected cells showed the same level of cytotoxicity. Doxorubicin 
was used as reference compound. A concentration of 3.15x10-5 M doxorubicin killed 
almost all cells and this concentration was set at 100% toxicity. 
Hierarchical clustering
Hierarchical clustering is a method that can be used to show the level of similarity 
between the assays or compounds. The closer the assays/compounds cluster together the 
higher the similarity is. In this way it is another way to present the data. reporter assay 
data were hierarchical clustered by using Spotfi re DecisionSite version 9.1 (TIBCO). The 
hierarchical clustering method used was UPGMA (unweighted average). The similarity 
measure used was Euclidean distance. 
Results 
Validation of the assay procedure with reference compounds and the reproducibility 
of the assays
The HepG2 reporter assays were evaluated by using the ECVAM compound list and an 
additional set of 192 compounds. The results are described in the next two sections. The 
results for a representative set of compounds with diverse mechanisms, i.e. 4-nitroquinole-
1-oxide (4NQO), benzo[a]pyrene (B[a]P), doxorubicin, cisplatin, 5-fl uorouracil, taxol 
and hydrogen peroxide (H2O2), are shown in Figure 1. The cytotoxicity data of the 
compounds tested in an Alamar Blue assay are also shown in Figure 1.
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Figure 1. Concentration-dependent genotoxicity and cytotoxicity of a representative set of seven 
compounds in de four HepG2 reporter and Alamar Blue assays. Compounds were tested in two 
independently performed experiments. A representative curve is shown.
The direct-acting genotoxicant 4NQO showed induction in all four reporter assays with 
a maximal induction at ≤ 1.00x10-6 M or 3.16x10-6 M. After the maximum induction the 
luminescence drops sharply due to the cytotoxicity of 4NQO. 
B[a]P which is activated by CYP1A1 showed activity in all four reporter assays. The 
Lowest Effective Concentration (LEC) in the HepG2 RAD51C_luc and p53_luc reporter 
assay was ≤1.00x10-6 M. Subsequently the LEC was 3.16x10-6 M in the Nrf2_luc and 
Cystatin A_luc reporter assay. 
The cross-linking agent cisplatin showed activity in the HepG2 Cystatin A_luc, p53_
luc and Nrf2_luc reporter assays with a LEC of 3.16x10-5, 3.16x10-4 M, and 1.00x10-5 
M, respectively. The maximum induction in these assays was between 4-, and 5-fold. 
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Cisplatin showed no activity in the HepG2 RAD51C_luc assay. 
The anti-metabolite 5-fl uorouracil had a LEC of 3.16x10-6 M in the HepG2 RAD51C_luc, 
p53_luc and Nrf2_luc assay. In the HepG2 Cystatin A_luc reporter assay 5-fl uorouracil 
showed already activity at 1.00x10-6 M. The maximum induction was respectively 5, 
60, 7, and 13-fold in the HepG2 RAD51C_luc, Cystatin A_luc, p53_luc and Nrf2_luc 
reporter assays. 
The spindle poison taxol showed already activity in all reporter assays at a concentration 
of ≤ 1.00x10-6 M. The maximum induction in the HepG2 RAD51C_luc, Cystatin A_luc, 
p53_luc, and Nrf2_luc assay was 7, 2, 55, and 102-fold, respectively. 
Hydrogen peroxide causes DNA damage as a result of the formation of reactive 
oxygen species. Hydrogen peroxide caused an induction of the luminescence in the 
HepG2 RAD51C_luc, Cystatin A_luc and p53_luc reporter assays at a concentration 
of 1.00x10-3 M. The maximum induction in these assays was just below 2-fold. The 
maximum induction in the HepG2 Nrf2_luc assay was 19-fold. In this assay a signifi cant 
induction was already observed at a concentration of 3.16x10-4 M. 
To show the reproducibility of the reporter assays, doxorubicin and B[a]P were tested 
in 10 independent experiments (different compound stocks and days, same operator) 
(Figure 2). Doxorubicin had a LEC of ≤ 1.00x10-7 M in all 10 experiments in the HepG2 
Rad51C_luc, Cystatin A_luc and p53_luc assays. In the p53_luc assay, B[a]P had 
an LEC of 3.16x10-6 M in 8 experiments and of 1.00x10-6 M in 2 experiments. The 
variation in the RAD51C_luc assay was a bit larger. B[a]P had an LEC of 1.00x10-6 M, 
3.16x10-6 M, and 1.00x10-5 M in 4, 4 and 2 experiments, respectively. In the Cystatin 
A_luc assay the reproducibility was high with an LEC for B[a]P of 1.00x10-6 M in 6 
experiments and of 3.16x10-6 M in 4 experiments. The reproducibility of the Nrf2_luc 
assay was also high. Doxorubicin had a LEC of  3.16x10-7 M in 7 experiments and of 
1.00x10-6 M in 3 experiments. The LEC of B[a]P was 1.00x10-6 M in all 10 experiments. 
Overall the experiments with the 2 reference compounds gave a fi rst indication that the 
reproducibility of the HepG2 reporter assays is good. 
Validation of the HepG2 RAD51C_luc, Cystatin A_luc, p53_luc, and Nrf2_luc reporter 
assays with respect to the ECVAM compound list
The effects of the 62 ECVAM compounds were tested in the four luciferase based 
reporter assays. The overall results are shown in Tables 1-3. Data were compared with 
the genotoxic/non-genotoxic classifi cation of the compounds. The sensitivity, specifi city 
and predictivity of the HepG2 RAD51C_luc, Cystatin A_luc, and p53_luc reporter 
assays were calculated (Table 4). 
The HepG2 p53_luc assay had the highest sensitivity with a score of 85%. Among the 
20 genotoxic compounds cyclophosphamide, dimethylnitrosamine and chloramphenicol 
were not detected. Several compounds that need metabolic activation like B[a]P, 
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7,12-dimethylbenzanthracene, 2-acetylaminofl uorene, 2,4-diaminotoluene, IQ, PhIP.
HCl and afl atoxin B1 gave a positive score in the HepG2 p53_luc reporter assay. As 
no S9 mixture was used, this indicates that endogenous metabolism in HepG2 cells 
was suffi cient for the metabolic activation of these compounds. On the other hand, 
metabolism by CYP2B6 and CYP2E1 seems to be too low to activate cyclophosphamide 
and dimethylnitrosamine, respectively.   
Cyclophosphamide, dimethylnitrosamine, and chloramphenicol were also not detected 
in the RAD51C and Cystatin A_luc reporter assays. In addition PhIP.HCl, cadmium 
chloride, cisplatin, p-chloroaniline, and hydroquinone were not detected in the RAD51C_
luc assay indicating that double strand break repair by homologous recombination is 
not involved. In the Cystatin A_luc reporter assay PhIP.HCl, cadmium chloride, and 
p-chloroaniline came out negative. The HepG2 Rad51C_luc and Cystatin A_luc reporter 
assays had a sensitivity of 60% and 70%, respectively.
Among the 20 genotoxic compounds, 15 had a positive score in the Nrf2_luc reporter 
assay (75%) indicating that the formation of reactive intermediates might play a role in 
the genotoxic effects of these compounds. Cyclophosphamide, dimethylnotrosamine, 
PhIP.HCl, p-chloraniline, and chloramphenicol were not active in the Nrf2_luc assay.
The HepG2 RAD51C_luc, Cystatin A_luc and p53_luc reporter assays had also a high 
specifi city for genotoxic compounds. The specifi city of the RAD51C_luc, and Cystatin 
A_luc and p53_luc reporter assay was 93, 90 and 93%, respectively. 
Of the 19 compounds that give often false positive results in vitro only propyl gallate 
was positive in the p53_luc assay. Although not positive curcumin showed a tendency to 
induction (>1.4 fold induction at 3.16x10-5 M). Propyl gallate and curcumin were positive 
in the RAD51C_luc assay. In the Cystatin A_luc assay tertiary-butylhydroquinone, urea, 
propyl gallate, and 2,4-dichlorophenol were positive. 
Of the non-DNA reactive chemicals that have not been reported to give positive results 
in vitro (23 compounds), fl uometron and phenanthrene scored positive in the p53_luc 
reporter assay. In the RAD51C_luc and Cystatin A_luc reporter assays only ampicillin 
showed a positive result. 
The overall predictivity of the HepG2 RAD51C_luc, Cystatin A_luc and p53_luc 
reporter assays for genotoxicity was high with scores of 82, 84 and 90%, respectively while 
these values were 85% and 79% for the VitotoxTM and RadarScreen assays, respectively. 
The predictivity for genotoxicity was 82% (sensitivity 85%; specifi city 81%) when the 
three reporter assays were combined. The percentage of Nrf2 positive compounds in 
the group of the non-genotoxic compounds was 31% (13/42). This percentage is much 
lower than the 75% measured for the group of genotoxic compounds. 
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Figure 2. The reproducibility of the concentration dependent effects of doxorubicin and benzo[a]pyrene 
(B[a]P) in the four HepG2 reporter assays in ten independently performed experiments. The dashed line 
represents the genotoxicity threshold.
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Evaluation of the HepG2 reporter assays with respect to the additional set of 192 
compounds
Besides with the compounds from the ECVAM list, the assays were further validated 
with an additional set of 192 compounds. The data set was not complete for all of these 
chemicals. Bacterial mutagenicity (Ames test) data were available for 145 compounds, 
in vitro mammalian genotoxicity data for 124 compounds, and in vivo genotoxicity 
data for 70 compounds. Moreover, for all compounds VitotoxTM and RadarScreen data 
are available. The results from the HepG2 RAD51C_luc, Cystatin A_luc, p53_luc and 
Nrf2_luc reporter assays and additional genotoxicity data available for these compounds 
are shown in Tables 5 and 6. The number of positive scores in the different compound 
groups are shown in Table 7.
Validation of the HepG2 RAD51C_luc reporter assay
Of the 192 tested compounds, 22 (11%) had a positive result in the HepG2 RAD51C_
luc assay. Of these, 19 compounds were genotoxic in the regulatory genotoxicity tests. 
Similar to what was observed with the ECVAM compound list, the indicates the high 
specifi city of this assay. 
Sulfamoxole had a positive result in the RAD51C_luc reporter assay with a LEC 
of 3.16x10-5 M, but, no bacterial mutagenicity or mammalian genotoxicity data were 
available for this compound. The VitotoxTM  and RadarScreen assays showed a negative 
result for this compound. As also the p53_luc and Cystatin A_luc reporter assay in HepG2 
cells came out negative for this compound, the positive result in the RAD51C_luc assay 
was quite surprising. The Nrf2_luc assay showed a positive response, but this effect was 
only seen at the much higher concentration of 1.00x10-3 M. 
Of the compounds with equivocal genotoxicity data in the regulatory assays, Org 9217 
and Org 9935 showed a positive response in the RAD51C_luc reporter assay. These 
compounds showed also a positive result in the p53_luc reporter assay.
Table 4. The sensitivity (Sens), specificity (Spec) and predictivity (Pred) of the VitotoxTM, 
RadarScreen, and HepG2 reporter assays with respect to the ECVAM compound list.
Vitotox Radar
Screen
HepG2 genotox reporters Nrf2
RAD51C Cystatin A p53 Total 
Sens (%) 70 (14/20) 70 (14/20) 60 (12/20) 70 (14/20) 85 (17/20) 85 (17/20) 75 (15/20)
Spec (%) 93 (39/42) 83 (35/42) 93 (39/42) 90 (38/42) 93 (39/42) 81 (34/42) 69 (29/42)
Pred (%) 85 (53/62) 79 (49/62) 82  (51/62) 84 (52/62) 90 (56/62) 82 (51/62) 71 (44/62)
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Table 7. Number of scores in the reporter assays in each of the different groups from Tables 5 and 6
Group RAD51C
luc
Cystatin A
luc
p53
luc
Nrf2
luc
N
I. Genotoxic compounds 19 34 44 67 108
 i.   Ames positive compounds 15 23 27 37 49
 ii.  Equivocal for Ames in vitro/in vivo mammalian genotoxic 1 1 1 1 1
 iii. No Ames data or neg. in vitro/in vivo mammalian genotoxic 3 10 16 29 58
II. Not genotoxic or no genotoxicity reported 1 4 7 30 80
III. Equivocal for genotoxicity 2 1 2 3 4
Total 22 39 53 100 192
Validation of the HepG2 Cystatin A_luc reporter assay
In the Cystatin A_luc reporter assay, 39 of the 192 tested compounds (20%) compounds 
showed a positive result. As was observed in the p53_luc and RAD51C_luc reporter 
assays, most of the positive results in this assay were seen with genotoxic compounds 
(34/39).  
Four compounds with a positive score were non-genotoxic or no genotoxicity data 
were reported. Like in the p53 reporter assay, bishydroxycoumarin had a positive result 
in this assay. Furthermore Org 30189, strychnine, and Tularik 0191317 had a positive 
result in the assay. Mammalian genotoxicity data was not available for Org 30189. With 
exception of the Nrf2_luc reporter assay this compound gave a negative result. 
For both strychnine and Tularik 0191317, bacterial mutagenicity and mammalian 
genotoxicity data were lacking. With exception of Nrf2 induction, the compound showed 
no induction in the other assays. 
Of the compounds with equivocal genotoxicity data, Org 9217 had a positive result in 
the Cystatin A_luc reporter assay.
Validation of the HepG2  p53_luc reporter assay
Of the 192 tested compounds, 53 (28%) had a positive score in the HepG2 p53_luc 
assay. Of which 44 compounds were genotoxic in one or more regulatory genotoxicity 
assays. For only seven compounds with a positive result, the regulatory genotoxicity 
data were negative or no genotoxicity was reported for these compounds. These results 
indicate that the specifi city of this assay is high (44 scores in the group of 108 genotoxic 
compounds vs. 7 scores in the group of 81 compounds with negative genotoxicity data/
or compounds that lack genotoxicity data). This confi rms the results that were found 
with the ECVAM compound list. 
The seven compounds that might have a false-positive result were bishydroxycoumarin, 
dimethisterone, iodoacetate, ketoconazole, lilopristone (with an additional 17α carbon), 
onapristone, and RU58668. Bishydroxycoumarin was negative in the regulatory Ames, 
mammalian tests, and VitotoxTM assay. But this compound had a positive result in the 
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RadarScreen assay with a LEC of 1.00x10-4 M. In addition a positive result was observed 
in the Cystatin A_luc assay. As the Nrf2_luc assay showed a positive result, oxidative 
stress might be involved in this effect. 
The progestin dimethisterone was not tested in the Ames assay and gave a negative 
result in the in vitro mammalian genotoxicity tests (no in vivo genotoxicity data). In the 
RadarScreen assay this compound showed a positive result, but it was negative in the 
RAD51C_luc, Cystatin A_luc, and Nrf2_luc assays. Besides this steroid, three other 
steroidal compounds were positive, i.e. the progestin lilopristone (with an additional 
17α carbon), the anti-progestin onapristone, and the anti-estrogen RU 58668. 
Lilopristone was reported to be negative in the Ames assay. Mammalian genotoxicity 
data were not available for this compound, but positive results were observed in the 
VitotoxTM  and RadarScreen assay. This indicates that this compound may be genotoxic. 
On the other hand, the other reporter assays in the HepG2 cells showed negative 
results.  
Onapristone showed a positive result in the RadarScreen assay, but it was negative in 
all the regulatory tests and other HepG2 reporter assays. 
RU58668 lacks Ames and mammalian genotoxicity data. Furthermore, this compound 
had a positive result in the RadarScreen and Nrf2 reporter assays. 
Surprisingly, iodoacetate gave a positive results in the p53_luc assay. With exception 
of the Nrf2_luc assay all other assays showed negative results for this compound. 
Four compounds have equivocal results for genotoxicity. Of these, Org 9217 and Org 
9935 had a positive result in the p53_luc reporter assay.
Validation of the Nrf2 reporter assay
Of the 192 tested compounds, 100 gave a response in the Nrf2 assay (52%). The 
percentage of compounds among the genotoxic compounds that had a positive response 
in the Nrf2 assay was 62% (67/108). In the group of non-genotoxins/compounds for 
which no genotoxicity data have been reported, the percentage of Nrf2 inducers was 
lower with 38% (30/80). These results confi rm the observations with the ECVAM 
compound list. The percentage of Nrf2 positive compounds was especially high for 
bacterial mutagenic (positive Ames test) compounds with a score of 76% (37/49). 
Of the four compounds that were equivocal for genotoxicity, Org 30002, Org 9217, 
and Org 9935 showed a positive response in the Nrf2 reporter assay.
Comparison of the reporter assays with the Ames assay, in vitro mammalian genotoxicity 
data and in vivo genotoxicity data
 The results from the HepG2 luciferase reporter assays were compared with the results 
from the Ames assay and in vitro/in vivo mammalian genotoxicity assays (Tables 8-10). 
The HepG2 p53_luc assay had a correlation with the Ames assay of 73% (106/145). 
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The sensitivity was low with 55% (27/49), but the specifi city was high with 82% 
(79/96). Similar results were observed with the HepG2 RAD51C_luc assay (sensitivity, 
31%; specifi city, 97%; correlation, 75%) and HepG2 Cystatin A_luc assay (sensitivity, 
47%; specifi city, 88%; correlation, 74%). When the three HepG2 reporter assay were 
combined the sensitivity was 61% (30/49). The specifi city was high with 80% (77/96). 
This resulted in a correlation with the Ames test of 74% (107/145). 
The results from the HepG2 reporter assays were also compared with the available 
in vitro mammalian genotoxicity data. The specifi city of the HepG2 RAD51C_luc, 
Cystatin A_luc, and p53_luc reporter assays was high with scores of >83%. However, 
the sensitivity scores were low with 15% (12/78), 30% (23/78) and 40% (31/78) for 
the HepG2 RAD51C_luc, Cystatin A_luc and p53_luc assay, respectively. This resulted 
in a correlation with the in vitro mammalian genotoxicity scores for the HepG2 
RAD51C_luc, Cystatin A_luc and p53_luc assay of 45% (56/124), 52% (65/124) and 
56% (69/124), respectively. The overall correlation of the three reporter assays with 
in vitro mammalian genotoxicity was 59% (73/124). The sensitivity was 45% (35/78) 
and the specifi city 83% (38/46). The correlation of the reporter assays with in vitro 
mammalian genotoxicity was relatively low compared to the correlation observed with 
the RadarScreen assay (76%). 
The results were also compared with the in vivo genotoxicity data. For this comparison 
the sensitivity and predictivity were much better. The overall correlation of the three 
reporter assays with in vivo genotoxicity was 77% (54/70). Furthermore, the sensitivity 
and specifi city were 74% (28/38) and 81% (26/32), respectively. For the individual 
assays, the correlations were 76% (53/70) for the HepG2 p53_luc assay (sensitivity, 71% 
(27/38); specifi city, 81% (26/32)), 59% for the HepG2 RAD51C_luc assay (sensitivity, 
29% (11/38); specifi city, 94% (30/32)), and 76% (53/70) for the HepG2 Cystatin A_luc 
assay (sensitivity, 61% (23/38); specifi city, 94% (30/32)). The overall correlation of 
the HepG2 reporters with in vivo genotoxicity was higher than the correlation that was 
measured with the RadarScreen assay (correlation 54% (37/69), sensitivity 68% (25/37), 
specifi city 38% (12/32)). The in vitro mammalian genotoxicity tests detected almost all 
in vivo clastogenic compounds (sensitivity 94%), however, as expected the number of 
false positive results was high with a specifi city score of only 46% (12/26).   
Hierarchical clustering was also performed to show the similarity between the assays 
(Supplementary data, Figure 1; doi:10.1016/j/mrgentox.2009.12.007). The clustering 
was performed for a subset of compounds for which both in vitro and in vivo genotoxicity 
data were available. Hierarchical clustering shows that the HepG2 genotox reporters 
cluster with the in vivo genotoxicity assays and that the RadarScreen assay clusters with 
the in vitro mammalian genotoxicity assays.  
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Risk analysis of genotoxicity in the early research phase of drug development by using 
the in vitro assays and hierarchical clustering 
We evaluated six different mechanism-based in vitro assays that can help to detect 
genotoxic compounds. The data from all these compounds (with exception of 
mestranol) were hierarchically clustered. After clustering the available regulatory 
genotoxicity data was added to the list (Supplementary data, Figure 2; doi:10.1016/j/
mrgentox.2009.12.007). In case of the ECVAM compounds this data was not added as for 
a lot of these compounds in vitro data is positive however irrelevant due to cytotoxicity 
or another mechanism of action. Performing hierarchical clustering makes it possible to 
easily detect compounds that show species specifi c genotoxicity and to detect structural 
components in compounds that might cause genotoxicity.
Most of the compounds that were negative in all the assays were also negative in 
the reported regulatory genotoxicity data. Exceptions were tamoxifen, ment-bucyclate, 
hydrochlorothiazide, dexamethasone and carbon tetrachloride. For other compounds 
only Nrf2 activity was observed. 
Clustering of the compounds also shows that most compounds that are strong 
genotoxicants like for example MMS, cisplatin and ENU give a positive response in 
most or all of the assays. Compounds between number 93 and 105 in Supplementary data 
showed only activity in the VitotoxTM assay. Most of these compounds are structurally 
related. Similarly there were quite a few compounds that showed only activity in the 
RadarScreen assay (± Nrf2 activity). Many of these are steroids, which stresses the 
high sensitivity of this assay for this structure class. In in vitro mammalian genotoxicity 
tests positive results have been reported for these or structurally related compounds. 
In vivo most of these compounds show a negative result. In addition, several of these 
RadarScreen positive compounds are genotoxic compounds that need activation by 
CYP2B6 and CYP2E1, which are not detected in HepG2 cells. 
The RAD51C_luc assay focuses on a specifi c mechanism. In almost all cases where 
RAD51C activation was observed, p53 was also induced (31/37). In the case of curcumin, 
4NQO and Org 5695 a reproducible tendency for induction between 1.3 and 1.5 fold 
was observed. The same was true for Cystatin A as most of the compounds that showed 
a positive response in the Cystatin A assay were also positive in the p53_luc assay, or 
showed a tendency to induction in the p53_luc assay. 
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Discussion
The reporter assays
In the present study, four mechanism-based luciferase reporter assays were developed. 
Reporter assays with a p53- and Nrf2-responsive element have already been described 
by others. However, the number of compounds that were used for the evaluation of these 
assays were much smaller. 
Reporter assays involving p53 have been developed by Ohno et al. [33, 34] and 
Sohn et al. [35]. Both studies describe the development of a stable cell line transfected 
with a luciferase based p53 reporter system. Like in the study performed by Sohn et 
al., we used a construct with four copies of the 10-bp motif: 5’-PuPuPuC/(A/T)(T/A)
GPyPyPy-3’. Ohno et al. used a slightly different sequence. They used a small part of 
the p53R2 promoter. Their reporter vector fi nally contained six times the 10-bp motif. 
We cannot exclude that this difference can result in a different test outcome. Moreover, 
the application of different cell lines might cause differences in responses.
Sohn et al. develop their assay in the human pancreatic carcinoma cell line HS776T and 
showed that p53 was activated by alkylating agents, intercalating agents, anti-metabolites, 
topoisomerase inhibitors and anti-microtubule agents. In their assay cyclophosphamide 
did like in the present study not induce p53. 
Ohno et al. made their assay in the human breast adenocarcinoma cell line MCF-7 and 
HepG2 cells. They found that MCF-7 cells were slightly more sensitive than HepG2 cells, 
and validated their assays with 80 chemicals [34]. Data were compared with data from 
the Ames assay and data from other genotoxicity assays including the mouse lymphoma 
assay, chromosome aberration test, sister chromatid exchange (SCE) assay, and in vivo 
carcinogenicity data from rats or mice. Forty eight chemicals were positive in their 
assay. Of these, 40 were positive in the Ames test. The eight remaining compounds were 
all positive in other genotoxicity tests, and seven were carcinogenic in mice or rats. 
This indicates that a p53 reporter assay may indeed have additional value compared to 
the Ames test. Furthermore the addition of S9 mixture was tested by Ohno et al. [34]. 
They could trigger the induction of some compounds. However, the six compounds that 
needed S9 mixture for a positive result in the Ames test already showed a positive result 
in the p53-reporter assay without S9 mixture indicating that metabolism was present in 
HepG2 (and MCF-7) cells. Three mutagenic (Ames positive) compounds were negative 
in the p53 reporter assay. Surprisingly, one of these compounds was 5-fl uorouracil. This 
compound was clearly positive in the present assay and in the assay described by Sohn 
et al [35]. 
The insert in the Nrf2 reporter assay was based on the study of Boerboom et al. [36]. 
A functional ARE sequence of the human NQO1 gene was placed in a pGL3 vector. A 
study of Wang et al. [37] showed that placing more AREs before the luciferase gene can 
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increase the level of induction. For this reason, we prepared a vector with a single ARE 
and a vector with three ARE repeats. Experiments using transient transfection did not 
show any difference in the induction of the luminescence between these two constructs. 
The same was observed for stably transfected cell pools (Schering-Plough, unpublished 
data). In the end, a single cell clone with a single ARE showed the largest induction of 
the luminescence. This cell clone was used for the experiments.
Luciferase reporters driven by the RAD51C and Cystatin A promoter were also 
generated. As far as we know it is the fi rst time that results from a RAD51C and Cystatin 
A reporter assay are presented. RAD51C was chosen as this gene plays an important role 
in double strand break repair. 
The role of the anti-apoptotic protein Cystatin A in relation to genotoxicity is less 
clear. The results in this study showed that induction of Cystatin A is quite specifi c for 
genotoxicity. However, also bile acids can induce this gene [21]. The induction found 
in this study with the LXR agonist Tularik 0191317 may be related to this effect. Thus 
some non-genotoxic compounds might induce Cystatin A.
The assays developed in the present study have a sensitive luminescence read-
out. An advantage of this system over a more common used fl uorescent read-out is 
that autofl uorescence of compounds does not hamper genotoxicity assessment [38]. 
Furthermore a sensitive assay makes the assessment of a NOEL (no observed effect 
level) more accurate which is very important for proper risk assessment.
Validation of the assays with the ECVAM compound list
A compound list published by the ECVAM was used for the evaluation of the four 
reporter assays [28]. The sensitivity of the HepG2 p53_luc, RAD51C_luc, Cystatin A_
luc assays was 85% (17/20), 60% (12/20) and 70% (14/20), respectively. The fact that 
the RAD51C reporter assay measures the induction of a more specifi c mechanism than 
induction of for example p53, was the reason for the lower sensitivity of this assay. An 
advantage of measuring the induction of such a specifi c mechanism is the mechanism-
based insight and the high specifi city of such an assay. 
The metabolic capacity present in the HepG2 cell line was suffi cient to activate 
several proximate genotoxins such as benzo[a]pyrene, 7,12-dimethylbenzanthracene, 
2-acetylaminofl uorene, 2,4-diaminotoluene, IQ, PhIP.HCl and afl atoxin B1. All these 
compounds showed a positive result in the p53_luc assay without the addition of S9 
mixture. Not all compounds that needed metabolic activation were positive in the 
p53_luc assay. Cyclophosphamide and dimethylnitrosamine showed a negative results. 
As CYP2B6 and CYP2E1 are expressed at a very low levels in the HepG2 cells [28] 
this is a plausible reason for the fact that these compounds were not detected. These 
two compounds were detected in the RadarScreen assay and they showed the highest 
activity in this assay after the addition of S9 mixture [1]. Besides these two compounds, 
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chloramphenicol was not detected in the p53_luc assay. 
Induction in the RAD51C_luc assay was found for 12 of the 20 compounds showing 
that double strand break repair is involved in the genotoxic mode of action of these 
compounds. Of the compounds positive in the p53_luc assay PhIP.HCl, cadmium chloride, 
cisplatin and p-chloroaniline did not induce the luminescence in the RAD51C_luc assay. 
In addition, as seen in the p53_luc assay, cyclophosphamide, dimethylnitrosamine and 
chloramphenicol were negative in the RAD51C_luc assay. 
The same compounds were also not detected in the Cystatin A_luc assay. Activity was 
also not measured for PhIP.HCl, cadmium chloride and p-chloroaniline. 
When the HepG2 genotoxicity reporter assays were combined the sensitivity was similar 
to that found for the p53_luc assay, i.e. 85% (17/20). Of the 20 genotoxic compounds 
75% (15/20) showed activation of the Nrf2 pathway. 
Application of a pre-screen that consists of a VitotoxTM assay, RadarScreen assay and 
the three HepG2 genotoxicity reporters would result in a sensitivity of 95% (19/20). 
The three HepG2 genotoxicity reporter assays showed all a specifi city that was >90%. 
Of the 23 compounds that were defi ned by the ECVAM as non-DNA reactive chemicals 
fl uometron and phenanthrene showed a positive response in the p53_luc assay. Both 
compounds also caused oxidative stress. Fluometron showed a negative response in the 
remaining assays. Phenanthrene was positive in the VitotoxTM assay after the addition of 
S9 mixture. The effects of these two compounds were only observed at the highest test 
dose of 1.00x10-3 M indicating that the effects are only small. Ampicillin was positive 
in the RAD51C_luc assay and showed a tendency to induction in the Cystatin A_luc 
assay. Moreover, a positive response in the RadarScreen was observed in the presence 
of S9. Of the 23 non DNA-reactive compounds, fi ve showed a positive response in the 
Nrf2_luc assay. 
For two of the ECVAM compounds that are in the ‘false positive group’, i.e. tertiary-
butylhydroquinone and curcumin, there is still discussion within the ECVAM working 
group whether these compounds are real genotoxic positives as they give rise to oxidative 
stress which can result in DNA damage (personal communication with David Kirkland). 
In both the VitotoxTM and RadarScreen assay tertiary-butylhydroquinone gave a positive 
response. In the HepG2 Nrf2_luc reporter assay it was shown that this compound indeed 
caused oxidative stress with a LEC of 1.00x10-5 M. In the other three reporter assays 
only an induction was observed in the Cystatin A_luc assay. Overall, the six assays 
show that this compound might indeed be genotoxic. The same is true for curcumin. 
Although this compound was negative in the VitotoxTM assay, it showed a positive result 
in the RadarScreen assay. In HepG2 cells this compound showed Nrf2 activation and an 
induction of double strand break repair. Moreover, a tendency for induction (just below 
1.5 fold) was observed in the HepG2 p53_luc assay. Overall, these results indicate that 
curcumin indeed might be a genotoxic compound. 
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Of the other compounds in the ‘false positives group’, propyl gallate was positive 
in the four HepG2 reporter assays. None of the other compounds were positive in the 
HepG2 p53_luc assay. Fluometron and phenanthrene were positive in the p53_luc 
assay. Besides the above mentioned compounds, urea showed a positive response in the 
Cystatin A_luc assay. 
Induction of the luminescence in the Nrf2_luc assay was observed for 8 of the 19 
compounds in the ‘false positives group’. Overall this resulted in 31% positive scores 
(13/42) for the 42 non-genotoxic compounds. This percentage is much lower than the 
percentage of 75% that was observed with the genotoxic compounds. This may indicate 
that the number of compounds that cause oxidative stress is higher under the genotoxic 
compounds. 
However, cross-talk between the p53 and Nrf2 pathways makes interpretation of 
data more diffi cult. Recently Chen et al. [39] showed that p21 activates Nrf2 (p21 is 
activated by p53). On the other hand Faraonio et al. [40] showed that p53 suppresses 
Nrf2. However, these effects are suggested to occur only at such high levels of stress 
were damage is irreparable. This shifts the stress response towards cell death (apoptosis). 
Moreover, oxidative stress can of course result in activation of the Nrf2 response. At 
higher levels of stress, DNA damage and p53 activation can then occur. Because of the 
crosstalk between these two pathways it is diffi cult so not impossible to delineate cause 
and effect. The only conclusions that can be drawn is that genotoxicants show a high 
incidence of activation of the Nrf2 pathway.
When the three genotoxicity reporter assays are combined the specifi city decreases 
but is still 81% (34/42). Addition of the VitotoxTM and RadarScreen assay data to this 
pre-screen would result in a specifi city of 74% (31/42). These values result in an overall 
predictivity of the HepG2 reporter assays of 82% (51/62). The predictivity of a screen 
using all fi ve genotoxicity reporter assays is 81% (50/62). 
Validation of the assays with an additional set of compounds including a large set of 
steroidal compounds.
Besides the chemicals of the ECVAM list, an additional set of 192 compounds were 
tested. These were non-genotoxins and genotoxins with diverse mechanisms of action. 
However, for a large number of these compounds the mechanism is still unknown and 
the list also included compounds from which no genotoxicity data are available. The 
list also included a lot of steroidal compounds. In addition to progesterone, which was 
in the ECVAM compound list, several other steroidal compounds including estrogens, 
anti-estrogens, progestins, anti-progestins, androgens, glucocorticoids and anti-
glucocorticoids were tested. 
Estrogens are carcinogenic in humans and rodents [41, 42]. Epigenetic mechanisms 
that stimulate cell proliferation through the estrogen receptor are thought to be the 
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main factors that contribute to this effect. Genotoxic properties of estrogens may also 
contribute to this [43]. However, most genotoxic effects are observed at concentrations 
that are >1000-fold above the physiological concentration of 100 pM. During pregnancy 
the estrogens levels can reach a concentration of 10 nM. However, the physiological 
relevance of the reported genotoxic effects remains questionable. Only for catechol 
estrogens positive results for bacterial mutagenicity were demonstrated [44]. The other 
positive results were found in mammalian genotoxicity tests. Catechol estrogens are 
reported to be converted easily by various oxidation mechanisms to ortho-quinones 
[45]. These ortho-quinones react with all DNA bases with exception of thymidine. The 
six catechol estrogens showed a positive result in the p53 and Nrf2 reporter assays. 
None of these compounds seemed to induce double strand breaks as no induction of the 
luminescence was reported in the RAD51C_luc reporter assay. Moreover ,with exception 
of 2-hydroxy-estradiol and 2-methoxy-estradiol a positive result in the Cystatin A assay 
was reported. 
Besides the catechol estrogens, 16 other estrogens were tested. Of these compounds 
16α-hydroxy-estrone, diethylstilbestrol, equilin, equilin-7α-methyl, estradiol-17α, 
estradiol-17β, ethinylestradiol-17β and mestranol showed a positive result in the p53 
reporter assay. All these steroidal and stilbene estrogens contain an aromatic A-ring with 
a free hydroxyl group. The 2-hydroxylation or 4-hydroxylation of these compounds 
makes the formation of catechol estrogens possible [46]. Estrogens without an aromatic 
A ring like Org 34694, Org 37445, en Org 42788 did not show genotoxicity in the 
present study. Of these, Org 34694 has a Δ4(5) double bond, while Org 37445 and Org 
42788 contain a Δ5(10) double bond. Due to their conformation these compounds have 
estrogenic activity, but they lack the ability to form catechols. Therefore these estrogens 
may be less hazardous with respect to genotoxicity. Not all estrogens with an aromatic 
A ring and free OH group induced p53; estrone and estriol did not show these effects. 
Experiments performed by Yagi et al. [43], also showed that estrone induced no DNA 
damage. The four anti-estrogens (also without an aromatic A ring) do not induce 
genotoxicity in HepG2 cells. 
None of the tested androgens showed genotoxicity in the three HepG2 genotoxicity 
reporter assays. Generally androgens lack bacterial mutagenicity and mammalian 
genotoxicity in the regulatory tests [44]. Only for fl uoxymesterone a weak genotoxic 
potential has been reported [47]. 
Of the 21 tested progestins and anti-progestins only dimethysterone, lilopristone (with 
additional carbon in 17α chain) and onapristone showed a positive response. Onapristone 
and lilopristone contain a N-dialkyl group, which has been reported to be a structural 
property of many compounds that intercalate in the DNA [48]. This structural group may 
be the reason for the positive effect. However, not all tested compounds with a N-dialkyl 
group showed genotoxicity in the reporter assays in the HepG2 cells. Compounds like 
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for example chlorpromazine, chlorprothixene and imipramine did not show such an 
effect. Onapristone and dimethysterone were negative in the regulatory tests that were 
performed. Lilopristone with additional carbon in 17α chain, was not tested in the 
regulatory genotoxicity tests, but lilopristone was negative in these tests [44]. Progestins 
can be divided into the norethisterone, norgestrel, spirolactone and medroxyprogesterone 
group. The majority of studies with progestins from the fi rst three groups produced 
negative results in the regulatory genotoxicity assays. For several progestins from the 
medroxyprogesterone group, positive results have been described [44] Progestins in this 
group share the 17-hydroxy-3-oxo-pregna-4,6-diene structure. It has been shown for 
cyproterone acetate that a highly reactive carbonium ion is formed following reduction 
of the 3-keto group and sulfoconjugation [44]. The genotoxic potency was related to the 
capacity of metabolization through these pathways. However these reactions do not take 
place in the routine regulatory genotoxicity tests. The kidney of the hamster is a place 
where these reactions take place. In the HepG2 cells none of the tested progestins in this 
group showed a positive response.
Glucocorticoids were reported to be negative in the Ames and mammalian genotoxicity 
tests. An exception is dexamethasone, for which positive results have been reported. In 
the reporter assays, dexamethasone and the other tested corticosteroids corticosterone, 
cortisol and anti-glucocorticoid Org 34850 showed no genotoxicity. The positive 
results that were found with dexamethasone were suggested to be false-positive due to 
interpretation of micronucleus assay data, as dexamethasone causes the formation of 
apoptotic bodies. 
Overall, for many steroids genotoxicity has been reported. But in most cases positive 
as well as negative responses have been reported for these compounds. The assays in 
the present study give the indication that like reported in literature catechol estrogens 
and estrogens from which these catechols can be formed give the highest risk on 
genotoxicity. The assays described in the present study might help to develop non-
genotoxic estrogens.
Besides the steroidal compounds, the list of 192 compounds also contained other 
compounds. Importantly, the two aneugens in this list being colchicine and noscapine 
HCl were genotoxic in the HepG2 cells. Since taxol (ECVAM list) was also genotoxic 
in HepG2 cells, aneugenic compounds appear to be detected in the reporter assays. 
This is an advantage of these reporter assays, as these compounds were not detected in 
the RadarScreen assay. Moreover, topoisomerase II inhibitors, intercalating compounds, 
anti-metabolites and compounds causing oxidative stress could be detected in HepG2 
cells. 
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Comparison of the reporter cell line results with bacterial mutagenicity (Ames test) in 
vitro and in vivo mammalian genotoxicity data 
The results obtained with the 192 additional compounds were compared with the 
available bacterial mutagenicity data, in vitro mammalian genotoxicity data, and in vivo 
genotoxicity data. The correlation with bacterial mutagenicity was 74% (sensitivity, 
61%, 30/49; specifi city, 80%, 77/96). Besides Ames positive compounds, Ames negative 
clastogenic compounds were detected. However, the correlation between the results from 
the HepG2 reporter assays and in vitro mammalian genotoxicity was relatively low with 
only 59% (sensitivity, 45%, 35/78; specifi city 83%, 38/46). This score is lower than the 
predictivity of 76% (sensitivity, 77%, 59/77; specifi city 74%, 34/46) that was previously 
observed for the RadarScreen assay. However, the correlation between results from the 
HepG2 genotoxicity reporter assays and in vivo genotoxicity was much higher with 
77% (sensitivity, 74%, 28/38; specifi city 81%, 26/32). In case of in vivo genotoxicity 
the predictivity of the RadarScreen was only 54% (sensitivity, 68%, 25/37; specifi city 
38%, 12/32). These results show that the HepG2 cells have a better correlation with in 
vivo genotoxicity than with in vitro mammalian genotoxicity data. This was confi rmed 
by using hierarchical clustering. The presence of phase II metabolism and a functionally 
active p53 protein might be the reason for these scores.  
Recently a GADD45a-GFP assay in the human lymphoblastoid cell line TK6 
(GreenScreen HC, Gentronix) was developed by Hastwell et al. [49]. This assay had a 
high sensitivity and specifi city of respectively 71% and 100% for in vivo genotoxicity. 
With a different compound set Olaharski et al. [50] showed that the sensitivity of 
this assay dropped to only 30% (comparison with in vitro mammalian genotoxicity). 
However, the specifi city was still high with 97%. In response to this study, Walmsley 
and Billinton reanalyzed the data [51]. Given the fact that in vitro genotoxicity tests give 
often false positive results, a carcinogen with positive in vitro mammalian genotoxicity 
data may still be a non-genotoxic carcinogen. Hastwell et al. tried to make a better 
classifi cation of genotoxic carcinogens and non-genotoxic carcinogens. In their analysis 
the sensitivity of the GADD45 assay increased to 75%. However, the compound set 
became smaller. Moreover, as stated by Olaharski et al. such an analysis of the data 
might also introduce subjectivity. However, the importance of the comments made by 
Walmsley et al. surely is that in vitro mammalian genotoxicity tests give often false 
positive results and that this does not always refl ect the classifi cation of genotoxic/non-
genotoxic carcinogenicity. 
Therefore, it is in our view better to compare data from our HepG2 reporter assays to 
the in vivo genotoxicity tests when a prediction for (genotoxic) carcinogens is made. 
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Hierarchical clustering of the compounds
The results obtained with all compounds were ranked by hierarchical clustering. Doing 
this makes it more easy to detect species specifi c genotoxicity and structural components 
of compounds that may cause genotoxicity. Clustering of the compounds showed that 
most compounds that are strong genotoxicants give a positive response in most of the 
assays. Performing all six assays in parallel makes it possible to perform risk assessment 
at an early time point during the development of new drugs. Results from newly tested 
compounds can be compared with the pattern and structure of compounds that have 
already been tested. For doing this, it is very important to know the weaknesses of 
the assays. For example compounds that need metabolic activation by CYP2B6 and 
CYP2E1 are probably missed in the HepG2 reporters and aneugens are not detected in 
the RadarScreen assay. Furthermore, in the VitotoxTM assay mutagenic (Ames positive) 
compounds such as melphalan and cyclophosphamide, which have a N(CH2-CH2-Cl)2 
group, are missed.
Conclusion
We have developed four mechanism-based reporter assays in the HepG2 cell line, which 
can be applied for screening in the research phase of drug development. In combination 
with the previously validated VitotoxTM and RadarScreen assays it seems that a good 
prediction can be made for bacterial mutagenicity (Ames results), in vitro mammalian 
genotoxicity, and in vivo genotoxicity. Application of these assays in the research phase 
of drug development can visualize problems at an early stage before compounds enter 
the regulatory tests.  
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Abstract
Strong activation of the AhR can lead to various toxic effects such as (non-genotoxic) 
carcinogenicity. Moreover, drug-drug interactions by (non-)competitive inhibition of 
CYP1A1 and 1A2 may cause adverse side-effects. Normally the majority of toxicity 
studies are performed in rats, while for the prediction of human toxicity human AhR 
activation and CYP1A competition should be studied. The present study focused on 
the deselection of strong AhR activators and/or CYP1A inducers and (non-)competitive 
inhibitors in the early phase of drug development, as well as on species differences 
between humans and rats. 
Induction studies were performed in the human HepG2 and rat H4IIE cell lines. A set 
of 119 compounds, including known AhR ligands were tested. CYP1A induction was 
observed for 24 compounds. In H4IIE cells, more compounds showed induction and 
most EC50 values were below those of HepG2 cells. Species specifi c CYP1A induction 
in H4IIE and HepG2 cells was obtained for eight and three compounds, respectively.
The same compounds except four in-house NCEs were used to study differences between 
CYP1A1 and 1A2 competition in human and rat supersomes. Of the 115 compounds, 
46 showed CYP1A1 competition. Competition was human and rat specifi c for 12 and 
10 compounds, respectively. CYP1A2 competition was observed for 37 compounds of 
which 14 and 3 compounds showed human and rat specifi c inhibition, respectively. 
In conclusion, for several compounds species differences between CYP1A induction 
and competition in human and rat were found. Therefore, parallel screening in both 
species may be a useful strategy for toxicity screening in the early discovery phase of 
drug development.
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Introduction 
In drug therapy, cytochrome P450 (CYP) 1A induction may lead to drug-drug 
interactions and toxic side effects. The regulation of CYP1A is mainly aryl hydrocarbon 
receptor mediated (AhR). The AhR was discovered as the receptor that binds the 
environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [1]. The AhR 
is a basic helix-loop-helix protein belonging to the Per-ARNT-Sim (PAS) family [2] and 
is located in the cytoplasm in an inactive complex with Hsp90 and p23. Experiments 
in Hsp90 defi cient yeast show that Hsp90 is needed for gene induction by the AhR [3, 
4] Hsp90 is thought to protect AhR from degradation and to stabilize the high-affi nity 
ligand-binding conformation of the AhR [5]. Binding of a ligand to the AhR leads 
to activation of the receptor and subsequently in translocation to the nucleus. In the 
nucleus AhR releases its partner Hsp90 and forms a heterodimer with the AhR nuclear 
translocator protein (ARNT). Further activation of this heterodimer by phosphorylation 
and/or dephosphorylation is required for DNA binding [6, 7].
Strong activation of the AhR by TCDD results in toxic effects like a wasting syndrome, 
thymic involution, endocrine disorders, and very important teratogenicity and (non-
genotoxic) carcinogenicity. Mortality studies involving occupational exposure to TCDD 
have demonstrated an increased risk for several types of cancer in humans [8-10]. 
Important for this non-genotoxic carcinogenic effect might be the change in expression 
patterns of several factors that are involved in cellular growth and differentiation. Another 
effect contributing to carcinogenicity might be the impairment of the p53 response [11, 
12]. 
Studies in AhR-null mice have been used to investigate the role of the AhR in mediating 
the toxic effects. These studies revealed that AhR-null mice were resistant to TCDD 
induced lesions, strongly suggesting that the toxic effects are mediated by the AhR [13]. 
Furthermore, skin tumors that appear after topical application of the AhR agonist benzo[a]
pyrene (B[a]P) are absent in AhR-null mice [14]. Besides activating the AhR, B[a]P is 
metabolized by CYP1A1 to a genotoxic metabolite [15]. The metabolic activation of 
proximate carcinogens to reactive metabolites by CYP1A1 and 1A2 was also shown 
for other AhR agonists by using Aroclor pretreated rat liver S9 mixture for metabolic 
activation in the Ames test. CYP1A1 and/or 1A2 activates PAHs, nitrosamines and 
aryl amines into reactive metabolites that induce mutations [16]. Induction of CYP1A 
enzyme activity is often used for the detection of AhR ligands as good specifi c CYP1A 
substrates are available. 
Besides metabolic activation into genotoxic compounds, drug-drug interactions caused 
by (non-)competitive inhibition of CYP1A1 and 1A2 can also lead to adverse side-
effects. Many drugs are metabolized by CYP1A2 and therefore drug-drug interactions 
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caused by CYP1A2 inhibition are known. CYP1A2 constitutes about 13% of the total 
hepatic CYP content and is one of the clinically most relevant CYP isoenzymes. Together 
with CYP2C9, 2C19, 2D6, and 3A4 it performs the main part of drug metabolism. 
Examples of drugs metabolized by CYP1A2 are the antidepressants amitriptyline HCl, 
clomipramine HCl, and desipramine HCl [17-19]. The levels of CYP1A1 in the human 
liver are low, however, this enzyme is highly inducible in the liver and extra hepatic 
tissues. Induction of CYP1A1 by AhR agonists in human precision-cut liver slices and 
primary human hepatocytes has been shown in several studies [20-23]. Little is known 
about drug-drug interactions in which CYP1A1 is involved. However, some of the 
drug-drug interactions caused by ketoconazole might be the result of a lower CYP1A1 
enzyme activity caused by inhibition or competition in the intestine [24]. Furthermore, 
synergistic embryotoxicity of AhR agonists with CYP1A1 inhibitors has been shown 
[25]. This was probably due to a prolonged activation of the AhR. 
Because of the adverse side-effects it might be useful to screen for and deselect 
candidate drugs that are strong AhR activators and/or strong CYP1A1 and 1A2 inhibitors/
competitors in the early phase of drug development.
Induction of CYP1A enzyme activity was measured with the fl uorogenic substrate 
3-Cyano-7-ethoxycoumarin (CEC) and luminogenic P450-glo substrate Luciferin-CEE 
(Luc-CEE). The latter substrate is converted by CYP1A1 into luciferin, which in turn 
reacts with luciferase to produce light that is directly proportional to the activity of 
CYP1A1.
Because species differences have been reported between CYP1A induction in rats and 
humans [26], the CEC and the P450-glo 1A1 induction assays were performed in the 
human HepG2 as well as the rat H4IIE cell line.
CYP1A1 and 1A2 inhibition were measured in a 384-well high-throughput assay using 
CYP1A1 and 1A2 expressing supersomes and CEC as fl uorogenic substrate. With these 
assays competition was measured between the fl uorogenic substrate CEC and the tested 
compounds for both CYP1A1 and 1A2. Whether compounds are non-competitive or 
competitive CYP1A1/1A2 inhibitors cannot be determined with these assays. Moreover, 
in order to study species differences, competition experiments were performed by 
using both human and rat supersomes. A total of approximately 119 compounds were 
tested in the CYP1A induction and competition assays. These compounds included 
narcotic analgesics, hypnotics, vasodilators, specifi c cellular energy blockers, cellular 
proliferation inhibitors, ion channel blockers, estrogens, antiestrogens, androgens, 
progestagens, polychlorinated biphenyls (PCBs), and others.
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Materials and methods
Materials 
All compounds and reagents were of analytical grade. Polychlorinated  biphenyls 
including:   
2,3’,4,4’-tetrachlorobiphenyl (PCB 77), 2,3,3’,4,4’-pentachlorobiphenyl (PCB 105), 
2,3,4,4’,5 pentachlorobiphenyl (PCB 114), 2,3’,4,4’,5’-pentachlorobiphenyl (PCB 118), 
2,3’,4,4’,5’-pentachlorobiphenyl (PCB 123), 3,3’,4,4’,5’-pentachlorobiphenyl (PCB 126), 
2,3,3’,4,4’,5-hexachlorobiphenyl (PCB 156), 2,3,3’,4,4’,5’-hexachlorobiphenyl (PCB 
157), 2,3’,4,4’,5,5’-hexachlorobiphenyl (PCB 167), 3,3’,4,4’,5,5’-hexachlorobiphenyl 
(PCB 169), 2,3,3’,4,4’,5,5’-heptachlorobiphenyl (PCB 189), and 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD) were purchased from Promochem (Wesel, Germany). 
All other compounds were from Sigma-Aldrich (St. Louis, USA). Luciferin-CEE 
(Luc-CEE) was from Promega (Madison, USA). CEC and supersomes expressing 
human and rat CYP1A1 and 1A2 were from BD Biosciences (San Jose, USA). Trypsin 
and Dulbecco’s Modifi ed Eagles medium, Nutrient Mixture F-12 (DMEM/HAM F12 
medium in a ratio of 1:1) without phenol red was from Invitrogen (Kalsruhe, Germany), 
defi ned supplemented bovine calf serum (dBCS) from Hyclone (Utah, USA) and white 
96- and 384-well culture plates from Perkin Elmer (Groningen, The Netherlands).
Cell culture
HepG2 and H4IIE cells were obtained from the American Type Culture Collection 
(Rockville, MD, USA). Cells were cultured in Dulbecco’s Modifi ed Eagles medium 
and Nutrient mixture F-12 mixed in a ratio of 1:1 with 10% dBCS and 1% Penicillin-
Streptomycin (10,000 U/ml, Invitrogen). Cultures were maintained in a humidifi ed 
atmosphere with 5% CO2 at 37 °C and medium was refreshed every 3 or 4 days with 
subculturing.
Preparation of compound solutions
Stock solutions of 0.1 M were dissolved in 100% dimethyl sulfoxide (DMSO). The 
stock solution of TCDD had a concentration of 3.16x10-4 M. From the stock, √10 
dilutions were prepared in DMSO.
Test plate preparation induction assays
HepG2 and H4IIE cells were trypsinized, counted and seeded in 96-well plates. HepG2 
and H4IIE cells were resuspended in culture medium to a fi nal concentration of 3x104 
and 2x104 cells/well, respectively. The 96-well microtiter plates were incubated for 24 h 
in a humidifi ed atmosphere at 37°C under 5% CO2. Following the incubation, 11 serial 
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culture medium dilutions of the compounds or a control sample were added as 10 μl 
fractions to HepG2 and H4IIE cells leading to a fi nal volume of 200 μl. The highest 
tested concentration for the compounds was 10-4 M. An exception was TCDD for which 
the highest tested concentration was 3.16x10-7 M. The fi nal concentration of DMSO in 
the assays was 0.1 %. 
CEC CYP1A induction assay
The induction of CYP1A activity in HepG2 and H4IIE cells was measured with the 
fl uorogenic substrate CEC. CEC reacts with both CYP1A1 and 1A2. After incubation 
of cells with compounds for 24 h, cells were washed twice with PBS. Next 100 μl of 
40 μM CEC dissolved in culture medium without dBCS was added. After 30 min the 
fl uorescent signal was read on the Victor II (Perkin Elmer) by means of excitation at 409 
nm and emission measurement at 460 nm. 
P450-Glo CYP1A1 induction assay
The induction of CYP1A1 activity in HepG2 and H4IIE cells was measured with the 
luminogenic substrate Luc-CEE. After incubation of cells with compounds for 24 h, 
HepG2 and H4IIE cells were washed twice with PBS and the CYP1A1 induction was 
assessed with Luc-CEE. To the plates 50 μl Luc-CEE (30 μM) was added. Subsequently, 
50 μl luciferin detection reagent was added. Plates were shaken for 10 min and the 
luminescence signal was measured with a TopCountNT luminometer (Perkin-Elmer).
Cytochrome P450 1A1 and 1A2 competition assays
CYP1A1 and 1A2 competition assays were carried out by using supersomes. 
Compounds were tested at concentrations of 10-7 M to 10-4 M with √10-fold dilution steps 
in a 384-well plate in 0.1% DMSO. The highest concentration TCDD in the assay was 
3.16x10-7 M. The cofactor solution was prepared in 25 mM phosphate buffer (pH 7.4) 
and contained 2.6 mM NADP+, 6.6 mM glucose-6-phosphate, 6.6 mM MgCl2 and 0.8 
U/ml glucose-6-phosphate dehydrogenase. This solution was prewarmed at 37ºC. Five 
minutes before the start of the reaction, human or rat CYP1A1 or 1A2 supersomes were 
added to the cofactor solution leading to a concentration of 5 pmol/ml supersomes in 
the fi nal reaction. To the 384-well plates, containing 10 μl compound dilution or DMSO 
control, 10 μl of a substrate solution containing 20 μM CEC in 325 mM phosphate 
buffer was added. The plates were covered with a lid and shaken for 20 min. Then plates 
were pre-warmed at 37ºC in an incubator and 20 μl of an enzyme/cofactor solution was 
added leading to a fi nal volume of 40 μl/well. Thereafter the plate was put in the Victor 
II reader, shaken for 20 s and pre-incubated for 2 min at 37ºC. Next the fl uorescence 
was measured (t=0 min). The excitation wavelength was set at 409 nm and the emission 
was measured at 460 nm. Then the plate was incubated for 30 min at 37ºC. Thereafter 
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the fl uorescence was measured (t=30 min). The difference in fl uorescence between the 
measurement at 0 and 30 min was used for calculation of CYP competition. The increase 
in fl uorescence of the solvent control (0.1% DMSO) during these 30 min was set at 
100% activity. For calculation of the IC50 values of competitors, the data were logit 
transformed. The software program Xlfi t (version 4.1, ID business solutions limited) 
was used for the calculation of the best line fi tting the experimental data. From this line 
the IC50 was determined. The effi cacy was defi ned in percentage by means of the total 
inhibition of the fl uorescence increase at the highest tested compound concentration. This 
concentration was 10-4 M, with exception for TCDD for which the highest concentration 
tested was 3.16x10-7 M.
Statistical analysis
Each experiment was performed in duplicate in three independent experiments. Data 
analysis was performed by using a Student’s t test. This indicated that an induction 
above control level of 20% and 50% for the CEC and P450-glo assay, respectively, was 
statistical signifi cant. For the assessment of this threshold 5 independent experiments 
were performed with 3-methylcholanthrene, indirubin, and indigo (data not shown). 
Since compounds with an induction factor equal to or greater than 2-fold are defi ned 
as inducers this is based on statistically signifi cant differences. Likewise 5 independent 
competition assays were carried out with furafylline and ketoconazole. The Student’s t 
test showed that an inhibition of 20% was statistically signifi cant. Therefore the IC50 
values are based on statistically signifi cant differences.
Results
Cytochrome P450 1A induction measured with CEC
HepG2 and H4IIE cells were exposed for 24 h to a dose-range of 119 different 
compounds. Thereafter the CYP1A activity was measured with CEC. Exposure to 95 
of these compounds did not affect CYP1A activity (Table 1). However, 24 compounds 
caused an induction of the CYP1A activity in either HepG2, H4IIE, or both cell lines. 
These compounds are listed in Table 2 that shows also the EC50 values and induction 
factors (ratio of treated cells:0.1% DMSO control). Dose response curves are presented 
in Figure 1. 
The results clearly show that there was a difference between CYP1A induction in 
the human HepG2 and rat H4IIE cell line. More compounds caused CYP1A induction 
in H4IIE cells and most EC50 values were lower than in HepG2 cells. TCDD was as 
expected the most potent CYP1A inducer in both H4IIE and HepG2 cells. The EC50 
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value was 1.35x10-9 M in H4IIE cells and 36-times higher in HepG2 cells. Furthermore, 
benzo[a]pyrene (B[a]P), β-naphthofl avone (BNF), dihydroergotamine mesylate (DHE), 
2,4-dinitrophenol, ellipticin, fl utamide, indigo, indirubin, 3-methylcholanthrene (3MC), 
Org C, Org D, PCB 77, PCB 105, PCB 114, PCB 118, PCB 123, PCB 126, PCB 156, 
PCB 157, and PCB 167 induced the CYP1A activity in the H4IIE cell line. Of these 20 
compounds B[a]P, BNF, indigo, indirubin, 3MC, Org C, PCB 77, PCB 114, PCB 123, 
PCB 126, and PCB 167 also induced the CYP1A activity in HepG2 cells. Menadione, 
Org A, and Org B were HepG2 specifi c CYP1A inducers. Moreover, Org C was more 
potent in HepG2 than in H4IIE cells.
Cytochrome P450 1A1 induction measured with Luciferin-CEE 
Luc-CEE was used to measure the CYP1A1 induction in HepG2 and H4IIE cells. 
The same compounds except the four Org compounds were tested. Results were 
comparable with the results measured with CEC. The same compounds with exception 
of 2,4-dinitrophenol caused CYP1A1 induction in either HepG2, H4IIE, or both cell lines 
(Table 2). Although not statistically signifi cant, 2,4-dinitrophenol showed a tendency to 
induction (1.8-fold) in H4IIE cells. The EC50 values of the CEC and Luc-CEE assay 
were almost similar. Nevertheless, the induction factors were for most compounds higher 
in the Luc-CEE assay.
 Table 1. Compounds that do not activate CYP1A activity in the human HepG2 and rat H4IIE cell line
Acetylsalicylic acid Ferrous sulfate Orphenadrine citrate
α-Naphthofl avone Fluorouracil Papaverine
Quinoline Furafylline PCB 169
Aminophylline Gentamicin A PCB 189
Amiodarone HCl Hexachlorobutadiene Paracetamol
Antazoline mesylate 2,5-Hexanedione Perhexiline
Atropine sulfate Hydralazine HCl Perphenazine
Bishydroxycoumarin Hydrochlorothiazide Phenobarbital sodium
Bromobenzene Hydroxychloroquinone sulfate Phentolamine mesylate
Carbon tetrachloride 4-Hydroxytamoxifen Quinidine
Chlorpromazine HCl ICI 164.384 (anti-estrogen) Quinidine sulfate
Cisplatin Imipramine HCl Raloxifen
CITCO Indomethacin Reserpine
Clozapine Iodoacetate Rifampicin
Colchicine Iproniazid HCl Rotenone
Cyclophosphamide Isoprenaline HCl RU 1881
Cytarabine Ketoconazole RU 58668
Dacarbazine Labetalol Salicylamide
Dantrolene sodium L-DOPA Strychnine nitrate
Dehydroepiandrosterone Levonorgestrel Sulfamoxole
Dexamethasone Medroxyprogesterone acetate Sulphaphenazole
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Diclofenac Melphalan Tacrine
Diethyldithio-carbamic acid Methadone HCl Tamoxifen
Diethylstilbestrol Methampyrone Tertiair-butyl-hydroperoxide
Digoxin Methotrexate Testosterone
2,7-Dinitrofl uorene 7α-Methyltestosterone Tetracycline HCl
Dopamine HCl 17α-Methyltestosterone Tolcapone
Doxorubicin Naphazoline nitrate Tularik 901317
Erythromycin N-ethylmaleimide Uramustine
Estradiol-17β Nitrofurantoin
Ethacrinic acid Nitropyrene
Ethinylestradiol-17β 4-Nitrosoquinoline-1-oxide 
Ethionine Noscapine HCl
Table 2. Cytochrome P450 1A induction measured with CEC and Luc-CEE in human HepG2 and rat 
H4IIE cells. Compounds indicated in bold and italic show rat and human specifi c CYP1A activation, 
respectively. The EC50 values and induction factors (IF) are shown.
Compound HepG2 H4IIE
CEC Luc-CEE CEC Luc-CEE
 EC50 (mol/l)    IF  EC50 (mol/l)    IF  EC50 (mol/l)  IF  EC50 (mol/l)    IF
B[a]P 3.73x10-6 10.2 2.00x10-6 2.8 2.08x10-8 16.7 8.00x10-8 33.2
BNF 1.22x10-5 20.3 3.16x10-6 9.2 2.95x10-8 24.6 3.16x10-8 52.9
DHE 1.21x10-5 7.9 6.09x10-6 11 3.35x10-6 2.43 1.00x10-5 6.5
Dinitrophenol >1.00x10-4 >1.00x10-4 2.59x10-6 3.79 >1.00x10-4
Ellipticin >1.00x10-4 >1.00x10-4 1.00x10-8 4.6 1.00x10-8 5.8
Flutamide >1.00x10-4 >1.00x10-4 7.89x10-7 13.1 5.00x10-7 25.7
Indigo 5.79x10-6 49.7 3.85x10-6 116 8.52x10-9 25.3 3.16x10-8 63.0
Indirubin 1.73x10-7 93 1.27x10-7 368 4.91x10-8 29 2.00x10-7 68.3
Menadione 1.29x10-5 16.9 1.00x10-5 20.4 >1.00x10-4 >1.00x10-4
3MC 6.48x10-7 62.3 5.22x10-7 222 4.45x10-8 24.4 3.16x10-8 69.5
Org A 2.00x10-6 9.94 ND >1.00x10-4 ND
Org B 2.00x10-6 14.0 ND >1.00x10-4 ND
Org C 2.00x10-6 22.6 ND 3.16x10-5 2.34 ND
Org D >1.00x10-4 ND 2.00x10-7 9.50 ND
PCB 77 8.27x10-6 7.9 2.56x10-6 25.5 4.35x10-8 17.5 7.00x10-8 25.5
PCB 105 >1.00x10-4 >1.00x10-4 >1.00x10-4 11.5 >1.00x10-4 9.6
PCB 114 >1.00x10-4 32.4 >1.00x10-4 29.8 1.30x10-6 13.6 2.35x10-6 15.6
PCB 118 >1.00x10-4 >1.00x10-4 >1.00x10-4 8.9 >1.00x10-4 13.6
PCB 123 >1.00x10-4 2.2 >1.00x10-4 3.5 >1.00x10-4 2.4 >1.00x10-4 3.5
PCB 126 1.65x10-6 50.6 2.55x10-6 65.4 1.00x10-9 21.6 2.00x10-9 23.6
PCB 156 >1.00x10-4 >1.00x10-4 5.37x10-6 16.0 3.09x10-6 24
PCB 157 >1.00x10-4 >1.00x10-4 8.15x10-6 19.7 7.56x10-6 40.6
PCB 167 >1.00x10-4 52.6 >1.00x10-4 45.5 3.55x10-8 15.3 3.02x10-8 30.5
TCDD 4.88x10-8 61.8 4.00x10-8 250 1.35x10-9 22.3 1.25x10-9 78.5
Abbreviations: B[a]P=benzo[a]pyrene; BNF=β-naphthofl avone; DHE=dehydroergotamine mesylate; 
3MC=3-methylcholanthrene; PCB=polychlorobiphenyl; TCDD=2,3,7,8-tetrachlorodibenzo-p-dioxin
Table 1. Continued
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Figure 1. Induction of CYP1A activity measured with CEC in human HepG2 and rat H4IIE cells after 
24 h exposure to the compounds. Of the 119 compounds, 13 induced CYP1A activity in both HepG2 and 
H4IIE cells (A and B), 8 showed H4IIE specifi c induction (C and D), and 3 compounds showed HepG2 
specifi c induction (E and F). Results are presented as the mean of three independent measurements. 
The SD is not shown as it interferes with the reading of the marker spots. However, SD is <5% for 
all data points. Abbreviations: BNF=β-naphthofl avone; DHE=dehydroergotamine mesylate; 3MC=3-
methylcholanthrene; TCDD=2,3,7,8-tetrachlorodibenzo-p-dioxin.
Cytochrome P450 1A1 and 1A2 competition
CYP1A1 and 1A2 competition in human and rat supersomes was measured for 115 
compound, four compounds were skipped from analysis i.e. Org A, B, C, and D. In Figure 
2 the dose-related competition for human and rat CYP1A1 and 1A2 is demonstrated for 
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a representative set of 8 compounds, i.e. B[a]P, ellipticine, furafylline, indigo, indirubin, 
ketoconazole, nitrofurantoin and 4-NQO. The effi cacies (EFF) and IC50 values are 
shown in Table 3. Differences were observed between CYP1A1 and 1A2 competition in 
human and rat supersomes. Of the 115 tested compounds, 36 compounds inhibited human 
CYP1A1 activity for 50% or more. Human competition for CYP1A1 was found specifi c 
for 12 compounds, being β-naphthofl avone, cisplatin, dehydroergotamine mesylate, 
dopamine HCl, 17β-estradiol, 4-hydroxytamoxifen, noscapine HCl, papaverine, 
quinidine, quinidine sulfate, reserpine and RU 58668. The remaining 24 compounds 
also inhibited rat CYP1A1. Furthermore, rat specifi c competition for CYP1A1 was 
found for ten compounds.
Similar differences were observed for CYP1A2. Competition was found for 37 
compounds of which 14 and 3 compounds showed specifi c competition for human and 
rat CYP1A2, respectively.  
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Figure 2. CYP1A1 and 1A2 competition in human and rat supersomes by benzo[a]pyrene (B[a]P), 
ellipticine, furafylline, indigo, indirubin, ketoconazole, nitrofurantoin and 4-nitrosoquinolineoxide-1-
oxide (4-NQO). Results are presented as the mean of three independent measurements (0.1% DMSO 
control = 100%). The SD is not shown as it interferes with the reading of the marker spots. However, 
SD is <5% for all data points. 
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Figure 3. Comparison of the IC50 values of human versus rat for CYP1A1 and 1A2 competition. The 
numbers represent the compounds in Table 3. The solid line is the line of identity (x=y).
 
A x:y plot for the IC50 values of human versus rat competition for both CYP1A1 and 1A2 is 
shown in Figure 3. The numbers in the Figure 3 represent the compounds in Table 3. The solid 
line in Figure 3 is the line of identity (x = y). The outlier hydralazine HCl is not shown in the 
CYP1A1 plot. As can be seen in Figure 3, there are besides the human and rat specifi c CYP1A1 
competitors, compounds that are almost equally potent in both species (compounds around the 
line of identity). However, the potency is for most compounds higher in human supersomes 
as compared to rat supersomes (compounds above the line of identity). The same is true for 
CYP1A2 as almost all competitors have a lower IC50 value in human supersomes as compared 
to rat supersomes.
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Table 3. Compounds that show CYP1A1 and 1A2 competition in human and rat supersomes. The 
effi cacy (EFF) and IC50 values are shown. Values are marked in bold when EFF>50% (p<0.05).
No Compound Human  Rat  
 CYP 1A1 
inhibition
CYP1A2 
inhibition
CYP1A1 
inhibition
CYP1A2 
inhibition
  EFF 
(%)
IC50
 (M)
EFF 
(%)
IC50
(M)
EFF
(%)
IC50 
(M)
EFF
(%)
IC50 
(M)
1 α-Naphthofl avone 111 3.47x10-6 104 2.43x10-6 101 1.00x10-5 98 3.60x10-6
2 Quinoline 67 5.75x10-5 95 2.64x10-6 53 4.71x10-5 56 3.11x10-4
3 B[a]P 33 >1.00x10-4 61 1.50x10-6 23 >1.00x10-4 51 2.30x10-5
4 BNF 91 2.01x10-6 83 8.07x10-7 11 >1.00x10-4 108 3.80x10-6
5 Chlorpromazine 74 1.81x10-5 72 8.56x10-6 98 2.50x10-6 31 >1.00x10-4
6 Cisplatin 72 3.02x10-5 82 1.29x10-5 43 >1.00x10-4 93 1.96x10-5
7 Clozapine -3 >1.00x10-4 52 1.00x10-4 107 1.88x10-6 47 1.15x10-4
8 Dantrolene 
sodium
91 1.34x10-5 60 7.74x10-5 75 3.00x10-5 39 >1.00x10-4
9 DETC 37 >1.00x10-4 71 5.73x10-5 12 >1.00x10-4 87 3.00x10-5
10 DHE 66 4.25x10-5 -6 >1.00x10-4 19 >1.00x10-4 -29 >1.00x10-4
11 2,7-Dinitrofl uorene 64 6.61x10-5 86 3.85x10-7 53 2.75x10-5 61 2.62x10-5
12 DNP 69 8.01x10-6 81 4.20x10-6 49 2.27x10-5 51 5.82x10-5
13 Dopamine HCl 84 3.13x10-5 8 >1.00x10-4 27 >1.00x10-4 2 >1.00x10-4
14 Doxorubicin 73 3.80x10-5 67 4.29x10-5 90 6.16x10-6 69 4.89x10-5
15 Ellipticine 87 1.08x10-6 98 4.71x10-8 104 1.42x10-6 100 3.23x10-7
16 Estradiol-17β 73 2.75x10-5 30 >1.00x10-4 4 >1.00x10-4 -2 >1.00x10-4
17 Ethacrinic acid 14 >1.00x10-4 20 >1.00x10-4 53 7.01x10-5 9 >1.00x10-4
18 Flutamide 30 >1.00x10-4 71 8.97x10-6 -16 >1.00x10-4 9 >1.00x10-4
19 Furafylline 43 >1.00x10-4 100 8.01x10-7 77 3.01x10-5 56 3.68x10-5
20 HCBD 83 1.75x10-6 5 >1.00x10-4 59 1.89x10-5 5 >1.00x10-4
21 Hydralazine HCl 69 5.99x10-5 58 3.35x10-5 66 5.80x10-8 55 3.05x10-5
22 4-OH-Tamoxifen 81 3.34 x10-5 -14 >1.00x10-4 6 >1.00x10-4 17 >1.00x10-4
23 Indigo 71 2.83x10-5 43 >1.00x10-4 53 7.00x10-5 36 >1.00x10-4
24 Indirubin 65 8.90x10-6 11 >1.00x10-4 99 3.53x10-6 46 >1.00x10-4
25 Isoprenaline HCl 10 >1.00x10-4 64 9.43x10-5 7 >1.00x10-4 14 >1.00x10-4
26 Ketoconazole 100 2.00x10-7 45 >1.00x10-4 100 3.00x10-6 -14 >1.00x10-4
27 L-DOPA 18 >1.00x10-4 -62 >1.00x10-4 56 1.31x10-4 112 1.14x10-5
28 Melphalan 66 4.68x10-5 53 7.41x10-5 63 6.84x10-5 59 7.51x10-5
29 Menadione 85 1.02x10-5 102 2.43x10-7 80 1.52x10-5 93 2.88x10-7
30 Methotrexate 18 >1.00x10-4 88 2.70x10-5 4 >1.00x10-4 28 >1.00x10-4
31 3MC 25 >1.00x10-4 74 4.79x10-6 8 >1.00x10-4 57 1.10x10-5
32 7α-methyl-
testosterone
64 5.47x10-5 6 >1.00x10-4 116 1.74 x10-7 10 >1.00x10-4
33 Nitrofurantoin 103 1.11x10-5 84 2.01x10-5 55 3.48x10-4 2 >1.00x10-4
34 Nitropyrene 83 1.63x10-6 92 1.00x10-7 99 3.58x10-7 108 1.00x10-7
35 4-NQO 41 >1.00x10-4 86 2.41x10-5 19 >1.00x10-4 27 >1.00x10-4
36 Noscapine HCl 65 4.04x10-5 1 >1.00x10-4 12 >1.00x10-4 5 >1.00x10-4
37 Orphenadrine 
citrate
33 >1.00x10-4 40 >1.00x10-4 15 >1.00x10-4 53 1.03 x10-4
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No Compound Human  Rat  
 CYP1A1 
inhibition
CYP1A2 
inhibition
CYP1A1 
inhibition
CYP1A2 
inhibition
 EFF 
(%)
IC50
 (M)
EFF 
(%)
IC50
(M)
EFF
(%)
IC50 
(M)
EFF
(%)
IC50 
(M)
38 Papaverine 92 9.15x10-6 71 3.06x10-5 38 >1.00x10-4 18 >1.00x10-4
39 PCB 105 11 >1.00x10-4 42 7.59x10-5 57 5.18x10-5 22 >1.00x10-4
40 PCB 114 -8 >1.00x10-4 69 2.21x10-5 95 1.19x10-5 34 >1.00x10-4
41 PCB 118 22 >1.00x10-4 54 2.54x10-5 86 2.96x10-6 24 >1.00x10-4
44 PCB 167 28 >1.00x10-4 53 3.22x10-5 72 4.32x10-5 45 >1.00x10-4
47 Perphenazine 101 4.52x10-6 1 >1.00x10-4 82 1.02x10-5 1 >1.00x10-4
48 Quinidine 76 1.87x10-5 -2 >1.00x10-4 27 >1.00x10-4 30 >1.00x10-4
49 Quinidine sulfate 89 1.10x10-5 24 >1.00x10-4 20 >1.00x10-4 5 >1.00x10-4
50 Raloxifen 100 3.80x10-6 43 >1.00x10-4 80 1.56x10-5 23 >1.00x10-4
51 Reserpine 59 1.73x10-5 47 >1.00x10-4 23 >1.00x10-4 -5 >1.00x10-4
52 Rifampicin 74 2.08x10-5 90 6.22x10-6 60 4.18x10-5 58 4.68x10-5
53 RU 58668 102 5.70x10-5 2 >1.00x10-4 -15 >1.00x10-4 39 >1.00x10-4
54 Tacrine 115 6.32x10-7 108 7.79x10-7 131 2.01x10-6 50 1.30E-04
55 Testosterone 64 7.47x10-5 -6 >1.00x10-4 45 2.40x10-4 -4 >1.00x10-4
56 Tolcapone 91 2.53x10-5 92 9.15 x10-6 110 2.17x10-5 92 2.11x10-5
Abbreviations: B[a]P=benzo[a]pyrene; BNF=β-naphthofl avone; DETC=Diethyldithio-carbamic acid; 
DNP=2,4 dinitrophenol; 3MC=3-methylcholanthrene; 4-NQO=4-nitrosoquinolineoxide-1-oxide
Discussion
The present study focused on CYP1A induction, (non-)competitive inhibition and 
species differences between human and rat. Strong AhR activation leads to a series of 
toxic effects and consequently it may be useful for the pharmaceutical industry to screen 
for and deselect NCEs that are strong CYP1A inducers (AhR activators) in the early 
phase of drug development. 
Primary cultures of hepatocytes can be used for CYP1A induction studies, however, 
donor variation and a high number of compounds in the early developmental phase 
make the use of cell lines preferable. Two such cell lines may be the human and rat 
hepatoma cell lines HepG2 and H4IIE. Previously we demonstrated that the effects of 
AhR agonists in HepG2 on cytochrome P450 enzymes are similar to the effects observed 
in primary human hepatocytes [27]. In line with this it was reported that HepG2 cells are 
a better model refl ecting CYP1A induction in human hepatocytes than hepatocytes from 
Rhesus monkeys and Sprague-Dawley rats [28]. Others found that the H4IIE cell line 
is a good model to study CYP1A induction refl ecting effects in primary rat hepatocytes 
[26]. Thus it seems that HepG2 and H4IIE cells are good cell lines to study human and 
Table 3. Continued
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rat CYP1A induction, respectively.
For induction studies the fl uorogenic substrate CEC was used. Fluorescence detection 
of the deethylation of CEC was reported to be 50- up to 100-times more sensitive than 
that of ethoxyresorufi n, primarily because of the faster turnover rate of CEC [29]. CEC 
is not specifi c for a CYP1A isoform, it reacts with both human and rat CYP1A1 and 
1A2 with a preference for CYP1A1 [30]. Besides CEC, the luminogenic substrate Luc-
CEE was used for measuring CYP1A induction. The results were quite similar to results 
observed with CEC. An advance of this substrate may be it’s specifi city for human and rat 
CYP1A1 (Promega). There is also a CYP1A2 specifi c luminogenic substrate (Luciferin-
BE) available. In the present study this substrate was not used because it reacts only with 
human CYP1A2 and shows no reactivity for rat CYP1A2 (data not shown).
Of the 119 compounds that were tested, 24 compounds were able to induce the CYP1A 
activity in either human HepG2, rat H4IIE, or both cell lines. Pronounced differences 
were observed between induction in the cells of human and rat origin. Zeiger et al. [26] 
reported similar differences. In their study HepG2 and H4IIE cells were also exposed 
to the dioxin like PCBs 77, 105, 114, 118, 123, 126, 156, 157, 167, 169, and 189. In 
H4IIE cells, they found in concordance with the present study induction after exposure 
to PCB 77, 105, 114, 118, 123, 126, 156, 157, and no induction after exposure to PCB 
189. However, in contradiction we did not fi nd induction with PCB 169 in H4IIE cells. 
Induction in HepG2 cells was found for less compounds at higher doses. In both studies 
induction was measured after exposure to PCB 77, 114, and 126. In contradiction with 
Zeiger et al. [26], we found induction in HepG2 cells by PCB 123 and 167. The results 
suggest that the rat cell line H4IIE is more sensitive to detect CYP1A inducers than the 
HepG2 cell line. 
The high sensitivity of rat for CYP1A inducers was also reported by Silkworth et al. 
[28] , who found CYP1A induction at much lower concentrations after exposure to PCB 
126 and Aroclor 1254 in rat than human cells. A study by Aluru et al. [31] also revealed 
species differences. While in humans α-naphthofl avone (ANF) is an AhR antagonist, in 
rainbow trout hepatocytes it was a partial agonist. 
Although mono-ortho PCBs such as PCB 114, PCB126, and PCB167 are considered 
as weak AhR agonists [32] they showed a high potency in the present study. Peters 
et al.  [32] showed that after purifi cation of mono-ortho PCBs with active charcoal, 
mono-ortho PCBs showed only a low potency in an AhR-EGFP reporter assay mouse 
Hepa1c1c7 and rat H4IIE cells. The purity of the PCBs in the present study was 99%. 
Therefore we do not expect large effects of impurities on CYP1A induction, however 
we cannot exclude that contaminations with AhR agonists of high activity had an effect 
on the activity.   
The importance of deselecting CYP1A inducers was stressed by Org D. This rat 
specifi c CYP1A inducer caused non-genotoxic carcinogenicity in in vivo rat studies 
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(unpublished in house data).
We observed that Org A and B were HepG2 specifi c CYP1A inducers and Org C was 
much more potent in the HepG2 cell line. Menadione was also active in HepG2 cells and 
not in H4IIE cells. Apparently there are CYP1A inducers that are more potent in humans 
than rats. In line with this, in human, but not in mouse and in rat, the anti-ulcer drug 
omeprazole has been reported to induce CYP1A2 [33-35]. Overall these observations 
make screening in cell lines from both rat and human a useful strategy.
Recently Sonneveld et al. [36] showed that glucocorticoids enhance the induction of 
CYP1A1 and other AhR target genes in rat H4IIE cells but not in human cells. In the 
present study we did not observe an effect of dexamethasone in H4IIE cells also not 
when charcoal treated serum was used (data not shown). 
There are also other methods available for screening CYP1A inducers and/or AhR 
activators. Two often used methods are the CALUX bioassay [37] and the use of 101L 
cells [38]. In the CALUX bioassay rat H4IIE and mouse Hepa1c1c7 cells containing a 
luciferase gene under control of dioxin responsive elements are used. A disadvantage of 
this assay is that rodent cells are used which not always refl ect effects in humans. The 
101L cell line is a stable cell line derived from HepG2 cells which contain a human 
CYP1A1 luciferase reporter. An advantage of this system may be that substrate inhibition 
of CYP1A1 does not play a role. However, in our assay we included a washing step after 
compound incubation which reduced substrate inhibition of CEC.   
Ellipticine showed CYP1A induction in the H4IIE cell line. In HepG2 cells induction 
was just below 2-fold and directly after the increase in activity the signal dropped 
sharply again. The problem with the detection of ellipticine in the HepG2 cell line was 
cytotoxicity. At the concentration where this compound starts to activate the AhR it 
shows also a strong cytotoxic effect [39, 40]. All other compounds in the present study 
were tested for cytotoxicity by using the glutathione depletion and calcein-AM assay 
[39, 40]. These results revealed (data not shown) that compounds not showing CYP1A 
induction in HepG2 cells but showing CYP1A induction in H4IIE cells were not missed 
in HepG2 cells because of cytotoxicity.
CYP1A induction can easily be used in the early developmental phase to detect 
compounds that may show dioxin-like toxicity. However, care should be taken to deselect 
such compounds directly as CYP1A activation does not necessarily mean dioxin-like 
toxicity. There are for example marketed therapeutics like omeprazole, lefl unomide, 
fl utamide, and nimodipine which are safely used but have been proven to be AhR agonists 
[41]. Furthermore AhR agonists like indirubin and meisoindigo have been shown to be 
effective in the treatment of chronic myelogenous leukemia [42]. Hu et al. [41] also 
demonstrated that induction of CYP1A1 is a non-specifi c marker of direct AhR affi nity. 
In the present study we measured CYP1A induction and not AhR activation. Therefore 
also compounds are detected that alter the CYP1A expression by pathways in addition 
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to those mediated by the AhR. Induction of CYP1A has been reported after oxidative 
stress [43, 44]. These compounds do not have the side-effects reported for some AhR 
activators, however, an adverse side-effect of these compounds may be the effect of 
increased CYP1A activity on the effi cacy of the compound itself or the induction could 
result in drug-drug interactions.  
The potentially toxic effect of CYP1A inducers can be confi rmed by using in vitro or in 
vivo transcriptional profi ling. By studying the change of a broad set of genes dioxin-like 
toxicity may be predicted more precisely. Consequently a compound may be deselected 
or selected.
Thus summarized, CYP1A induction can be used as a pre-screening tool to detect 
compounds that may show dioxin-like toxicity. However, further studies are needed 
to confi rm this dioxin-like toxicity. When during drug development equally potent 
compounds without CYP1A induction are available, selection of these compounds may 
be preferred to avoid possible safety problems. 
Besides species differences between CYP1A1 induction, species differences between 
the AhR receptor of human and rat could lead to differentially regulated gene expression. 
Recently it has been shown by Flaveny et al. [45] that differences between the 
transactivation domains of the human and mouse AhR result in differential recruitment 
of co-activators. It is likely that this leads to a divergent regulation of target genes. 
Differences in the recruitment of co-activators between the human and rat AhR receptor 
have not been studied yet, however, similar differences as found between human and 
mouse may exist.  
CYP1A1 and 1A2 competition assays were performed by using human and rat 
supersomes. The same set of compounds with exception of four in-house NCEs was 
tested. Like for induction species differences were observed. Of the 115 compounds 
46 showed CYP1A1 competition. Competition was human and rat specifi c for 12 and 
10 compounds, respectively. CYP1A2 competition was observed for 37 compounds of 
which 14 and 3 compounds showed human and rat specifi c inhibition, respectively. The 
similarity between the amino acid sequence of human and rat CYP1A1 is 79%, and of 
human and rat CYP1A2 73%. The difference in amino acid sequences might account for 
the differences in competition. Other studies also reported species differences between 
CYP1A metabolism in humans and rats. Shinkyo et al. [46] studied the metabolism of 
TCDD and other polychlorinated dibenzo-p-dioxins in human and rat microsomes and 
found signifi cant species differences. Boogaards et al. [47] compared the CYP activities 
towards marker CYP substrates for human, rat, rabbit, dog, and micropig microsomes. 
They found that in none of the tested species metabolism was similar to CYP metabolism 
in man. With respect to CYP1A human metabolism was most similar to mouse, followed 
by rabbit, micropig, rat and dog.    
In summary, we used a medium-/high-throughput assay in a 96-well format for detecting 
230
Chapter 8 
CYP1A inducers in the human HepG2 and rat H4IIE cell line. Moreover, CYP1A1 
and 1A2 competition assays were performed by using human and rat supersomes in 
a 384-well high-throughput assay. The induction and competition assays revealed for 
several compounds a species difference between human and rat. Therefore, parallel 
screening in both species may be a useful strategy for toxicity screening in the early 
discovery phase of drug development.
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Background
In drug development the costs spend on R&D have increased tremendously during the 
last decades. In spite of the increase in R&D expenses, the development of new assay 
methods, new techniques in liquid handling, robotics, analytical tools and software, the 
number of approved new drugs on a yearly basis has declined. 
In drug development, toxicity is an important factor for attrition, resulting in a failure 
rate of 30%-40%. Hepatotoxicity, nephrotoxicity, cardiovascular safety, reproductive 
toxicity, developmental toxicity (teratogenicity), genotoxicity and carcinogenicity are 
important causes for attrition in safety assessment.  
Screening on these aspects of toxicity in the early discovery phase of drug development 
and using these data for compound optimization and deselection might proof to be a 
strategy that results in drug development candidates with an improved success rate. The 
present thesis is focused on early screening for genotoxicity and carcinogenicity. 
In regulatory genotoxicity testing a stepwise approach (tiered approach) is applied and 
in this strategy in vitro assays are used as a fi rst step to see whether the test compounds 
have intrinsic genotoxic activity. These tests, especially when positive, are followed by 
in vivo tests that are designed to assess the relevance of the in vitro result for the in vivo 
situation. 
The regulatory test strategy consists of a battery of tests to assess gene mutations 
and chromosome damage (clastogenicity and aneugenicity). The standard test battery 
required for genotoxicity testing consists of (1) the Ames assay to detect gene mutations 
in bacteria and (2) an in vitro chromosome aberration (CA) + (or) mouse lymphoma 
TK assay (MLA) in mammalian cells to detect chromosome damage. A combination of 
these in vitro screens has a high sensitivity for genotoxic potential (Table 1). These tests 
are then followed by (3) an in vivo chromosome damage assay (chromosome aberration 
or micronucleus assay). Depending on the results, additional testing might be necessary. 
For the determination of carcinogenic potential, the induction of tumors is monitored 
in a 2-year, life time exposure of mice and rats. The regulatory tests to detect genotoxic 
potential are performed in the preclinical phase before the fi rst into man studies are 
initiated. Testing for carcinogenic potential is performed later on during the clinical 
development. 
The regulatory tests to detect genotoxic and carcinogenic potential have in general a 
low-throughput, need a high amount of compound, and are laborious. Therefore these 
assays are at least in their current format not suitable for medium- or high-throughput 
screening in the early discovery phase.
In recent years some progress has been made with earlier screening procedures for 
determining genotoxic and carcinogenic potential at the end of the discovery phase. 
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However, generally these assays are performed at a relatively late time point in the drug 
discovery phase at which chemical optimization of compounds on both pharmacological 
activity as well as on adverse properties is hard to achieve. Only a few genotoxicity and 
carcinogenicity assays for such a strategy of early phase testing are available and the 
throughput of these assays is in general low and mostly these assays were not thoroughly 
validated. An additional drawback is that the current in vitro assays for the detection of 
genotoxicity give a high rate of false positive results (low specifi city see Table 1), which 
makes application in the early discovery phase of drug development cumbersome.
The goal of this thesis was therefore to develop improved in vitro assays for detecting 
the genotoxic and non-genotoxic carcinogenic potential of chemicals, validate these 
assays with proper reference compounds and to develop a strategy for application of 
these assays in the early discovery phase of drug development. To this end assay systems 
based on bacteria, yeast, and rodent and human cell lines were developed and validated 
(Table 1). In the case of human cell lines, the focus was on the HepG2 cell line as the 
properties of HepG2 cells are expected to give a good prediction for in vivo genotoxicity 
because these cells display active p53, active DNA repair and have retained activities of 
phase I and II metabolizing enzymes.
The next sections summarize and discuss the results obtained in the present thesis. The 
fi rst section summarizes, based on Chapter 2, the results obtained with the bacterial based 
reporter assay VitotoxTM. This assay was evaluated as a rapid prescreen for the regulatory 
Ames test. Besides assays that are able to detect gene mutations (bacterial mutagenicity) 
a prescreen for genotoxicity in the early drug discovery phase should be able to rapidly 
detect compounds that cause chromosome damage (clastogenicity and aneugenicity). 
For this reason model systems in yeast and mammalian cells were evaluated. Section 
2 summarizes, based on results in Chapter 2 and 7, the results obtained with the yeast 
based RAD54 reporter assay. The third section summarizes the results obtained with the 
human HepG2 cell line, which were described in Chapters 3, 4, 5, 6 and 7. The third 
section starts with summarizing the results from the characterization of cytochrome 
P450 and phase II metabolism in HepG2 cells (Chapters 3 and 4). Then the results from 
the development and evaluation of a high content screening in vitro micronucleus assay 
in the HepG2 cell line as well as in the commonly used Chinese hamster ovary cell line 
k1 (CHO-k1) are described (Chapter 5). The third part of the section summarizes, the 
results from a gene expression profi ling study in HepG2 cells to fi nd sensitive and specifi c 
biomarkers (gene subsets) for genotoxicity (Chapter 6). Based on this study luciferase 
based reporter assays with individual genes were developed and evaluated in the HepG2 
cell line (Chapter 7). The third section is fi nalized with a summary of these results. 
Besides the detection of compounds with genotoxic potential it would be useful to be able 
to detect non-genotoxic carcinogens in the early discovery phase of drug development. 
Section four will focus on the detection of non-genotoxic carcinogenic potential caused 
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by aryl hydrocarbon receptor activators and species differences between rat and human. 
After summarizing the results from all the individual assays, combinations of the assays 
will be discussed for the development of an early screening strategy. Finally an overall 
conclusion is given, followed by additional considerations for the future. 
The detection of genotoxicity with the bacterial based VitotoxTM 
test 
A HTS alternative for the rapid detection of bacterial mutagenicity with the Ames 
assay, might be an assay, in which the induction of genes involved in repair of bacterial 
DNA damage (SOS-response) can be measured for the identifi cation of the mutagenic 
potential of compounds. An assay that is based on this principle is the VitotoxTM assay, 
which is a bacterial reporter assay in Salmonella typhimurium based on activation of the 
SOS-response with a recN promoter controlled luminometric read-out. In Chapter 2 the 
VitotoxTM was evaluated as early screen for bacterial mutagenicity. 
A recommended ECVAM compound list was used for the validation of the genotoxicity 
assays. This compound list consists of 20 well defi ned genotoxic carcinogens and 42 
non-genotoxic compounds. Of the 20 genotoxic carcinogens 14 compounds are positive 
in the Ames test. The remaining genotoxins cause chromosome damage but give 
negative or equivocal results in the Ames assay. The 42 non-genotoxic compounds (non-
carcinogens and non-genotoxic carcinogens) contain 19 compounds that give often false 
positive results in in vitro mammalian genotoxicity assays. 
Moreover, an additional set of 192 compounds was used to broaden this validation 
study. The compounds of this additional set can be classifi ed as non-genotoxins and 
genotoxins and consist of both in-house compounds from the legacy N.V. Organon and 
reference compounds. The compound list contains several steroidal compounds that 
have been reported as being clastogenic or aneugenic. Of these 192 compounds, Ames 
data were available for 145 compounds, mammalian in vitro genotoxicity data for 124 
compounds and in vivo genotoxicity data for 70 compounds. 
The sensitivity (percentage of genotoxic carcinogens that tested positive) of the 
VitotoxTM assay with respect to the ECVAM compound list was 70% (14/20). Excluding 
clastogenic and aneugenic compounds that gave negative or equivocal results in the Ames 
test, resulted in a sensitivity of 79% (11/14). The VitotoxTM assay gave a low number 
of false positive results as the specifi city (percentage of non-genotoxic compounds that 
tested negative) was 93% (39/42). 
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The results with respect to the additional list of 192 compounds confi rmed the results 
found with the ECVAM compound list. The VitotoxTM assay showed a high correlation 
with the Ames test of 91% (sensitivity, 86% (42/49); specifi city, 94% (90/96)). The 
correlation with in vitro mammalian genotoxicity and in vivo mammalian genotoxicity 
results was much lower with respectively 50% (sensitivity 27% (21/78); specifi city 89% 
(41/46)) and 54% (sensitivity 33% (13/38); specifi city 78% (25/32)). 
The overall results showed that the VitotoxTM assay is a good and rapid prescreen for 
bacterial mutagenicity. The regulatory Ames and VitotoxTM gave similar scores for the 
compounds that were tested. The throughput of the assay (16 compounds per day) and 
low amount of compound needed (5 mg) make the VitotoxTM more applicable in the 
early phase of drug discovery than the Ames assay or the miniaturized versions of the 
Ames assay. In comparison, even miniaturized versions of the Ames assay still need 
approximately 300 mg compound and have a throughput of less than 5 compounds per 
week [1]. As a consequence these assays are generally performed at a later time point in 
the drug discovery phase which renders compound optimization on both pharmacological 
properties as well as on genotoxicity more diffi cult. Complementary to the assessment 
of bacterial mutagenicity with the VitotoxTM assay the results in the Chapter 2 showed 
that for the rapid detection of chromosome damage additional testing is needed.
The detection of genotoxicity with the yeast based RadarScreen 
assay
Eukaryotic cell based systems are needed to detect compounds that cause chromosome 
damage (structural damage, clastogenicity; numerical damage, aneugenicity). In 
this aspect the eukaryotic yeast based RadarScreen was validated (Chapter 2). The 
RadarScreen assay is a RAD54 promoter-linked β-galactosidase reporter assay of 
which the β-galactosidase expression can be quantifi ed luminometrically. The level of 
luminescence might be a good measure for DNA damage as RAD54 plays a pivotal role 
in DNA repair in yeast. 
The reproducibility of the assay was tested with the genotoxic reference compounds 
methyl methane sulphonate and benzo[a]pyrene and appeared to be good. Validation 
with respect to the ECVAM compound list resulted in a correlation with (in vivo) 
genotoxicity of 79% (sensitivity, 70% (14/20); specifi city, 83% (35/42)). For the 
additional set of 192 compounds, the RadarScreen assay had a correlation with in vitro 
mammalian genotoxicity (clastogenicity) of 76% (sensitivity, 77% (59/77); specifi city, 
74% (34/46)). 
Validation with the ECVAM compound list indicated that the number of falsely predicted 
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in vivo genotoxicity results is low, whereas results with the additional compound set 
showed the opposite with a predictivity of only 54% (sensitivity, 68% (25/37); specifi city, 
38% (12/32)). Especially the steroids in the second list of compounds gave false positive 
results for in vivo genotoxicity. The exact reason for these results obtained cannot be 
given. A lack of or (species) difference in metabolizing enzymes might have been the 
reason for the low predictivity. In addition, well known aneugens were diffi cult to detect 
with the RadarScreen assay. 
Thus although a good predictivity for in vitro mammalian genotoxicity was measured, 
the predictivity for in vivo genotoxicity was low. Therefore other assays are needed. 
The detection of genotoxicity with the human HepG2 cell line
A disadvantage of most proliferative carcinogenic cell lines is that they have lost 
their responsiveness for p53 activation, DNA repair response systems and/or their 
metabolizing capacities. Impairment of these systems might be the reason for the low in 
vitro predictivity of in vivo genotoxicity. The application of the human hepatoma cell 
line HepG2 might be useful in this aspect as HepG2 cells display active p53 protein, 
active DNA repair systems and have retained activities of phase I and II enzymes. 
Several studies were performed with the HepG2 cell line, including the following 
investigations: (1) phase I and II metabolism was characterized (Chapters 3 and 4), 
(2) a high content screening in vitro micronucleus assay was developed and validated 
in HepG2 cells as well as in CHO-k1 cells, of which the latter are commonly used in 
regulatory in vitro micronucleus assays (Chapter 5), (3) transcriptomics in HepG2 cells 
exposed to genotoxic and non-genotoxic liver toxicants was used to assess biomarkers 
for genotoxicity (Chapter 6), (4) and fi nally, based on these transcriptomics data, 
luciferase based reporter assays for the detection of genotoxic potential were developed 
and validated (Chapter 7). 
Characterization of phase I and II metabolism in the HepG2 cell line
Metabolism can result in toxifi cation and detoxifi cation of compounds. Knowledge of 
the metabolic status of cell lines used for in vitro genotoxicity testing is a prerequisite to 
understand the results obtained and to pinpoint at weaknesses and strengths of the in vitro 
genotoxicity assays being carried out. Therefore, a detailed metabolic characterization 
of the HepG2 cell line was performed, i.e. messenger RNA (mRNA) levels and enzyme 
activities of several important phase I cytochrome P450 enzymes (CYPs) and phase 
II enzymes were quantifi ed under control conditions and compared with their levels 
of cryopreserved primary human hepatocytes as well as with their levels after specifi c 
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nuclear receptor activations (Chapter 3 and 4). These cryopreserved primary hepatocytes 
were reported to be representative for fresh primary hepatocytes with respect to their 
CYP and phase I enzymes activities towards a range of substrates [2]. 
The transcript levels of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 
3A4 were measured with quantitative PCR. Results showed that transcripts of all CYPs 
were present in HepG2; however mRNA levels of most CYPs were signifi cantly lower 
than in cryopreserved primary human hepatocytes. These results were confi rmed with 
luminometric assays which were used to measure the enzyme activities of CYP1A1, 
1A2, 2C9, and 3A4. 
Regulation of CYP1A1, 1A2, 2B6, 2C8, 2D6, 2E1, and 3A4 by the aryl hydrocarbon 
receptor (AhR), pregnane X receptor (PXR) and constitutive androstane receptor 
(CAR) was studied in HepG2 cells at the mRNA and/or enzyme level. Regulation of 
CYP1A1, 1A2, 2B6, and 3A4 mRNA levels was similar to the regulation in primary 
human hepatocytes. In contrast, CYP2C8 mRNA levels are inducible in cryopreserved 
human hepatocytes, but not in HepG2 cells, after treatment with PXR/CAR activators. 
Consistent with other studies, CYP2D6 and 2E1 transcript levels were not changed after 
treatment with AhR, PXR, and CAR activators. Moreover, CYP1A1 and 1A2 enzyme 
activities could be induced by AhR agonists and CYP3A4 by PXR agonists. 
Thus characterization of phase I CYPs showed that the enzymes were in general 
present in HepG2 cells, but at much lower levels than in cryopreserved primary human 
hepatocytes. Levels of these enzymes can be induced by activation of the AhR, PXR, 
and CAR.
Transcript levels of phase II UDP-glucuronosyl transferases (UGTs), sulfotransferases 
(SULTs), glutathione S-transferases (GSTs), N-acetyltransferase-1 (NAT1) and 
epoxide hydrolase (EPHX1) were measured with quantitative PCR in HepG2 cells and 
cryopreserved primary human hepatocytes. Levels of SULT1A1, 1A2, 1E1, 1A2, and 
2A1, microsomal GST 1, GST μ1, NAT1, and EPHX1 in HepG2 cells were almost 
similar to levels in cryopreserved primary human hepatocytes. In contrast, levels of 
UGT1A1 and 1A6 transcripts were between 10- and more than 1000-fold higher in 
the cryopreserved primary hepatocytes. The regulatory processes of phase II enzymes 
by the AhR, PXR and CAR were studied in HepG2 cells and appeared quite similar to 
those in primary human hepatocytes. Due to the involvement of phase II enzymes in 
the toxifi cation of several compounds, HepG2 cells can be a valuable cellular system to 
predict toxicity for these compounds. 
The normal expression of most phase II enzymes in combination with the lower 
expression of CYPs in HepG2 cells might however result in an underestimation of toxicity 
for several compounds. Proximate genotoxins that need activation by low expressed 
CYPs (i.e. cyclophosphamide that is activated by CYP2B6) might be diffi cult to detect 
in HepG2 cells. The usage of S9 mixture or pre-stimulation of HepG2 cells with AhR, 
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PXR, or CAR agonists to induce CYP levels may be methods to solve these issues.
The development of a HCS in vitro micronucleus assay in the HepG2 and CHO-k1 
cell line
To be able to rapidly assess chromosome damage (clastogenicity and aneugenicity) an 
automated image analysis assisted high content screening (HCS) in vitro micronucleus 
(IVMN) assay was developed using both the rodent CHO-k1 cell line commonly used in 
regulatory genotoxicity assays as well as the human HepG2 hepatoma cell line.
The reproducibility of the CHO-k1 and HepG2 HCS IVMN assays was tested with 
the genotoxic reference compound taxol and appeared to be good. The HCS IVMN 
assays were both evaluated by testing the ECVAM compound list. The sensitivity 
(number of genotoxic carcinogens correctly predicted) (80%; 16/20) and specifi city 
(percentage of non-genotoxins correctly predicted)  (88%; 37/42) of the CHO-k1 cell 
line were high. Proximate genotoxins that are activated by CYP1A (i.e. benzo[a]pyrene 
and 7,12-dimethylbenzanthracene) were already genotoxic in CHO-k1 cells without S9 
mixture indicating that these enzymes are probably active in CHO-k1 cells. Addition of 
S9 mixture resulted even in a decrease in the genotoxic effects for these compounds.
The sensitivity of the HepG2 cell line was lower, being 60% (12/20), the specifi city 
was high amounting to 88% (37/42). The metabolic capacity in hepG2 cells was able 
to detect genotoxic potential of compounds that need metabolic activity to exert their 
genotoxic activity. Seven out of the nine proximate genotoxins showed genotoxic 
potential, i.e. cyclophosphamide, benzo[a]pyrene, 7,12-dimethylbenzanthracene, 
dimethylnitrosamine, 2,4-diaminotoluene, PhIP.HCl and afl atoxin B1. The proximate 
genotoxins 2-acetylaminofl uorene and IQ showed a negative result. The addition of S9 
mixture did not result in activation of these two compounds. 
Testing of an additional set of 16 genotoxic compounds confi rmed results that were 
obtained with the ECVAM compound list. The sensitivity of the CHO-k1 cell line was 
69% (11/16) and thus higher than the sensitivity of 56% (9/16) that was obtained for the 
HepG2 cell line. For both the CHO-k1 as well as HepG2 cell line it was possible to size-
classify micronuclei enabling discrimination of aneugens from clastogens.
It was concluded that two high-throughput micronucleus assays were developed that 
can detect genotoxic potential (chromosome damage) and allow differentiation into 
clastogens and aneugens. 
The identifi cation of biomarkers for genotoxicity in HepG2 cells by gene expression 
profi ling
Gene expression profi ling in HepG2 cells was used to fi nd biomarkers (genes and 
responsive elements) that can be used for the development of high-throughput luciferase 
based reporter assays that can assess the genotoxic potential of compounds and 
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discriminate genotoxic carcinogens from non-genotoxic liver toxicants. 
HepG2 cells have been successfully used to discriminate genotoxic from non-genotoxic 
carcinogens by gene expression profi ling. Classifi ers that discriminated genotoxic and 
non-genotoxic carcinogens were involved in cell cycle regulation, cell cycle arrest, 
DNA damage related processes, immune and stress responses, and apoptosis. The focus 
in these studies was on the determination of genotoxic and non-genotoxic pathways 
involved in carcinogenesis and therefore in these studies non-toxic concentrations of the 
non-genotoxic carcinogens were used. 
In the present study gene expression profi ling in HepG2 cells was used to fi nd genes 
and responsive elements that can not only assess the genotoxic potential of compounds 
but also discriminate genotoxic carcinogens from non-genotoxic liver toxicants. HepG2 
cells were exposed to cytotoxic concentrations of the non-genotoxic liver toxicants as 
cytotoxicity can activate stress pathways, may cause DNA damage, and may thus result 
in a false-positive in vitro prediction for in vivo genotoxicity. The differences between 
the expression profi les of the genotoxic and liver non-genotoxic toxicants will be used 
to determine biomarker genes or responsive elements that are specifi c for genotoxins. 
Application of such biomarkers may result in a high-throughput luciferase based assay 
with a good sensitivity for genotoxicity and low false positive rate for non-carcinogens 
and in vivo genotoxicity.
HepG2 cells were treated with four genotoxic and seven non-genotoxic liver toxicants 
for 6h, 24h and 72h. Discrimination between the two classes of compounds was limited 
when all differentially expresses genes (DEG) were used. Pathway analysis of the 
DEG in the class of genotoxins revealed multiple affected pathways, of which the main 
ones at the three time points were involved in cell cycle control. At 72h several of 
the genotoxicity pathways were activated by the non-genotoxic liver toxicants (i.e. p53 
pathway, ATM pathway, G2/M cell cycle checkpoint regulation). 
Additional data analysis with Qlucore Omics Explorer was performed to fi nd genes 
that differentiate both classes of compounds. This analysis yielded for each time point 
a subset of genes (6h, 362 genes; 24h, 1914 genes; 72h, 498 genes). Pathway analysis 
showed that the 6h and 24h gene subsets were mainly involved in the cell cycle, apoptosis, 
and DNA repair. No pathways were affected by the 72h subset of genes. 
The most pronounced induced genes (top 10) in the three sets of genes were mainly 
downstream targets of p53, involved in apoptosis or the oxidative stress response. Several 
other pivotal genes involved in the DNA damage response were also present in the three 
subsets (i.e. GADD45A, GADD45B, PCNA, POLH, and XPC).
In summary, gene expression analysis with Qlucore Omics Explorer revealed a 6h, 
24h, and 72h gene subset that discriminated genotoxic from non-genotoxic toxicants 
exerting their effect through cytotoxicity. The most prominent induced genes in the three 
subsets of genes were mainly involved in cell cycle control or were downstream targets 
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of p53. The application of these potential biomarkers in luciferase based reporter assays 
may provide a tool for screening genotoxicity with lower levels of false positives.
The development of luciferase based reporter assays for genotoxicity and oxidative 
stress 
Gene expression analysis (Chapter 6) showed that the application of the promoters 
(or responsive elements) of genes involved in cell cycle control or of genes that are 
downstream targets of p53, might result in sensitive luciferase based reporter assays that 
can rapidly assess mammalian genotoxicity with a low rate of false positive results due 
to cytotoxicity. In addition, gene expression analysis indicated that RAD51C may be a 
specifi c marker for DNA double strand breaks.  
Based on these data the promoter regions of RAD51C and cystatin A (downstream target 
of p53 involved in apoptosis), as well as the responsive element of the p53 protein, were 
selected for the generation of three genotoxicity reporter assays. Moreover, a luciferase-
based reporter assay was generated that measures the activation of the Nrf2 electrophile 
responsive pathway (Chapter 7).
The reproducibility of the four reporter assays was tested with the genotoxic reference 
compounds doxorubicin and benzo[a]pyrene and appeared to be good for all four assays. 
Validation with respect to the ECVAM compound list resulted in an predictivity (total 
percentage correctly predicted genotoxic carcinogens plus non-genotoxic compounds) 
for the individual genotoxicity reporter assays of 82% for the HepG2 RAD51C_luc 
assay (sensitivity 60%, 12/20; specifi city 93%, 39/42), 84% for the HepG2 Cystatin 
A_luc assay (sensitivity 70%, 14/20; specifi city 90%, 38/42), and 90% for the HepG2 
p53_luc assay (sensitivity 85%, 17/20; specifi city 93%, 39/42). The overall predictivity 
of the three HepG2 reporter assays for genotoxicity was high with 82% (sensitivity 85%, 
17/20; specifi city 81%, 34/42). In addition, the percentage of genotoxic compounds that 
activated the Nrf2 pathway was high with 75% (15/20). Of the non-genotoxic compounds 
in the ECVAM list only 31% (13/42) activated the Nrf2 pathway. 
The metabolic capacity in HepG2 cells was suffi cient to activate seven out of the 
nine proximate genotoxins i.e. benzo[a]pyrene, 7,12-dimethylbenzanthracene, 
2-acetylaminofl uorene, 2,4-diaminotoluene, IQ, PhIP.HCl and afl atoxin B1. Of these 
seven compounds 2-acetylamininofl uorene and IQ were not detected in the HepG2 
HCS IVMN assay (Chapter 5) which might indicate that the activation of the p53 
responsive element is a more sensitive endpoint for these compounds in HepG2 cells 
than the formation of micronuclei (DNA damage). The activation of the DNA repair 
response in HepG2 cells may have prevented a signifi cant induction of micronuclei 
in the HepG2 HCS IVMN assay. The proximate genotoxins cyclophosphamide 
and dimethylnitrosamine were not detected in the genotoxicity reporter assays. As 
cyclophosphamide and dimethylnitrosamine are respectively activated by CYP2B6 and 
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2E1, which are expressed at low levels in HepG2 cells (Chapter 3), this low expression 
is a plausible reason for the fact that these two proximate genotoxins were not detected. 
However, this hypothesis is not supported by the fact that with the HepG2 HCS IVMN 
assay these compounds could be identifi ed as genotoxic without the addition of S9 
mixtures, implying that the endogenous enzyme levels are high enough for the detection 
in this assay. Therefore the formation of micronuclei might be a more sensitive endpoint 
for the detection of cyclophosphamide and dimethylnitrosamine. Notheworthy, in a study 
performed by Sohn et al. [3] there was also no p53 activation observed after exposure of 
cells to cyclophosphamide. 
The data from the genotoxicity reporter assays were also compared with the available 
data on bacterial mutagenicity (Ames test), in vitro mammalian genotoxicity and in 
vivo genotoxicity for an additional set of 192 compounds. The predictivity for bacterial 
mutagenicity results was 74% (sensitivity 61%, 30/49; specifi city 80%, 77/96) and for 
in vitro mammalian genotoxicity 59% (sensitivity 45%, 35/78; specifi city 83%, 38/46). 
The correlation between results from the HepG2 genotoxicity reporter assays and in vivo 
genotoxicity was higher with 77% (sensitivity 74%, 28/38; specifi city 81% 26/32). For 
the individual genotoxicity reporter assays, the correlations with in vivo genotoxicity 
were 76% for the HepG2 p53_luc assay (sensitivity 71%, 27/38; specifi city 81%, 26/32), 
59% for the HepG2 RAD51C_luc assay (sensitivity 29%, 11/38; specifi city 94%, 30/32), 
and 76% for the HepG2 Cystatin A_luc assay (sensitivity 61%, 23/38; specifi city 94%, 
30/32). Like observed with the ECVAM compound list the HepG2 p53_luc assay and 
Cystatin A_luc assay are assays with a relative high sensitivity and specifi city. The HepG2 
RAD51C_luc assay has a lower sensitivity but the specifi city is high indicating that only 
a few compounds induce double DNA strand breaks. Of the 108 compounds in the 
additional list of 192 compounds that have a positive result for bacterial or mammalian 
genotoxicity 62% (67 compounds) activate the Nrf2 pathway. This percentage was only 
38% (30/80) in the group of compounds with negative of no genotoxicity data. These 
data confi rm the results that were found with the ECVAM compound list that a large 
percentage of the genotoxic compounds activate the Nrf2 pathway. Activation of the 
Nrf2 pathway gives information about the mode of action of a genotoxic compound. 
This assay should however not be used to identify and subsequently deselect genotoxic 
compounds as this pathway is also activated by cytotoxic compounds and by various 
benefi cial compounds that protect cells against genotoxic and cytotoxic compounds [4-6]. 
Activation of this pathway results in up-regulation of phase-II detoxifying enzymes and 
antioxidant-stress proteins. In addition, cross-talk between the p53 and Nrf2 pathways 
makes the individual role of Nrf2 in the genotoxic potential assessment as such very 
diffi cult [7]. 
In summary, three luciferase based reporter assays for the rapid assessment of genotoxic 
potential were generated. The p53 and cystatin A reporter assays had a high sensitivity 
Summary, discussion, conclusion and additional considerations
245
and specifi city for genotoxic carcinogenicity and in vivo genotoxicity. The RAD51C 
reporter assay was a more specifi c assay that gave information about the formation 
of double strand breaks. The results of these individual assays supported the results 
that were found with gene expression profi ling studies in HepG2 cells. In addition a 
Nrf2 reporter assay was developed that can help to elucidate the mode of action of a 
genotoxicant. Based on the obtained results with the different high-throughput reporter 
assays it can be concluded that application of these assays may be a useful strategy to 
rapidly assess genotoxic potential in the early discovery phase.
In this and the previous sections the focus was on the development and validation of 
assays for the detection of compounds with genotoxic potential. Besides the detection 
of genotoxic compounds (genotoxic carcinogens) it would also be useful to detect non-
genotoxic carcinogens in the discovery phase of drug development. Non-genotoxic 
carcinogens can induce tumor formation by many different mechanisms [8]. One of the 
mechanisms is receptor mediated induction by the aryl hydrocarbon receptor which is 
focused on in the next section.    
Detection of CYP1A inducers and species differences between 
human and rat 
Strong activation of the AhR can lead to various toxic effects such as (non-genotoxic) 
carcinogenicity. Normally the majority of carcinogenicity studies are performed in rats, 
while for the prediction of human carcinogenicity human AhR activation should be 
studied. 
CYP1A was used as marker for AhR activation as AhR activators induce this gene 
to high levels. CYP1A induction studies were performed in the human HepG2 and rat 
H4IIE cell lines. CYP1A induction in the HepG2 and H4IIE cell line has been shown to 
be representative for CYP1A induction in human and rat, respectively [2, 9, 10].
A set of 119 compounds, including known AhR ligands were tested. CYP1A induction 
was observed for 24 compounds. In H4IIE cells, more compounds resulted in induction 
and most EC50 values were below those of HepG2 cells. Species specifi c CYP1A 
induction in H4IIE and HepG2 cells was obtained for eight and three compounds, 
respectively. 
Thus for several compounds species differences between CYP1A induction in human 
and rat were found. Therefore, given that possible subsequent carcinogenicity studies 
will be performed in rats but that risks should be determined for the human population, 
parallel screening in both species seems the best strategy in the pharmaceutical industry. 
Care should be taken to directly deselect compounds that are positive in these tests as 
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AhR activation does not necessarily indicate dioxin-like toxicity. There are for example 
marketed therapeutics like omeprazole, lefl unomide, fl utamide, and nimodipine which 
are safely used but have been proven to be AhR agonists [11]. Moreover, CYP1A 
induction by other pathways than the AhR is known, resulting in possible false positives 
in this assay [11]. In summary, both the human and rat CYP1A induction assays are 
useful for prescreening but care should be taken to deselect CYP1A inducers.
Comparison of the sensitivity and specifi city of the regulatory and 
high-throughput in vitro genotoxicity assay  
In the present thesis several high-throughput assays for the detection of genotoxic potential 
were evaluated. In this section the sensitivity and specifi city of the newly developed 
high-throughput in vitro genotoxicity assays will be compared with the regulatory in 
vitro genotoxicity assays. Since in the current regulatory practice combinations of assays 
are used to detect bacterial mutagenicity (gene mutations) and mammalian genotoxicity 
(chromosome damage) a combined use of HTS assays will be discussed in this chapter. 
The sensitivity and specifi city of the regulatory in vitro genotoxicity assay will be 
discussed fi rst. 
Sensitivity and specifi city of combinations of regulatory in vitro genotoxicity assays
Kirkland et al. [12] evaluated the ability of single and combined use of the regulatory in 
vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. Hereby 
the authors stated that it is important to discriminate carcinogens into carcinogens that 
act via a genotoxic and non-genotoxic mode of action, as carcinogens that act via a non-
genotoxic mode cannot be readily detected in in vitro genotoxicity assays [12]. Thus 
genotoxic carcinogens should give positive results in in vitro genotoxicity assay and 
non-genotoxic carcinogens and non-carcinogens should give negative results. 
The performance scores of the individual in vitro genotoxicity assays are shown 
in Chapter 1 Table 3. These data clearly show that the specifi city of the individual 
mammalian in vitro genotoxicity assays for non-carcinogens is relatively low resulting 
in a high percentage of false positives. In general a combination of the Ames test + 
MLA + chromosome aberration assay is used in regulatory testing [12] (Table 2). This 
combination has a sensitivity for carcinogenicity of 84.7% (171/202) but extremely low 
specifi city for non-carcinogens of only 22.9 % (22/96). The combined use of two tests 
(i.e. Ames + CA, AMES + IVMN, AMES+MLA) gives similar scores [12]. The overlap 
between the compounds used by Kirkland et al. and the compounds used in the present 
thesis is however rather limited and therefore a straight comparison is not possible as 
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such. Also since mechanistic data was lacking for most carcinogens it was not possible 
for Kirkland et al. to calculate the performance scores for genotoxic carcinogenicity 
[12].
The assess the sensitivity and specifi city of the proposed in vitro models, as shown in the 
present thesis an ‘ECVAM compound list’ was used [13]. This list consists of well defi ned 
genotoxic carcinogens, non-genotoxic carcinogens and non-carcinogens. The compound 
list was used to calculate the sensitivity and specifi city for genotoxic carcinogenicity 
(Table 2). Application of the regulatory accepted test strategy (combination of Ames + 
MLA + CA test) gives in case of these ECVAM compounds a sensitivity for genotoxic 
carcinogenicity of 100% (20/20) and specifi city of 55% (23/42). The low specifi city is 
mainly caused by the in vitro mammalian genotoxicity assays (MLA + CA) that give 19 
false positive results.  
Besides the ECVAM compounds an additional list of 192 compounds was used in the 
present thesis (Chapters 2 and 7). Genotoxicity and carcinogenicity data are limited for 
these compounds and a clear classifi cation in genotoxic carcinogens and non-genotoxins 
(non-genotoxic carcinogens + non-carcinogens) is not available. For these compounds 
we made therefore the choice to compare the assay data with in vivo genotoxicity data, 
of which the result are most likely the best refl ection of the discrimination between 
genotoxic carcinogens and non-genotoxins. With the use of  this additional compound 
set, the combination AMES + in vitro mammalian assays (Table 2) shows a sensitivity 
of 97% (37/38) and specifi city of 41% (12/29). Also here the low specifi city is caused 
by the results from the in vitro mammalian genotoxicity assays (Table 2).
Overall the two compound sets that were used in the present thesis give, although 
the way of comparing was different, similar results as shown in the Kirkland study 
[12]. A combination of the AMES + in vitro mammalian genotoxicity assays gives a 
high sensitivity but low specifi city. The ECVAM and additional compound list make 
a direct comparison between results from regulatory in vitro genotoxicity tests (Ames 
+ in vitro mammalian assays) and the high-throughput assays developed in the present 
thesis possible. Different combinations of the high-throughput assays will be discussed 
below and the scores will be compared with those of the regulatory in vitro genotoxicity 
assays.
Sensitivity and specifi city of combinations of the HTS genotoxicity assays and 
comparison with the regulatory in vitro screening battery
Taking as starting point that a screening battery for early genotoxicity screening 
should contain a bacterial based assay to be able to detect gene mutations, the VitotoxTM 
assay should be present. The high sensitivity and specifi city of the VitotoxTM for Ames 
results of respectively more than 80% and 90% (Chapter 2), the high-throughput and 
low amount of compound needed makes this assay a valuable prescreen that can rapidly 
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predict Ames test results in the discovery phase of drug development.
Besides bacterial mutagens, an early screening battery should contain assays that are 
able to detect compounds causing chromosome damage. Several assays that have the 
potential to detect chromosome damage were validated in the present study, Combinations 
of these assays, i.e. (1) the yeast based RadarScreen assay, (2) the CHO-k1 HCS IVMN 
assay, (3) the HepG2 HCS IVMN assay, and (4) the luciferase based p53 reporter assays 
in HepG2, with the VitotoxTM are discussed below. The sensitivity and specifi city scores 
of the combinations of assays are summarized in Table 3. 
1. Vitotox + RadarScreen
In case of the ECVAM compounds the sensitivity (80%) and specifi city (81%) is high. 
However, in case of the additional list of compounds the specifi city score is low with 
only 28%. Therefore this combination of tests is diffi cult to use in the early discovery 
phase as too many pharmacologically interesting compounds will be deselected based 
on a false positive result. 
2. Vitotox + CHO-k1 HCS IVMN assay 
This combination gives in case of the ECVAM compounds a sensitivity of 95% (19/20). 
The specifi city of the combination VitotoxTM + CHO-k1 HCS IVMN is with 83% (35/42) 
much higher than the specifi city of 55% (23/42) of the combination regulatory Ames + in 
vitro mammalian genotoxicity assays. These performance scores make the combination 
VitotoxTM + CHO-k1 HCS IVMN assay applicable for early screening. 
Additional validation may be essential as the regulatory IVMN assay in which also 
often CHO-k1 cells are used gives a much lower specifi city (30.8% for non-carcinogens 
[12]). Reasons for the differences between the present and previous studies might be 
the presence of a functionally active p53 protein (non published studies with the p53 
inhibitor pifi thrin-α show that p53 is at least partly functional in the CHO-k1 cell line 
used) and/or the application of the HCS technique. This HCS technique gives promising 
results and seems to be more consistent and reliable also due to the lack of observer 
variability that is seen with manual scoring of micronuclei [14].
3. Vitotox + HepG2 HCS IVMN assay
A combination of these assays gives in case of the ECVAM compounds a sensitivity of 
90% (18/20) and specifi city of 83% (35/42). Similar to the HCS IVMN assay in CHO-k1 
cells, the specifi city of the HepG2 HCS IVMN assay is considerably higher (83%) than 
the specifi city of the regulatory Ames + in vitro mammalian genotoxicity assays. The 
observed sensitivity and specifi city scores indicate that application of a combination of 
these two assays in the discovery phase will be a useful test strategy.
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4. Vitotox + HepG2 p53_luc
This combination of assays gives in case of the ECVAM compounds a sensitivity of 
85% (17/20) and specifi city of 88% (37/42). Only three genotoxic carcinogens are not 
detected and the specifi city of 88% is much higher than the specifi city of 55% (23/42) 
with the regulatory Ames + mammalian in vitro genotoxicity assays. 
For the additional set of compounds a sensitivity and specifi city of respectively 76% 
(29/38) and 72% (23/32) is measured. These sensitivity scores appeared to be lower 
than those of the Ames + in vitro mammalian genotoxicity assays combination (97%, 
37/38) but the specifi city is with 72% much higher than the 41% (12/29) measured with 
the Ames + in vitro mammalian genotoxicity assays combination. Overall the results 
show that a combination of VitotoxTM + HepG2 p53_luc gives a high sensitivity and high 
specifi city which make this combination most suitable for early screening. An additional 
advantage of the tested combination of these two assays is that the validation studies 
were performed with a large set of compounds (ECVAM + additional set).
Combinations of the VitotoxTM with the cystatin A and RAD51C reporter will not be 
discussed as both these genes are p53 dependent for their transcription [15]. Therefore 
these assays are not essential to perform and do have (almost) no effect on the performance 
scores (Chapter 7). Thus of these three reporter assays, the p53 assay is the most useful 
for the detection of genotoxic potential. Additional reporter assays like cystatin A, 
RAD51C, but also Nrf2 give information about the mode of action and can therefore 
also be of use. Addition of these assays in the test strategy does however not result in a 
decrease of specifi city or an increase of sensitivity. 
Thus in summary, four combinations of HTS assays were evaluated. The combination 
VitotoxTM + RadarScreen resulted in a specifi city that is generally too low. The other 
three combinations of assays (VitotoxTM + CHO-k1 HCS IVMN assay, VitotoxTM  + 
HepG2 HCS IVMN assay, and VitotoxTM  + HepG2 p53_luc) seem all to be useful for 
screening in the early discovery phase as both the sensitivity and specifi city are high. 
The specifi city of all three combinations is higher than the combination regulatory Ames 
+ mammalian in vitro genotoxicity assay. Of the three combinations the VitotoxTM + 
HepG2 p53_luc test strategy is the one who could be validated with the largest compound 
set, which resulted overall in the highest confi dence during its use. Therefore at present 
this combination is preferably be used for an early screening strategy. 
Further validation of the HCS IVMN assays with a larger compound set is proposed. 
Depending on the results a HCS IVMN assay may be added to the VitotoxTM + p53_luc 
combination which will make a direct discrimination of genotoxins between aneugens 
and clastogens possible in the near future.
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Conclusion
In the present thesis several high-throughput assays to detect genotoxic and non-
genotoxic carcinogenic potential were developed and validated with proper reference 
compounds. The results in this thesis show that an early prediction can be made for 
bacterial mutagenicity (gene mutations), mammalian genotoxicity (chromosome 
damage), and non-genotoxic carcinogenic potential by AhR activation. 
To develop a strategy for application of the HTS genotoxicity assays in the early 
discovery phase several combinations of assays were evaluated. The combination 
VitotoxTM + HepG2 p53 reporter assay was based on the presented results in this thesis 
the most useful for screening compounds for their genotoxic potential in the early drug 
discovery phase without the risk on high numbers of false positives. CYP1A induction 
assays in human HepG2 and rat H4IIE cells may be performed in parallel with these assays 
to be able to detect non-genotoxic carcinogenic potential by AhR activators. Further 
application of these assays may prove useful in future drug development strategies.
Additional considerations
The regulatory genotoxicity assays and genotoxicity assays for early screening are in 
general performed in serial order. For each individual assay compound stocks are ordered 
and from these stocks dilution series are prepared. This strategy is relatively laborious, 
needs a high amount of compound and is especially a problem for screening in the 
discovery phase where the number of compounds is high and the amount of compound 
available is limited. The strategy of parallel screening may be more useful for early 
screening [16]. In parallel screening, one compound stock plate with dilution series is 
prepared and used to add the compound dilutions (by using a robotic device) to assay 
plates from different assays that are performed in parallel. This strategy saves compound 
and results in a quick generation of assay data.
Another important determinant for the success of early screening is the purity of 
compounds. In the early research phase there is a balance between the quick preparation 
of new chemical entities and the extent of impurities. In pharmacological testing small 
amounts of impurities are often not a problem due to the concentrations used however 
as the concentrations used in the genotoxicity assays go up to a high concentration of 
10-3 M, genotoxic impurities that are present in only low amounts might generate false 
positive results. Therefore the purity of the compounds should be high enough to generate 
not too much false positive results. On a case by case base it is for pharmacologically 
interesting compounds that show genotoxic potential possible to purify compounds by 
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crystallization or HPLC separation.
The application of an S9 metabolic system in the HepG2 and CHO-k1 cell lines needs 
also some consideration. Although we (Chapter 5) and others [17] showed that it is 
possible to use an S9 metabolic system in combination with HepG2 and CHO-k1 cells to 
activate proximate genotoxins like afl atoxin B1, the results in the present thesis showed 
also that the application of S9 mixture in bacteria and yeast gives sometimes different 
results than in CHO-k1 and HepG2 cells. In bacteria and yeast proximate genotoxins were 
not active without S9 mixture and addition of S9 mixture resulted in activation. This was 
also the case for HepG2 and CHO-k1 cells when there was no or very limited activation 
by endogenous metabolism. When however there was already a strong activation without 
S9 mixture, addition of S9 mixture resulted in a decrease of the genotoxic effects. The 
bacteria and yeast that were used in the present thesis contain genetic modifi cations that 
make the membranes more permeable so that genotoxic metabolites that are formed 
outside the cell by S9 mixture can easily enter the cells and reach the DNA. Moreover, 
in bacteria the compounds have to pass only one membrane to reach the DNA. In the 
human HepG2 (and rodent CHO-k1) cell line the hydrophilic metabolites might enter the 
cells slower than the parent compound. This might result in a lower amount of reactive 
metabolites reaching the DNA than in the case where the parent compound is activated 
endogenously within the cells. 
Another consideration to be discussed is the method of validation. The validations 
performed in the present study gave a fi rst indication that the methods developed are 
reproducible. These validations were however not yet performed according to the 
validation process defi ned by the ECVAM which would ultimately be required if one 
would aim at regulatory acceptance of the tests. This way of validation is a long lasting 
process that consists of a lot of steps (http://tsar.jcr.ec.europa.eu/), including method 
submission, regulatory relevance assessment, pre-validation, validation, peer review 
of results, validation statement, post-validation and fi nally the regulatory approval 
process. The strength of the current assays is the applicability in the early phase of drug 
development, and for this application an offi cial validation is not needed. However, 
fi nally for some of the presented assays like for example the p53 reporter assay in HepG2 
cells it might be useful to get regulatory acceptance. 
  The last consideration is about additional assays that might be useful to develop in the 
future. Gene expression analysis with genotoxic and non-genotoxic toxicants revealed 
several biomarker genes that discriminated genotoxic from non-genotoxic toxicants 
exerting their effect through cytotoxicity. Based on these data three luciferase based 
genotoxicity reporter assays were developed. Two of these luciferase based reporter 
assays appeared to be useful for the identifi cation of compounds with genotoxic potential 
(p53 and cystatin A reporter assays). The third assay being the RAD51C reporter assay 
was more specifi c and identifi ed the mode of action of genotoxins, being the generation 
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of DNA double strand breaks. Additional gene expression profi ling studies in HepG2 
cells may result in the identifi cation of more biomarker genes that can discriminate  the 
mode of action of a genotoxin. It would be useful to fi nally have a set of biomarkers 
that can discriminate direct acting genotoxins, cross-linking agents, topoisomerase 
inhibitors, DNA synthesis inhibitors, reactive oxygen species generators and aneugens. 
Such biomarker genes may be used for the development of high-throughput assays like 
luciferase based reporter assays. As proposed in this thesis high-throughput assays that 
can detect the non-genotoxic carcinogenic potential of compounds in the early discovery 
phase of drug development might be useful. We presented the development of an assay 
that is able to detect compounds that cause non-genotoxic carcinogenicity by activation 
of the AhR. This is however only one of many mechanisms that cause non-genotoxic 
carcinogenicity. Activation of several other receptors than the AhR can also result in 
non-genotoxic carcinogenicity. For such receptors like for example the peroxisome 
proliferator activated receptor α, CAR, thyroid hormone receptor it might therefore also 
be useful to develop screenings assays in human and/or rodent cell lines.   
All together the results of the present thesis present several newly developed genotoxicity 
assays and demonstrate that these new assays may provide a reliable and useful high-
throughput alternative for regulatory genotoxicity tests. Especially a combination of some 
of the newly developed test was shown to provide excellent possibilities for screening 
compounds for their genotoxic potential in the early drug discovery phase without the 
risk on high numbers of false positives. In addition, two assays to detect non-genotoxic 
carcinogenic potential by AhR activators in human and rat were presented. Several of 
the newly developed assays in this thesis may prove useful in future drug development 
strategies. 
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Achtergrondinformatie 
De investeringen van de farmaceutische industrie in het onderzoek naar en de 
ontwikkeling van geneesmiddelen zijn de afgelopen decennia fors gestegen. Ondanks 
deze toename in R&D kosten, het gebruik van nieuwe test- en meettechnieken, 
automatisering en robotisering is het aantal nieuwe geneesmiddelen dat per jaar op de 
markt komt afgenomen.
Toxiciteit is in 30 tot 40% van de gevallen de oorzaak voor het feit dat potentiële 
geneesmiddelen niet verder ontwikkeld kunnen worden. Lever-, nier-, hart- en 
reproductie-toxiciteit, embryotoxiciteit, genotoxiciteit en carcinogeniciteit zijn de 
belangrijkste oorzaken. 
Het vroegtijdig detecteren van toxiciteit in de eerste onderzoeksfase (discovery) 
van het geneesmiddelenonderzoek kan er uiteindelijk toe leiden dat geneesmiddelen 
met verbeterde profi elen de latere fase van het geneesmiddelenonderzoek bereiken. 
Het onderzoek dat beschreven wordt in dit proefschrift, richt zich op de detectie 
van genotoxiciteit en carcinogeniciteit in deze vroege fase van het geneesmiddelen 
onderzoek. 
Om te onderzoeken of potentiële geneesmiddelen veilig zijn, moeten deze voor 
de regelgevende (regulatoire) autoriteiten getest worden op o.a. genotoxiciteit en 
carcinogeniciteit. Het vaststellen van genotoxische eigenschappen van kandidaat-
geneesmiddelen en het eventueel onderzoeken of deze effecten schadelijk kunnen zijn 
voor de mens, gebeurt in een gefaseerde aanpak. Als eerste worden cellulaire in vitro 
assays uitgevoerd om te onderzoeken of de testverbindingen intrinsieke genotoxische 
activiteit hebben. Deze in vitro testen worden opgevolgd door in vivo testen (dierproeven) 
die de relevantie van deze in vitro testen voor de mens vaststellen. 
De teststrategie die voorgeschreven wordt door de regelgevende autoriteiten bestaat 
uit een combinatie van testen die samen zowel genmutaties als chromosoomschade 
(toename v.h. aantal chromosoombreuken, clastogeniciteit, en verandering van het 
aantal chromosomen per cel, aneugeniciteit genoemd) kunnen vaststellen. De standaard 
genotoxiciteitstesten die voor de regelgevende autoriteiten uitgevoerd moeten worden, 
voordat geneesmiddelen op de markt toegelaten worden, zijn (1) de Amestest voor het 
identifi ceren van genmutaties in bacteriën, (2) een in vitro chromosoomaberratietest (CA) 
en/of een ‘muize-lymphoma-TK-assay (MLA)’ om chromosoomschade in zoogdiercellen 
te detecteren. Deze testen worden dan eventueel opgevolgd door (3) een in vivo test die 
chromosoomschade kan detecteren (een CA- of micronucleustest). Eventueel kunnen 
aanvullende testen nodig zijn. Voor de bepaling van de mogelijke carcinogene werking 
van een teststof, worden muizen of ratten chronisch (twee jaar) blootgesteld aan deze 
teststof en wordt de vorming van tumoren gevolgd en geanalyseerd. De testen om 
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de eventuele genotoxiciteit van teststoffen vast te stellen, worden uitgevoerd in de 
preklinische fase van het ontwikkelingstraject van een nieuw geneesmiddel voordat de 
eerste klinische testen op mensen uitgevoerd worden. De mogelijke carcinogeniciteit 
wordt later onderzocht, parallel aan klinische fase II- en III-studies.
De regulatoire testen voor het vaststellen van mogelijke genotoxiciteit en 
carcinogeniciteit hebben een lage doorvoer snelheid (throughput), verbruiken relatief 
veel teststof en zijn arbeidsintensief. Vanwege deze eigenschappen zijn de regulatoire 
testen minder geschikt voor het snel testen van genotoxiciteit en carcinogeniciteit in de 
discovery fase van het geneesmiddelenonderzoek. 
De afgelopen jaren is er binnen de farmaceutische industrie al enige vooruitgang 
geboekt met de ontwikkeling van testsystemen voor het bepalen van genotoxische en 
carcinogene eigenschappen aan het einde van de discovery fase. Echter aan het einde van 
de discovery fase is chemische optimalisatie van teststoffen op zowel farmacologische 
activiteit, als op ongewenste eigenschappen moeilijk te realiseren. Voor deze toepassing 
moeten de testen dus in de vroegere fase van de discovery toegepast worden.
Momenteel zijn er echter nog maar enkele testsystemen beschikbaar voor het bepalen 
van genotoxiciteit en carcinogeniciteit in de vroege discovery fase, de doorvoer snelheid 
van deze testen is over het algemeen nog te laag en meestal zijn deze testen nog niet 
afdoende gevalideerd. Een belangrijk aspect is dat de huidige in vitro testsystemen 
voor de detectie van genotoxiciteit een hoog percentage fout-positieve resultaten 
geven (zie tabel 1). Dit maakt de toepassing van deze testen in de vroege fase van 
geneesmiddelenontwikkeling problematisch.
Het doel van het onderzoek in dit proefschrift is betere in vitro testsystemen te 
ontwikkelen voor de vroege detectie van de genotoxische en niet-genotoxische 
carcinogene eigenschappen van potentiële geneesmiddelkandidaten en deze testen te 
valideren met referentieverbindingen en uiteindelijk een strategie op te zetten voor de 
toepassing van deze testen in de vroege discovery fase. In dit proefschrift zijn testsystemen 
op basis van bacteriën, gist-, knaagdier- en menselijke cellen ontwikkeld en gevalideerd. 
Bij de humane cellen lag de focus op het gebruik van (lever hepatoma) HepG2 cellen, 
omdat een aantal gunstige eigenschappen van deze cellen, zoals een actief p53 eiwit, 
actief DNA herstel, en het bezit van metaboliserende enzymen, er toe zal bijdragen 
dat deze cellen een nauwkeuriger voorspelling geven voor in vivo genotoxiciteit (hoge 
gevoeligheid (sensitiviteit), laag percentage fout positieve resultaten). 
Dit hoofdstuk geeft een samenvatting en discussie van de resultaten van dit 
proefschrift. Het eerste deel geeft een overzicht, op basis van hoofdstuk 2, van de 
resultaten die verkregen zijn met de bacteriële reporter assay VitotoxTM. Deze test 
werd gevalideerd als snelle prescreen voor de regulatoire Amestest. Naast testen die in 
staat zijn om genmutaties te detecteren (bacteriële mutageniciteit) zou een prescreen 
voor het vaststellen van genotoxiciteit ook teststoffen moeten kunnen detecteren 
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die chromosoombeschadigingen veroorzaken (clastogeniciteit en aneugeniciteit). 
Om die reden zijn ook modelsystemen in gist en zoogdiercellen geëvalueerd. In het 
tweede deel van deze samenvatting wordt op basis van de hoofdstukken 2 en 7 een 
overzicht gegeven van de resultaten die verkregen zijn met de gist-RAD54-reporter 
assay. In het derde deel wordt een overzicht gegeven van de resultaten die verkregen 
zijn met de HepG2 cellijn (hoofdstukken 3, 4, 5, 6 en 7). Dit derde deel start met een 
beschrijving van de resultaten van de karakterisering van het cytochroom P450 en 
fase-II- metabolisme in HepG2-cellen (hoofdstukken 3 en 4). Vervolgens worden de 
resultaten besproken betreffende de ontwikkeling en validatie van twee high content 
screening (HCS) in vitro micronucleus(IVMN)-assays in de HepG2-cellen en CHO-
k1-cellen (hoofdstuk 5). De CHO-k1-cellen werden als referentiecellijn meegenomen 
in het validatieproces omdat deze cellen gebruikt worden in de regulatoire IVMN-test. 
Vervolgens worden de de resultaten beschreven van een genexpressieprofi leringstudie 
in HepG2-cellen. Deze studie werd gebruikt om gevoelige en specifi eke biomarkers 
te vinden voor genotoxiciteit (hoofdstuk 6). Op basis van deze studie zijn luciferase 
reporterassays in HepG2-cellen ontwikkeld en geëvalueerd (hoofdstuk 7). Het derde 
gedeelte van de samenvatting wordt afgesloten met een beschrijving van deze resultaten. 
Naast het uitvoeren van testen die stoffen met genotoxische eigenschappen kunnen 
detecteren, is het ook nuttig om stoffen met een niet-genotoxisch carcinogene werking 
te detecteren in de discovery fase van de geneesmiddelenontwikkeling. Deel vier van 
deze samenvatting beschrijft daarom op basis van hoofdstuk 8 één van de mechanismen 
die niet-genotoxische carcinogeniciteit kan veroorzaken, namelijk de activatie van de 
aryl-hydrocarbon-receptor (AhR). De verschillen tussen de activering van deze receptor 
in de rat en in de mens werd onderzocht. Na een samenvatting van de resultaten van alle 
individuele testen zullen tot slot combinaties van testen worden besproken in relatie tot 
de ontwikkeling van een strategie voor het gebruik van de testsystemen in de discovery 
fase van het geneesmiddelenonderzoek. De samenvatting wordt afgesloten met een 
algemene conclusie, gevolgd door een aantal additionele opmerkingen. 
Het bepalen van genotoxiciteit met de bacteriële VitotoxTM-test
Normaal gesproken wordt bacteriële mutageniciteit met de Amestest bepaald, waarbij 
sprake is van een lage throughput. Een alternatief voor de detectie van bacteriële 
mutageniciteit zou een test kunnen zijn waarbij de inductie van genen wordt gemeten die 
betrokken zijn bij de reparatie van bacterieel DNA (SOS response). Door deze activatie 
fl uorometrisch of luminometrisch te meten kan een test met een hoge throughput 
ontstaan. Een test die is gebaseerd op dit principe is de VitotoxTM-test. 
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Deze VitotoxTM-test is een bacteriële reporter assay in Salmonella typhimurium. In 
de genetisch gemodifi ceerde bacteriestam die gebruikt wordt in de VitotoxTM-assay 
resulteert activatie van de SOS-response in een verhoogde concentratie luciferase die 
luminometrisch gemeten kan worden. In hoofdstuk 2 van dit proefschrift wordt de 
VitotoxTM geëvalueerd als vroege bepaling voor bacteriële mutageniciteit.
Een door de ECVAM aanbevolen lijst met teststoffen werd gebruikt voor de validatie van 
de VitotoxTM en andere genotoxiciteitstesten in dit proefschrift. Deze lijst met teststoffen 
bestaat uit 20 genotoxische carcinogenen en 42 niet-genotoxische chemicaliën. Van de 20 
genotoxische carcinogenen veroorzaken 14 teststoffen bacteriële mutageniciteit (positief 
resultaat in de Amestest). De resterende 6 veroorzaken chromosoombeschadigingen, 
maar geven negatieve of niet eenduidige resultaten in de Amestest. De groep van 42 
niet-genotoxische teststoffen (niet-genotoxische niet-carcinogene teststoffen en niet-
genotoxische carcinogenen) bevat 19 verbindingen die fout-positieve resultaten geven 
in in vitro genotoxiciteitstesten in zoogdiercellen. Bovendien werd een extra set van 192 
teststoffen gebruikt voor de verdere validatie van de high-througput testen. Deze groep 
van 192 teststoffen bevat zowel genotoxische als niet-genotoxische verbindingen en bevat 
zowel teststoffen van de voormalige NV Organon alsook bekende referentieverbindingen. 
De lijst bevat bovendien een relatief groot aantal steroïdale teststoffen waarvan beschreven 
is dat ze clastogene en/of aneugene eigenschappen hebben. Van deze 192 teststoffen 
waren Amesgegevens beschikbaar voor 145 teststoffen, in vitro genotoxiciteitsdata in 
zoogdiercellen voor 124 teststoffen en in vivo genotoxiciteitsdata voor 70 teststoffen. 
De sensitiviteit (percentage van de genotoxische carcinogenen die een positief resultaat 
geven) van de VitotoxTM-test met betrekking tot de ECVAM stoffenlijst was 70% (14/20). 
Zonder de teststoffen die een negatief of onduidelijk resultaat in de Amestest geven, steeg 
de sensitiviteit naar 79% (11/14). De specifi citeit (percentage van niet-genotoxische 
verbindingen die negatief resultaat geven) van de VitotoxTM-test was met 93% (39/42) 
hoog. De resultaten met betrekking tot de extra lijst van 192 stoffen bevestigden de 
resultaten die gemeten werden met de ECVAM-lijst. De validatie met deze extra stoffen 
liet zien dat de resultaten van de VitotoxTM een hoge correlatie met de resultaten van de 
Amestest hebben van 91% (sensitiviteit, 86% (42/49); specifi citeit, 94% (90/96)). De 
correlatie met in vitro genotoxiciteitstesten in zoogdiercellen en in vivo genotoxiciteit 
was veel lager met respectievelijk 50% (sensitiviteit 27% (21/78); specifi citeit 89% 
(41/46)) en 54% (sensitiviteit 33% (13/38 ); specifi citeit 78% (25/32)).
Samengevat lieten de resultaten in hoofdstuk 2 zien dat de VitotoxTM-test een goede 
methode is om de resultaten van de Amestest mee te voorspellen. De VitotoxTM-test 
gaf vergelijkbare resultaten als de Amestest. De hoge doorvoersnelheid van de test 
(16 verbindingen per dag) en lage hoeveelheid teststof die nodig is (5 mg) resulteren 
erin dat de VitotoxTM-test geschikt is voor het testen in de vroege fase van het 
geneesmiddelenonderzoek. Ter vergelijking: zelfs geminiaturaliseerde versies van de 
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Amestest hebben nog steeds 300 mg testverbinding nodig en de throughput van de mini-
Ames is minder dan 5 teststoffen per week [1]. Dit heeft als gevolg dat de mini-Amestest 
wordt uitgevoerd op een later tijdstip in de drug discovery fase, waarbij optimalisatie op 
zowel farmacologische eigenschappen, als op genotoxiciteit moeilijk te verwezenlijken 
is. De resultaten met de VitotoxTM laten ook duidelijk zien dat voor de detectie van 
chromosoomschade andere modelsystemen vereist zijn.
Het bepalen van genotoxiciteit met de op gistcellen gebaseerde 
RadarScreen-assay
Om chromosoomschade te kunnen detecteren zijn modelsystemen in eukaryote cellen 
nodig. Een modelsysteem dat gebaseerd is op het gebruik van eukaryote cellen en dat 
werd gevalideerd in hoofdstuk 2 van dit proefschrift is de op gistcellen gebaseerde 
RadarScreen-test. De RadarScreen-test maakt gebruik van een β-galactosidase reporter-
gen dat onder controle staat van een RAD54-promoter. De β-galactosidase expressie kan 
luminometrisch gekwantifi ceerd worden. RAD54 speelt een centrale rol in het herstel 
van DNA-schade in gist en activatie van dit gen leidt in deze assay tot een lichtreactie 
(luminescentie), die daarom een maat is voor de mate van DNA schade. 
De reproduceerbaarheid van de test werd getest met de genotoxische referentiestoffen 
methyl-methaan-sulfonaat en benzo[a]pyrene en bleek hoog te zijn. Validatie met 
betrekking tot de ECVAM-stoffenlijst resulteerde in een correlatie met (in vivo) 
genotoxiciteit van 79% (sensitiviteit, 70% (14/20); specifi citeit 83% (35/42)). Voor 
de extra set van 192 verbindingen, had de RadarScreen een correlatie met in vitro 
genotoxiciteit in zoogdiercellen van 76% (sensitiviteit, 77% (59/77); specifi citeit, 74% 
(34/46)). De resultaten met de ECVAM-stoffenlijst gaven de indicatie dat het aantal fout-
positieve resultaten met deze test waarschijnlijk laag is. Dit werd echter niet bevestigd 
met de aanvullende lijst van 192 teststoffen. Met deze teststoffen bleek de predictiviteit 
voor in vivo genotoxiciteit slechts 54% (sensitiviteit, 68% (25/37); specifi citeit, 38% 
(12/32)). Vooral de steroïdale verbindingen in de aanvullende lijst gaven veel fout-
positieve resultaten voor in vivo genotoxiciteit. De exacte reden voor deze resultaten 
is niet bekend. Een mogelijke oorzaak voor de lage voorspelbaarheid zou een verschil 
in metaboliserende enzymen kunnen zijn geweest. Bovendien bleek de detectie van 
aneugenen moeilijk met de RadarScreen-test. 
Samenvattend kan worden gesteld dat met de RadarScreen-test een goede 
voorspelbaarheid voor in vitro genotoxiciteit in zoogdiercellen werd gemeten maar dat 
de voorspelbaarheid van de test voor in vivo genotoxiciteit laag is. Om die reden zijn 
betere modelsystemen noodzakelijk.
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Het bepalen van genotoxiciteit met de humane HepG2-cellijn
Een nadeel van het gebruik van de meeste permanente cellijnen is dat ze geen functioneel 
p53 eiwit, DNA-reparatierespons en metaboliserende capaciteit bezitten. Een gebrek aan 
functionaliteit in deze systemen zou de reden kunnen zijn voor de lage voorspelbaarheid 
van de meeste in vitro modelsystemen voor in vivo genotoxiciteit. Het gebruik van de 
menselijke hepatoma cellijn HepG2 zou daarom nuttig kunnen zijn omdat deze cellen 
een actief p53-eiwit, DNA-reparatiesystemen en fase I- en II-metaboliserende enzymen 
bevatten.
In dit proefschrift zijn de volgende studies met deze cellijn uitgevoerd: (1) fase I- 
en II-metabolisme werd gekarakteriseerd (hoofdstukken 3 en 4), (2) een high content 
screening (HCS) in vitro micronucleus(IVMN)test werd ontwikkeld en gevalideerd 
in HepG2-cellen evenals in CHO-k1-cellen. Deze CHO-k1-cellijn wordt veelvuldig 
in de in de regulatoire IVMN-test gebruikt (hoofdstuk 5), (3) genexpressieprofi elen 
werden geanalyseerd in HepG2-cellen die blootgesteld werden aan genotoxische- en 
niet-genotoxische levertoxische stoffen. De resultaten werden gebruikt om biomarkers 
voor genotoxiciteit te bepalen (hoofdstuk 6), (4) en ten slotte zijn op basis van deze 
genexpressieprofi elen luciferase reporter assays voor de detectie van genotoxische 
teststoffen ontwikkeld en gevalideerd (hoofdstuk 7).
Karakterisering van fase I- en II-metabolisme in de HepG2-cellijn
Metabolisme van teststoffen door fase I- en II-enzymen kan resulteren in de vorming van 
metabolieten die juist meer of minder toxisch zijn dan de teststoffen zelf. Kennis van de 
metabole status van cellijnen die gebruikt worden voor in vitro toxiciteitstesten is daarom 
een belangrijke factor om de resultaten van in vitro (geno-) toxiciteitstesten te begrijpen 
en de waarde deze testen te onderkennen. Om deze redenen werd in dit proefschrift het 
fase I- en II-metabolisme in de HepG2- cellijn gedetailleerd gekarakteriseerd. De basale 
messenger-RNA(mRNA)-niveaus en enzymactiviteiten van een aantal belangrijke fase 
I-cytochroom P450 (CYP) en fase II-enzymen werden gemeten en vergeleken met de 
mRNA-niveaus en -activiteiten in gecryopreserveerde primaire humane hepatocyten 
(levercellen). Daarnaast zijn de mRNA-niveaus en enzymactiviteiten ook gemeten na 
activatie van specifi eke nucleaire receptoren (hoofdstuk 3 en 4). De gecryopreserveerde 
primaire hepatocyten die werden gebruikt in de studies hadden vergelijkbare 
enzymactiviteiten als verse primaire hepatocyten [2].
De mRNA-niveaus van CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 en 3A4 
werden gemeten met kwantitatieve PCR (qPCR). De resultaten toonden aan dat mRNA’s 
van al deze CYP’s aanwezig waren in HepG2. Maar de mRNA-niveaus van de meeste 
CYP’s waren signifi cant lager dan de niveaus in gecryopreserveerde primaire humane 
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hepatocyten. Deze resultaten werden bevestigd met luminometrische bepalingen, die 
werden gebruikt om de enzymactiviteiten van CYP1A1, 1A2, 2C9 en 3A4 te meten.
Regulatie van CYP1A1, 1A2, 2B6, 2C8, 2D6, 2E1 en 3A4 door de aryl hydrocarbon 
receptor (AhR), pregnane X receptor (PXR) en constitutieve androstane receptor (CAR) 
werd bestudeerd in HepG2-cellen op het mRNA- en/of enzymniveau. Regulatie van 
de CYP1A1-, 1A2-, 2B6- en 3A4-mRNA-niveaus in HepG2 was vergelijkbaar met 
de regulatie in primaire humane hepatocyten. Echter, CYP2C8-mRNA-niveaus zijn 
induceerbaar in gecryopreserveerde humane hepatocyten, maar dit werd niet gezien 
in HepG2-cellen na behandeling met PXR/CAR-activatoren. In overeenstemming 
met andere studies waren CYP2D6- en 2E1-mRNA-niveaus niet te reguleren met 
AhR, PXR, en CAR activatoren. De resultaten in hoofdstuk 3 lieten verder zien dat 
in overeenstemming met up-regulatie mRNA-niveaus ook de enzymactiviteiten van 
CYP1A1 en 1A2 werden geïnduceerd door AhR agonisten. Vergelijkbaar resulteerde 
behandeling met PXR-activatoren in een hogere CYP3A4-enzymactiviteit.
Samengevat geven de resultaten in hoofdstuk 3 aan dat de meeste fase I-CYP’s aanwezig 
zijn in HepG2-cellen, maar dan wel op een lager niveau dan in gecryopreserveerde 
primaire humane hepatocyten. Activatie van de AhR, PXR en CAR leidt tot hogere 
enzymniveaus en -activiteiten.
Hoofdstuk 4 beschrijft de karakterisatie van het fase II-metabolisme in HepG2-cellen. 
De mRNA-niveaus van UDP-glucuronosyl transferases (UGTs), sulfotransferases 
(SULTs), glutathione S-transferases (GSTs), N-acetyltransferase-1 (NAT1) en 
epoxide hydroxylase-1 (EPHX1), werden gemeten met qPCR in HepG2-cellen en 
gecryopreserveerde primaire humane hepatocyten en daarna vergeleken. De mRNA-
niveaus van SULT1A1, 1A2, 1E1, 1A2, 2A1 en microsomaal GST 1, GST μ1, NAT1 en 
EPHX1 in HepG2-cellen waren nagenoeg gelijk aan de niveaus in gecryopreserveerde 
primaire humane hepatocyten. Echter, de niveaus van UGT1A1 en 1A6 waren tussen 
de 10- en meer dan 1000-voudig lager in HepG2-cellen. De regulatie van de fase II-
enzymen door de AhR-, PXR- en CAR-receptoren werd bestudeerd en was vergelijkbaar 
in HepG2- en primaire humane hepatocyten.
Aangezien fase II-metabolisme kan resulteren in genotoxiciteit kunnen HepG2-
cellen een goed modelsysteem zijn om de toxiciteit van zulke teststoffen te bepalen. 
Voor andere teststoffen zal een combinatie van de lage expressie van CYP’s en normale 
niveaus van fase II-enzymen echter kunnen leiden tot een onderschatting van toxiciteit. 
Pro-genotoxische testverbindingen die geactiveerd worden door CYP’s die laag tot 
expressie komen, zullen mogelijk moeilijk te detecteren kunnen zijn in HepG2-cellen 
(bijv. cyclophosphamide die geactiveerd wordt door CYP2B6). Het toepassen van een 
S9-leverextract of het induceren van CYP-levels in HepG2-cellen door het toevoegen 
van AhR-, PXR-, of CAR-agonisten zou een oplossing kunnen zijn.
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De ontwikkeling van een HCS in vitro micronucleus test in de HepG2- en CHO-k1-
cellijn
Om op een snelle manier chromosoomschade (clastogeniciteit en aneugeniciteit) te 
kunnen vaststellen, zijn twee high content screening (HCS) in vitro micronucleus(IVMN)-
assays in de humane HepG2-hepatoma-cellijn en hamster CHO-k1-cellijn opgezet. 
De CHO-k1-cellijn werd gevalideerd omdat deze cellijn dikwijls in de regulatoire 
gentoxtesten gebruikt wordt. 
De genotoxische referentiestof taxol werd gebruikt om de reproduceerbaarheid 
van beide HCS-IVMN-testen te bepalen. Deze bleek in beide gevallen goed te zijn. 
Vervolgens werden de testen geëvalueerd met de referentieverbindingen uit de ECVAM-
validatielijst. De sensitiviteit (percentage genotoxische carcinogenen die goed voorspeld 
werden) (80%; 16/20) en specifi citeit (percentage niet-genotoxische teststoffen die 
goed voorspeld werden) (88%; 37/42) van de HCS-IVMN-assay in CHO-k1-cellen 
was hoog. Opvallend hierbij was dat pro-genotoxische verbindingen die geactiveerd 
worden door CYP1A-metabolisme, al actief waren in de CHO-k1-cellen zonder de 
toevoeging van een S9-leverextract. Voorbeelden van zulke stoffen zijn benzo[a]pyrene 
en 7,12-dimethylbenzanthrene. Dit geeft aan dat CYP1A-metabolisme waarschijnlijk 
actief was in de gebruikte CHO-k1-cellijn. Toevoeging van een S9-leverextract 
resulteerde zelfs in een afname van de genotoxische effecten van stoffen die door CYP1A 
geactiveerd worden. 
De sensitiviteit van de HepG2-cellijn was met 60% (12/20) lager dan van de CHO-
k1-cellijn. De specifi citeit van de HepG2-cellijn had dezelfde hoge waarde als van de 
CHO-k1-cellijn (88%; 37/42). De intrinsieke metabole activiteit in de HepG2-cellen 
was hoog genoeg om 7 van de 9 pro-genotoxische testverbindingen in de ECVAM-
lijst te activeren: cyclophosphamide, benzo[a]pyrene, 7,12-dimethylbenzanthracene, 
dimethylnitrosamine, 2,4-diaminotoluene, PhIP.HCl en afl atoxin B1. De twee pro-
genotoxische testverbindingen die geen micronuclei inductie in HepG2-cellen gaven 
waren 2-acetylaminofl uorene en IQ. Toevoeging van een S9-leverextract resulteerde 
voor deze twee teststoffen niet in het genotoxisch worden.
Evaluatie van een additionele set van 16 genotoxische referentieverbindingen 
bevestigde de resultaten die gevonden werden met ECVAM stoffen lijst. De sensitiviteit 
van de CHO-k1-cellijn was met 69% (11/16) hoger dan de sensitiviteit van 56% (9/16) 
die gevonden werd met HepG2-cellijn. Bij beide cellijnen was het mogelijk om de 
micronuclei op basis van grootte te classifi ceren, hetgeen  een verdere discriminatie van 
genotoxische teststoffen in aneugene en clastogene teststoffen mogelijk maakt. 
Samengevat laten de resultaten in hoofdstuk 5 zien dat twee HCS-IVMN-testen zijn 
ontwikkeld die op een snelle manier chromosoomschade kunnen detecteren. Met deze 
testen kunnen genotoxische teststoffen bovendien geclassifi ceerd worden als clastogeen 
of aneugeen. 
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De identifi catie van biomarkers voor de bepaling van genotoxiciteit in HepG2-cellen 
met behulp van genexpressie profi lering
De analyse van genexpressieprofi elen werd gebruikt om biomarkers voor genotoxiciteit 
te bepalen. Biomarkers (genen) werden geselecteerd die niet geactiveerd werden 
door niet-genotoxische levertoxische teststoffen. Zulke biomarkers kunnen gebruikt 
worden voor het ontwikkelen van high-througput luciferase reporter assays waarmee 
genotoxische teststoffen gedetecteerd kunnen worden.
HepG2-cellen zijn al eerder gebruikt in genexpressieprofi leringstudies waarin de 
genexpressieprofi elen in de HepG2-cellen in staat bleken om een duidelijk onderscheid 
te kunnen maken tussen genotoxische- en niet-genotoxische carcinogenen. Genen 
die een discriminerend effect gaven, waren vooral betrokken bij de regulatie van de 
celcyclus, reparatie van DNA, de immuun- en stressrespons alsook apoptose. Het doel 
van deze studies was het bepalen van pathways (mechanismen) die betrokken zijn 
bij genotoxische en niet-genotoxische carcinogeniciteit. Om deze reden werden niet-
toxische concentraties van de niet-genotoxische carcinogenen gebruikt.
In het onderzoek dat beschreven is in dit proefschrift werd genexpressieanalyse niet 
alleen gebruikt voor het bepalen van biomarkers die genotoxiciteit kunnen detecteren, 
maar de geselecteerde biomarkers moesten bovendien een duidelijk onderscheid 
kunnen aantonen tussen genotoxische carcinogenen en niet-genotoxische levertoxische 
teststoffen. Daarvoor werden HepG2-cellen blootgesteld aan cytotoxische concentraties 
van de niet-genotoxische levertoxische stoffen omdat cytotoxiciteit stresspathways kan 
activeren en dit mogelijk DNA-schade kan veroorzaken. Het gebruik van cytotoxische 
stofconcentraties kan daarom leiden tot fout-positieve resultaten voor genotoxiciteit. 
De verschillen in de genexpressieprofi elen van de genotoxische en niet-genotoxisch 
toxische stoffen werden gebruikt om biomarkergenen of responsieve elementen te 
bepalen die specifi ek waren voor de genotoxische verbindingen. Toepassing van deze 
biomarkers zou kunnen resulteren in een high-throughput luciferase reporter assay met 
een goede gevoeligheid voor genotoxiciteit en een laag percentage fout-positieven (voor 
niet-carcinogenen en in vivo genotoxiciteit).
HepG2-cellen werden gedurende 6, 24 en 72 uur behandeld met 4 genotoxische en 7 
niet-genotoxische levertoxische stoffen. Discriminatie tussen de twee stofklasses was 
beperkt als alle signifi cant gereguleerde genen (DEG’s) werden gebruikt. Pathway-
analyse van de DEG’s in de klasse van genotoxische stoffen liet zien dat meerdere 
pathways signifi cant gereguleerd werden. De belangrijkste gereguleerde pathways op 
de drie tijdstippen waren betrokken bij de regulatie van de celcyclus. Op het 72 uur-
tijdstip activeerden de niet-genotoxische levertoxische stoffen meerdere pathways die 
kenmerkend zijn voor genotoxische verbindingen zoals bijv. de p53 pathway, ATM 
pathway, en G2/M-celcyclus regulatie-pathway.
Om genen te vinden die een duidelijk onderscheid geven tussen de twee klassen van 
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stoffen werd een meer diepgaande genexpressieanalyse uitgevoerd met behulp van 
Qlucore Omics Explorer. Deze analyse leverde voor elk tijdstip een cluster (subset) van 
genen op (6 uur, 362 genen; 24 uur, 1914 genen; 72 uur, 498 genen). Pathway-analyse 
toonde aan dat de genen in de 6 uur- en 24 uur-gensubsets vooral betrokken waren 
bij de celcyclus, apoptose en DNA-herstel. Analyse van de 72 uur-subset leverde geen 
signifi cant gereguleerde pathways op. De genen met de hoogste inductiefactoren (top 
10) werden in detail geanalyseerd en bleken voornamelijk downstream targets van p53 
te zijn en waren betrokken bij apoptose of de oxidatieve stressrespons. Verder waren er 
in de drie subsets van genen meerdere genen aanwezig die een belangrijke rol hebben 
bij de DNA-schadeherstelrespons zoals bijv. GADD45A, GADD45B, PCNA, POLH en 
XPC.
Samengevat: genexpressieanalyse met Qlucore Omics Explorer resulteerde in drie 
subsets van genen die een duidelijke discriminatie mogelijk maken tussen genotoxische 
en niet-genotoxische toxische teststoffen. De genen die de hoogste inductie lieten 
zien bij de klasse van genotoxische verbindingen, waren voornamelijk betrokken bij 
regulatie van de celcyclus of waren downstream targets van p53. Het toepassen van deze 
potentiële biomarkers in luciferase reporter assays zou kunnen resulteren in testsystemen 
die op een snelle manier genotoxiciteit kunnen detecteren met een laag percentage fout-
positieve resultaten.
De ontwikkeling van luciferase reporter assays voor de bepaling van genotoxiciteit en 
oxidatieve stress 
De analyse van genexpressieprofi elen in HepG2-cellen liet zien dat de toepassing van 
promotorgebieden van genen, die betrokken zijn bij de regulatie van de celcyclus of 
downstream targets van p53 zijn, zou kunnen resulteren in gevoelige luciferase reporter 
assays voor genotoxiciteit. Deze assays zouden op een snelle manier genotoxiciteit in 
zoogdiercellen kunnen bepalen met een laag percentage fout-positieve resultaten t.g.v. 
cytotoxiciteit. De analyse van genexpressieprofi elen gaf bovendien aan dat RAD51C 
een goede biomarker zou kunnen zijn voor stoffen die DNA-dubbelstrengsbreuken 
veroorzaken. Op basis van de genexpressieprofi elen werden de promotorregio’s van 
RAD51C en cystatin A (downstream target van p53, die betrokken is bij apoptose), 
evenals het responsieve element van het p53-eiwit, geselecteerd voor de ontwikkeling 
van drie luciferase reporter assays die genotoxiciteit kunnen detecteren. Daarnaast 
werd een luciferase reporter assay ontwikkeld die de activering van de Nrf2 electrofi ele 
responsieve pathway meet (hoofdstuk 7). 
De reproduceerbaarheid van de vier reporter assays werd gemeten met de genotoxische 
referentieverbindingen doxorubicine en benzo[a]pyrene. De reproduceerbaarheid 
bleek goed te zijn voor alle vier de testen. Validatie van de drie reporter assays voor 
genotoxiciteit met de ECVAM-stoffen resulteerde in een voorspelbaarheid (totale 
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percentage correct voorspelde genotoxische carcinogenen plus niet genotoxische 
verbindingen) van de individuele reporter assays van 82% voor de HepG2 RAD51C_
luc-assay (sensitiviteit 60%, 12/20; specifi citeit 93%, 39/42), van 84% voor de HepG2 
cystatin A_luc-assay (sensitiviteit 70%, 14/20; specifi citeit 90%, 38/42), en van 90% 
voor de HepG2 p53_luc-assay (sensitiviteit 85%, 17/20; specifi citeit 93%, 39/42). De 
cumulatieve voorspelbaarheid van de drie HepG2 reporter assays voor genotoxiciteit was 
hoog met 82% (sensitiviteit 85%, 17/20; specifi citeit 81%, 34/42). Het percentage van de 
genotoxische teststoffen dat de Nrf2 pathway activeerde was hoog met 75% (15/20). Van 
de niet-genotoxische verbindingen in de ECVAM-lijst activeerde slechts 31% (13/42) 
de Nrf2 pathway. Verder bleek de metabole capaciteit in HepG2-cellen voldoende te zijn 
voor activatie van zeven van de negen pro-genotoxische testverbindingen. Deze zeven 
teststoffen waren benzo[a]pyrene, 7,12-dimethylbenzanthracene, 2-acetylaminofl uorene, 
2,4-diaminotoluene, IQ, PhIP.HCl en afl atoxin B1. Van deze zeven testverbindingen 
gaven 2-acetylaminofl uorene en IQ een negatief resultaat in de HepG2-HCS-IVMN 
assay (Hoofdstuk 5). Activatie van het p53 responsive element is daarom een gevoeliger 
eindpunt voor de detectie van deze twee stoffen dan de vorming van micronuclei (DNA 
schade). Mogelijk heeft de activatie van de DNA herstelrespons ertoe geleid dat er geen 
signifi cante inductie van micronuclei in de HepG2-HCS-IVMN-test te meten was. De pro-
genotoxische testverbindingen cyclophosphamide en dimethylnitrosamine gaven geen 
genotoxische respons in de reporter assays. Cyclophosphamide en dimethylnitrosamine 
worden geactiveerd door respectievelijk CYP2B6 en CYP2E1 (hoofdstuk 3). Deze 
CYP’s komen in HepG2-cellen beide laag tot expressie wat de reden zou kunnen zijn 
voor het niet genotoxisch worden van deze testverbindingen. Deze hypothese wordt 
echter niet ondersteund door het feit dat deze twee testverbindingen een positief 
resultaat geven in de HCS-IVMN-assay (zonder toevoeging van S9-mix) wat aangeeft 
dat de endogene niveaus van deze enzymen in de HepG2-cellijn blijkbaar hoog genoeg 
zijn voor metabole activatie van deze twee testverbindingen. Dit geeft verder aan dat 
voor deze twee testverbindingen de vorming van micronuclei een gevoelig eindpunt is. 
Opmerkelijk is dat in een studie die uitgevoerd werd door Sohn et al. [3] behandeling 
van cellen met cyclophosphamide ook geen p53 activatie veroorzaakte. 
De resultaten van de drie reporter assays voor genotoxiciteit werden ook vergeleken 
met de beschikbare data betreffende bacteriële mutageniteit (Amestest), in vitro 
genotoxiciteit in zoogdiercellen en in vivo genotoxiciteit voor een extra set van 192 
testverbindingen. De voorspelbaarheid voor bacteriële mutageniciteit was 74% 
(sensitiviteit 61%, 30/49; specifi citeit 80%, 77/96), en voor in vitro genotoxiciteit in 
zoogdiercellen 59% (sensitiviteit 45%, 35/78; specifi citeit 83%, 38/46). De correlatie 
tussen de resultaten van de HepG2 reporter assays en in vivo genotoxiciteit was hoger 
met 77% (sensitiviteit 74%, 28/38; specifi citeit 81% 26/32). De correlaties van de 
individuele assays met in vivo genotoxiciteit waren 76% voor de HepG2-p53_luc-test 
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(sensitiviteit 71%, 27/38; specifi citeit 81%, 26/32), 59% voor de HepG2-RAD51C_luc-
test (sensitiviteit 29%, 11/38; specifi citeit 94%, 30/32), en 76% voor de HepG2-cystatin 
A_luc-test (sensitiviteit 61%, 23/38; specifi citeit 94%, 30/32). Zoals ook gemeten werd 
met de ECVAM-stoffenlijst zijn de HepG2-p53_luc-test en de HepG2-cystatin A_luc-test 
modelsystemen met een relatief hoge sensitiviteit en specifi citeit. De HepG2-RAD51C_
luc-test had een lagere gevoeligheid, maar de specifi citeit was hoog waaruit blijkt dat 
slechts een beperkt aantal teststoffen dubbelstrengsbreuken in het DNA veroorzaken. 
Van de 108 teststoffen in de extra lijst van 192 stoffen die een positief resultaat gaven 
voor bacteriële of in vitro/in vivo genotoxiciteit  in zoogdiercellen, activeerde 62% (67 
verbindingen) de Nrf2 pathway. Wanneer we binnen deze set van 192 compounds kijken 
naar de groep van teststoffen zonder of met negatieve resultaten voor genotoxiciteit dan 
is het percentage Nrf2 positieve stoffen slechts 38% (30/80). Deze resultaten bevestigen 
de resultaten die gevonden werden met de chemicaliën uit de ECVAM-lijst. Activering 
van de Nrf2-pathway geeft informatie over het werkingsmechanisme van genotoxische 
stoffen. Positieve resultaten in de Nrf2-reporter assay kunnen echter niet gebruikt 
worden voor het identifi ceren en deselecteren van genotoxische stoffen omdat deze 
pathway ook wordt geactiveerd door cytotoxische stoffen en diverse stoffen die juist 
een beschermende werking hebben tegen cytotoxiciteit en genotoxiciteit [4-6]. Deze 
beschermende werking heeft te maken met het feit dat activering van de Nrf2 pathway 
resulteert in een verhoogde expressie van fase II- en antioxidant stresseiwitten. Een 
andere factor die interpretatie van de Nrf2-data moeilijk maakt, is cross-talk tussen de 
p53- en Nrf2-pathway [7].
Samenvattend kan worden gesteld dat er drie luciferase reporter assays ontwikkeld 
zijn die gebruikt kunnen worden voor de (snelle) detectie van stoffen met genotoxische 
eigenschappen. De p53- en cystatin A-reporter assays lieten een hoge sensitiviteit en 
specifi citeit zien voor genotoxische carcinogeniciteit en in vivo genotoxiciteit. De 
RAD51C-reporter assay was veel specifi eker en gaf informatie over de vorming van 
dubbelstrengsbreuken in het DNA. De resultaten in hoofdstuk 7 bevestigden de resultaten 
die gevonden werden met de analyse van genexpressieprofi elen. Er werd ook een Nrf2-
reporter assay ontwikkeld die kan helpen bij het ophelderen van het werkingsmechanisme 
van genotoxische stoffen. Gebaseerd op de resultaten die beschreven staan in hoofdstuk 
7 lijkt het dat toepassing van de ontwikkelde high-throughput reporter assays in de 
vroege discovery fase van het geneesmiddelenonderzoek een heel bruikbare strategie is 
voor het snel beoordelen van stoffen op genotoxische eigenschappen. 
In deze en de vorige paragrafen lag de focus op de ontwikkeling en validatie van 
testsystemen voor de detectie van teststoffen met genotoxische eigenschappen. 
Naast de detectie van genotoxische teststoffen zou het ook nuttig zijn om niet-
genotoxische carcinogenen vroegtijdig te detecteren in de discovery fase van het 
geneesmiddelenonderzoek. Niet-genotoxische carcinogenen kunnen tumorvorming 
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induceren via een groot aantal werkingsmechanismen [8]. Eén van de mechanismen die 
daarbij een rol speelt is receptor-gemedieerde inductie via de aryl hydrocarbon receptor 
welke hieronder verder besproken wordt.
De bepaling van CYP1A-inducers en soortspecifi eke verschillen 
tussen de mens en rat
Sterke activering van de AhR kan resulteren in toxische effecten zoals (niet-
genotoxische) carcinogeniteit. Aangezien het merendeel van de carcinogeniciteitsstudies 
wordt uitgevoerd bij ratten, kan de voorspelling van activering van de ratte AhR nuttig 
zijn. Echter voor de voorspelling van het risico op carcinogeniciteit in de mens zou 
activering van de humane AhR bestudeerd moeten worden.
Omdat AhR-activatoren een sterke inductie van CYP1A veroorzaken werd CYP1A-
inductie in de uitgevoerde studies gebruikt als marker voor AhR-activering. De CYP1A-
inductie studies werden uitgevoerd in de humane HepG2- en ratte H4IIE-cellijn. Voor 
CYP1A-inductie in HepG2- en H4IIE-cellijnen is aangetoond dat deze CYP1A-inductie 
representatief is voor CYP1A-activering in respectievelijk de mens en rat [2, 9, 10].
Een set bestaande uit 119 teststoffen, waaronder bekende AhR-liganden, werden 
getest. CYP1A-inductie werd waargenomen voor 24 verbindingen. In H4IIE-cellen, 
gaven meer teststoffen CYP1A-inductie en de meeste EC50-waarden waren lager dan 
die in HepG2-cellen. Soortspecifi eke CYP1A-inductie in H4IIE- en HepG2-cellen werd 
waargenomen voor respectievelijk 8 en 3 teststoffen. Aangezien voor meerdere teststoffen 
soortspecifi eke CYP1A-inductie werd gemeten, en het feit dat carcinogeniciteitsstudies in 
de rat uitgevoerd worden, maar dat de risico’s voor de mens ook bepaald moeten worden 
lijkt parallel screenen in ratte en humane cellen de beste strategie voor de farmaceutische 
industrie. Teststoffen die CYP1A-inductie laten zien hoeven niet direct gedeselecteerd te 
worden aangezien lang niet alle CYP1A-inducers dioxineachtige toxiciteit laten zien. Zo 
zijn er meerdere geneesmiddelen bekend die AhR-activatoren zijn maar geen toxiciteit 
geven zoals bijv. omeprazol, lefl unomide, fl utamide en nimodipine [11]. Verder zijn er 
naast de AhR-pathway nog andere pathways die CYP1A kunnen activeren en daarom 
leiden tot fout-positieve resultaten. Samenvattend kan worden geconcludeerd dat zowel 
de ratte- als humane CYP1A-inductieassays nuttig zijn voor het voorscreenen in de 
discovery fase van de ontwikkeling van geneesmiddelen, maar er moet wel voorzichtig 
omgegaan worden met het deselecteren van teststoffen die CYP1A inductie geven.  
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Vergelijking van de sensitiviteit en specifi citeit van de regulatoire 
en high-throughput in vitro genotoxiciteitsassays 
In dit proefschrift zijn verschillende high-throughput assays voor de detectie van 
genotoxische stoffen geëvalueerd. In deze paragraaf worden de sensitiviteit en specifi citeit 
van de nieuw ontwikkelde in vitro genotoxiciteitstesten met een hoge doorvoersnelheid 
(high-throughput) vergeleken met de resultaten van de regulatoire genotoxiciteitstesten. 
Omdat bij de huidige gebruikte regulatoire teststrategie combinaties van assays 
gebruikt worden om zowel bacteriële mutageniciteit (genmutaties) als genotoxiciteit 
in zoogdiercellen (chromosoomschade) te kunnen detecteren, zullen ook verschillende 
combinaties van de high-throughput assays bediscussieerd worden. 
Sensitiviteit en specifi citeit van gecombineerd gebruik van regulatoire in vitro 
genotoxiciteitstesten 
Het onderscheidende vermogen van individuele en combinaties van de regulatoire in 
vitro genotoxiciteitstesten voor carcinogene en niet-carcinogene stoffen in knaagdieren 
werd geëvalueerd door Kirkland et al. [12]. Daarbij werd door de auteurs opgemerkt 
dat het van belang is om de carcinogene stoffen onder te verdelen in genotoxische- 
en niet-genotoxische carcinogenen, aangezien niet-genotoxische carcinogenen 
logischerwijs niet gedetecteerd kunnen worden in in vitro genotoxiciteitstesten [12]. 
Genotoxische carcinogenen dienen dus in principe een positief resultaat te geven in in 
vitro genotoxiciteitstesten en niet-genotoxische carcinogenen en niet-carcinogenen een 
negatief resultaat. Echter voor veel carcinogenen die geëvalueerd werden door Kirkland 
et al. [12] ontbraken de mechanistische data die een goede classifi catie in genotoxische 
en niet-genotoxische carcinogenen mogelijk maakte. Scores werden daarom berekend 
t.o.v. carcinogeen/niet-carcinogeen.
De sensitiviteit- en specifi citeitscores van de individuele regulatoire genotoxiciteits-
assays zijn opgesomd in tabel 3 van hoofdstuk 1. Deze scores laten duidelijk zien dat de 
specifi citeit van de in vitro genotoxiciteitstesten in zoogdiercellen voor niet-carcinogenen 
laag is, wat dus resulteert in een relatief groot aantal fout-positieve resultaten. Normaal 
gesproken wordt in de regulatoire teststrategie een combinatie van de Amestest + MLA 
test + chromosoomaberratietest gebruikt (CA) [12] (zie tabel 2). Deze combinatie heeft 
een hoge sensitiviteit voor knaagdiercarcinogenen van 87,7% (171/202), maar een 
lage specifi citeit voor niet-carcinogenen van slechts 22,9% (22/96). Combinaties van 
twee regulatoire testen (d.w.z. Ames + CA, AMES + IVMN, AMES + MLA) geven 
vergelijkbare scores [12]. De overlap tussen de teststoffen die gebruikt werden door 
Kirkland et al. [12] en de teststoffen die gebruikt werden in dit proefschrift was zeer 
beperkt. Een directe vergelijking is daarom niet mogelijk. 
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Voor het berekenen van de sensitiviteit en specifi citeit van de nieuw ontwikkelde in 
vitro testsystemen werd in dit proefschrift de ECVAM-stoffenlijst gebruikt [13]. Deze 
lijst bestaat uit goed gedefi nieerde genotoxische carcinogenen, niet-genotoxische 
carcinogenen en niet-carcinogenen. Deze lijst kan daarom gebruikt worden voor het 
berekenen van de sensitiviteit en specifi citeit voor genotoxische carcinogenen (zie tabel 
2). Toepassing van de geaccepteerde regulatoire teststrategie (een combinatie van Ames 
+ MLA + CA-test) geeft voor deze ECVAM-stoffen een sensitiviteit voor genotoxische 
carcinogenen van 100% (20/20) en specifi citeit van 55% (23/42). De lage specifi citeit 
wordt veroorzaakt door de in vitro genotoxiciteitstesten in zoogdiercellen (MLA + CA) 
die samen 19 fout-positieve resultaten lieten zien in de ECVAM stoffenlijst. 
Naast de ECVAM-stoffen is ook een aanvullende set van 192 stoffen gebruikt in dit 
proefschrift (hoofdstukken 2 en 7). De data betreffende genotoxiciteit en carcinogeniciteit 
van deze 192 stoffen zijn beperkt en een duidelijke classifi catie van deze stoffen in 
genotoxische carcinogenen en niet-genotoxische stoffen (niet-genotoxische carcinogenen 
+ niet-carcinogenen) ontbreekt. Voor deze stoffen hebben we daarom de keuze gemaakt 
om de testgegevens te vergelijken met de in vivo genotoxiciteitsgegevens, aangezien deze 
gegevens waarschijnlijk de beste indicatie geven of stoffen genotoxische carcinogenen 
of niet-genotoxisch zijn. Voor deze aanvullende set van 192 stoffen geeft de combinatie 
AMES + in vitro genotoxiciteitstesten in zoogdiercellen (zie tabel 2) een sensitiviteit 
van 97% (37/38) en specifi citeit van 41% (12/29). Ook hier werd de lage specifi citeit 
veroorzaakt door de in vitro genotoxiciteitstesten in zoogdiercellen (zie tabel 2). 
Samenvattend kan gesteld worden dat, ondanks dat de manier van vergelijken 
verschillend is (verschillende eindpunten zie tabel 2) de resultaten met de twee stoffensets 
die gebruikt werden in het huidige proefschrift, vergelijkbare scores voor de regulatoire 
testen geven als de scores die verkregen werden met de studie die beschreven werd 
door Kirkland et al. [12]. Een combinatie van de AMES + in vitro genotoxiciteitstesten 
in zoogdiercellen heeft een hoge gevoeligheid, maar lage specifi citeit. De ECVAM-
stoffenlijst en additionele set van 192 compounds maken een direct vergelijk tussen de 
resultaten van de regulatoire genotoxiciteitstesten (Ames + in vitro assays zoogdieren) 
en de in dit proefschrift ontwikkelde high-throughput assays mogelijk. Verschillende 
combinaties van de in dit proefschrift ontwikkelde high-throughput assays worden in 
de volgende paragraaf besproken en de scores zullen worden vergeleken met die van de 
regulatoire in vitro genotoxiciteitstesten. 
Sensitiviteit en specifi citeit van gecombineerd gebruik van de high-throughput 
genotoxiciteitstesten en vergelijking met de regulatoire in vitro genotoxiciteitstesten 
Door als uitgangspunt te nemen dat een vroege screen voor genotoxiciteit bacteriële 
mutageniciteit moet kunnen detecteren (genmutaties) moet in een combinatie van high-
throughput assays in ieder geval de VitotoxTM-test aanwezig zijn. De hoge sensitiviteit 
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en specifi citeit van de VitotoxTM voor Amesresultaten van respectievelijk meer dan 
80% en 90% (hoofdstuk 2), de hoge throughput en kleine stofhoeveelheid die nodig is, 
zijn eigenschappen die dit testsysteem een waardevolle prescreen voor Amesresultaten 
maken. De VitotoxTM-test kan dus op een snelle manier Amesresultaten goed voorspellen 
in de vroege discovery fase van het geneesmiddelenonderzoek. Naast bacteriële 
mutagenen moet een vroege screen voor genotoxiciteit ook teststoffen detecteren die 
chromosoomschade veroorzaken. In dit proefschrift werden meerdere assays geëvalueerd 
die de potentie hebben om chromosoomschade te detecteren: (1) de op gistcellen 
gebaseerde RadarScreen-test, (2) de CHO-k1-HCS-IVMN-assay, (3) de HepG2-HCS-
IVMN-assay, en (4) de HepG2 p53-luciferase reporter assay. Combinaties van deze 4 
testsystemen met de VitotoxTM-assay worden hieronder besproken. De sensitiviteit en 
specifi citeit scores van het gecombineerde gebruik zijn samengevat in tabel 3. 
1. Vitotox + RadarScreen-test 
Het testen van de ECVAM-stoffen resulteerde in een hoge sensitiviteit (80%) en 
specifi citeit (81%). Daarentegen was de specifi citeit die gemeten werd met de aanvullende 
set van stoffen laag met slechts 28%. Deze combinatie van testen is daarom moeilijk te 
gebruiken in de vroege discovery fase van het geneesmiddelenonderzoek. Bij gebruik 
van deze combinatie en het deselecteren van stoffen die een positief resultaat geven, 
zouden wellicht te veel stoffen gedeselecteerd worden.
2. Vitotox + CHO-K1-HCS-IVMN-assay 
Deze combinatie geeft voor de 62 ECVAM-stoffen een sensitiviteit van 95% (19/20). 
De specifi citeit van de combinatie VitotoxTM + CHO-K1 HCS IVMN is met 83% (35/42) 
veel hoger dan de specifi citeit van 55% (23/42) die de combinatie van de regulatoire 
Ames- + in vitro genotoxiciteitstesten in  zoogdiercellen geeft. Deze scores geven aan 
dat gecombineerd gebruik van de VitotoxTM + CHO-K1-HCS-IVMN-test waardevol kan 
zijn voor het vroeg screenen op genotoxische eigenschappen van stoffen. 
Wel is het zo dat additionele validatie aan te bevelen is aangezien de regulatoire IVMN-
test in CHO-k1-cellen een veel lagere specifi citeit heeft (30,8% voor niet-carcinogenen 
[12]). Redenen voor deze opmerkelijke grote verschillen tussen eerdere en recente studies 
beschreven in dit proefschrift, kan de aanwezigheid van een functioneel actief p53-eiwit 
in de gebruikte CHO-k1-cellijn zijn. Uit niet gepubliceerde studies met de p53-remmer 
pifi thrin-α blijkt dat p53 op zijn minst deels functioneel is in de CHO-k1-cellijn die 
gebruikt werd in dit proefschrift. Een andere reden voor het grote verschil in specifi citeit 
zou de toepassing van de HCS-techniek kunnen zijn aangezien de variatie die normaal 
gesproken aanwezig is bij het visueel tellen van micronuclei in de regulatoire IVMN-
test afwezig is bij gebruik van de HCS-techniek [14]. 
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3. Vitotox + HepG2-HCS-IVMN-assay 
Voor de ECVAM-teststoffen geeft een combinatie van deze twee testen een sensitiviteit 
van 90% (18/20) en een specifi citeit van 83% (35/42). Net als al gemeten werd voor 
VitotoxTM + CHO-k1-HCS-IVMN-combinatie is de specifi citeit van de HCS-assays veel 
hoger dan de specifi citeit van de Ames + in vitro genotoxiciteitstesten in zoogdiercellen. 
De sensitiviteit- en specifi citeitscores geven aan dat gecombineerd gebruik van de 
VitotoxTM + HepG2-HCS-IVMN-test een goede strategie zou kunnen zijn voor het 
screenen in de discovery fase. 
4. Vitotox + HepG2-p53_luc-test 
Deze combinatie van testsystemen geeft voor de ECVAM-teststoffen een gevoeligheid 
van 85% (17/20) en een specifi citeit van 88% (37/42). Slechts drie genotoxische 
carcinogenen worden niet gedetecteerd en de specifi citeit van 88% is veel hoger dan 
de specifi citeit van 55% (23/42) met de regulatoire testcombinatie Ames- + in vitro 
genotoxiciteitstesten in zoogdiercellen. Voor de extra set van teststoffen zijn de sensitiviteit 
en specifi citeit respectievelijk 76% (29/38) en 72% (23/32). Deze sensitiviteit is lager 
dan van de combinatie Ames- + in vitro genotoxiciteitstesten in zoogdiercellen (97%, 
37/38). De specifi citeit is met 72% veel hoger dan de 41% (12/29) die gemeten wordt bij 
gecombineerd gebruik van de Ames- + in vitro genotoxiciteitstesten in zoogdiercellen. 
Evaluatie met de twee sets van stoffen laat dus duidelijk zien dat gecombineerd gebruik 
van de VitotoxTM-test + HepG2-p53_luc-test een hoge sensitiviteit en specifi citeit 
geeft. Dit maakt dat deze combinatie nuttig zou kunnen zijn voor het snel screenen op 
genotoxiciteit in de discovery fase van de geneesmiddelenontwikkeling. Een voordeel 
van deze combinatie is dat de validatie werd uitgevoerd met een grote set van teststoffen 
(ECVAM + extra set van 192 stoffen). 
Combinaties van de VitotoxTM met de cystatin A- en RAD51C-reporter assays zullen 
hier niet worden besproken omdat zowel cystatin A als RAD51C voor hun transcriptie 
afhankelijk zijn van p53-activatie [15]. Het gebruik van deze testen geeft daarom geen 
betere scores (hoofdstuk 7). Dus van deze drie reporter assays, blijkt de p53-reportertest het 
meest waardevol te zijn voor het detecteren van stoffen met genotoxische eigenschappen. 
Het uitvoeren van de aanvullende assays zoals de cystatin A-, RAD51C-, maar ook 
Nrf2-reporter-assays kan wel van nut zijn aangezien deze testsystemen informatie geven 
over het mechanisme van genotoxische stoffen. Het gebruik resulteert echter niet in het 
detecteren van meer genotoxische stoffen (of in een daling van de specifi citeit). Zoals al 
eerder besproken in deze samenvatting kan de Nrf2- reporter nuttig zijn maar kan deze 
assay niet gebruikt worden voor het deselecteren van compounds. 
Samenvattend kan gesteld worden dat er vier combinaties van high-throughput 
genotoxiciteitstesten zijn geëvalueerd. De combinatie VitotoxTM + RadarScreen heeft 
een specifi citeit die te laag is. De andere drie combinaties (VitotoxTM + CHO-K1-HCS-
IVMN-assay, VitotoxTM + HepG2-HCS-IVMN-assay en VitotoxTM + HepG2 p53_luc) 
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geven goede scores voor de sensitiviteit en specifi citeit wat aangeeft dat gebruik van deze 
combinaties voor screening in de vroege discovery fase nuttig kan zijn. De specifi citeit 
van deze drie combinaties is hoger dan van gecombineerd gebruik van de regulatoire 
testcombinatie Ames + in vitro genotoxiciteitstesten in zoogdiercellen. Van de drie 
combinaties is de VitotoxTM- + HepG2-p53_luc-combinatie degene die is gevalideerd 
met het grootste aantal teststoffen wat het meeste vertrouwen in deze combinatie 
geeft. Daarom is gebruik van deze combinatie (in eerste instantie) aan te bevelen om 
als teststrategie te gebruiken in de vroege fase (discovery) van het geneesmiddelen 
onderzoek.
Verdere validatie van de HCS-IVMN-testen met meer teststoffen wordt tevens 
aanbevolen. Afhankelijk van de resultaten kan een HCS-IVMN-assay worden 
toegevoegd aan de VitotoxTM- + p53_luc-combinatie. Dit zal een directe discriminatie 
van genotoxische stoffen in clastogene en aneugene stoffen mogelijk maken.
Conclusie
In dit proefschrift zijn meerdere high-throughput testsystemen voor het detecteren van 
stoffen met genotoxische en niet-genotoxische carcinogene eigenschappen ontwikkeld 
en gevalideerd met referentieverbindingen. De resultaten die beschreven zijn in dit 
proefschrift laten zien dat een vroegtijdige voorspelling gedaan kan worden voor 
bacteriële mutageniteit (genmutaties), chromosoomschade en activering van de AhR.
Verschillende combinaties van de high-throughput testsystemen werden geëvalueerd 
om de beste strategie te bepalen voor het vroeg in de discovery fase kunnen detecteren 
van genotoxiciteit. De combinatie VitotoxTM- + HepG2-p53_luc-reporter-assay is 
gebaseerd op de gepresenteerde resultaten in dit proefschrift het meest bruikbaar voor 
het screenen van teststoffen op genotoxische eigenschappen. Deze combinatie geeft 
een hoge sensitiviteit en een laag risico op fout-positieve resultaten. Parallel aan de 
VitotoxTM-assay en HepG2-p53_luc-reporter-assay kunnen CYP1A-inductieproeven 
in menselijke HepG2- en ratte-H4IIE-cellen uitgevoerd worden om mogelijke niet-
genotoxische carcinogene AhR-activatoren te detecteren. Toepassing van deze 
testsystemen zou waardevol kunnen zijn in toekomstige strategieën voor de ontwikkeling 
van geneesmiddelen.
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Additionele opmerkingen
De regulatoire genotoxiciteitstesten en de genotoxiciteitstesten in de discovery fase 
worden in het algemeen serieel uitgevoerd. Voor elke individuele assay wordt teststof 
besteld en vervolgens worden verdunningsreeksen gemaakt. Deze manier van werken 
is relatief arbeidsintensief en resulteert bovendien in verbruik van grote hoeveelheden 
teststof. Dit is vooral in de vroege discovery fase een probleem omdat het aantal stoffen 
dat getest moet worden in die fase hoog is en bovendien is de hoeveelheid stof die 
beschikbaar is klein. Een strategie waarin testen parallel uitgevoerd worden zou een 
effi ciente alternatieve strategie kunnen zijn in de discovery fase [16]. Bij parallel 
screenen wordt maar één keer stof besteld en een verdunningsreeks gemaakt. Deze 
verdunningen worden vervolgens (m.b.v. een pipetteerrobot) toegevoegd aan assayplaten 
van verschillende testen die parallel uitgevoerd worden. Deze strategie resulteert in een 
effectief gebruik van de kleine beschikbare hoeveelheid stof en het snel beschikbaar 
komen van (veel) assaydata.
Een andere belangrijke determinant voor het succes van het vroeg screenen is de 
zuiverheid van de teststoffen. In de vroege fase van het geneesmiddelenonderzoek is 
er een bepaald evenwicht tussen de snelle synthese van nieuwe verbindingen en het 
percentage onzuiverheden in batches van de teststoffen. In testen die de farmacologische 
eigenschappen van deze stoffen bepalen, zijn kleine hoeveelheden verontreinigingen 
vaak geen probleem omdat lage concentraties teststof over het algemeen voldoende zijn 
voor farmacologische activiteit. Daarentegen moeten voor de analyse van genotoxische 
eigenschappen hoge concentraties tot zelfs 10-3 M getest worden. Door deze hoge 
concentraties kunnen verontreinigingen die maar in kleine hoeveelheden aanwezig 
zijn, toch fout-positieve resultaten veroorzaken. De zuiverheid van de stoffen in de 
discovery fase moet daarom hoog genoeg zijn om niet te veel fout-positieve resultaten 
te veroorzaken. Per geval kan voor farmacologisch interessante verbindingen die een 
positief resultaat in de genotoxiciteitstesten geven, besloten worden om de stoffen 
opnieuw te testen na opzuivering met HPLC of kristallisatie.
De toepassing van een S9-metabool systeem in HepG2- en CHO-k1-cellen verdient 
ook een opmerking. Ondanks dat wijzelf (hoofdstuk 5) en anderen [17] hebben 
aangetoond dat het mogelijk is om een S9-metabool systeem in combinatie met HepG2- 
en CHO-k1-cellen te gebruiken om pro-genotoxische teststoffen zoals afl atoxin B1 
te activeren, laten de resultaten in dit proefschrift ook duidelijk zien dat het gebruik 
van een S9-metabool systeem soms verschillende resultaten geeft in modelsystemen 
in bacteriën en gistcellen t.o.v. CHO-k1- en HepG2-cellen. In bacteriën en gistcellen 
waren pro-genotoxische stoffen niet actief zonder de additie van S9-mix. Na de additie 
van S9-mix werden de pro-genotoxische teststoffen geactiveerd (positief resultaat 
Samenvatting, discussie, conclusie and additionele opmerkingen
277
voor genotoxiciteit). Ditzelfde werd waargenomen voor pro-genotoxische teststoffen 
in CHO-k1- en HepG2-cellen wanneer endogeen metabolisme, dat nodig was voor 
activatie van deze testverbindingen, niet of zeer beperkt aanwezig was in de cellijnen. 
Wanneer er echter al een sterke activatie van de pro-genotoxische teststoffen werd 
waargenomen (door endogeen metabolisme) zonder toevoeging van S9-mix, resulteerde 
toevoeging van S9-mix juist in een afname van de genotoxische effecten. De bacteriën 
en gistcellen die in dit proefschrift gebruikt zijn, bevatten genetische modifi caties 
waardoor de celmembranen beter doorlaatbaar worden voor teststoffen zodat deze het 
DNA makkelijk kunnen bereiken. Bovendien hoeven de teststoffen in bacteriën slechts 
één membraan te passeren om het DNA te bereiken. In de HepG2- en CHO-k1-cellijn 
kunnen de hydrofi ele metabolieten die gevormd worden door de S9-mix buiten de cel 
waarschijnlijk het DNA minder makkelijk bereiken dan de teststof zelf. Dit zou kunnen 
resulteren in een kleinere hoeveelheid reactieve metaboliet in de cellen dan in de situatie 
waarin de teststof geactiveerd wordt door endogeen metabolisme.
Een ander opmerking die hier geplaatst wordt gaat over de methode van validatie. De 
validaties die uitgevoerd werden in dit proefschrift geven een eerste goede indicatie over 
de bruikbaarheid en reproduceerbaarheid van de testen. De validaties werden echter niet 
uitgevoerd volgens de offi ciële ECVAM-richtlijnen. Een validatie volgens ECVAM-
richtlijnen is echter wel noodzakelijk om te komen tot acceptatie van een test door 
regulatoire autoriteiten. De validatie volgens de ECVAM-procedure is een langdurig 
proces dat bestaat uit een groot aantal stappen (http://tsar.jcr.ec.europa.eu/). De kracht 
van de in dit proefschrift ontwikkelde testsystemen is de praktische toepasbaarheid in 
de vroege fase van de ontwikkeling van geneesmiddelen. Voor deze toepassing is een 
offi ciële validatie volgens de ECVAM-regels niet nodig. Echter, voor een aantal van de 
ontwikkelde testen zoals bijv. de p53-luciferase reporter assay zou regulatoire erkenning 
uiteindelijk wel nuttig kunnen zijn.
De laatste opmerking gaat over modelsystemen die in de toekomst ontwikkeld zouden 
kunnen worden. De analyse van genexpressieprofi elen met genotoxische- en niet-
genotoxische toxische teststoffen resulteerde in meerdere biomarkers die gebruikt kunnen 
worden voor de discriminatie tussen genotoxische en niet-genotoxische teststoffen (die 
een cytotoxische werking hebben). Gebaseerd op de genexpressieprofi elen werden drie 
luciferase reporter assays ontwikkeld. Twee van deze assays bleken geschikt te zijn 
voor het detecteren van teststoffen met genotoxische eigenschappen (p53- en cystatin 
A-reporters). De RAD51C-reporter assay was specifi eker en identifi ceerde een bepaald 
werkingsmechanisme van de genotoxische verbindingen, namelijk de vorming van 
DNA-dubbelstrengsbreuken. Aanvullende genexpressieprofi leringsstudies in HepG2-
cellen zouden nuttig zijn voor het bepalen van additionele specifi eke biomarkers die ook 
andere werkingsmechanismen van genotoxische teststoffen zouden kunnen ophelderen. 
Zo zou het nuttig zijn om een set te hebben van biomarkers die een onderscheid kunnen 
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maken tussen direct werkende genotoxische stoffen, genotoxische stoffen die DNA 
cross-linking veroorzaken, topoisomerase remmers, DNA-synthese remmers, stoffen 
die oxidatieve stress veroorzaken, en aneugenen. Dergelijke biomarkergenen kunnen 
dan weer gebruikt worden voor de ontwikkeling van high-throughput testsystemen 
zoals luciferase reporter assays. Zoals eerder besproken in dit proefschrift kunnen 
high-throughput assays die niet-genotoxische carcinogenen detecteren, nuttig zijn in de 
discovery fase van het geneesmiddelenonderzoek. In dit proefschrift zijn twee van zulke 
testen geëvalueerd. Deze twee testsystemen werden gebruikt om de activatie van de 
humane- en ratte-AhR-receptor te meten. Activatie van de AhR is echter slechts één van 
de vele mechanismen die niet-genotoxische carcinogeniteit veroorzaakt. Activering van 
een aantal andere receptoren dan de AhR kan ook resulteren in een niet-genotoxische 
carcinogeniteit. Voor dergelijke receptoren, zoals de peroxisome proliferator activated 
receptor α, CAR en thyroid hormoonreceptor kan het daarom wellicht ook nuttig zijn 
om screeningstesten te ontwikkelen in humane-  en/of knaagdiercellijnen.
Samenvattend kan gesteld worden dat er in dit proefschrift nieuwe snelle 
genotoxiciteitstesten ontwikkeld zijn. Evaluatie heeft aangetoond dat een aantal van 
deze testen een betrouwbaar high-throughput alternatief zijn voor de regulatoire 
genotoxiciteitstesten. Vooral bepaalde combinaties van de ontwikkelde testen blijken 
uitstekende mogelijkheden te bieden voor het snel screenen van teststoffen op genotoxische 
eigenschappen zonder het risico op veel fout-positieve resultaten. Bovendien zijn twee 
testsystemen ontwikkeld voor het detecteren van AhR-activatoren in de mens en rat. Een 
aantal van de nieuw ontwikkelde testen in dit proefschrift zal daarom zijn nut kunnen 
bewijzen in toekomstige teststrategieën voor de ontwikkeling van geneesmiddelen.
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me enthousiast heeft gemaakt voor dit promotieonderzoek. Bedankt voor de vele uren die 
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veel ruimte hadden om nieuwe testen op te zetten. Gedurende die periode is dan ook een 
solide basis gelegd voor dit proefschrift. Jasper, Carolien, Joe, André bedankt voor jullie 
hulp. Helaas moesten we na de overname van Organon door Schering-Plough afscheid 
nemen van Jasper, Carolien en Joe. Gelukkig hebben jullie allemaal een goede werkplek 
gevonden binnen of buiten het bedrijf. 
Mijn paranimfen Joe en Mirjam bedankt dat jullie me op de dag van de verdediging 
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beschreven wordt. Mirjam bedankt voor de goede samenwerking en gezelligheid tijdens 
de periode waarin we samen de master of science opleiding in Nijmegen volgden.
De laatste anderhalf jaar van het promotieonderzoek werd na het samengaan van 
Schering-Plough met MSD uitgevoerd binnen de sectie mechanistic and investigative 
toxicology op de locatie Schaijk. Het was na meer dan 10 jaar in Oss gewerkt te hebben 
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inrichten van het nieuwe discovery lab weer goed lopen. In het bijzonder wil ik de ‘gentox 
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Jan Polman, bedankt voor je hulp bij het analyseren van de HepG2 toxicogenomics 
data. Jou data analyse is de basis geweest voor hoofdstuk 6 uit dit proefschrift.
Verder wil ik nog de master student Tom Schirris bedanken. Dankzij jou kennis van 
high-content-screening en het harde werken kon het micronucleus hoofdstuk ondanks de 
complexheid op tijd afgerond worden. Veel succes in je verdere carrière! Olaf Deppe en 
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high-content-screening en het ontwikkelen van de HCS micronucleus-assay software. 
Pa, ma, Manon en familie, bedankt voor jullie interesse en dat jullie voor mij klaarstaan. 
Pa, ma en schoonouders bedankt dat jullie vooral tijdens de laatste periode van het 
promotieonderzoek wat vaker op Imke wilden passen als ik weer eens thuis aan het 
werk was. Lieve Imke, bedankt voor de afl eiding en grappige momenten die je me gaf 
tussen het schrijven door. Nu heeft papa weer meer tijd voor je! Tot slot, lieve Wendy 
dankjewel voor alle liefde en steun tijdens al die avonden en weekenden dat ik weinig 
tijd voor je had en druk was met het schrijven van artikelen.
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school at the Pius X College (VWO) in 1993. The same year he started the Bsc study 
Medical Biochemistry at the Hogeschool Enschede. In July 1997 he graduated (with 
distinction) and became research assistant at NV Organon were he studied the effects 
of estrogens on the cardiovascular system and bone. In 2000 he became as senior 
research assistant involved in the development and implementation of assays for early 
toxicity screening in the discovery phase of drug development. During this period he 
got inspired for high-throughput screening, molecular toxicology and genotoxicity. In 
2005 he started the study molecular life sciences at the HAN University (Nijmegen). 
The main topics were infection diseases, biotechnology and carcinogenesis. In February 
2007 he acquired his Master of Science degree ‘with distinction’. From 2006 he carried 
out the investigations described in this thesis. Meanwhile NV Organon was acquired 
by Schering-Plough and thereafter Schering-Plough merged with MSD. Presently, he is 
working at MSD as scientist in the department of toxicology and drug disposition where 
he is involved in mechanistic and investigative toxicology.  
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